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 The study of comorbidity is becoming a key topic in biomedical research, which is especially 
relevant in the context of population ageing. Comorbidity has profound implications for individuals, 
practitioners, and health care systems. As a consequence, increasing efforts are being made by the 
scientific community to characterize better how disorders relate to each other and to identify the 
factors producing these associations. 
 Cancer and central nervous system (CNS) disorders are among the top leading causes of 
death and disease burden worldwide. In recent decades direct and inverse patterns of association 
between CNS disorders and cancer have been reported. However, observational studies have often 
found contrasting results. Consequently, evidence synthesis methods such as systematic reviews 
and meta-analysis have emerged as a critical tool to synthesize and evaluate the quality of the 
evidence regarding a specific research question. 
 In addition, in the course of the Omics era, an unprecedented amount of information 
regarding the molecular bases of individual disorders has been produced, opening the door to the 
study of comorbidity from a molecular perspective through the identification of joint alterations in 
variants, genes, and biological processes. 
 In the present thesis, we aimed to characterize the epidemiological and molecular 
associations between CNS disorders and cancer and to identify the potential role of their indicated 
medications. To this end, we first determined if CNS disorder patients presented an altered risk of 
subsequent cancer incidence and mortality by conducting systematic reviews and meta-analyses of 
observational studies. Second, we investigated if CNS disorders and cancers presented joint 
patterns of transcriptomic dysregulation using differential gene expression meta-analysis and 
weighed co-expression network analysis methods. Third, interactome-based methods and genetic 
correlations were employed to study the involvement of disease-associated genes and shared 
genetic variability. Finally, the impact of the medications indicated for the treatment of both sets 
of disorders in the reported comorbidities was assessed by the analysis of a large repository 
including information of cell lines treated with the indicated drugs. 
 Our results suggest that patients suffering from neurodegenerative disorders are at a 
reduced risk of subsequent cancer incidence and mortality compared to controls. Autism spectrum 
disorder, bipolar disorder, and schizophrenia (SCZ) patients are at an increased risk of cancer 
mortality but not cancer incidence, whereas major depression patients presented an increased risk 
of cancer incidence and mortality. Several associations between CNS disorders and site-specific 
cancers were also identified. Significant direct and inverse patterns of transcriptomic dysregulation 
between CNS disorders and cancers were observed in our transcriptomic analyses, as well as the 
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presence of joint alterations in several biological processes (i.e., cell cycle, apoptosis, immune 
system, and oxidative phosphorylation). Significant genetic correlations were also identified 
between CNS disorders and cancers, including those observed between Parkinson’s disease and 
melanoma and SCZ and breast cancer. Finally, several drugs indicated for the treatment of CNS 
disorders, such as antipsychotics, antidepressants, and acetyl-cholinesterase inhibitors were found 
to produce transcriptomic alterations that mimicked or reversed those found in some cancer types, 
indicating their potential role in the CNS and cancer comorbidity. 
 
 Keywords: comorbidity, central nervous system disorders, cancer, systematic reviews, 






























Alvan R. Feinstein acuñó el término comorbilidad en 1970 para referirse a “Cualquier 
entidad adicional que haya existido o pueda ocurrir en el transcurso clínico de un paciente que 
presente una enfermedad índice”. Durante las décadas que siguieron a esta definición emergieron 
nuevos conceptos relacionados con la idea inicial de Feinstein, como por ejemplo los términos 
multimorbilidad, carga de enfermedad y fragilidad. La comorbilidad se define en términos 
epidemiológicos como la presencia de una probabilidad mayor que la esperada en la coocurrencia 
de dos patologías. Además, en los últimos años un número creciente de estudios ha puesto de 
manifiesto la importancia de la comorbilidad inversa, que se define como la presencia de una 
probabilidad menor que la esperada en la coocurrencia de dos enfermedades. 
El estudio de la comorbilidad se está convirtiendo en un tema clave en la investigación 
biomédica, que es especialmente relevante en el contexto de los países con poblaciones 
envejecidas. La comorbilidad tiene implicaciones importantes para los pacientes, los profesionales 
sanitarios y los sistemas de salud. En este contexto, el esfuerzo conjunto de la comunidad científica 
está ayudando a caracterizar los patrones de asociación existentes entre los distintos trastornos, 
así como a elucidar los mecanismos y factores implicados en su origen.  
 El cáncer y las enfermedades del sistema nervioso central (SNC) se encuentran entre las 
principales causas de muerte y carga de enfermedad a nivel mundial. En las últimas décadas un 
número creciente de estudios ha sugerido la existencia de asociaciones epidemiológicas directas e 
inversas entre estos dos grupos de enfermedades. Sin embargo, estos han arrojado con frecuencia 
resultados discrepantes. En este sentido, los métodos de síntesis de le evidencia, tales como las 
revisiones sistemáticas y metaanálisis proporcionan una herramienta fundamental para evaluar la 
calidad de la evidencia disponible con respecto a una pregunta de investigación concreta. 
 El estudio más exhaustivo dedicado a analizar las asociaciones epidemiológicas entre el 
cáncer y las enfermedades del SNC publicado hasta la fecha sugiere que estos pacientes presentan 
un riesgo reducido en la incidencia de cáncer. En particular, los pacientes con enfermedades 
neurodegenerativas presentaron una reducción del riesgo más pronunciada. Además, también se 
identificaron incrementos en el riesgo de desarrollar tipos tumorales específicos. Por ejemplo, los 
pacientes con enfermedad de Párkinson (EP) están sujetos a una mayor incidencia de melanoma y 
las pacientes diagnosticadas con esquizofrenia (EZF) presentan una incidencia elevada de cáncer de 
mama en comparación con los grupos control.  
 Se han propuesto una amplia variedad de mecanismos para tratar de explicar las causas de 
las asociaciones epidemiológicas observadas. Estos incluyen la presencia de alteraciones 
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compartidas en genes y procesos biológicos, la influencia conjunta de variantes genéticas, la 
exposición a factores de riesgo comunes, así como la presencia de sesgos sistemáticos en los 
estudios observacionales, tales como el sesgo muestral o la falta de consideración de variables de 
confusión relevantes como los hábitos de consumo de tabaco. Además del rol potencial de 
determinados tratamientos farmacológicos. 
 Durante el transcurso de la era ómica se ha producido una acumulación de información sin 
precedentes sobre las bases moleculares de las enfermedades individuales. Este hecho ha abierto 
la puerta al estudio de la comorbilidad desde una perspectiva molecular, a través de la 
identificación de alteraciones compartidas en variantes, genes y procesos biológicos. Algunos 
estudios han intentado arrojar luz sobre la existencia de dichas alteraciones y sobre su implicación 
conjunta en la fisiopatología del cáncer y las enfermedades del SNC, señalando que las mismas 
podrían tener un papel modulador en las asociaciones epidemiológicas observadas. Por ejemplo, 
se ha sugerido que determinadas parejas de enfermedades del SNC y ciertos tipos tumorales, que 
presentan relaciones de comorbilidad inversa a nivel epidemiológico, exhiben también patrones de 
expresión diferencial opuestos. Es decir, que aquellos genes que tienden a estar sobreexpresados 
en un miembro de la pareja tienden a estar infraexpresados en el otro miembro y viceversa. A este 
respecto, se ha observado que los pacientes con EZF, enfermedad de Alzheimer (EA) y EP presentan 
patrones de expresión diferencial opuestos con los cánceres colorrectales, de pulmón y de próstata 
y se ha sugerido que genes como PIN1 y ATP13A2 y rutas biológicas como la señalización a través 
de P53 y Wnt podrían tener un papel clave en estos procesos. 
 Además de las aproximaciones basadas en métodos transcriptómicos, otros estudios han 
iniciado a explorar el efecto conjunto de variantes genéticas en parejas de enfermedades del SNC 
y tumores específicos. Por ejemplo, empleando un método denominado cross-trait LD score 
regression, un estudio reciente encontró correlaciones genéticas significativas entre EA y cánceres 
de mama y pulmón, sugiriendo que determinadas variantes genéticas podrían estar asociadas a la 
modulación conjunta del riesgo de ambas enfermedades. 
 Finalmente, el uso de determinados tratamientos farmacológicos se ha propuesto como un 
elemento de potencial relevancia en la modulación de las relaciones de comorbilidad entre las 
enfermedades del SNC y el cáncer. Por ejemplo, el disulfiram (DSF), un fármaco empleado durante 
décadas para el tratamiento de la dependencia al alcohol, se ha mostrado capaz de reducir la tasa 
de mortalidad por cáncer en pacientes que mantuvieron su uso durante el transcurso de la 
enfermedad en comparación con aquellos pacientes que fueron usuarios previos de DSF, pero que 
abandonaron el tratamiento al menos un año antes de ser diagnosticados de cáncer. Otros 
ejemplos de fármacos que han sido señalados como potenciales moduladores de las asociaciones 




en el aumento en el riesgo de cáncer de mama observado en pacientes con esquizofrenia o el uso 
de levodopa, que ha sido vinculado al aumento de riesgo de melanoma observado en pacientes con 
EP.  
 Objetivos 
 El objetivo general de la presente tesis es el de evaluar las relaciones de comorbilidad entre 
una selección de enfermedades del SNC que incluyen la EA, los trastornos del espectro autista (TEA), 
la EP, la enfermedad de Huntington (EH), la depresión mayor (DM), el trastorno bipolar (TB), la EZF, 
y el cáncer desde una perspectiva epidemiológica y molecular, además de examinar el posible papel 
de los fármacos de uso frecuente en dichas asociaciones. Para ello proponemos una serie de 
objetivos específicos. 
 Objetivo 1: Sintetizar la evidencia epidemiológica existente sobre las asociaciones entre las 
enfermedades del SNC seleccionadas y el cáncer a través de la elaboración de revisiones 
sistemáticas y metaanálisis de estudios observacionales. Estos estudios deben incluir como 
exposición el diagnóstico de alguna de las enfermedades del SNC y como outcome la incidencia o 
mortalidad por cualquier tipo de cáncer o por tipos tumorales específicos. 
Objetivo 2: Analizar las asociaciones transcriptómicas entre las siete enfermedades del 
sistema nervioso central incluidas y 22 tipos tumorales específicos. Los tipos tumorales 
seleccionados son: leucemia linfoblástica aguda, leucemia mieloide aguda, cáncer de vejiga, cáncer 
de mama, cánceres cerebrales, cáncer de cérvix, colangiocarcinoma, leucemia linfocítica crónica, 
leucemia mieloide crónica, cáncer colorrectal, linfoma difuso de células B grandes, linfoma folicular, 
carcinoma de cabeza y cuello, cáncer de riñón, cáncer de pulmón, cáncer hepático, cáncer de 
ovario, cáncer de páncreas, melanoma, cáncer gástrico y cáncer de tiroides. El cálculo de las 
asociaciones transcriptómicas se basa en la comparación de las firmas de expresión obtenidas 
mediante el metaanálisis de expresión diferencial de múltiples estudios transcriptómicos para cada 
enfermedad y en la identificación de módulos de coexpesión asociados a cada una de las 
enfermedades y su comparación entre todas las posibles parejas formadas por cada enfermedad 
del SNC y cada tipo tumoral. 
 Objetivo 3: Evaluar la presencia de asociaciones a nivel del interactoma humano y de 
correlaciones genéticas entre las enfermedades del SNC y el cáncer. Los genes y proteínas 
relacionados con una enfermedad concreta tienden a interaccionar entre ellos y a formar subgrafos 
conexos dentro del interactoma humano, denominados módulos de enfermedad. Desde esta 
perspectiva, las enfermedades son producidas por perturbaciones locales en estos módulos y las 
comorbilidades podrían surgir como consecuencia de la perturbación de módulos de enfermedad 
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superpuestos. En otras palabras, si los módulos de enfermedad de dos desórdenes se superponen 
a nivel del interactoma, las perturbaciones locales causantes de la primea enfermedad alterarían 
también las rutas biológicas relacionadas con la segunda. Por tanto, la presencia de superposiciones 
significativas a nivel del interactoma humano entre las enfermedades del SNC y el cáncer podría 
constituir un indicio en favor del potencial sustrato biológico de las relaciones de comorbilidad 
observadas entre ambos grupos de enfermedades. Asimismo, la presencia de correlaciones 
genéticas significativas entre parejas de enfermedades, calculadas a partir de estudios de 
asociación de genoma completo (GWAS), por sus siglas en inglés, podría ser indicativa de la 
existencia de variabilidad genética compartida con la capacidad de modular el riesgo de ambas 
enfermedades. 
 Objetivo 4: Estudiar el posible impacto de las indicaciones farmacológicas empleadas para 
el tratamiento de las enfermedades del sistema nervioso central y el cáncer en las relaciones de 
comorbilidad observadas entre ambos grupos de enfermedades. El efecto de la medicación se 
estudió empleando dos aproximaciones complementarias. La primera basada en el cómputo de 
distancias entre las dianas moleculares de los fármacos y los módulos de cada una de las 
enfermedades a nivel del interactoma humano y la segunda mediante el análisis de las firmas de 
expresión genética producidas al tratar líneas celulares con dichos fármacos y el cómputo de 
correlaciones entre los perfiles obtenidos y las firmas de expresión de cada una de las 
enfermedades del SNC y cánceres seleccionados.  
 Material y métodos 
  Material y métodos empleados en el desarrollo del objetivo 1: 
 Con el objetivo de sintetizar la evidencia disponible sobre las asociaciones entre las 
enfermedades del SNC y el cáncer desde una perspectiva epidemiológica, se efectuaron revisiones 
sistemáticas y metaanálisis de estudios observacionales previos siguiendo las guías de publicación 
proporcionadas por PRISMA-P y MOOSE. Se llevaron a cabo búsquedas sistemáticas en cuatro bases 
de datos de literatura científica (MEDLINE, Scopus, Embase y Web of Science) y se seleccionaron 
aquellos estudios en los que la exposición fuese el diagnóstico de alguna de las enfermedades del 
SNC seleccionadas y el outcome, la incidencia o mortalidad subsiguiente por cualquier tipo de 
cáncer o por tipos tumorales específicos, a través de un proceso de cribado basado en la lectura de 
títulos, resúmenes y textos completos. Se seleccionaron aquellos estudios observacionales (caso-
control o de cohorte) que incluyesen medidas cuantificando el grado de asociación entre la 
exposición y el outcome en forma de riesgos relativo, razón de probabilidades y razones de tasas 




cumplieron con los criterios de inclusión. Los elementos extraídos fueron, entre otros, el año de 
publicación, el país, el diseño del estudio, la duración del seguimiento de las cohortes, el número 
de participantes diagnosticados con la enfermedad del SNC, la presencia de ajuste por variables de 
confusión y los tamaños de efecto de las asociaciones, así como sus intervalos de confianza al 95%. 
La calidad de cada uno de los estudios observacionales seleccionados fue evaluada empleando la 
escala Newcastle-Ottawa. Para cada uno de los posibles outcomes se llevaron a cabo metaanálisis 
empleando el método inverso de la varianza y un modelo de efectos aleatorios debido a la 
heterogeneidad esperada en los datos. Finalmente, se evaluó el sesgo de publicación mediante la 
visualización de gráficos de embudo y mediante el cómputo de los tests de Eggers y Beggs.  
  Material y métodos empleados en el desarrollo del objetivo 2: 
 Con la finalidad de evaluar la presencia de asociaciones transcritómicas entre las 
enfermedades del SNC y el cáncer y estudiar el papel potencial de las alteraciones conjuntas en 
rutas y procesos biológicos se siguió el siguiente esquema de trabajo: En primer lugar, se efectuaron 
búsquedas de conjuntos de datos de expresión de RNA en Gene Expression Omnibus (GEO), Array 
Express (AE), Stanley Medical Research Institute y The Cancer Genome Atlas (TCGA) para cada una 
de las enfermedades consideradas. Únicamente se seleccionaron aquellos conjuntos de datos con 
al menos tres muestras derivadas de casos y tres muestras derivadas de controles procedentes del 
mismo tejido. Para garantizar la aplicación de métodos de normalización compatibles, solo se 
eligieron aquellos estudios generados empleando las plataformas de un solo canal más populares 
de Affymetrix, Illumina y Agilent. Para cada una de las enfermedades del SNC, con el objetivo de 
reducir la heterogeneidad de los datos, se seleccionaron estudios y muestras de una sola región 
cerebral para la que existiesen evidencias sólidas de su implicación en la fisiopatología de la misma. 
En el caso de los cánceres, se incluyeron estudios con muestras de tumores primarios y sus 
respectivos controles. Los estudios y muestras obtenidos a partir de líneas celulares y muestras 
derivadas de metástasis fueron descartados. Los estudios fueron preprocesados de manera 
individual y sometidos a un proceso de detección de valores atípicos a nivel de muestra y de 
conjunto de datos. Para cada una de las enfermedades incluidas se efectuó un meta-análisis de 
expresión diferencial integrando la información de los distintos estudios disponibles. Aquellos 
genes que presentaron p-valores ajustados por comparaciones múltiples menores de 0.05 (FDR < 
0.05) se consideraron genes diferencialmente expresados. Posteriormente, los perfiles de cada una 
de las enfermedades del SNC se compararon con los del todos los tipos tumorales. En breve, la 
probabilidad de encontrar un número mayor de genes que esperado por azar en cada una de las 
cuatro intersecciones formadas por los genes sobreexpresados e infraexpresados en cada pareja 
de enfermedades fue evaluada mediante el uso de tests hipergeométricos. El enriquecimiento en 
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categorías funcionales de los genes ubicados en las intersecciones se evaluó mediante análisis de 
sobrerrepresentación. Los perfiles de expresión diferencial de cada una de las enfermedades fueron 
empleados como input para efectuar un enriquecimiento en conjuntos de genes (Gene Set 
Enrichment Analysis, GSEA). Los resultados fueron comparados entre las distintas parejas de 
enfermedades del SNC y los diferentes tipos tumorales con el objetivo de encontrar rutas y 
procesos biológicos alterados de manera conjunta en ambos grupos de enfermedades. Un conjunto 
alternativo de estudios transcriptómicos con información sobre 15 tipos tumorales, que fué 
generado empleando técnicas de secuenciación de RNA, se utilizó para validar las asociaciones 
transcriptócmicas observadas en los análisis basados en arrays de expresión. Finalmente, se 
generaron módulos consenso de coexpresión usando, para cada una de las enfermedades, todos 
los estudios transcriptómicos disponibles y el método de análisis ponderado de redes de 
coexpresión, WGCNA por sus siglas en inglés. Se computaron mediadas de asociación de cada uno 
de los módulos de coexpresión detectados con el estatus de enfermedad de las muestras, de modo 
que se identificaron aquellos módulos consenso de genes que tienden a estar sobreexpresados en 
los casos respecto a los controles y aquellos módulos que tienden a estar infraexprados en los casos 
con respecto a los controles. Se efectuó un análisis de enriquecimiento en procesos biológicos y 
marcadores genéticos vinculados a tipos celulares específicos de los genes contenidos en cada 
módulo de coexpresión. Por último, la superposición en el contenido de genes de los módulos 
asociados cada pareja de enfermedades se evaluó mediante el cómputo de tests hipergeométricos. 
  Material y métodos empleados en el desarrollo del objetivo 3: 
 En primer lugar, se construyó un interactoma humano mediante la integración de 
diferentes fuentes de información sobre interacciones entre genes y proteínas humanas. Estas 
incluyeron interacciones proteína-proteína derivadas de The Human Reference Interactome (HuRI), 
parejas de genes coexpresados obtenidas a partir del análisis de los datos de the Genotype-Tissue 
Expression (GTEx), información sobre complejos proteicos derivada de the comprehensive resource 
of mammalian protein complexes (CORUM), información sobre factores de transcripción y sus 
dianas obtenida a partir de TRANSFAC, interacciones quinasa-sustrato derivadas de 
PhosphoSitePlus y asociaciones metabólicas obtenidas a partir de the Kyoto Encyclopedia of Genes 
and Genomes (KEGG). Dos interactomas adicionales previamente publicados derivados de STRING 
y BIOGRID fueron seleccionados con el objetivo de evaluar el impacto de los distintos parámetros 
asociados con cada interactoma (número de genes incluidos, número de conexiones entre genes, 
grado promedio, etc.) en los resultados. En segundo lugar, se efectuaron búsquedas de genes y 
genes asociados a variantes implicados en cada una de las enfermedades incluidas en los análisis 




Network DisGeNet, Phenotype-Genotype Integrator (PheGenI) y la base de datos de asociaciones 
gen-enfermedad eDGAR. Se emplearon dos umbrales distintos a la hora de seleccionar genes y 
variantes asociados a enfermedad en DisGeNET y PhenGeI, de modo que para cada enfermedad se 
generaron dos conjuntos de genes asociados, uno obtenido aplicando criterios de selección 
relajados y otro obtenido aplicando criterios de selección estrictos. Para cada enfermedad se 
calcularon dos medidas de localización a nivel del interactoma de sus genes asociados, con el 
objetivo de determinar si estos tienden a concentrarse en un vecindario específico del interactoma 
humano. Para ello se emplearon dos métricas previamente descritas y tests de permutaciones para 
el cómputo de la significatividad de los valores observados. Posteriormente el grado de 
superposición de los módulos de enfermedad de todas las posibles parejas de enfermedades fue 
computado mediante una métrica adicional denominada separación entre enfermedades (SEE). El 
grado de significatividad de esta medida de asociación, así como de las anteriores, fue evaluado 
mediante tests de permutaciones en los que se tuvo en cuenta la distribución de los grados de los 
genes asociados a enfermedad de los conjuntos de genes iniciales. Por último, se efectuaron 
búsquedas de estudios de GWAS previos dedicados a la identificación de variantes genéticas 
asociadas con una modulación del riesgo de desarrollo de las enfermedades bajo análisis. Se 
obtuvieron los datos resumidos de cada estudio de GWAS a partir de varios repositorios públicos y 
en algunos casos, a través del contacto directo con los autores de los mismos. Empleando estos 
datos y un método denominado cross-trait LD-score regression se computaron las correlaciones 
genéticas entre todas las posibles parejas de enfermedades disponibles. 
  Material y métodos empleados en el desarrollo del objetivo 4: 
 Se evaluó el papel de las medicaciones indicadas para el tratamiento de los desórdenes del 
SNC y el cáncer en sus relaciones de comorbilidad mediante el uso de dos metodologías distintas. 
La primera está basada en el cómputo de distancias a nivel del interactoma entre las dianas de los 
fármacos indicados y los módulos de enfermedad de cada una de las enfermedades estudiadas. La 
segunda implicó la obtención de firmas de expresión de líneas celulares tratadas con los fármacos 
indicados y su comparación con los perfiles de expresión diferencial de cada una de las 
enfermedades del SNC y cánceres generadas en el objetivo 2 mediante el cómputo de 
correlaciones. Las indicaciones para cada una de las enfermedades fueron obtenidas a partir de 
MEDI-an, un repositorio de indicaciones que almacena información de diferentes fuentes, mientras 
que los datos sobre las dianas moleculares conocidas de cada fármaco fueron obtenidos a partir de 
DruBank. Se utilizó una métrica similar a las descritas en el objetivo dos con la finalidad de medir la 
cercanía de cada fármaco al módulo de enfermedad característico de cada uno de los desórdenes 
incluidos y se siguió la misma estrategia a la hora de calcular la significatividad de las asociaciones 
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descritas. Distancias significativamente menores a las observadas por azar indicarían el impacto de 
un fármaco concreto en el módulo de enfermedad característico de un desorden específico. Los 
perfiles de expresión diferencial de líneas celulares tratadas con las indicaciones identificadas 
fueros obtenidos a partir de LINCS L1000, un repositorio público que contiene información sobre 
los perfiles de expresión diferencial generados por miles de perturbaciones (moléculas pequeñas, 
ligados, kncokdowns, etc.). Se calcularon las correlaciones entre los perfiles producidos por estas 
moléculas y los perfiles de expresión diferencial idiosincráticos de cada una de las enfermedades 
obtenidos en desarrollo del objetivo 2. Las correlaciones positivas sugieren que un fármaco 
concreto produce firmas de expresión que asemejan a las firmas observadas en una enfermedad 
determinada, mientras que las correlaciones negativas sugieren que un determinado fármaco 
tendría el potencial de revertir las alteraciones transcriptómicas observadas en una enfermedad 
concreta. 
 Resultados y conclusiones  
  Resultados y conclusiones del objetivo 1:  
Las búsquedas sistemáticas en las bases de datos de literatura científica permitieron la 
identificación de un total de 8749 referencias. Tras los cribados basados en la lectura de títulos, 
resúmenes y textos completos, 192 artículos cumplieron con los criterios de inclusión y fueron 
empleados en los análisis sucesivos. En el caso de los resultados primarios (incidencia y mortalidad 
por cualquier tipo de cáncer) nuestros análisis incluyeron información sobre 1075159 y 2325378 
individuos diagnosticados con alguna de las enfermedades del SNC y sus respectivas tasas de 
incidencia o mortalidad por cáncer. En general, los resultados de los metaanálisis efectuados 
sugieren una disminución significativa en la incidencia y mortalidad por cáncer en los pacientes con 
cualquiera de las enfermedades neurodegenerativas estudiadas. Se identificaron 7 estudios con 
información relativa a la incidencia de cáncer en pacientes previamente diagnosticados con EA. El 
metaanálisis de estos estudios sugiere que los pacientes con EA presentan una disminución del 31% 
en el riesgo de cáncer en comparación con los grupos control (RR = 0.69; 95% IC: 0.59-0.81). Seis 
estudios presentaron información sobre las asociaciones entre EA y la mortalidad por cáncer. Su 
análisis conjunto indica una reducción del 55% en la mortalidad por cáncer en pacientes 
previamente diagnosticados con EA (RR = 0.45; 95% IC: 0.33-0.61). En esta misma línea, los 
resultados de EP indican una reducción tanto de la incidencia (n = 17; RR = 0.85; 95% IC: 0.76-0.96) 
como de la mortalidad (n = 15; RR = 0.69; 95% IC: 0.54-0.87) por cualquier tipo de cáncer. Los 
pacientes con EH presentaron también un riesgo significativamente reducido en la incidencia y 




identificado fue escaso, con 4 estudios disponibles en el metaanálisis de incidencia y 2 en el de 
mortalidad.  
No se observaron alteraciones en el riesgo de incidencia de cualquier tipo de cáncer para 
TB, EZF o TEA. En cambio, se observó un incremento significativo en el caso de DM (RR = 1.17; 95% 
IC: 1.05-1.29) en el metaanálisis efectuado a partir de la información de 22 estudios 
observacionales. La mortalidad por cualquier tipo de cáncer presenta un incremento significativo 
en TB (n = 9; RR = 1.09; 95% IC: 1.03-1.15), EZF (n = 37; RR = 1.34; 95% CI: 1.23-1.46; I2 = 94.53%), 
TEA (n = 2; RR = 1.92; 95% IC: 1.58-2.32) y DM (n = 21; RR = 1.24; 95% IC: 1.15-1.34). 
Varios tipos tumorales específicos presentaron patrones asociación significativos con 
distintas enfermedades del SNC. Entre ellos cabe destacar la reducción en el riesgo de cáncer de 
pulmón observada en pacientes con EA  (n = 4; RR = 0.81; 95% IC: 0.7-0.94) y EP (n = 13; RR = 0.6; 
95% IC: 0.47-0.76), las reducciones en el riesgo en cánceres hepáticos (n = 3; RR = 0.72; 95% IC: 
0.61-0.85) y melanomas (n = 3; RR = 0.81; 95% IC: 0.69-0.94) observadas en EA, así como la 
disminución en la incidencia de cánceres de vejiga (n = 8; RR = 0.73; 95% IC: 0.57-0.93) y 
colorrectales (n = 15; RR = 0.8; 95% IC: 0.7-0.91) presentes en pacientes con EP. Además, los 
pacientes con EH presentaron una reducción significativa en el riesgo de cánceres colorrectales (n 
= 3; RR = 0.5; 95% IC: 0.27-0.93) y de próstata (n = 3; RR = 0.36; 95% IC: 0.25-0.5). Finalmente, los 
hombres con EZF presentaron una menor incidencia de cáncer de próstata (n = 14; RR = 0.56; 95% 
IC: 0.47-0.65). 
Nuestros resultados también sugieren la presencia de incrementos en la incidencia de 
determinados tipos tumorales en pacientes con enfermedades del SNC. Entre los que cabe destacar 
aquellos observados entre EP y los cánceres cerebrales (n = 7; RR = 1.5; 95% IC: 1.11-2.04; I2 = 
64.49%) y melanomas (n = 13; RR = 1.49; 95% IC: 1.17-1.89), DM y cánceres de mama (n = 15; RR = 
1.24; 95% IC: 1.02-1.52) y pulmón (n = 9; RR = 1.31; 95% IC: 1.18-1.44), así como los incrementos 
en el riesgo de cánceres de mama (n = 18; RR = 1.37; 95% IC: 1.23-1.53) y útero presentes en 
mujeres con EZF (n = 11; RR = 1.35; 95% IC, 1.07-1.7). 
La interpretación de estos resultados debe de tener en consideración las limitaciones 
inherentes a este estudio. En primer lugar, el número de trabajos dedicados al análisis de cada una 
de las asociaciones es altamente heterogéneo con una carencia evidente de estudios dedicados al 
análisis de los pacientes de TEA y EH. Estas carencias son especialmente relevantes en el caso del 
estudio de los resultados secundarios (incidencia y mortalidad por tipos tumorales específicos). En 
segundo lugar, el efecto de determinadas variables de confusión, tales como los hábitos de 
consumo de tabaco no son consideradas en la inmensa mayoría de los estudios observacionales 
identificados. Finalmente, la presencia de otras fuentes de sesgo, tales como el diagnóstico 
eclipsado y el sesgo maestral tampoco pueden ser excluidas. 
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 Resultados y conclusiones del objetivo 2:  
Ciento noventa y dos conjuntos de datos trasctriptómicos únicos, obtenidos mediante 
arrays de expresión, con muestras derivadas de tejidos procedentes de individuos con alguna de 
las 29 enfermedades estudiadas y sus respectivos controles sanos, fueron identificados tras 
efectuar las búsquedas pertinentes en repositorios públicos de datos ómicos. Después de aplicar 
los criterios de inclusión y la detección de muestras y estudios atípicos, 160 estudios incluyendo un 
total de 16132 muestras fueron seleccionados para su análisis subsiguiente. Además, diecisiete 
conjuntos de datos derivados de estudios efectuados mediante técnicas de secuenciación de RNA 
con muestras de 15 de los tipos tumorales estudiados mediante arrays de expresión, fueron 
empleados como cohorte de validación. Estos incluyeron un total de 7361 muestras. Los 
metaanálisis de expresión diferencial llevados a cabo arrojaron un número variable de genes 
diferencialmente expresados (GDE) en los distintos desórdenes estudiados (FDR < 0.05). Las 
enfermedades neurodegenerativas y el TEA presentaron un elevado número de GDEs que oscilaron 
entre los 1003 identificados en metaanálisis de TEA y los 4504 observados en EH. Por el contrario, 
las enfermedades neuropsiquiatrías (TB, DM, EZF) presentaron un número reducido de GDEs que 
oscilaron entre los 3 observados en EZF y los 15 identificados en DM. En el caso de los distintos 
tipos tumorales incluidos, el número de GDEs varió entre los 581 observados en AML y los 9757 
detectados en tumores cerebrales. 
Se observaron distintos patrones de asociación transcriptómica, tanto directos como 
inversos entre las enfermedades del SNC y los distintos tipos tumorales estudiados. En concreto, 
entre las asociaciones observadas en los análisis efectuados mediante arrays de expresión que 
fueron posteriormente validadas empleando estudios de RNA-seq, encontramos asociaciones 
directas entre EA, EP y EH, TEA y cánceres cerebrales, así como asociaciones directas entre EP, HD, 
TEA y cáncer de riñón. En estas asociaciones los genes tienden a estar desregulados en la misma 
dirección en cada pareja de desórdenes. Además, también se observó un número importante de 
patrones de desregulación en direcciones opuestas, que incluye las asociaciones transcriptómicas 
inversas observadas entre EA, EP, y EH y los cánceres de mama y pulmón, las asociaciones inversas 
entre EA, EP y cáncer de próstata y las asociaciones inversas identificadas entre EA y los cánceres 
hepáticos y de vejiga. En estos casos, aquellos genes sobreexpresados o infraexpesados en una de 
las enfermedades tienden a estar desregulados en direcciones opuestas en la otra enfermedad. Los 
análisis de enriquecimiento en categorías funcionales y los análisis de módulos de coexpresión 
consenso apuntan a la implicación conjunta de varios procesos biológicos en las enfermedades del 
SNC y el cáncer que incluyen alteraciones en el sistema inmune, señalización a través de P53, 
respuesta a proteínas no plegadas, señalización a través de MTOR C1, reparación del DNA, ciclo 




 Resultados y conclusiones del objetivo 3:  
No se obtuvieron solapamientos significativos a nivel del interactoma en los módulos de 
enfermedad entre las enfermedades del SNC y el cáncer en ninguno de los análisis efectuados en 
los que se emplearon tres interactomas distintos y listas de genes y variantes asociados a 
enfermedad, construidas empleando criterios de inclusión restrictivos y relajados. Por el contrario, 
sí que se detectaron solapamientos significativos entre parejas de enfermedades del SNC y parejas 
de distiontos tipos tumorales que incluyeron, entre otros, aquellos observados entre TB y DM, DM 
y EZF, cánceres cerebrales y de pulmón y cáncer de pulmón y de ovario. Por su parte, el cómputo 
de correlaciones genéticas basadas en estudios de GWAS produjo correlaciones genéticas 
significativas entre enfermedades del SNC y tipos tumorales específicos, que incluyeron las 
correlaciones negativas observadas entre TEA y los cánceres de próstata  (𝑟  = -0.16, p-val = 7.30e-
03) y mama (𝑟   = -0.1, p-val = 1.60e-02), además de las correlaciones genéticas positivas observadas 
entre TB y cáncer de mama (𝑟  = 0.11, p-val = 6.00e-03), DM y cánceres de mama (𝑟 = 0.09, p-val = 
4.02e-05) y pulmón (𝑟  = 0.28, p-val = 5.00e-04). EP presentó correlaciones genéticas positivas con 
melanoma (𝑟  = 0.14, p-val = 4.00e-02) y cáncer de próstata (𝑟 = 0.09, p-val = 3.16e-02). 
Finalmente, se observaron correlaciones genéticas positivas entre EZF cánceres de mama (𝑟  =  0.14, 
p-val = 1.75e-08) y ováricos (𝑟  = 0.12, p-val = 0.04). Estos resultados sugieren la presencia de 
variabilidad genética compartida asociada a una modulación conjunta del riesgo en determinadas 
parejas de enfermedades del SNC y tipos tumorales específicos. No obstante, la mayor parte de las 
correlaciones genéticas observadas son tenues y las repercusiones potenciales de estos hallazgos a 
la hora de modular las asociaciones epidemiológicas descritas deberá ser objeto de futuras 
investigaciones. 
  Resultados y conclusiones del objetivo 4:  
 El estudio del impacto de los fármacos indicados para el tratamiento de las enfermedades 
del SNC y el cáncer en la modulación de las relaciones de comorbilidad observadas entre ambos 
grupos de enfermedades sugiere que miembros de las familias de los inhibidores selectivos de la 
acetilcolinesterasa, anticonvulsivos, antipsicóticos, antidepresivos y benzodiacepinas, entre otros, 
tienen la capacidad de producir cambios transcripcionales que asemejan o podrían revertir aquellos 
observados en distintos tipos tumorales. Por ejemplo, los perfiles de expresión generados mediante 
el tratamiento de líneas celulares con dos bloqueadores de los canales de sodio, lamotrigina y 
carbamazepina, presentaron correlaciones negativas con los perfiles de expresión diferencial de los 
cánceres de próstata e hígado. Es tratamiento con galantamina, un inhibidor selectivo de la 
acetilcolinesterasa empleado en el tratamiento de EA produce alteraciones transcriptómicas en 
líneas celulares opuestas a las observadas en tumores colorrectales, estomacales y pancréaticos. 
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Por el contrario, el tratamiento con otros fármacos como el ácido valproico produce cambios de 
expresión en líneas celulares semejantes a aquellos observados en distintos tipos tumorales 
incluyendo los cánceres cervicales, hepáticos y pancreáticos. 
 
Palabras clave: comorbilidad, enfermedades del sistema nervioso central, cancer, revisiones 

































Chapter 1. General introduction and objectives of this thesis 
 The study of disease-disease associations is becoming an increasingly important topic in 
biomedical research. The impact of comorbidity, especially in the context of population ageing, and 
the challenge it represents for practitioners and healthcare systems, are compelling the scientific 
community to deeper characterize this phenomenon from multiple perspectives [1]. Epidemiology 
provides insights into how disorders relate to each other, estimates their association’s magnitude, 
and furnishes information about the risk factors contributing to them. Complementary, biomedical 
and molecular research have the potential to explore the underlying biological causes of 
comorbidity, which comprise the presence of shared genetic variability and joint alterations in 
genes and pathways, as well as the possible role of specific medications. 
 Cancer and central nervous system (CNS) disorders are among the top leading causes of 
death and disease burden worldwide. The last decades have witnessed the accumulation of 
observational studies addressed to explore CNS and cancer associations, which have often reported 
inconsistent findings. Consequently, evidence synthesis methods such as systematic reviews and 
meta-analysis have started to be applied to summarize the available data and appraise its quality. 
These ideas have been integrated into the theoretical framework of evidence-based medicine.  
 Furthermore, the emergence of the omics era has led to the unprecedented accumulation 
of data regarding disease’s molecular bases, opening the door to the study of comorbidity from a 
molecular perspective through the identification of joint alterations in variants, genes, and 
biological processes. 
 In the following sections, we introduce the concept of comorbidity and its causal 
mechanisms and describe the tools used to study it from both an epidemiological and a molecular 
perspective.  
1.1 The concept of comorbidity and its related constructs. 
 Alvan Feinstein first coined the term comorbidity in an article published in 1970 [2]. He 
initially formalized it as "Any distinct additional entity that has existed or may occur during the 
clinical course of a patient who has the index disease under study". Feinstein's seminal definition 
implied a reference disorder linked to other secondary conditions that could take place at different 
points in the temporal dimension of the patient's life. In his view, at that time, clinical sciences were 
paying little attention to disease-disease inter-relationships and their effect on individuals. He also 
expressed his preoccupation with the potential impact that comorbidity could produce in clinical 
trials’ outcomes if information regarding it was neglected.  
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 Feinstein classified comorbidities in the following groups: ancestral if a preexisting disease 
was converted into the index disease, supervening if the secondary condition was caused by a new 
pathologic process that was predisposed by anatomic effects of the index disease at the primary 
site, and derivative if the comorbid disorder was produced by the dissemination of the same 
pathologic process present in the index disease. 
 Fifty years later, new concepts linked to the idea of comorbidity have emerged, including 
multimorbidity, the burden of disease, and frailty, among others. Each term provides a slightly 
different conceptualization of the general idea of disease-disease association that differs in the 
description of some of its features (i.e., the nature of the health conditions, their relative 
importance, and their chronology) and is used preferentially by different sets of professionals, 
including researchers, physicians, and policymakers. 
 Expanded conceptualizations have also been created. An important example is the one 
provided by the comorbidity burden [3], which is defined as the total amount of disease load 
present on an individual. Different measures to quantify it have been developed, including the 
Charlson’s Index [4], the Cumulative Illness Rating Scale (CIRS) [5], and the Index of Coexisting 
Disease (ICED) [6]. Finally, the term patient’s complexity [7] adds to the comorbidity burden idea 
the effects of several factors (i.e., socioeconomic, cultural, environmental, behavioral). 
 The comorbidity picture has been completed in recent years with the introduction of the 
term inverse comorbidity. Contrary to direct comorbidity, which is defined as a higher-than-
expected probability of disease occurring in individuals who have been diagnosed with other 
medical conditions, Inverse comorbidity is defined as a lower-than-expected probability of disease 
occurring in individuals who have been diagnosed with other medical conditions [8]. A close 
examination of of both direct and inverse comorbid associations could help to better understand 
the interplay between disorders and to gain insight into each disorder's physiopathological 
processes [9]. 
 Some authors have pointed out that the heterogeneity of the available concepts is 
confusing and have advocated for a systematic reformulation of these ideas. Interesting reviews of 
this topic are available in references [10] and [3]. One of the causes of ambiguity is that most of the 
available terms can be seen from two different perspectives (i.e., the individual and the population). 
For instance, in some disciplines such as epidemiology, comorbidity is observed from a population 
rather than a patient’s perspective. In this context, the critical element is to determine if a given 
pair of disorders co-occur in populations in frequencies that deviate from what is expected by 
chance. In contrast, from the medical practitioner’s point of view, comorbidity is a patient-centered 
phenomenon in which chronology is essential and directly influences patient management, 




to note that epidemiological studies can present different designs. In this context, there is a clear 
distinction between prevalence and incidence studies. In prevalence studies, exposures and 
outcomes are measured simultaneously, disregarding aspects, such as the chronology in which 
conditions appear. In contrast, incidence studies focus on new cases of a particular outcome in a 
specific population allowing researchers to study causal associations.  
1.2 Potential causes of direct and inverse comorbidity 
 Comorbidities can arise as a consequence of diverse causes [3]. First, two or more disorders 
can be observed in the same patient simply by chance. Comorbid association due to chance can be 
identified at a population level when the frequency of their joint manifestation does not deviate 
from the product of the individual frequencies. The second mechanism by which comorbidities can 
be observed is the presence of systematic biases in epidemiological studies. For instance, selection 
bias arises because patients seeking medical attention present an increased likelihood of receiving 
a diagnosis of additional conditions. In other instances, a particular disorder’s specific features 
could make patients less prone to seek medical care. This could result in the observation of a 
negative association between a given pair of diseases. Besides, systematic biases also include the 
lack of account for important confounding factors in epidemiological research, which could distort 
the results of observational studies and meta-analysis. In the cases of chance and systematic bias, 
the observed comorbidities do not indicate shared etiological factors. 
 Comorbidity can also emerge due to causal associations that can be divided into different 
categories. First, direct causation implies that disease A is responsible for increasing or decreasing 
the likelihood of developing disease B. Mechanisms involved in direct causation include shared 
genetic variability, such as in the case of the direct association found between type I diabetes and 
celiac disease [11], joint alterations in higher levels of biological organization, such as pathways, 
cell types, tissues, or organs, and pharmacological treatment's potential effects. The decreased risk 
of colorectal cancer observed in patients treated with high doses of selective serotonin reuptake 
inhibitors and [12] and the reduced cancer mortalities reported in patients with alcohol addiction 
treated with disulfiram [13] provide two examples of the latter. In the second place, causal links 
can also be due to the presence of associated risk factors. Environmental or behavioral correlated 
risk factors can be the cause of disease-disease associations. In this model, risk factors linked to 
disease A are correlated to disease B’s risk factors, increasing the risk of both disorders. For 
instance, smoking and alcohol consumption are correlated risk factors that increase the risk of 
chronic obstructive pulmonary disease and liver disease, respectively. In other instances, risk 
factors are not correlated to each other, but each one can modulate the risk of specific disorders 
linked to the other. For instance, smoking and age are not correlated but are independent risk 
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factors for both cardiovascular disease and cancer. Besides, the presence of disease A could 
modulate the exposure of risk factors for disease B. For instance, neuropsychiatric patients are at a 
higher risk of being heavy smokers, increasing the likelihood of certain types of cancer, such as lung 
cancer. Finally, it is also possible that a given pair of associated diseases are not directly linked but 
are both due to the presence of a third disease. 
1.3 The study of comorbidity using systematic reviews and meta-analyses of 
epidemiological data 
 The first known reported observation about the association of two conditions is due to 
Hippocrates, who noted that fever alleviated psychotic disorders [14]. Since this early finding, the 
study of comorbidity gradually developed with significant advances concentrating in the second 
half of the twentieth century. In 1909 the Commissioners of Lunacy for England and Wales reported 
that psychiatric patients appeared to be relatively immune to cancer, which constituted the first 
known association between a central nervous system (CNS) disorder and cancer [15]. A gap of more 
than 70 years separates this early event from the first epidemiological study on the topic in which 
Shekelle and co-workers observed that depressed patients presented a twofold increase of death 
from cancer [16].  
 Posterior decades have witnessed a gradual increase in the number of published studies 
aiming to characterize the associations between CNS disorders and cancer and the improvement of 
their sample sizes and statistical methods. Nevertheless, results have often led to contradictory 
conclusions, probably, as a consequence of the heterogeneity present in study designs and the 
limitations imposed by this particular research question, which relies on observational studies and 
cannot be addressed using more sophisticated forms of medical research such as randomized 
controlled trials [17].  
 The inconsistencies mentioned above claimed for methods that allowed researchers to 
synthesize and appraise the available evidence. In this context, systematic reviews and meta-
analyses were introduced as analytical tools that allow to summarize the available data from a 
particular research question. 
 British statistician Karl Pearson published the first report including methods for combining 
the outcomes from different studies. In his work about enteric fever inoculation, he synthesized 
correlation estimates derived from different studies and provided combined significance measures. 
In the 20’s Ronald Fisher, who was working on agricultural research, further developed methods 
for study combination and introduced the ideas of publication bias and heterogeneity. Later, one 
of Fisher’s co-workers, William Cochran, created the theoretical framework of random-effect 




analysis of an extensive collection of results derived from various individual studies. Soon after, 
meta-analytical methods started to be applied in clinical research. For instance, through a 
quantitative combination of the results of previous trials Peter Elwood and Archie Cochrane 
observed that patients treated with aspirin were at a reduced risk of heart attack [18].  
 Since then, evidence synthesis methods have continued to evolve and have been integrated 
into an epistemological framework known as evidence-based medicine, emphasizing the use of 
evidence derived from well-designed research to inform and optimize decision-making. One core 
element of the field is the classification of evidence according to its epistemological strength and 
the requirement that only the most substantial types, which are those derived from systematic 
reviews, meta-analysis, and randomized control trials, are employed to guide the clinical decision.  
 A systematic review can be defined as “the application of strategies that limit bias in the 
assembly, critical appraisal, and synthesis of all relevant studies on a specific topic” [19]. The 
concept meta-analysis refers to the use of statistical methods that combine the results of multiple 
scientific studies. Since meta-analysis methods applied to the integration of observational and 
transcriptomic data are a core part of chapters 2 and 3 of this thesis, we will briefly review them. 
Therefore, we will present the two main statistical models employed in a meta-analysis, Fixed Effect 
Models (FEM) and Random Effect Models (REM). The variations of these methods developed to 
analyze transcriptomic data will be described in Section 1.5.  
 Fixed effect models (FEM) 
 Fixed effects models assume that the studies’ effect sizes included in a particular meta-
analysis are drawn from a distribution with true effect size 𝜇 and variance 𝜎 . Therefore, each effect 
size 𝑂  can be decomposed as the sum of two terms: 𝑂 =  𝜇 +  𝜖 , where 𝜇 is the true underlying 
effect, an 𝜖  is an error term which measures how much 𝑂  deviates from 𝜇 (Figure 1A). The pooled 
effect computed through FEM is an estimate of this true underlying effect 𝜇. Under FEM weights 
are assigned to each study based on the inverse of the variance method. Therefore, the weight of 
study 𝑖, denoted 𝑊 , is defined as the reciprocal of its variance (Figure 1C eq.2). The pooled effect 
size estimate is then computed, as shown in Figure 1C eq. 3, which involves a quotient between the 
summation of the effect sizes multiplied by their respective weights the weights’ summation. The 
pooled effect size variance is computed as the reciprocal of the summation of weights (Figure 1C 
eq. 4), and the standard error as the square root of the variance Figure 1C eq.5. The confidence 
intervals for the estimated pooled effect size are finally computed from the standard errors (Figure 






 Random effects model (REM) 
 Contrary to the fixed effects model, the random effects model allows the true underlying 
effect to vary between studies. In other words, instead of a single true effect size, we start from a 
distribution of true effect sizes. This model better captures the inherent heterogeneity of 
observational studies, which do not present identical designs and often differ on the disposal of 
different covariates (i.e., the age and gender proportion of the studied population, the instruments 
employed to carry out diagnosis, the smoking status). Those covariates could influence the 
magnitude of the observed effect sizes. Therefore, the combined effect obtained when applying 
REM represents the mean of the distribution of true effects. Let’s assume 𝑂  to be the observed 
effect size derived from a particular study. 𝑂  is determined by the true effect 𝜃  plus the within-
study error 𝜀 , and 𝜃  is, in turn, determined by the mean of all true effects 𝜇, and the between-
study error ζ  (See Figure 1B). Thus, any observed effect 𝑂  can be decomposed as depicted in 
Figure 1D eq.1. 
 As we have seen, under the random-effects model, there are two levels of sampling and 
two levels of error. The true effect sizes 𝜃 are distributed arround 𝜇 with variance τ  and the 
observed effect 𝑂  for a given 𝜃  is distributed around 𝜃  with variance 𝜎 . 𝜎  depends on the 
sample size of that particular study. In the process of estimating 𝜇, we will need to deal with both 
sources of sampling error. Therefore, an important aspect of REM is to decompose the observed 
variance into its two components, within-studies, and between-studies variances. This is achieved 
by computing the total variance (observed variance) and the within-studies variance (𝜎 ). Then, the 
between-studies variance (τ ) is computed as the difference between the two previous values. 
 The total variance, denoted as 𝑄is computed according to the formula displayed in Figure 
1D eq.2. In short, the sum of the squared deviations of each study 𝑂  to the combined mean 𝑂⦁ is 
computed and weighted by the inverse of the variance (𝑊 ) of each study. According to this 
equation, larger studies deviating from the mean will have more impact on 𝑄 than smaller studies. 
 If the only source of variance contributing to the total observed variance was within-study 
error, then the expected value of 𝑄 would be equivalent to the degrees of freedom for the meta-
analysis, which is defined to be the number of included studies minus one. 𝑑𝑓 =
(𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑆𝑡𝑢𝑑𝑖𝑒𝑠) − 1. Therefore, we can compute the between-study variance τ , as 
depicted in Figunre 1. D) eq.3. The numerator 𝑄 – 𝑑𝑓, represents the excess variance, and the 
denominator C is a scaling factor that deals with the fact of 𝑄 being a weighted sum of squares and 
ensures that 𝜏  is computed in the same metric as the within-study variance (See Figure. 1D eq. 4). 
 Next, each study is weighted based on the inverse of its variance. As we have already seen, 




variances. Figure 1D eqs. 5 6, and 7 are used in order to calculate the combined effects under 
random-effects models weighted by their variance.  
 Finally, the variance and the standard error of the combined effect are computed, as shown 
in Figure 1D eqs. 8 and 9, which will be in turn used to compute the confidence intervals as depicted 
in Figure 1D eqs.10 and 11. 
 In the present thesis, random effect models were selected a priori to synthesize the 
epidemiological evidence of the associations between CNS disorders and cancer since high levels 
of heterogeneity were expected due to the presence of differences in study designs, diagnosis 
























Figure 1: Equations used to carry out fixed and random effects model meta-analyses in Chapters 2 and 
3. A) Fixed effects model design. B) Random effects model design. C) Equations used for FEM meta-
analysis of observational studies. D) Equations used REM meta-analysis of observational studies E) 




 In 1994, McGee and co-workers reported the first systematic review and meta-analysis 
aimed to summarize the available evidence of the associations between a CNS disorder and cancer. 
They described a positive but not significant link between depression and later development of 
cancer [20]. However, it was not until the late 2000’s when most systematic reviews and meta-
analyses focusing on this topic started to appear. 
 To date, the work of Catalá et al. [21] constitutes the most exhaustive systematic review 
analyzing the epidemiological associations between CNS disorders and cancer. In summary, the 
authors observed that CNS disorders were associated with a decrease in overall cancer risk, which 
was especially evident in the case of patients with neurodegenerative disorders. In addition, some 
CNS diseases were also found to be associated with an increased risk of several site-specific cancers 
(See Section 2.1). This fact, together with the lack of sufficient data characterizing all possible CNS 
and site-specific cancer associations, has compelled the scientific community to keep characterizing 
this phenomenon with the publication of new observational studies that should be integrated with 
previous data through systematic reviews and meta-analysis. 
1.4 The study of comorbidity from a molecular perspective 
 The history of the molecular study of disease starts in 1949 with the identification of Sickle 
cell anemia as a molecular disorder by Linus Pauling and collaborators [22]. They observed that the 
structural features of sickle cells were due to the presence of an abnormal form of hemoglobin. 
Soon after their discovery, Pauling claimed:  
‘…our structural chemistry and understanding of molecules is getting to the point in which it should 
be of assistance in converting medicine into a real science’.  
 He was right. His work served to inaugurate a new research field that was the germen of 
what is currently known as biomedical research. After his discovery, unprecedented advances in 
the area of molecular biology propelled the molecular study of disease. DNA structure was solved 
in 1953 by Watson and Crick thanks to the DNA crystal structure obtained by Rosalind Franklin, 
Arthur Kornberg isolated DNA polymerase in 1955, and Crick proposed the central dogma of 
molecular biology in 1958. Soon after, in 1961, Crick, working with Sydney Brenner, suggested that 
each amino acid was encoded by a group of three nucleotide bases that were called a codon. 
Messenger RNA (mRNA) was discovered in 1961, as well as the function of the ribosome as a protein 
building machine. 
 Technical advances played a pivotal role in the discoveries that took place in further 
decades. Sanger and co-workers developed the chain termination sequencing method between 
1975 and 1977. In 1985 Kray B. and Mullis created the polymerase chain reaction technique (PCR). 
Things scaled up from the nineties onwards after the completion of the human genome project in 
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2004, and the emergence of several analysis methods such as the quantitative PCR (qPCR) and the 
irruption of techniques that produced genome-scale information such as gene expression 
microarrays, comparative genomic hybridization (CGH) arrays, methylation arrays, and the more 
recent next-generation sequencing techniques. 
 Those breakthroughs have profoundly impacted the understanding of biology and disease 
and are at the core of the transition of the study of diseases as single entities to the study of the 
molecular bases of comorbidity [23].  
 The first genomic regions linked to disease date from the 80s. The application of linkage 
analysis allowed researchers to map the gene responsible for Huntington’s disease in 1983 [24], 
and the Duchenne muscular dystrophy and cystic fibrosis genomic locations were identified in 1987 
and 1989, respectively [24, 25]. In the case of Huntington’s disease, the transition from linkage 
studies to the effective identification of the underlying pathogenic mutations took about a decade 
[26]. 
 It has been estimated that in the period comprehended between 1980 and 2000, the 
molecular bases of about 1000 Mendelian disorders were identified. These numbers were 
multiplied by three in the first decade after the completion of the Human Genome Project [23].  
 The introduction of next-generation sequencing techniques also greatly impacted the 
research of the molecular bases of disease. For instance, only one year after the introduction of the 
exome sequencing techniques in 2009, the genetic causes of Miller’s syndrome were established 
[27]. 
 The study of the molecular bases of complex disorders has proven more challenging. 
Advances in this field have been driven by the technical and conceptual developments in high-
throughput genotyping technologies and improvements in the knowledge of the patterns of linkage 
disequilibrium (LD) present in human populations [28]  
 At the present time, the GWAS catalog, a database of published genome-wide association 
studies, contains 138312 phenotype variant associations retrieved from 3989 publications. 
However, in the case of complex diseases, the discovered variants usually confer only a small 
increase in risk. In general, GWAS has failed in identifying disease genes presenting large effects. 
The concept of missing heritability describes the fact that single genetic variation only accounts for 
a small fraction of the heritability of complex disorders [29]. Some potential causes have been 
invoked to explain this phenomenon, including the role of rare and structural variants that are not 
represented in GWAS studies [29] and the inaccuracy of heritability estimates due to the effect of 
gene-gene interactions [30].  
 As we have seen, the development of molecular biology and the omics methods have 




shift from the study of single diseases to disease-disease associations from the molecular point of 
view has also started to take place powered by data accumulation regarding the molecular bases 
of individual disorders. Many open-access platforms that store gene-disease association, variant-
disease association, and omic data repositories are now available online, including the Online 
Mendelian Inheritance in Man (OMIM), The Genome-Wide Association Studies Catalog (GWAS 
catalog), the Gene Expression Omnibus (GEO), Array Express (AE) and The Cancer Genome Atlas 
(TCGA). 
 In 2007 Goh and co-workers presented the first large-scale study design to uncover disease-
disease associations based on molecular data [31]. Using the information about disease-associated 
genes available in OMIM, they created a bipartite graph containing two kinds of nodes (diseases 
and genes). The resulting graph was called human diseaseasome. They observed that it was highly 
interconnected, with most disorders having a link to at least another disease. In addition, links 
between diseases were not random, and diseases with similar pathophysiology tended to form 
clusters. Genes associated with the same disease were found to encode proteins that were more 
likely to interact with one another, shared more gene ontology terms, and were prone to be 
expressed in the same set of human tissues. 
 Several exiting extensions of the human disease network have been developed. Based on 
the disease module hypothesis, which models a disease as a result of the perturbation in a specific 
functional module, and using interactome-based distances and sets of genes linked to disease, 
Barabási and co-workers determined that diseases with overlapping network modules presented 
significant co-expression patterns, symptoms similarity, and comorbidity values [32]. Another 
interesting instance is the creation of the drugome, which consists of a bipartite network combining 
the set of available drug chemicals and their target genes [33]. The study of the drugome, in 
combination with the diseasome, provided some interesting insights. The authors noted that 
available drugs tend to concentrate in specific regions of the diseasome and that the majority of 
existing drugs target genes far away from the disease-causing genes, which suggests that most of 
them were developed for palliative treatment rather than curative. This approach also opened a 
door for interesting practical applications such as drug repurposing. 
 In a follow-up article published in 2012, Goh and co-workers proposed a roadmap to the 
complete diseasome that should integrate several types of data, including information derived from 
transcriptomic studies, disease-drug interactions, the influence of environmental factors, metabolic 
links, interactome-based measures of association, and genetic links [30]. 
 Despite the importance of the studies mentioned above, most molecular approaches to the 
study of disease-disease associations have neglected the idea of inverse comorbidity.  
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 Only a handful of works addressing the topic of CNS and cancer associations from the 
molecular perspective have been published to date. In 2014 Ibañez and co-workers reported that 
epidemiological data describing inverse comorbid patterns of association between three CNS 
disorders (schizophrenia, Alzheimer’s disease, and Parkinson’s disease) and three cancer types 
(colorectal cancer, lung cancer, and prostate cancer) translated into opposite patterns of 
differentially expressed genes [34]. In other words, according to the authors, genes that tended to 
be upregulated in CNS disorders were found to be downregulated in cancer and vice versa. Altered 
expression in genes such as PIN1 and ATP13A2 and pathways, such as P53 signaling, Wnt, and 
folding and protein degradation pathways were identified as potential agents modulating some of 
the reported associations.  
 More recently, in 2017, using a similar methodology, Sanchez and co-workers identified 
potential molecular substrates that could underlie both the direct and the inverse epidemiological 
associations found between AD and glioblastoma and AD and lung cancer, respectively [35]. Their 
results suggested that immune system-related processes and mitochondrial metabolism could 
constitute the molecular substrates of the direct epidemiological associations observed between 
AD and glioblastoma and the inverse epidemiological associations between AD and lung cancer, 
respectively. 
 As Ibañez and Sanchez work, Chapter 3 of the present thesis is also based on differential 
gene expression meta-analysis methods. Therefore, we will briefly introduce them.  
 Differential gene expression meta-analyses 
 The differential gene expression analyses carried out in this thesis are based on Choi’s 
method [36]. For each available transcriptomic dataset, the differences in gene expression between 
cases and controls are computed using an estimator for the standardized mean denoted as 𝑑, which 
is computed as shown in Figure 1E eq. 1, where 𝑋  and 𝑋  represent the gene expression means 
of the diseased tissue and the healthy tissue, respectively, and 𝑆  is an estimated of the pooled 
standard deviation. An unbiased estimate of 𝑑, denoted as 𝑑  is obtained using the following Figure 
1E eq.2 formula and its variance computed as shown in Figure 1E eq.3. Where 𝑛  and 𝑛  are the 
disease and control group sample sizes, respectively. As in the case of the meta-analysis of 
observational studies, a random-effects model was selected to combine the outputs of the available 
study since high between-study heterogeneity was expected. Let 𝑦  be the observed effect size for 
independent studies 𝑖 = 1,2, … , 𝑘.  The observed 𝑦  is derived from the model presented in Figure 
1E eqs. 4 and 5. Where 𝜇 is the overall mean (i.e., the average measure of differential expression 
across the datasets for each gene), 𝜏  represents the between-study variability, and 𝑠  is the 




we have seen under FEM, the differences in effect sizes observed between different studies are 
due to sampling error alone. Therefore, under FEM, 𝜏  = 0. In consequence, 𝑦  ~𝑁( 𝜇, 𝑠 ). On the 
other hand, under REM, each effect size is supposed to be drawn from a distribution with mean 𝜃  
and variance 𝑠 , in turn, each 𝜃  is assumed to be drawn from a superpopulation with overall mean 
𝜇 and variance 𝜏 . Figure 1E eqs. 6 and 7 show the equations used for estimating ?̂?(𝜏 ) and its 
variance ,𝑉𝑎𝑟[?̂?(𝜏 )], respectively. Both equations depend upon the computation of 𝜏 .  𝜏  is 
estimated by applying the method of moments developed by DerSimonian and Laird presented in 
Figure 1E eq. 8 and is denoted as ?̂?  which in tur is based on 𝑄, a widely used statistic for between-
study homogeneity computation proposed by Cochran in 1954 (See Fiugre 1E eq. 9) and 𝑆  (Figure 
1E eq. 10). The computation of 𝑄 and 𝑆  depend upon the values of 𝑤  and ?̂?.  ?̂? is the the weighted 
least squares estimator, which ignores between-study variance (Figure 1E eq. 11) and 𝑤  is defined 
as depicted in Figure 1E eq. 12. Finally, the Z statistic is computed as the ratio of ?̂?(𝜏 ) over its 
standard error and the significance of the Z statistics is computed by the generation of empirical 
distributions by random permutations.  
 Finally, other approaches have also been developed to explore CNS and cancer associations 
from the molecular perspective. An interesting instance is the one provided by the work of Jane 
Driver and co-workers [37]. Making use of GWAS summary statistics and a method called cross-trait 
LD score regression, they found significant genetic correlations between AD and breast and lung 
cancer [38], suggesting that shared genetic variability could be involved in the modulation of their 
comorbid associations. 
1.5 Characteristics of the CNS disorders and cancers studied in this thesis 
 Epidemiological and molecular associations between seven CNS disorders (Alzheimer’s 
disease (AD), autism spectrum disorders (ASD), bipolar disorder (BD), Huntington’s disease (HD), 
major depression (MD), Parkinson’s disease (PD), and schizophrenia (SCZ)) and cancer were 
investigated and integrated into the present thesis. This section provides a description of the 
included disorders. The selection of the diseases was based on their relevance as medical entities 
and the feasibility to perform the differential gene expression meta-analyses counterpart of the 
study presented in Chapter 3 due to data availability constraints.  
 Alzheimer’s disease 
 AD is the most prevalent neurodegenerative disorder of aging people and constitutes 
almost 70% of cases of dementia, with over 50 million affected patients worldwide [39]. Core AD 
symptoms include memory loss and cognitive impairment, but additional symptoms such as 
problems with language, disorientation, and mood changes are also present. Genetically, AD is 
divided into familial and sporadic cases. Familial AD represents less than 1%, and it has been linked 
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to autosomal dominant mutations in the amyloid precursor protein (APP), presenilin 1, (PSEN1), or 
presenilin 2 (PSEN2) [40]. By its side, sporadic AD constitutes more than 90% of cases. APOE has 
been identified as a susceptibility gene for AD. In particular, the presence of one of its three 
common polymorphisms (epsilon 4) is linked to an increased risk of AD. Both types of AD share a 
set of neuropathological manifestations, including the accumulation of misfolded and aggregated 
proteins, the deposition of senile plaques in the extracellular space formed by β-amyloid peptides 
and the intracellular formation of neurofibrillary tangles of which hyperphosphorylated tau protein 
is a major constituent [40]. The accumulation of Aβ aggregates eventually triggers a cascade of 
cellular changes, including mitochondrial oxidative damage, tau hyperphosphorylation, synaptic 
failure, and inflammation, which is associated with the loss of synapses and neuronal death, initially 
in focal areas including the entorhinal cortex and hippocampus and ultimately more broadly in the 
cortex [41]. 
 Autism spectrum disorders 
 The estimated prevalence of ASD in developed countries is 1.5% [42]. ASD affects more 
than 24 million individuals worldwide [43]. Disease onset is situated around the second or third 
year of life, and it is four times more frequent in males than in females [42]. The heritability of the 
disease based on twin studies is 0.7 [44]. ASD symptoms include impairment in social interactions, 
communication deficits, patterns of restricted interests, and repetitive behaviors. In some cases, 
episodes of self-injury are also present [45]. ASD is often associated with other conditions such as 
intellectual disability, attention-deficit/hyperactivity disorder (ADHD), anxiety disorder, and 
epilepsy [45].  
 Two forms of ASD (syndromic and idiopathic) have been described. Syndromic ASD, which 
represents between 3% and 5% of ASD cases, is regarded as the behavioral manifestation of known 
monogenic disorders, including type 1 neurofibromatosis, fragile X syndrome, tuberous sclerosis 
syndrome, and Rett syndrome, among others, which are driven by mutations in the NF1, FMR1, 
TSC1, and MECP2 genes respectively [46]. Idiopathic ASD represents more than 80% of cases and is 
linked to other genetic variability sources such as common variation and recurrent copy number 
variants [47]. Several cellular and tissular alterations have been observed in ASD patients, including 
an excess of neurons that lead to over connection of specific brain areas, impaired neuronal 
migration, unbalance in excitatory and inhibitory networks, and alterations in synapses and 
dendritic spines due to changes in adhesion molecules. Other biological processes such as 
peripheral and central nervous system inflammation with increased pro-inflammatory cytokines 
and microglial activation [48-50] have been linked to ASD. A proportion of ASD patients present 
macrocephaly and faster brain growth than control children. This event is often followed by regular 




 Bipolar disorder 
 Bipolar disorder is a neuropsychiatric disease characterized by the alternation of periods of 
depression with periods of mania or hypomania, which are defined as situations of abnormally 
elevated mood [51, 52]. Changes in energy and activity usually follow these mood transitions. The 
presence of mania or hypomania divides BD diagnosis in BD type I or BD type II, respectively. BD 
prevalence is around 0.6% for BD type I, and 0.4% for BD type II, and the median age of disease 
onset is 25 years [53]. The overall heritability of the disease has been estimated to be 0.71 [54]. 
Imbalances in neurotransmitters concentrations have been suggested to be an important factor in 
the disease, including alterations in dopamine and glutamatergic transmission [55-57]. Bipolar 
disorder is regarded to be a complex disease for which GWAS studies have only found variants 
presenting small effect sizes. In addition, BD GWAS studies have often shown inconsistent 
outcomes [58-60]. Alterations in several biological pathways have been linked to the disease, 
including glutamate receptor signaling and Wnt and Notch signaling, among others [61]. 
 Major depression 
 According to DSM-VI [62], MD diagnosis requires the presence of at least five symptoms of 
the following list for a two weeks period: 1. Depressed mood most of the day (i.e., feels sad, empty, 
hopeless), 2. Markedly diminished interest or pleasure in almost all activities nearly every day, 3. 
Significant appetite changes or significant weight loss or gain, 4. Insomnia or hypersomnia nearly 
every day, 5. Psychomotor agitation or retardation, 6. Fatigue or loss of energy, 7. Feelings of 
worthlessness or excessive guilt, 8. Diminished ability to think or concentrate or indecisiveness. In 
the USA, the lifetime prevalence of MD has been estimated to be 16% [63], whereas worldwide 
estimates suggest that it affects more than 350 million people [64]. Classical hypotheses have 
attributed depression to functional imbalances and deficiencies in monoamine-series 
neurotransmitters, including dopamine, serotonin (5-HT), and norepinephrine (NE). According to it, 
the depletion of serotonin and norepinephrine in the synapse triggers the development of 
depressive symptoms. These views have been supported by the outcomes of treatments with 
selective serotonin reuptake inhibitors (SSRI) [65]. Several alternative and complementary 
hypotheses have also been proposed in order to explain some phenomena linked to depression 
that cannot be explained by the monoamine hypothesis [66]. In general, studies have reported 
limited success in finding MD-associated variants, although some genes have been linked to the 
disease, including serotonin transporter SLC6A4, Piccolo presynaptic cytomatrix protein (PCLO), and 






 Huntington’s disease 
 Historically known as Huntington’s Chorea, HD is characterized by early symptoms such as 
mood problems and cognitive dysfunction, followed by a general lack of coordination and a random 
and uncontrollable movement at later stages [67]. As the disease progresses to its most advanced 
phases, it also leads to dementia [68]. HD prevalence has been estimated to be 2.71 per 100,000 
(95% CI: 1.55-4.72) worldwide [69]. Disease onset takes place between the third and the fifth 
decade of life [68], with about 10% of the patients showing disease onset before the age of 20 [70]. 
HD is a monogenic disease caused by an autosomal dominant mutation in the Huntingtin gene (HTT) 
located on chromosome 4, which consists of an expansion of a cytosine-guanine-adenine triplet 
that results in an abnormal protein that triggers the cascade of events that result in neuronal 
damage. The repeated codon encodes for the amino acid glutamine, and its expansion generates a 
polyglutamine tract in the resulting protein. Sequences containing more than 36 glutamines 
produce proteins with altered properties. Thirty-six to thirty-nine repeats result in a reduced-
penetrance form of the disease, whereas very large repeat counts are associated with a full 
penetrance form of HD. In addition, the length of the polyQ expansion is inversely correlated with 
the age of disease onset. The mutated version of the HTT gene first produces damage on the 
striatum and other cerebral areas, including the substantia nigra,  layers 3, 5, and 6 of the cerebral 
cortex, and the hippocampus [67], and it is linked to the presence of alterations in several biological 
processes such as the mitochondrial function, immune system-related processes, high astrocyte 
counts and microglia activation [71, 72]. 
 Parkinson’s disease 
 PD is characterized by the presence of motor and non-motor symptoms such as resting 
tremor, postural instability, rigidity, bradykinesia, slight depression, constipation, fatigue, sleep 
disturbances, and hyposmia. Cognitive impairment increases as the disease progress [73]. It is the 
second more prevalent neurodegenerative disorder affecting more than 2% of the population older 
than 65 years [74]. Two types of PD, hereditary, and idiopathic have been identified. The first 
represents 15% of PD cases, and it is caused by mutations in specific genes such as SNCA (PARK1), 
LRRK2 (PARK8), and Parkin (PARK2), among others [75, 76]. The second comprises most PD cases, 
and it is thought to be prompted by interactions between genetic and environmental risk factors. 
PD neuropathological hallmarks include dopamine reduction in the basal ganglia due to neuronal 
death in the Substantia Nigra pars compacta (SNpc) and the presence of abnormal intra-cytoplasmic 
deposits called Lewy bodies (LB), which are protein aggregates where the major component is 
alpha-synuclein associated with other proteins [77, 78]. Alterations in several biological processes 




protein homeostasis dysregulation, impairments in the ubiquitin-proteasome system, and 
lysosomal-mediated autophagy, and neuroinflammation, among others [73].  
 Schizophrenia 
 Schizophrenia is a neuropsychiatric illness defined by three groups of symptoms, positive, 
negative, and cognitive. Positive symptoms include delusion, disorganized thoughts and speech, 
and hallucinations. Negative symptoms are deficits in the normal emotional response, such as little 
emotion, poverty of speech, anhedonia, and lack of motivation. Cognitive abilities are also impaired 
in SCZ patients, with deficient working and long-term, verbal declarative memory, semantic 
processing, and attention insufficiencies. SCZ affects 1% of the population, and it is linked to poor 
vital outcomes. It presents a heritability estimate of 0.81 [79]. The dopaminergic hypothesis states 
that SCZ is characterized by alterations of the dopamine neurotransmission in the mesolimbic 
system, which would be responsible for the positive symptoms and in the mesocortical pathway 
that would cause negative symptoms. Structural brain alterations such as the enlargement of the 
third and lateral ventricles and the reduction in total brain and grey matter volume have also been 
reported in SCZ patients. GWAS studies have identified several common SCZ risk alleles presenting 
weak individual effects in SCZ risk (OR < 1.2). Based on these studies, SCZ has been established to 
be a polygenic disease involving a thousand common alleles [80]. Advances in the last decade have 
helped in the identification of de novo mutations, rare copy number variation (CNV), rare single 
point nucleotide variants, and small insertion/deletion and single nucleotide polymorphisms [81]. 
 Cancer 
 Only in 2017, 24.5 million cases of cancer incidence and 9.6 cancer deaths were observed 
worldwide. Cancer incidence was found to be on the rise in the period comprehended between 
2007 and 2017. The top five site-specific cancers ranked by incidence were nonmelanoma skin 
cancer, tracheal, bronchus, and lung, breast, colorectal, and prostate cancers [82]. 
 Cancer is a heterogeneous disease, and a detailed description of the specific characteristics 
of the complete set of cancer types included in this thesis is out of the scope of this introduction. 
Thus, we will summarize the main characteristics of cancer pathogenesis. 
 In 2000, Douglas Hanahan and Robert A. Weinberg gathered the available evidence about 
the mechanisms involved in cancer pathogenesis and hypothesized that the variety of cancer 
manifestations would be due to six essential alterations in cell physiology, termed “The Hallmarks 
of Cancer” [83]. The first hallmark is based on the acquisition of cancer cells of self-sufficiency in 
growth signals. In healthy cells, growth is modulated by the presence or absence of exogenous 
growth factors (GFs). Cancer cells display different strategies to overcome this limitation. For 
instance, some cancer cells are able to synthesize the very growth factors to which they are 
responsive (e.g., glioblastomas produce platelet-derived growth factor PDGF). Cell surface 
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receptors, which are responsible for transducing the signals delivered by GFs, are also modified in 
cancer. For example, the HER2/neu receptor is overexpressed in a subset of mammary carcinomas. 
Finally, alterations in intracellular transducer systems, such as SOS-Ras-Raf-MAPK are also found in 
cancer. The second hallmark consists of if the acquisition of insensitivity to growth-inhibitory 
signals. Healthy cells are responsive to antiproliferative signals which function is to maintain cellular 
quiescence by arresting them in the G0 phase of the cell cycle or by inducing them to enter 
postmitotic differentiated states. Examples of these hallmarks include tumor suppressor genes such 
as RB and TP53, which are responsible for the transduction of extracellular and intracellular growth-
inhibitory signals, respectively, which are frequently disrupted in cancer cells. The third hallmark 
implies the development of mechanisms that allow cancer cells to evade programmed cell death 
(i.e., apoptosis). Intracellular and extracellular conditions cell conditions are monitored by sensors 
that regulate apoptotic effectors that can trigger programmed cell death when conditions require 
it. When pro-apoptotic signals are produced, the mitochondria respond by liberating the 
cytochrome C, a process mediated by the Bcl-2 protein family. P53 mediates apoptosis in response 
to DNA damage through the upregulation of the Bax pro-apoptotic factor, and it is found frequently 
mutated in most cancers representing a common mechanism of apoptosis resistance acquisition. 
The fourth hallmark involves the acquisition of limitless replicative potential. A cell-autonomous 
program limits the number of divisions that a cell can undergo in many normal mammalian cell 
types. This finite replicative potential ends with a phase called senescence, which can be 
circumvented by pRb and p53 inactivation. If those genes are inactivated, cells continue replicating 
until they reach a stage called crisis characterized by massive cell death, karyotic disarray, and 
chromosomes end-to-end fusions. This second stage is thought to be controlled by telomere length. 
Progressive telomere shortening takes place in each replication round, which implies a loss of 50 to 
100 bp. Eventually, this progressive erosion causes the loss of telomere capacity to protect the 
chromosome ends, leading to the chromosome fusion associated with the crisis stage. Cancer cells 
upregulate telomerase, an enzyme that catalyzes telomere extension to circumvent this problem. 
The fifth hallmark implies the acquisition of sustained angiogenesis. Cells must be placed within 
100 µm of a capillary blood vessel in order to be supplied with the appropriate amount of oxygen 
and nutrients.  Tumors activate the angiogenic switch by changing the balance between angiogenic 
inducers and inhibitors. For instance, increased expression of VEGF or EGFs is observed in many 
tumors. The sixth hallmark implies tissue invasion and metastatic potential, which enables cancer 
cells to abandon the primary tumor mass and colonize new tissues. Alterations in cell-cell adhesion 
molecules (CAMs), including immunoglobulin, calcium-dependent cadherin-families, and integrins, 
which link cells to extracellular matrix substrates, are often found in cancer. For instance, E-




β-catenin genes. N-CAM switches from an isoform with highly adhesive properties to a poorly 
adhesive isoform in several cancer types. Besides, changes in integrin expression are also observed 
in metastatic cells. 
 In 2011 Harahan and Weinberg [84] updated their previous list, including two additional 
items (the metabolic reprogramming of tumor cells and the development of mechanisms to evade 
immune surveillance). The seventh hallmark regards the ability of cancer cells to reprogram 
metabolism. Otto Warburg observed that even in the presence of oxygen, cancer cells were able to 
reprogram their glucose metabolism by limiting their energy metabolism to glycolysis. Paradoxically 
glycolysis generates a low ATP yield compared to oxidative phosphorylation but allows the diversion 
of glycolytic intermediates to biosynthetic pathways. Cancer cells circumvent this problem by 
upregulating glucose transporters such as GLUT1, which increases the flux of glucose to the 
cytoplasm. Finally, the eighth hallmark is based on the ability of cancer cells to escape from immune 
surveillance. 
1.6 Proposed mechanisms to explain the comorbidity patterns observed between 
CNS diseases and cancer. 
  Several mechanisms have been proposed to explain the disease-disease associations 
observed between CNS disorders and cancer, including biases in the epidemiological studies, 
behavioral changes, and alterations in the exposure to risk factors, biological factors, effects derived 
from pharmacological treatment. Some instances are provided in the following paragraph. In 
addition, a more exhaustive description can be found in the discussion sections of the following 
chapters.  
 Biases and flaws in the observational studies may occur as a consequence of the use of 
inadequate study designs. For instance, it has been suggested that the use of hospital-based 
samples could result in artificially inflated estimates of CNS disorders and cancer associations. The 
study of community-based samples has been proposed in order to avoid this kind of bias. The 
diversity of the psychometric scales used to diagnose some CNS disorders has also been reported 
as a potential confounding factor in the case of depression [85]. In addition, the lack of control for 
cancer-promoting lifestyle confounding factors in observational studies has also been reported to 
be a potential factor distorting observational studies results [86]. Behavioral changes in CNS 
disorders patients are also thought to modulate changes in cancer risk. It is known that patients 
with severe mental illness present high rates of morbidity and mortality and are more prone to 
exhibit unhealthy behaviors [87], including increased risks of obesity [88], heavy smoking 
habits[88], alcohol abuse, lack of physical activity, and poor diet [88-90]. In addition, it has also been 
reported that they are less likely to receive preventive care and access medical care [91, 92] and 
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tend to revive cancer diagnoses significantly later than their control counterparts, which decreases 
the chances of effective treatment [93, 94]. Several biological hypotheses have also been proposed 
to explain the direct and inverse associations observed between CNS disorders and cancer. They 
include alterations at different molecular levels, including changes in patterns of methylation, the 
presence of shared genetic variability, the existence of mutations on overlapping sets of genes, the 
joint alteration of biological processes and pathways, and changes in cellular activity and system-
level processes they will be covered in Chapters 3 and 4. Finally, pharmacological treatment has 
also been invoked as a relevant factor that could modulate CNS disorders and cancer associations. 
Treatment with antipsychotics has been linked to the increase in breast cancer risk observed in SCZ 
patients [95], whereas the use of levodopa to treat PD patients has been implicated in the increased 
melanoma risk observed in those patients [96]. The role of drugs in these associations will be further 


























1.7 Thesis objectives: 
 Main objective: 
 The present thesis aims to evaluate the comorbidities between CNS disorders and cancer 
from both an epidemiological and a molecular perspective and examine the potential effect of 
frequently prescribed medications on the associations. 
 Specific objectives: 
Objective 1: Synthesize the available evidence regarding the epidemiological associations 
between CNS disorders and cancer 
 We aimed to synthesize the current knowledge about the epidemiological associations 
between seven CNS disorders (AD, ASD, PD, HD, MD, BD, and SCZ) and both all-cancer and site-
specific cancer incidence and mortality through systematic reviews and meta-analyses. To this end, 
we searched scientific literature repositories for previous systematic reviews and observational 
studies reporting measures of association between the diagnosis of any of the included CNS 
disorders and subsequent all-cancer and site-specific cancer incidence or mortality and combined 
them by means of random effects models meta-analyses (See Chapter 2). 
 Objective 2: Analyze the transcriptomic associations between CNS disorders and cancers 
 We identified transcriptomic associations between seven CNS disorders and 22 site-specific 
cancers (acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), bladder cancer (BLCA), 
breast cancer (BRCA), brain cancers (BRNCA), cervical cancer (CERV), cholangiocarcinoma (CHLCA), 
chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), colorectal cancer (CRCA), 
diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FLYMPH), head and neck carcinomas 
(HANC), kidney cancer (KDNCA), lung cancer (LGCA), liver cancer (LIVCA), ovarian cancer (OVCA), 
pancreatic cancer (PACA), prostate cancer (PRCA), melanoma (SKCM), gastric cancer (STCA), and 
thyroid cancer(THCA). We carried out differential gene expression meta-analyses of micro-array 
studies for each disorder and then assessed the presence of shared deregulated genes and 
pathways between them. In addition, we presented a network-based approach to explore the 
overlaps between the gene co-expression modules significantly associated with each disorder. 
Finally, we partially validated our observations using an independent cohort of cancers derived 
from RNA-seq experiments (See Chapter 3). 
 Objective 3: Assess the interactome-based overlap of genes associated with CNS 
disorders and cancers and study their genetic correlations 
 We determined whether disease-associated genes linked to CNS disorders and cancer are 
placed in overlapping regions of the human interactome. The disease module hypothesis states that 
the components associated with a particular disease tend to be distributed in the same 
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neighborhood of the human interactome called the disease module. According to it, a particular 
disorder could arise as a consequence of the disruption of the function of genes placed at the 
disease module. In addition, comorbidity patterns between a given pair of disorders could be due 
to the existence of overlapping disease modules between both disorders. If disease modules 
overlap, it can be expected that the disruption of their genes jointly impacts the likelihood of 
developing both disorders. Therefore, we determined if the set of disease-associated genes of CNS 
disorders and cancers present interactome based overlaps (See Chapter 4). 
 In addition, we determined whether genetic relationships between CNS diseases and 
cancer exist. Genome-Wide Association Studies (GWAS) allow us to obtain associations between a 
particular trait and millions of genetic variants. We used a recently developed method (cross-trait 
LD-score regression), which allows the computation of genetic correlations between pairs of 
disorders using GWAS summary statistics as an input. This provides information about the role that 
shared genetic variability could play in the observed comorbidity patterns (See Chapter 4). 
 Objective 4: Study the potential impact of frequently used CNS and cancer medications 
in the observed comorbidities. 
 Medications administered to treat CNS disorders or cancer could act as modulating agents 
that shape the observed population patterns of association between them. Furthermore, 
understanding the transcriptomic impact of particular drugs employed in both sets of diseases 
opens the door to drug repositioning, an essential topic in translational medicine and a pressing 
issue given its potentially beneficial consequences for patients and healthcare systems. To 
determine the potential impact of frequently used medications in the observed associations 
between CNS disorders and cancer, we used two complementary approaches. The first was a 
network approach based on the computations of the distances of drug targets to disease modules 
in the human interactome, whereas the second was based on the comparison of thousands of 
transcriptomic profiles generated by treating cell lines with the drugs indicated for the treatment 
of CNS disorders (LINCS L1000 repository) and cancers with the differential expression profiles of 
each disorder obtained by means of differential gene expression meta-analyses in chapter 2. We 
seek to understand if the transcriptomic alterations produced by these drugs were able to mimic 







Chapter 2. Epidemiological associations between CNS disorders and 
cancer 
2.1 Introduction 
 Cancer and CNS disorders are among the top leading causes of death and disease burden 
internationally. On the one hand, only in 2017, 24.5 million incident cancer cases and 9.6 million 
cancer deaths were registered worldwide [82], with estimates suggesting that one-third of the men 
and one-fourth of the women would develop cancer during their lifetime. Besides, far from having 
reached a steady-state, cancer incidence dynamics continue on the rise, as it is suggested by the 
fact that age-standardized averages for annual overall-cancer incidence have increased in 123 out 
of 195 countries in the ten-year period comprehended between 2007 and 2017 [82]. Although the 
average death rates for all cancers have decreased in most countries in the same timeframe, cancer 
still is the second cause of death worldwide surpassed only by cardiovascular diseases [97]. On the 
other hand, CNS disorders have been identified as one of the leading causes of disease burden in 
the Global Burden of Disease study [43, 98, 99]. In the period comprehended between 2005 to 
2015, almost all neurological disorders presented an increase in disease burden or disability 
indicators, such as the total disability-adjusted life years (DALYs). 
 The demographic shift towards larger and older populations is generating an 
epidemiological transition from communicable to chronic non-communicable diseases and from 
premature mortality to morbidity and a rise in the global burden of chronic conditions such as CNS 
disorders and cancer [43, 99, 100]. Also, this transition has propelled a passage from a paradigm 
focused on the study and treatment of single diseases to one characterized by the presence of 
multiple co-occurring conditions known as comorbidity or multimorbidity [100, 101]. Therefore, it 
is becoming critical to understand how diseases interact from multiple perspectives ranging from 
epidemiology to the study of shared molecular traits and the analysis of the exposure to 
environmental factors and drugs. The epidemiological study of disease associations can stimulate 
the development of specific screening and prevention programs, which could, in turn, translate into 
better clinical outcomes for the patients and more efficient use of the available resources.  
 An increasing body of knowledge regarding the CNS disorders and cancer associations has 
been produced during the last decades, with dozens of observational studies available in the 
literature. In some instances, authors have concluded that CNS disorders are associated with an 
increased risk of specific cancer types (direct comorbidity). For example, PD patients have been 
documented to be at a higher risk of melanoma than controls, whereas SCZ patients have been 
observed to present a higher probability of developing breast cancer [86, 102-106]. Other studies 
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have reported that specific CNS disorders are linked to decreased cancer risk (inverse comorbidity). 
Some representative examples include the decreased overall cancer risk observed in AD and PD 
patients [107-114]. However, the available observational studies have often produced 
heterogeneous and contrasting results, which highlighted the need for the application of methods 
of evidence synthesis, such as systematic reviews and meta-analyses. 
 To date, the most comprehensive systematic review and meta-analysis addressing the topic 
of CNS disorders and cancer associations is the work carried out by Catalá and co-workers in 2014 
[21]. In their study, information regarding 577,013 participants derived from 50 observational 
studies involving eight CNS disorders (AD, amyotrophic lateral sclerosis, ASD, Down’s syndrome, 
HD, multiple sclerosis (MS), PD, and SCZ) and several site-specific cancers was evaluated through 
meta-analyses. Their results suggested that CNS disorders are associated with a decrease in overall 
cancer risk. This risk reduction was found to be stronger in neurodegenerative disorders patients. 
The general trend towards overall cancer risk reduction was accompanied by some specific 
instances in which a higher co-occurrence of some site-specific cancers was observed. For instance, 
PD was found to be associated with an increased risk of melanoma, MS was linked to an increased 
risk of brain cancer risk, and SCZ patients were found to present a higher incidence of breast cancer 
compared to controls. 
 Since the presentation of Catalá’s work in 2014, several observational studies reporting CNS 
and cancer associations have been published. Thus, in the context of an ongoing project [1] we 
considered timely to update previous results with the newly released data and expand them by 
exploring the associations between CNS disorder diagnosis and subsequent cancer mortality. 
Therefore, this chapter aims to evaluate the associations of seven CNS disorders (AD, ASD, BD, HD, 













2.2 Material and methods 
 The present analysis was guided by a study protocol and previous research carried out by 
our group. The protocol was registered in PROSPERO (registration number CRD42016052762) and 
subsequently published [1]. The complete study aims to conduct an umbrella review with multiple 
meta-analyses addressing cancer and CNS associations. This thesis will present a preliminary update 
of the meta-analyses of observational studies of a subset of CNS disorders included in the ongoing 
project. The analyses have been reported in accordance with the reporting guidance provided in 
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) 
statement [115, 116] and the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) 
reporting guideline [117]. 
 2.2.1 Inclusion criteria 
  2.2.1.1 Participants and exposure 
 This study included human participants of any age and sex. The exposure was defined as 
the incidence of a specific CNS disorder. CNS definitions should be based on accepted diagnostic 
criteria, including the International Classification of Disease (ICD) codes and Diagnosis and 
Statistical Manual of Mental Disorders (DSM). The central nervous system disorders included in our 
analysis were Alzheimer’s disease (AD: ICD-9: 331.0, 290.1; ICD-10: F00, G30), autism spectrum 
disorders (ASD: ICD-9: 299.0, 299.8; ICD-10: F84), bipolar disorder (BD: ICD-9: 296-296.16, 296.4-
296.99, 301.1-301.13; ICD-10: F06.3-F06.34, F30-F31.9, F34.0), major depression (MD: ICD-9: 296.2-
296.36, 311-311.9, V11.1, V11.2; ICD-10: F32-F33.9), Huntington’s disease (HD: ICD-9: 294.1, 333.4; 
ICD-10: F02.2, G10), Parkinson’s disease (PD: ICD-9: 332-332.9; ICD-10: G20-G21.0, G21.2-G22.0), 
and schizophrenia (SCZ: ICD-9: 295-295.95, 301.0, 301.2-301.22, V11.0; ICD-10: F06.2, F20-F23.9, 
F25-F29.9). Exclusion criteria were animal studies and in vitro or in vivo experiments. The selection 
of the CNS disorders included in this thesis was based on two criteria. First, we intended to capture 
some of the variability existent in CNS disorders, which are characterized by the presence of diverse 
etiological origins and pathological manifestations. Therefore, we included instances of 
neurodegenerative (AD, HD, and PD), neuropsychiatric (BD, MD, and SCZ), and neurodevelopmental 
(ASD) conditions. The second involved the availability of enough data to carry out the 






  2.2.1.2 Outcomes 
 The primary outcomes of interest were all-cancer incidence and mortality (all malignant 
neoplasms; ICD-9 codes 140-209; IDC-10 codes C00-C97). Secondary outcome measures were site-
specific cancer incidence and mortality. Appendix I shows the ICD-9 and ICD-10 codes of the 
primary and secondary outcomes under consideration.  
  2.2.1.3 Study design 
 To be included, primary studies had to be observational studies, either case-control or 
cohort. Randomized control trials are not available given the nature of our research question. 
Studies could present any setting (inpatient, outpatient, or mixed) and coverage (single-center, 
multi-centric, or population-based). The articles must include a quantification of the degree of 
association between the exposure and the outcome in the form of relative risks (RR) or odds ratio 
(OR) for case-control studies or Standardized Incidence Ratios (SIR) and Standardized Mortality 
Ratios (SMR) in the case of cohort studies. Articles where the CNS disorder was not the exposure of 
interest and cancer incidence or mortality were not the outcomes of interest were excluded. No 
year-of-publication restrictions were applied.  
 2.2.2 Search strategy 
 One of us (J.F.M) queried MEDLINE, Scopus, Embase, and the Web of Science using the 
following search scheme from their inception up to November 2018. First, searches of previously 
published systematic reviews and meta-analyses examining the associations between a specific CNS 
disorder and the risk of developing or dying of cancer were carried out. The main search strategy 
for autism spectrum disorders in MEDLINE is presented in Table 1. This search strategy was 
adapted, when necessary, to fit the other databases. If previous systematic reviews and meta-
analyses were available and included information about both incidence and mortality, the relevant 
observational studies references were selected, and their information extracted. The list of PubMed 
IDs identified in the previous step was used as an input to perform a related article search query in 
PubMed, which aimed to find observational studies published out of the time frame of the detected 
systematic reviews. This search effectively identifies relevant studies in the presence of an already 
large evidence base [118]. In the case in which no systematic reviews reporting CNS and cancer 
incidence or CNS and cancer mortality associations were available systematic searches of 
observational studies were carried out from scratch following the query structures depicted in 
Table 2 (MEDLINE query structure). Two of us (F.C. L and J.F.M) independently screened the titles 
and abstracts of the retrieved studies. Full texts of potentially eligible studies were then assessed 





Search number Example 
#1 Exposure CNSd* (e.g. Autism OR ASD) 
#2 Outcome cancer OR carcinoma OR neoplasia OR tumor OR neoplasm OR maligna* 
#3 Systematic review systematic review* OR systematic overview* OR evidence based review* OR evidence-based 
overview* OR meta-review* OR meta-analy* OR metaanaly* OR matanaly* OR research overview* 
OR collaborative review* 
# Final search #1 AND #2 AND #3 
Table 1: MEDLINE query structure for systematic reviews and meta-analyses (AD example). 
 
Search number Example 
#1 Exposure CNSd* (e.g. Autism OR ASD) 
#2 Outcome cancer OR carcinoma OR neoplasia OR tumor OR neoplasm OR maligna* 
#3 Observational studies incidence OR comorbidity OR multimorbidity OR mortality OR death OR epidemiologic* OR cohort 
stud* OR longitudinal stud* OR case-control stud* 
#4 Final search #1 AND #2 AND #3 
Table 2: MEDLINE query structure example for observational studies (AD example). 
 2.2.3 Data extraction 
 Information regarding the following items was extracted from each article: Year of 
publication, country, study design (prospective, retrospective, cohort or nested case-control), 
setting (population-based or hospital-based), coverage (single-center, multicenter, population-
based), study years, mean follow-up, number of participants with the exposure of interest, 
characteristics of participants (sex and age), number of incident cases of cancer deaths in the 
exposed individuals, outcome definitions (i.e., ICD codes, DSM codes), endpoint measures (OR, RR, 
SIR, SMR), and the adjustment for confounding factors. In addition, effect sizes with their 
correspondent, 95% confidence intervals were also extracted from the original articles. For those 
studies in which both raw and adjusted effect sizes were reported, the effect sizes adjusted by the 
maximum number of confounding variables were retrieved.  
 Studies that independently reported measures for colon and rectum cancers were 
combined under FEM in a shared category (colorectal cancer). Studies including disaggregated 
information about myeloid and lymphoid leukemias were also combined by FEM meta-analyses in 




 2.2.4 Appraisal of the quality of observational studies. 
 One of us (J.F.M) evaluated the quality and the risk of bias of each observational study using 
the Newcastle-Ottawa scale (NOS)[119]. NOS evaluates different aspects of the study, including 
how participants are selected, the comparability between cases and controls or cohorts and the 
reference population, and how exposures and outcomes are defined. Stars are allocated based on 
the adherence to pre-specified criteria. The scale ranges from 0 (lowest quality) to 9 (highest 
quality). In our analysis, we divided studies into three groups according to their risk of bias. High 
risk (0 to 3 stars), moderate risk (4 to 6 stars), and low risk (7 to 9 stars). The complete list of items 
included in NOS can be checked in Appendix 2, which contains the templates of the scale for both 
case-control and cohort studies.  
 2.2.5 Data synthesis 
 Following Cochranes’ Handbook recommendations, all effect sizes retrieved from 
observational studies were subjected to the log transformation prior to meta-analytic integration, 
and standard errors were computed using the logarithms of the 95% confidence interval, as shown 
by the next equation: 
 
𝑆𝐸 =  




 Pooled estimates for each CNS disorder and cancer associations were computed through 
meta-analysis using the inverse-variance method. Random-effects models were selected a priori, 
given that between-study heterogeneity was expected [120]. Cochran Q tests [121] and the 𝐼  
statistic were used to assess heterogeneity between studies. Cochran Q tests p-values lower than 
0.05 suggest that heterogeneity is present. The 𝐼  statistic is expressed as a percentage. 𝐼  values 
of 0%-25%, 25%-50%, 50%-75%, and 75%-100% indicate low, moderate, substantial, and 
considerable heterogeneity respectively. All analyses were carried out using the R statistical 
programming language and the metafor package [122]. 
 2.2.6 Additional analyses  
 Potential sources of heterogeneity were studied when feasible. Subgroup analysis 
according to sex (male or female), study design (cohort or case-control), and risk of bias (high or 
low-moderate risk of bias) were conducted for overall cancer incidence and mortality. For cancer 
incidence, subgroup analysis was carried out comparing the site-specific cancers linked to smoking 
against those with no reported association with smoking status. Information regarding which site-
specific cancers are associated with smoking can be found in Appendix 1. We also carried out 




Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease) and their association with 
primary outcomes. 
 The potential publication bias was assessed for those meta-analyses including ten or more 
studies. Publication bias relies on the idea that significant findings or studies presenting large effect 
sizes are more likely to be published [123]. This implies that moderate and small-sized studies 
reporting non-significant results would be more likely to be missing and, therefore, would not be 
integrated into meta-analyses. Publication bias was assessed by funnel plot visualization and the 






























 2.3.1 Relevant literature identified. 
 Searches for previously published systematic reviews and meta-analyses yielded a total of 
9374 article references. After title, abstract, and full-text inspection, 28 previous systematic reviews 
were identified. (See Appendix 3) from which 487 references to observational studies were 
extracted. In the case of ASD, BD, HD, and PD, the searches for observational studies were carried 
out from scratch due to the lack of previous systematic reviews examining incidence, mortality, or 
none of them. In total, sixteen thousand one-hundred and twenty-one article references were 
yielded by these searches. In the case of AD, MD, and SCZ, a related article search was performed, 
and 8749 article references were recovered. Overall, 801, 1097, 2935, 3628, 4370, 8854, 3619 
unique references were obtained for AD, ASD, BD, HD, MD, PD, and SCZ, respectively. After 
screening titles and abstracts 30, 13, 55, 9, 423, 112, and 122, references for AD, ASD, BD, HD, MD, 
PD, and SCZ were selected for full-text review. Two-hundred and eighteen articles (192 unique 
articles) met inclusion criteria and were used in the downstream analysis, and 546 were excluded 
due to different reasons, which are summarized in Figure 2. Appendix 4 shows the characteristics 
of all the studies that met the inclusion criteria. 
 2.3.2 Description of the studies and participants 
 Data from one hundred and seventy-four cohorts reported in a total of 192 unique article 
references met inclusion criteria and were selected for downstream analysis. One hundred and 
seventy-two articles included information about one CNS disorder, whereas twenty-one studies 
incorporated information for associations between cancer incidence or mortality and more than 
one CNS disorder. Most of them presented data regarding different neuropsychiatric conditions. 
Six studies included associations between cancer and BD, MD, and SCZ [126-131], two studies 
reported information regarding associations between cancer and bipolar disorder or major 
depression [132, 133]. Eight showed results for BD and SCZ [134-141]. Three works had data on MD 
or SCZ and cancer associations [142-144]. Finally, only two articles presented data about two 




























Figure 3: Characteristics of the studies that met inclusion criteria. A) Proportion of the studies reporting 
associations for each CNS disorder and main outcome. B) Geographic distribution of the identified 




 The number of identified studies devoted to each disease and outcome was found to be 
highly heterogeneous. For instance, cancer incidence following schizophrenia diagnosis was 
reported in 26 studies, whereas cancer incidence following ASD diagnosis was reported only in four. 
In the case of cancer mortality, the number of available studies ranged between 37 in SCZ and 2 in 
Huntington’s disease. Figure 3 A graphically depicts the volume of studies available for each CNS 
disorder and each primary outcome. SCZ, MD, and PD were the most extensively studied CNS 
disorders, with more than ten studies available for both major outcomes. On the other hand, AD, 
ASD, BD, and HD presented less than ten studies reporting cancer incidence or mortality. The less 
extensively studied diseases were HD and ASD.  
 Regarding the geographical distribution of the research, fifty-one studies were based in 
North America (45 in the United States and 6 in Canada). Nordic countries produced a total of 45 
studies (19 in Denmark, 14 in Sweden, 8 in Finland, and 4 in Norway). East Asia contributed with 25 
studies (17 in Taiwan and 6 in Japan). The UK was another major contributor, with 19 studies. In 
the Middle East, only Israel contributed with seven studies. Works produced in nine other countries 
were available, with each country contributing with five or fewer studies. For studies analyzed data 
from cohorts derived from more than one country. There was a complete lack of research coming 
from Central and South America, Africa, and most of Asia.  
 More than 1075159 participants with a CNS disorder and more than 69359 incident cancers 
were included in the analyses of CNS and cancer incidence associations. CNS disorder patients raged 
between 31 and 219194, whereas the number of incident cancers ranged between 8 and 17524. In 
the case of mortality, information regarding more than 2325378 individuals (range: 59-1138853) 
with a particular CNS disorder and more than 22410 deaths due to cancer (range: 2-9638) in the 
CNS groups were included. For all-cancer incidence studies, female participant’s proportions ranged 
between 19.3% and 85.5%, whereas for all-cancer mortality, it ranged between 20.6% and 85.6%. 
 One hundred and sixty-one studies (89.5%) presented a cohort design, whereas 19 (10.5%) 
were case-control studies. Ninety-seven cohort studies (60.6%) were retrospective, and 63 (39.4%) 
were prospective studies. One hundred and sixty-five studies included information regarding their 
follow-up duration. One hundred and thirty-seven (83%) presented follow-up durations longer than 
five years, whereas 28 (17%) presented follow-up durations between 1 and 5 years. After the 
Newcastle Ottawa Scale quality appraisal, most studies 115 (63.9%) were placed in the low risk of 
bias category. Thirty-one percent were (56) were classified as a moderate risk of bias studies, and 
only 9 (0.5%) were considered to be a high risk of bias studies. 
 Regarding the publication dates, 74.7% of the studies were published after the year 2000, 
whereas 25.3% were published before. Site-specific cancer data was also highly heterogeneous in 
terms of the number of reports including information about each cancer type.  
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 The best-studied site-specific cancers in terms of incidence were breast, lung, prostate, 
colorectal, brain and central nervous, stomach, and malignant skin melanoma, with 57, 54, 52, 51, 
35, 34, and 31 studies reporting measures of associations between them and any of the included 
CNS disorders. Breast, Lung, colorectal, pancreatic, and prostate cancers with 15, 10, 9, 7, and 7 
studies reporting site-specific mortality rates were the most extensively studied cancers in the 
context of mortality. 
 2.3.3 Meta-analyses results 
  2.3.3.1 All-cancer incidence and mortality in patients with CNS disorders. 
 This section presents the meta-analysis results for the primary outcomes (all-cancer 
incidence and mortality) for all the CNS disorders included in our study. Figures 4 and 5 show the 
pooled estimates and their 95% confidence intervals of all-cancer incidence and mortality of all the 
studied CNS disorders. Table 3 includes the results stratified by gender and additional information 






























 Figure 4: Forest plot depicting the meta-analyses results for the associations between each CNS disorder 
and all-cancer incidence.  Points represent the pooled effect sizes for each meta-analysis, whereas 
whiskers show their 95% confidence intervals. Points situated to the left of the black line placed at 1 
with non-intersecting upper confidence intervals indicate significantly reduced risks, whereas points 












Figure 5: Forest plot depicting the meta-analyses results for the associations between each CNS disorder 
and all-cancer mortality. Points represent the pooled effect sizes for each meta-analysis, whereas 
whiskers show their 95% confidence intervals. Points situated to the left of the black line placed at 1 
with non-intersecting upper confidence intervals indicate significantly reduced risks, whereas points 





AD all cancer incidence and mortality 
 Alzheimer’s disease analyses included data from 43463 and 2278 AD patients for incidence 
and mortality divided into 7 and 6 studies, respectively. In both cases, AD patients presented 
significantly reduced overall cancer risks compared to controls. (Incidence: n = 7; RR = 0.69; 95% CI: 
0.59-0.81; I2 = 87.75%), (Mortality: n = 6; RR = 0.45; 95% CI: 0.33-0.61; I2 = 46.57%). Three studies 
included gender-specific incidence data and showed a significant reduction in the risk of cancer 
incidence in both sexes (Men incidence, n = 3; RR = 0.8; 95% CI: 0.66-0.97; I2 = 80.31%), (Women 
incidence, n = 3; RR = 0.74; 95% CI: 0.57-0.96; I2 = 89.53%). Gender-specific associations between 
AD and subsequent cancer mortality were not computed out due to the lack of data. 
HD all cancer incidence and mortality 
 HD patients were also found to be at a significantly lower risk of all-cancer incidence (n = 4; 
RR = 0.48; 95% CI: 0.29-0.78; I2 = 96.57%) and mortality (n = 2; RR = 0.12; 95% CI: 0.08-0.17; I2 = 
76.12%) using data derived from four and two studies, that included information regarding 13609 
and 954 HD patients, respectively. There were no studies reporting sex-specific associations. 
PD all cancer incidence and mortality 
 PD patients presented a significantly decreased risk of subsequent cancer incidence (n = 17; 
RR = 0.85; 95% CI: 0.76-0.96; I2 = 97.48%) and mortality (n = 15; RR = 0.69; 95% CI: 0.54-0.87; I2 = 
73.39%). The pooled estimates were computed using 17 incidence studies including 354971 PD 
patients and 15 mortality studies gathering information about 22245 PD patients. In the case of 
overall-cancer incidence, sex-specific analysis for men (n = 12; RR = 0.88; 95% CI: 0.74-1.05; I2 = 
97.56%) and women (n = 11; RR = 0.93; 95% CI: 0.81-1.08; I2 = 94.63%) did not show a significant 
reduction in cancer risk. However, a trend towards a negative association was observed in both 
cases. In contrast, both men (n = 3; RR = 0.56; 95% CI: 0.4-0.77; I2 = 0%) and women (n = 2; RR = 
0.62; 95% CI: 0.4-0.97; I2 = 19.42%) were found to be at a lower risk of all-cancer mortality than 
controls, however, these meta-analyses included only 3 and 2 observational studies, respectively. 
MD all cancer incidence and mortality 
 All-cancer incidence was found to be significantly increased in MD patients compared to 
controls (n = 22; RR = 1.17; 95% CI: 1.05-1.29; I2 = 91.51%). The analysis included more than 109742 
MD patients from 22 different studies. Seven studies included gender-specific estimates. Pooled 
estimates suggested a non-significant trend towards increased cancer risk in depressed men (n = 7; 
RR = 1.2; 95% CI: 0.99-1.45; I2 = 92.96%) and women (n = 7; RR = 1.1; 95% CI: 0.84-1.43; I2 = 96.62%), 
respectively. Associations between all-cancer mortality and MD were reported in 21 studies. Pooled 
estimates indicate that MD patients are at higher risk of dying due to cancer than controls (n = 21; 
RR = 1.24; 95% CI: 1.15-1.34; I2 = 80.83%). A similar significant association was also found for men 
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(n = 12; RR = 1.42; 95% CI: 1.18-1.71; I2 = 88.73%) and women (n = 8; RR = 1.24; 95% CI: 1.12-1.38; 
I2 = 58.45%). 
BD all-cancer incidence and mortality 
 BD patients were not found to be at higher risk of cancer incidence than controls (n = 9; RR 
= 1.1; 95% CI: 0.87-1.39; I2 = 96.69%) but presented a significantly increased probability of dying of 
cancer (n = 9; RR = 1.09; 95% CI: 1.03-1.15; I2 = 0%). Nine studies comprehending 59105 BD patients 
and 14 studies including information regarding 46406 BD patients were available for the incidence 
and mortality meta-analyses, respectively. The gender-specific analyses yielded no significant 
associations between previous exposure to BP and subsequent all-cancer incidence either for men 
(n = 7; RR = 0.98; 95% CI: 0.67-1.43; I2 = 94.01%) or women (n = 7; RR = 1.21; 95% CI: 0.84-1.73; I2 
= 95.3%). In contrast, both men (n = 9; RR = 1.09; 95% CI: 1.03-1.15; I2 = 0%) and women (n = 7; RR 
= 1.11; 95% CI, 1.04-1.19; I2 = 32.06%) were found to be at an increased risk of cancer mortality 
after BD diagnosis. 
SCZ all-cancer incidence and mortality 
 Twenty-six studies, including 505132 SCZ patients, reported associations between SCZ and 
subsequent cancer incidence. No differences in the risk of developing cancer were observed 
between SCZ patients and controls (n = 26; RR = 0.99; 95% CI: 0.92-1.07; I2 = 95.71%). A significant 
reduction of overall-cancer risk was found in males (n = 22; RR = 0.87; 95% CI: 0.78-0.96; I2 = 
95.05%) but not in female patients (n = 20; RR = 1.08; 95% CI, 0.99-1.18; I2 = 93.84%). Regarding 
cancer mortality, the meta-analysis of thirty-seven studies including 1978502 SCZ participants 
showed that SCZ patients are at an increased risk of cancer mortality compared to controls (n = 37; 
RR = 1.34; 95% CI: 1.23-1.46; I2 = 94.53%). Sex-specific analyses showed an increased risk in cancer 
mortality in both men (n = 22; RR = 1.28; 95% CI: 1.12-1.46; I2 = 94.17%) and women (n = 19; RR = 
1.43; 95% CI: 1.29-1.6; I2 = 93.11%) with SCZ. 
ASD and all-cancer incidence and mortality 
 All-cancer incidence was not found to be different in patients with ASD and controls (n = 4; 
RR = 1.04; 95% CI: 0.53-2.03; I2 = 78.06%). However, as in the case of HD, only four studies were 
available, which gathered data derived from 15388 participants. Gender-specific analyses based on 
three studies did not show significant differences. In the case of cancer mortality, ASD patients were 
found to be at a higher risk than controls (n = 2; RR = 1.92; 95% CI: 1.58-2.32; I2 = 49.36%). However, 
this meta-analysis was carried out only with two studies. The risk of mortality due to cancer was 
significantly increased for both men (RR = 1.79, 95% CI, 1.34-2.38) and women (RR = 1.83, 95% CI, 
1.33-2.5) in the unique observational study reporting these associations. 
 Considerable between-study heterogeneity was present in most of the meta-analyses (24 




the results of the Q-tests. In addition, those meta-analyses where considerable heterogeneity was 
not detected were characterized by the presence of a reduced number of studies. The only 
exceptions to this trend were the BD sex-specific cancer mortality analyses for men and women, 
which presented moderate and low heterogeneity and pooled data from 9 and 7 studies, 
respectively. Table 3 summarizes all the meta-analysis results obtained in this section, including the 
number of studies and participants, the pooled estimates, and heterogeneity measures. Appendix 








Pooled RR  
(95% CI) 




7 43463 0.69 (0.59-0.81) 5.60e-06 87.75% 48.99 (7.5e-09) 
AD All-cancer 
incidence men 
3 6839 0.8 (0.66-0.97) 2.10e-02 80.31% 10.16 (6.2e-03) 
AD  All-cancer 
incidence women 
3 10283 0.74 (0.57-0.96) 2.20e-02 89.53% 19.11 (7.1e-05) 
AD All-cancer mortality 6 2278 0.45 (0.33-0.61) 3.00e-07 46.57% 9.36 (9.6e-02) 
ASD All-cancer 
incidence both 
4 15388 1.04 (0.53-2.03) 9.20e-01 78.06% 13.67 (3.4e-03) 
ASD All-cancer 
incidence men 
3 8886 1.01 (0.37-2.76) 9.80e-01 85.43% 13.73 (1e-03) 
ASD All-cancer 
incidence women 
3 3462 1.16 (0.39-3.46) 7.90e-01 47.19% 3.79 (1.5e-01) 
ASD All-cancer 
mortality 
2 40233 1.92 (1.58-2.32) 3.30e-11 49.36% 1.97 (1.6e-01) 
ASD All-cancer 
mortality men 
1 18693 1.79 (1.34-2.38) - - - 
ASD All-cancer 
mortality women 
1 8429 1.83 (1.33-2.5) - - - 
BD All-cancer incidence 
both 
9 59105 1.1 (0.87-1.39) 4.40e-01 96.69% 241.89 (9e-48) 
BD All-cancer incidence 
men 
7 21977 0.98 (0.67-1.43) 9.00e-01 94.01% 100.16 (2.3e-19) 
BD All-cancer incidence 
women 
7 25248 1.21 (0.84-1.73) 3.00e-01 95.30% 127.61 (4.1e-25) 
BD All-cancer mortality 14 46406 1.16 (1.09-1.24) 7.50e-06 57.80% 30.8 (3.6e-03) 
BD All-cancer mortality 
men 
9 9636 1.09 (1.03-1.15) 1.50e-03 0% 6.95 (5.4e-01) 
BD All-cancer mortality 
women 
7 12927 1.11 (1.04-1.19) 3.40e-03 32% 8.83 (1.8e-01) 
HD All-cancer 
incidence both 
4 13609 0.48 (0.29-0.78) 3.40e-03 96.57% 87.47 (7.6e-19) 





22 109742 1.17 (1.05-1.29) 3.10e-03 91.51% 247.34 (1.4e-40) 
MD All-cancer 
incidence men 
7 45076 1.2 (0.99-1.45) 6.00e-02 92.96% 85.22 (3e-16) 
MD All-cancer 
incidence women 
7 21607 1.1 (0.84-1.43) 5.10e-01 96.62% 177.63 (1.1e-35) 
MD All-cancer 
mortality 
21 252573 1.24 (1.15-1.34) 1.00e-08 80.83% 104.33 (2.1e-13) 
MD All-cancer 
mortality men 
12 10078 1.42 (1.18-1.71) 2.50e-04 88.73% 97.61 (5.3e-16) 
MD All-cancer 
mortality women 
8 10140 1.24 (1.12-1.38) 2.70e-05 58.45% 16.85 (1.8e-02) 
PD All-cancer incidence 
both 
17 354971 0.85 (0.76-0.96) 9.10e-03 97.48% 634.69 (9.9e-125) 
PD All-cancer incidence 
men 
12 179269 0.88 (0.74-1.05) 1.60e-01 97.56% 450.71 (1e-89) 
PD All-cancer incidence 
women 
11 145229 0.93 (0.81-1.08) 3.70e-01 94.63% 186.27 (1.2e-34) 
PD All-cancer mortality 15 22245 0.69 (0.54-0.87) 2.00e-03 73.39% 52.61 (2.2e-06) 
PD All-cancer mortality 
men 
3 1207 0.56 (0.4-0.77) 5.00e-04 0.00% 1.95 (3.8e-01) 
PD All-cancer mortality 
women 
2 493 0.62 (0.4-0.97) 3.80e-02 19.42% 1.24 (2.7e-01) 
SCZ All-cancer 
incidence both 
26 505132 0.99 (0.92-1.07) 7.60e-01 95.71% 582.44 (5.6e-107) 
SCZ All-cancer 
incidence men 
22 257654 0.87 (0.78-0.96) 7.70e-03 95.05% 423.96 (1e-76) 
SCZ All-cancer 
incidence women 
20 196272 1.08 (0.99-1.18) 8.10e-02 93.84% 308.32 (3.9e-54) 
SCZ All-cancer 
mortality 
37 1978502 1.34 (1.23-1.46) 6.10e-12 94.53% 657.57 (2.9e-115) 
SCZ All-cancer 
mortality men 
22 837914 1.28 (1.12-1.46) 2.90e-04 94.17% 360.3 (1.4e-63) 
SCZ All-cancer 
mortality women 
19 706815 1.43 (1.29-1.6) 1.00e-10 93.11% 261.27 (4.1e-45) 
Table 3: All-cancer incidence and mortality meta-analysis results for the primary outcomes. Results 
stratified by gender are also reported.  
  2.3.3.2 Site-specific cancer incidence and mortality.  
 In this section, we present the results regarding secondary outcomes (site-specific cancer 
incidence and mortality). Overall, neurodegenerative disorders were characterized by the presence 
of negative patterns of associations with site-specific cancers. From the 27 significant associations 
reported in this section, 24 were found to point in the direction of cancer risk reduction, and only 




and SCZ and site-specific cancers were pointing to the direction of an increase of risk (18/22), 
whereas almost no data was available for ASD. 
 
AD site-specific cancer incidence and mortality 
 AD patients were found to present a significantly reduced risk of several site-specific 
cancers. Three of them were derived from meta-analyses carried out using three or more studies. 
Those were liver (n = 3; RR = 0.72; 95% CI: 0.61-0.85; I2 = 0%) and lung (n = 4; RR = 0.81; 95% CI: 
0.7-0.94; I2 = 59.23%) cancers and malignant skin melanoma (n = 3; RR = 0.81; 95% CI: 0.69-0.94; I2 
= 0%). A significant risk reduction was also observed for two site-specific cancers for which only two 
studies were available which were kidney (n = 2; RR = 0.77; 95% CI: 0.63-0.93; I2 = 0%) and uterus 
(n = 2; RR = 0.64; 95% CI: 0.52-0.78; I2 = 0%) cancers. In addition, AD patients were found to be at 
a reduced risk of cancers of the larynx (n = 1; RR = 0.52; 95% CI: 0.34-0.8), and thyroid (n = 1; RR = 
0.58; 95% CI: 0.36-0.94) with only one available observational study reporting these associations. 
Table 4 summarizes the significant results. Associations between AD status and site-specific cancer 
mortality could not be carried out due to the lack of data. 
 





Pooled RR  
(95% CI) 
P-value I2 Q 
(P-value) 
Kidney 2 14281 0.77 (0.63-0.93) 7.20E-03 0% 0.43 (5.1e-01) 
Larynx 1 7321 0.52 (0.34-0.8) - - - 
Liver 3 32577 0.72 (0.61-0.85) 1.10E-04 0% 1.95 (3.8e-01) 
Lung 4 42670 0.81 (0.7-0.94) 6.40E-03 59.23% 7.36 (6.1e-02) 
Malignant skin 
melanoma 
3 39838 0.81 (0.69-0.94) 7.20E-03 0.00% 1.06 (5.9e-01) 
Thyroid 1 7321 0.58 (0.36-0.94) - - - 
Uterus (Women) 2 8398 0.64 (0.52-0.78) 1.60E-05 0% 0.04 (8.3e-01) 
Table 4: Significant associations between AD and site-specific cancer incidence and mortality.  
HD site-specific cancer incidence and mortality 
 HD patients were found to be at a reduced incidence risk of colorectal (n = 3; RR = 0.5; 95% 
CI: 0.27-0.93; I2 = 75.89%), prostate (n = 3; RR = 0.36; 95% CI: 0.25-0.5; I2 = 6.96%), and stomach (n 
= 3; RR = 0.52; 95% CI: 0.36-0.74; p = 3.5e-04; I2 = 0%) cancers. An additional cancer type, breast 
cancer (n = 2; RR = 0.41; 95% CI: 0.31-0.53; I2 = 33.32%), showed a decreased incidence risk in HD 
patients compared to controls in a meta-analysis carried out using data from two studies. Finally, a 
single observational study reported a significant risk reduction of uterine cancer (n = 1; RR, 0.66; 











Pooled RR  
(95% CI) 




2 8050 0.41 (0.31-0.53) 2.90E-11 33.32% 1.5 (2.2e-01) 
Colorectal 3 12915 0.5 (0.27-0.93) 2.80E-02 75.89% 8.29 (1.6e-02) 
Prostate 
(Men) 
3 12915 0.36 (0.25-0.5) 4.80E-09 6.96% 2.15 (3.4e-01) 
Uterus 
(Women) 
1 6540  0.66 (0.36 - 0.96) - - - 
Table 5: Significant associations between HD and site-specific cancer incidence and mortality.  
PD site-specific cancer incidence and mortality 
 PD patients presented a lower risk for several site-specific cancers compared to controls, 
including bladder (n = 8; RR = 0.73; 95% CI: 0.57-0.93; I2 = 89.6%), colorectal (n = 15; RR = 0.8; 95% 
CI: 0.7-0.91; I2 = 88.51%), larynx (n = 5; RR = 0.57; 95% CI: 0.37-0.87; I2 = 57.45%), lip and oral cavity 
(n = 6; RR = 0.75; 95% CI: 0.62-0.89; I2 = 0%), and lung (n = 13; RR = 0.6; 95% CI: 0.47-0.76; I2 = 
94.56%). Contrarily, the incidences of brain cancer (n = 7; RR = 1.5; 95% CI: 1.11-2.04; I2 = 64.49%) 
and malignant skin melanoma (n = 13; RR = 1.49; 95% CI: 1.17-1.89; I2 = 76.21%) were found to be 
significantly increased in PD patients compared to controls. The risk of testicular cancer (n = 2; RR 
= 1.67; 95% CI: 1.03-2.68; I2 = 0%) was also found to be increased in PD patients. However, only 
two studies were available in this case. Regarding cancer mortality, bladder (n = 2; RR = 0.55; 95% 
CI:  0.35-0.85; I2 = 0%), colorectal (n = 3; RR = 0.62; 95% CI, 0.5-0.76; I2 = 0%), and lung (n = 4; RR = 
0.3; 95% CI: 0.17-0.52; I2 = 48.11%) cancers followed the same trend of risk reduction found in the 
incidence analyses, as well as pancreatic (n = 3; RR = 0.56; 95% CI: 0.32-0.97; I2 = 8.95%) and 
stomach (n = 3; RR = 0.53; 95% CI: 0.3-0.95; I2 = 13.78%; Q = 2.32) cancers. 
 The probabilities of dying from breast (n = 2; RR = 0.61; 95% CI: 0.41-0.89; I2 = 0%) and liver 
(n = 1; RR = 0.31; 95% CI: 0.17-0.51) cancer were also found to be lower for PD patients than in 
individuals without PD; however, only two and one studies reported these associations, 
respectively. Finally, the risk of dying by malignant skin melanoma (n = 2; RR = 1.86; 95% CI: 1.4-
2.48; I2 = 53.36%) was found to be increased in PD patients compared to controls, which was in 
agreement with the results of the incidence meta-analysis. Table 6 summarizes the results obtained 








Pooled RR  
(95% CI) 
P-value I2 Q 
(P-value) 




Bladder (death) 2 10790 0.55 (0.35-0.85) 6.6e-03 0% 0.05 (8.2e-01) 
Brain and CNS 7 327824 1.5 (1.11-2.04) 9.30E-03 64.49% 16.9 (9.7e-03) 
Breast (Women death) 2 5888 0.61 (0.41-0.89) 1.1e-02 0% 0.03 (8.7e-01) 
Colorectal 15 350055 0.8 (0.7-0.91) 8.90E-04 88.51% 121.83 (2.8e-19) 
Colorectal (death) 3 13788 0.62 (0.5-0.76) 4.2e-06 0% 0.59 (7.5e-01) 
Larynx 5 256871 0.57 (0.37-0.87) 9.60E-03 57.45% 9.4 (5.2e-02) 
Lip and oral cavity 6 40278 0.75 (0.62-0.89) 1.30E-03 0% 1.34 (9.3e-01) 
Liver (death) 1   10322   0.31 (0.17-0.51) - - - 
Lung 13 349150 0.6 (0.47-0.76) 3.00E-05 94.56% 220.66 (1.7e-40) 
Lung (death) 4 13958 0.3 (0.17-0.52) 2.5e-05 48.11% 5.78 (1.2e-01) 
Malignant skin 
melanoma 
13 335222 1.49 (1.17-1.89) 1.20E-03 76.21% 50.45 (1.2e-06) 
Malignant skin 
melanoma (deaths) 
2 13320 1.86 (1.4-2.48) 2.2e-05 53.36% 2.14 (1.4e-01) 
Pancreas (death) 3 13788 0.56 (0.32-0.97) 3.8e-02 8.95% 2.2 (3.3e-01) 
Stomach (deaths) 3 13788 0.53 (0.3-0.95) 3.2e-02 13.78% 2.32 (3.1e-01) 
Testicular 2 132076 1.67 (1.03-2.68) 3.60E-02 0% 0.62 (4.3e-01) 
Table 6: Significant associations between PD and site-specific cancer incidence and mortality.  
MD site-specific cancer incidence and mortality 
 MD was found to be associated with an increased risk of brain (n = 5; RR = 2.91; 95% CI: 
1.55-5.44; I2 = 90.05%), lung (n = 9; RR = 1.31; 95% CI: 1.18-1.44; I2 = 1.4%), and pancreatic (n = 3; 
RR = 2; 95% CI:1.11-3.59; I2 = 96.02%) cancer incidence. In addition, for three cancer types, 
esophagus (n = 2; RR = 1.81; 95% CI: 1.38-2.38; I2 = 94.49%), larynx (n = 2; RR = 2.02; 95% CI: 1.3-
3.11; I2 = 90.93%), and leukemia (n = 2; RR = 1.48; 95% CI: 1.17-1.87; I2 = 33.46%), significantly 
increased risk were also observed in meta-analyses carried out using only two observational 
studies. Depressed women were at a higher risk of both breast cancer incidence (n = 15; RR = 1.24; 
95% CI: 1.02-1.52; I2 = 81.61%) and mortality (n = 5; RR = 1.28; 95% CI: 1.15-1.43; I2 = 0%) compared 







Pooled RR  
(95% CI) 
P-value I2 Q 
(P-value) 
Brain and CNS 5 55147 2.91 (1.55-5.44) 8.70E-04 90.05% 40.19 (4e-08) 
Breast 
(Women) 
15 51645 1.24 (1.02-1.52) 3.30E-02 81.61% 76.14 (1.5e-10) 
Breast 
(Women death) 
5 3619 1.28 (1.15-1.43) 1.1e-05 0% 1.25 (8.7e-01) 
Esophagus 2 37012 1.81 (1.38-2.38) 1.70E-05 94.49% 18.15 (2e-05) 
Larynx 2 37012 2.02 (1.3-3.11) 1.60E-03 90.93% 11.02 (9e-04) 
Leukaemia 2 35979 1.48 (1.17-1.87) 9.90E-04 33.46% 1.5 (2.2e-01) 
Pancreas 3 45805 2 (1.11-3.59) 2.10E-02 96% 50.27 (1.2e-11) 
Lung 9 55964 1.31 (1.18-1.44) 9.60E-08 1.40% 8.11 (4.2e-01) 
Table 7: Significant associations between MD and site-specific cancer incidence and mortality.  
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BD and site-specific cancer incidence and mortality 
 BP patients showed higher stomach cancer incidence than controls (n = 5; RR = 1.37; 95% 
CI: 1.15-1.64; I2 = 0.53%) in a meta-analysis of five independent studies. Esophagus cancer risk was 
also found to be increased in BD patients after combing the information of two studies. (n = 2; RR 
= 2.56; 95% CI: 1.6-4.09; I2 = 0%). One study reported significant direct associations between BD 







Pooled RR  
(95% CI) 
P-value I2 Q 
(P-value) 
Colorectal (death) 1 6618 1.99 (1.29-3.05) - - - 
Esophagus 2 11845 2.56 (1.6-4.09) 8.40E-05 0% 0.83 (3.6e-01) 
Stomach 5 38468 1.37 (1.15-1.64) 4.90E-04 0.53% 4.02 (4e-01) 
Table 8: Significant associations between BD and site-specific cancer incidence and mortality.  
SCZ site-specific cancer incidence and mortality 
 Breast (n = 18; RR = 1.37; 95% CI: 1.23-1.53; I2 = 85.06%) and uterine (n = 11; RR = 1.35; 
95% CI, 1.07-1.7; I2 = 83.57%) cancer incidences were observed to be increased in women with 
schizophrenia compared to controls, as well as breast cancer mortality (n = 7; RR = 1.71; 95% CI: 
1.32-2.22; I2 = 66.12%).  In contrast, schizophrenic men were found to be at a reduced risk of 
prostate cancer (n = 14; RR = 0.56; 95% CI: 0.47-0.65; I2 = 53.46%). The risks of mortality due to 
colorectal (n = 5; RR = 1.71; 95% CI: 1.59-1.85; I2 = 0%), liver (n = 3; RR = 1.41; 95% CI: 1.26-1.57; I2 
= 0%), lung (n = 5; RR = 2.23; 95% CI: 1.85-2.69; I2 = 42.6%) and pancreatic cancer (n = 4; RR = 1.4; 
95% CI: 1.27-1.54; I2 = 0%) were also found to be increased in SCZ patients compared to controls. 
On the other hand, melanoma (n = 7; RR = 0.74; 95% CI: 0.64-0.86; I2 = 8.24%), nasopharynx (n = 7; 
RR = 0.74; 95% CI, 0.64-0.86; I2 = 8.24%) and thyroid (n = 6; RR = 0.69; 95% CI: 0.58-0.82; I2 = 0%) 








Pooled RR  
(95% CI) 




18 189804 1.37 (1.23-1.53) 1.70E-08 85.06% 113.78 (2.3e-16) 
Breast (Women 
deaths) 
7 534375 1.71 (1.32-2.22) 6e-05 66.12% 17.71 (7e-03) 
Colorectal (Deaths) 5 1160743 1.71 (1.59-1.85) 1.1e-44 0% 3.1 (5.4e-01) 
Liver (Deaths) 3 1150198 1.41 (1.26-1.57) 1.4e-09 0% 1.68 (4.3e-01) 
Lung (Deaths) 5 1158845 2.23 (1.85-2.69) 5.4e-17 42.6% 6.97 (1.4e-01) 
Malignant skin 
melanoma 
7 150049 0.74 (0.64-0.86) 9.50E-05 8.24% 6.54 (3.7e-01) 




Pancreas (Deaths) 4 1152466 1.4 (1.27-1.54) 5.3e-12 0% 0.14 (9.9e-01) 
Prostate 
(Men) 
14 212109 0.56 (0.47-0.65) 7.10E-13 53.46% 27.94 (9.2e-03) 
Thyroid 6 281469 0.69 (0.58-0.82) 1.70E-05 0% 4.66 (4.6e-01) 
Uterus 
(Women) 
11 163062 1.35 (1.07-1.7) 1.20E-02 83.57% 60.88 (2.5e-09) 
Table 9: Significant associations between Schizophrenia patients and site-specific cancer incidence and 
mortality.  
ASD site-specific cancer incidence and mortality 
 ASD studies reporting site-specific cancers were scarce. Only two significant results derived 
from the combination of two studies each were observed. The incidence risk of both tumor types, 
ovarian cancer (n = 2; RR = 10.26; 95% CI: 2.29-45.95; I2 = 0%) and eye cancer (n = 2; RR = 9.1; 95% 
CI: 1.16-71.67; I2 = 0%) was found to be increased in ASD patients compared to controls. 
Outcome Nº Studies 
 
Nº of participants 
with CNS 
Pooled RR  
(95% CI) 
P-value I2 Q 
(P-value) 
Eye 2 8556 9.1 (1.16-71.62) 3.60E-02 0% 0 (9.7e-01) 
Ovary 
(Women) 
2 3344 10.26 (2.29-
45.95) 
2.30E-03 0% 0.07 (7.9e-
01) 
Table 10: Significant associations between ASD and site-specific cancer incidence and mortality. 
 Supplementary Appendix 1 Figures 29 to 76 show the forest and funnel plots of the 
secondary outcomes for which ten or more observational studies were available, whereas 
Supplementary Appendix 1 Tables 1 to 7 present the complete meta-analysis results for all the CNS 
site-specific cancer analyses, both significant and non-significant.  
 2.3.4 Additional analyses results 
 In this section, we describe the additional analysis results. We start by reporting the pooled 
meta-analysis results of two subgroups of CNS disorders. Those whose main underlying processes 
are neurodegeneration (AD, HD, and PD) and those considered to be neuropsychiatric disorders 
(MD, BD, SCZ). The motivation to group neurodegenerative disorders together is that the 
underlying biological processes linked to neurodegeneration could be responsible for the reduced 
cancer incidence observed. Besides, neuropsychiatric disorders have been studied in combination 
in a number of previous publications, and patients suffering from them are known to be exposed 
to several shared risks, including unhealthy behaviors and impaired access to health care systems. 
 Second, we will present the sensitivity analysis results. The potential influence of several 
factors (Ethnicity, follow-up duration, number of participants with a specific CNS disorder included 
in the study, design, study quality, and smoking-related cancers versus non-smoking related 
cancers) on the meta-analyses results was evaluated when feasible. Those analyses were carried 
out only for the study's primary outcomes (all-cancer incidence and mortality). 
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 Finally, we assess the risk of publication bias for those meta-analyses, including information 
from ten or more observational studies are presented by means of Begg's and Egger's tests. 
  2.3.4.1 Associations between neurodegenerative and neuropsychiatric disorders 
and all-cancer incidence and mortality 
 Patients with neurodegenerative disorders presented a lower risk of all-cancer incidence (n 
= 28; RR = 0.73; 95% CI: 0.66-0.81; I2 = 97.4%) and mortality (n = 23; RR = 0.53; 95% CI: 0.42-0.67; 
I2 = 83.92%) compared to controls.  A significant reduction in cancer incidence was observed in 
both men (n = 15; RR = 0.86; 95% CI: 0.74-1; I2 = 97.02%) and women (n = 14; RR = 0.88; 95% CI: 
0.78-0.99; I2 = 94.09%). Gender-specific analyses also showed a reduced mortality risk in men (n = 
3; RR = 0.56; 95% CI: 0.4-0.77; I2 = 0%) and women (n = 2; RR = 0.62; 95% CI: 0.4-0.97; I2 = 19.42%). 
However, a small number of studies (3 and 2) were available in this case. 
 A slightly increased all-cancer incidence was observed in neuropsychiatric patients 
compared to controls (n = 56; RR = 1.06; 95% CI: 1-1.13; I2 = 95.36%). This trend was not observed 
in men (n = 35; RR = 0.94; 95% CI: 0.85-1.04; I2 = 96.39%), but it was also present in women (n = 34; 
RR = 1.11; 95% CI: 1.03-1.21; I2 = 94.71%). In the case of mortality due to cancer, neuropsychiatric 
patients were found to be at an increased risk compared to controls (n = 71; RR = 1.27; 95% CI: 
1.19-1.35; I2 = 95.01%). This trend was found to be present in both men (n = 42; RR = 1.25; 95% CI: 
1.13-1.38; I2 = 93.91%) and women (n = 33; RR = 1.48; 95% CI: 1.46-1.5; I2 = 96.15%). However, all-
cancer mortality was found to be significantly higher in women than in men with neuropsychiatric 
conditions.  
  2.3.4.2 Additional/Sensitivity analyses. 
 Additional analyses were carried out for potential confounding factors, including ethnicity, 
follow-up duration, the total number of patients with a particular CNS disorder, study design, and 
the study quality. A comparison between smoking-related cancers and cancers that have not been 
linked to cigarette consumption was also carried out. Meta-analyses in which only two data points 
were available are marked with an asterisk symbol, whereas items for which only one study was 
available are identified using a plus symbol in Tables 11 and 12. All other results are derived from 
meta-analyses for which information regarding three or more studies was available. 
 In the case of AD, we observed significant differences between the studies carried out in 
non-Asian (RR = 0.5, 95% CI:  0.34-0.73) and Asian (RR = 0.85, 95% CI: 0.8-0.9) populations. 
Significant differences were also observed between those studies including less than 500 AD 
patients (RR = 0.33, 95%: 0.22-0.47) and those studies reporting to include more than 1000 (RR = 
0.79, 95% CI: 0.69-0.89). PD patients were at a significantly lower risk for smoking-related cancers 




consumption (RR = 1.04, 95% CI: 0.91-1.2). The opposite pattern was observed in MD patients who 
were found to be at a higher risk of developing smoking-related cancers (RR = 1.36, 95% CI: 1.12-
1.65) than controls but were not found to be associated with non-smoking related cancers (RR = 
0.99, 95% CI: 0.72-1.35).  
 Studies including less than 500 PD participants showed significantly higher all-cancer 
mortality rates (RR = 0.82, 95% CI: 0.65-1.04) than those in which the number of participants was 
higher than 1000 (RR = 0.52, 95% CI: 0.37-0.74). However, in both cases, the reported associations 



































PD all-cancer  
incidence 
MD all-cancer  
incidence 
SCZ  all-cancer 
incidence 
Race Asian 0.85 (0.8-0.9) 
 
1.91 (0.52-4.88)+ 1.36 (1.25-1.48)* - 0.98 (0.57-1.68) 1.35 (0.91-2) 1.08 (0.88-1.33) 
 Non-Asian 0.5 (0.34-0.73) 
 
0.8 (0.43-1.49) 1.04 (0.76-1.41) 0.48 (0.29-0.78) 0.82 (0.76-0.89) 1.06 (1.01-1.11) 0.97 (0.89-1.07) 
Follow-up >1-5 0.72 (0.58-0.88) - 1.03 (0.93-1.15)+ - 0.87 (0.46-1.63) 1.17 (0.94-1.44) 1.1 (1.01-1.21) 
 >5 0.29 (0.18-0.47)* 1.41 (0.88-2.26) 1.29 (1.03-1.61) 0.59 (0.46-0.76) 0.87 (0.81-0.95) 1.16 (1.02-1.31) 0.98 (0.91-1.06) 
N total <500 0.33 (0.22-0.47) 
 
1.36 (0.54-3.21)+ - - 1.12 (0.88-1.43) 1.25 (1.03-1.5) 1.27 (0.78-2.06)+ 
 >500-1000 - - - 0.6 (0.5-0.8) 0.51 (0.25-1.06) 1.21 (1.03-1.44) 0.76 (0.54-1.06)* 
 >1000 0.79 (0.69-0.89) 0.96 (0.41-2.24) 1.1 (0.87-1.39) 0.62 (0.54-0.7) 0.85 (0.74-0.97) 1.11 (0.96-1.28) 0.99 (0.92-1.07) 
Design Case-control 0.85 (0.79-0.9)* 
 
0.65 (0.39-1.1)*  - 0.6 (0.5-0.8)+ 0.77 (0.72-0.83)* 1.21 (1.02-1.42)* - 
 Cohort 0.69 (0.56-0.85) 
 
1.49 (1.03-2.15)* 1.1 (0.87-1.39) 0.44 (0.24-0.83) 0.86 (0.75-0.97) 1.16 (1.04-1.29) 0.99 (0.92-1.07) 
Quality group Low-risk 0.61 (0.49-0.77) 
 
1.49 (1.03-2.15)* 1.12 (0.97-1.28) 0.52 (0.45-0.61)* 0.93 (0.82-1.07)* 1.18 (1.03-1.35) 0.99 (0.91-1.08) 
 Moderate-risk 0.86 (0.81- 0.92)+ 
 
0.65 (0.39-1.1)* 2.06 (1.76-2.41)* 0.43 (0.39-0.48)* 0.58 (0.44-0.76) 1.09 (1.02-1.16) 0.96 (0.92-1.01) 
 High-risk - - 0.27 (0.21-0.34)+ - - 1.35 (0.62-2.93)+ - 
Smoking 
related cancers 
Yes 0.88 (0.82-0.94) 
 
 
3.61 (1.12-11.68) 1.14 (0.94-1.39) 0.58 (0.44-0.77) 0.81 (0.75-0.88) 1.36 (1.12-1.65) 0.96 (0.89-1.03) 
 No 0.69 (0.52-0.91) 
 
2.48 (0.83-7.4) 1.08 (0.84-1.4) 0.84 (0.6-1.18) 1.04 (0.91-1.2) 0.99 (0.72-1.35) 0.73 (0.65-0.81) 
Table 11: Sensitivity analysis results for all-cancer incidence. Results marked with an asterisk (*) indicate results derived from the combination of only two studies. Results 





















Race Asian - - 1.35 (0.58-3.15)+ - 0.53 (0.23-1.23)+ 1.64 (1.05-2.58) 1.14 (0.87-1.48)* 
 Non-Asian 0.45 (0.33-0.61) 1.92 (1.58-2.32) 1.16 (1.09-1.24) 0.12 (0.08-0.17) 0.7 (0.55-0.9) 1.23 (1.14-1.33) 1.35 (1.24-1.47) 
Follow-up >1-5 0.83 (0.4-1.53) - - - 0.52 (0.37-0.74) 1.47 (1.21-1.78) 0.99 (0.54-1.82) 
 >5 0.48 (0.35-0.66) 2.59 (1.63-4.1)+ 1.17 (1.09-1.26) 0.05 (0.02-0.12)+ 0.69 (0.52-0.91) 1.19 (1.1-1.29) 1.34 (1.22-1.48) 
N total <500 0.52 (0.4-0.69) - 0.97 (0.71-1.35) 0.05 (0.02-0.12) 0.82 (0.65-1.04) 1.4 (1-1.97) 1.42 (1.09-1.85) 
 >500-1000 0.35 (0.26-0.48) - 2.05 (0.65-4.95)+ - 0.58 (0.4-0.85)+ 0.93 (0.55-1.56) 0.88 (0.63-1.23)* 
 >1000 - 1.92 (1.58-2.32)* 1.17 (1.09-1.25) - 0.53 (0.49-0.58) 1.27 (1.17-1.37) 1.31 (1.18-1.44) 
Design Cohort 0.51 (0.4-0.64) 2.59 (1.63-4.1)+ 1.16 (1.09-1.24) 0.12 (0.08-0.17)* 0.69 (0.54-0.87) 1.24 (1.15-1.34) 1.34 (1.23-1.46) 
 Case-control 0.25 (0.16-0.41)+ 1.8 (1.46-2.23)+ - - - - - 
Quality group Low-risk 0.63 (0.4-0.99) 1.92 (1.58-2.32)* 1.15 (1.07-1.24) 0.14 (0.093-0.212) 0.69 (0.54-0.87) 1.32 (1.22-1.44) 1.41 (1.28-1.56) 
 Moderate-risk 0.39 (0.26-0.57) - 1.21 (0.99-1.49) - 0.67 (0.42-1.06) 1.15 (0.98-1.35) 1.2 (0.99-1.46) 
 High-risk 0.44 (0.14-1.38)+ - 2.05 (0.65-4.95)+ 0.05 (0.02-0.12) 0.98 (0.22-4.35)+ 0.91 (0.76-1.09) 0.35 (0.23-0.55)+ 
Table 12: Sensitivity analysis results for all-cancer mortality.  Results marked with an asterisk (*) indicate results derived from the combination of only two studies. Results 












  2.3.4.3 Assessment of the risk of publication bias using Egger’s and Begg’s tests. 
 For those meta-analyses including information regarding ten or more different 
observational studies, we investigated if publication bias was present by means of visual inspection 
of the resulting funnel plots (Supplementary Appendix 1 Figures 29 to 76) and by means of two 
statistical tests design to detect asymmetries in the funnel plots (Egger’s and Begg’s tests). In 
general, we did not found evidence of publication bias. Only the SCZ all-cancer mortality meta-
analyses, including the overall analysis and the analyses stratified by sex, presented p-values < 0.05 
in the Egger’s test, as well as the cervical cancer incidence analysis in women with SCZ. 
Meta-analysis Egger’s test results Begg’s test results. 
BD (All cancer mortality) (n = 14; t = 1.15; p-val = 2.73e-01) (n = 14; t = 0.13; p-val = 5.11e-01) 
MD (All cancer incidence) (n = 22; t = 1.08; p-val = 2.92e-01) (n = 22; t = 0.29; p-val = 6.22e-02) 
MD (All cancer mortality men) (n = 12; t = 1.48; p-val = 1.69e-01) (n = 12; t = 0.06; p-val = 8.41e-01) 
MD (Breast cancer women) (n = 15;  t = 1.53; p-val = 1.49e-01) (n = 15; t = 0.33; p-val = 9.26e-02) 
MD (Prostate cancer men) (n = 12; t = 0.35; p-val = 7.31e-01) (n = 12; t = 0.21; p-val = 3.81e-01) 
PD (All cancer incidence) (n = 17; t = -0.32; p-val = 7.54e-01) (n = 17; t = 0.1; p-val = 5.98e-01) 
PD (All cancer incidence men) (n = 12; t = -0.13; p-val = 9.01e-01) (n = 12; t = 0.21; p-val = 3.81e-01) 
PD (All cancer incidence women) (n = 11; t = 0.14; p-val = 8.93e-01) (n = 11; t = 0.13; p-val = 6.48e-01) 
PD ( All cancer mortality) (n = 15; t = 1.53; p-val = 1.51e-01) (n = 15; t = 0.2; p-val = 3.28e-01) 
PD (Breast cancer women) (n = 11; t = -1.08; p-val = 3.07e-01) (n = 11; t = -0.2; p-val = 4.45e-01) 
PD (Colorectal cancer) (n = 15; t = -0.91; p-val = 3.78e-01) (n = 15; t = 0.07; p-val = 7.70e-01) 
PD (Lung cancer) (n = 13; t = -0.98; p-val = 3.48e-01) (n = 13; t = 0.08; p-val = 7.65e-01) 
PD( Malignant skin melanoma) (n = 13;; t = 1.13; p-val = 2.82e-01) (n = 13; t = 0.08; p-val = 7.65e-01) 
PD (Prostate cancer men) (n = 15; t = -0.85; p-val = 4.10e-01) (n = 15; t = 0.18; p-val = 3.79e-01) 
SCZ (All cancer incidence) (n = 26; t = 0.6; p-val = 5.54e-01) (n = 26; t = 0.05; p-val = 7.60e-01) 
SCZ (All cancer incidence men) (n = 22; t = 1.84; p-val = 8.05e-02) (n = 22; t = 0.13; p-val = 4.34e-01) 
SCZ (All cancer incidence women) (n = 20; t = -0.74; p-val = 4.71e-01) (n = 20; t = 0.04; p-val = 8.23e-01) 
SCZ (All cancer mortality) (n = 37; t = -3.09; p-val = 3.92e-03) (n = 37; t = 0.04; p-val = 7.65e-01) 
SCZ (All cancer mortality men) (n = 22; t = -2.3; p-val = 3.24e-02) (n = 22; t = 0.03; p-val = 8.67e-01) 
SCZ (All cancer mortality women) (n = 19; t = -2.57; p-val = 1.99e-02) (n = 19; t = 0.12; p-val = 4.89e-01) 
SCZ (Bladder cancer) (n = 10;; t = 2.16; p-val = 6.25e-02) (n = 10; t = 0.2; p-val = 4.84e-01) 
SCZ (Brain and CNS) (n = 11; t = -0.19; p-val = 8.51e-01) (n = 11; t = -0.02; p-val = 1.00e+00) 
SCZ (Breast cancer women) (n = 18; t = -0.25; p-val = 8.06e-01) (n = 18; t = 0.1; p-val = 6.01e-01) 
SCZ (Cervix cancer women) (n = 10; t = -2.62; p-val = 3.06e-02) (n = 10; t = -0.2; p-val = 4.84e-01) 
SCZ (Colorectal cancer)  (n = 14; t = 0.89; p-val = 3.90e-01) (n = 14; t = 0.05; p-val = 8.30e-01) 
SCZ (Kidney cancer) (n = 10; t = 1.13; p-val = 2.90e-01) (n = 10; t = 0.16; p-val = 6.01e-01) 
SCZ (Lung cancer) (n = 16; t = -0.41; p-val = 6.92e-01) (n = 16; t = -0.17; p-val = 3.98e-01) 
SCZ (Prostate cancer men) (n = 14; t = 0.72; p-val = 4.83e-01) (n = 14; t = 0.14; p-val = 5.18e-01) 
SCZ (Stomach cancer) (n = 10; t = 0; p-val = 9.99e-01) (n = 10; t = -0.07; p-val = 8.62e-01) 
SCZ (Uterus cancer women) (n = 11; t = -1.32; p-val = 2.19e-01) (n = 11; t = -0.02; p-val = 1.00e+00) 







 Our results suggest that CNS disorders present diverse patterns of associations with cancer. 
On the one hand, all three neurodegenerative disorders (AD, HD, and PD) were significantly linked 
to a reduction in the risk of subsequent overall cancer incidence and mortality. In the case of cancer 
incidence, HD presented the sharpest decrease in RR (52%), followed by AD (31%) and PD (15%). 
The same ordering was found in the case of cancer mortality with HD, AD, and PD, showing relative 
risk reductions of 78%, 55%, and 31%, respectively. However, the associations regarding HD should 
be taken with special caution due to the small number of studies included in the analyses. Gender-
specific analyses could not be performed for mortality in the case of AD nor for incidence or 
mortality in the case of HD due to the lack of data. Women and men with AD presented significant 
reductions in the relative risks of cancer incidence. In the case of PD patients, we did not observe 
significant reductions in cancer incidence, neither for men nor for women. However, a trend 
towards a risk reduction was observed in both cases (12% and 7% of relative risk reduction, 
respectively).  
 In addition to the body of research examining cancer incidence following the diagnosis of 
neurodegenerative disorders, several studies have investigated the reverse association. In the case 
of AD, at least seven observational studies have reported significantly reduced AD incidence after 
cancer diagnosis [108-110, 147-150]. However, previous data have pointed towards the possibility 
that cognitive impairment could arise as a result of cancer therapy. For instance, meta-analyses 
have provided some evidence for a possible link between chemotherapy and impairments in the 
domains of memory and executive function [151], and cranial irradiation could induce neuronal 
damage and loss [152]. In the case of PD, at least two works have suggested reduced PD risks after 
cancer diagnosis [153, 154], whereas some others have shown non-significant trends towards risk 
reduction or no associations [155-159]. Finally, one study found low cancer prevalence in 
Huntington’s disease patients compared to controls [160].  
 Different factors could account for the inverse patterns of comorbidity observed between 
neurodegenerative disorders and cancer. 
 First, both neurodegenerative disorders and cancer are characterized by the presence of 
abnormal cell behaviors. While a progressive neural loss is a hallmark of neurodegeneration, cancer 
is characterized by uncontrolled proliferation and survival of cells. The reported inverse comorbid 
associations between both sets of conditions indicate that neurodegeneration mechanisms could 
have a protective effect against cancer development, which translates into a reduced cancer 
incidence and mortalities. 
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 Other biological factors could also be the potential underlying causes of the observed 
inverse comorbidities. For instance, PIN1 is thought to play a role in the pathogenesis of both cancer 
and AD [161]. Deletions of this gene produce AD-like pathologic changes in mice [162], and its 
expression levels have been found to be downregulated in AD brain tissues and upregulated in 
several cancer types tissues [148, 163, 164]. Alterations in the PI3K/Akt/mTOR axis are a shared 
feature of both AD and cancer [165]. Estrogen has been found to reduce the risk of AD [166] and to 
increase the risk of certain cancers such as endometrial and breast cancer [167]. Given the cell 
proliferation stimulating effect of acetylcholine, the cholinergic system deficits found in AD patients 
have also been proposed as a potential candidate to explain the inverse patterns of comorbidity 
between AD and cancer [108, 168]. AD is associated with the degeneration of cholinergic neurons 
and reduced nicotinic acetylcholine receptor (nAChRs) signaling. In addition, acetylcholine and 
nAChRs can induce the synthesis and release of neurotrophins, growth factors, and angiogenic 
factors that can stimulate cancer proliferation. The inhibition of nAChRs causes apoptosis in 
cancerous cells [169]. Finally, Aβ, which plays a prominent role in AD pathogenesis, can activate the 
tumor suppressor p53, resulting in p53-dependent apoptosis. Several studies have found p53 to be 
upregulated in AD brains compared to controls [170]. 
 In the case of PD, some genes linked to its familial forms (INK1, LRRK2, C-terminal 
hydroxylase) have been found to be desregulated in tumor tissues [171]. The joint involvement of 
many biological processes has also been reported in both PD and cancer, including DNA damage, 
response to oxidative stress, metabolic dysregulation, and alterations in the ubiquitin-proteasome 
system. In addition, high levels of cholesterol and fatty acids have been linked to lower risks of PD 
and cancer-promoting effects [172]. 
 Regarding HD, mutant huntingtin has been shown to present a pro-apoptotic effect [173] 
based on the toxicity of the glutamine expansions (polyQ) present on the HTT protein. An 
alternative mechanism involving the role of the CAG triplet expansion at an RNA level has been 
shown to slow down tumor growth progression [174].  
 Second, the effect of some potential confounding covariates, including age, life 
expectancies, and smoking status, is thought to modulate the observed associations.  
 Aging is known to be the main risk factor for both AD and cancer [175, 176]. AD patients 
often present reduced life expectancies [177-182]. This could be associated with the reduced 
cancer risk observed in AD patients. However, all the observational studies reporting AD and cancer 
incidence associations used in our analyses accounted for age either by design or by adjustment. 
 Differences in patients' smoking habits could also constitute a confounding factor. For 
instance, AD patients are thought to smoke less than the general population, which could explain 




site-specific cancer analyses (with a relative risk reduction of 19%). However, our results suggest 
that AD is associated with a risk reduction of smoking-related (12%) and smoking-unrelated cancers 
(31%). Therefore, in the light of our data, it seems unlikely that differences in the smoking habits 
account for all the cancer risk reductions observed in AD patients. 
 A different conclusion can be drawn in the case of PD. PD patients have been shown to be 
lifelong non-smokers [183]. Our subgroup analyses showed that PD patients presented a significant 
reduction in the risk of smoking-related cancers (19%) but not in the risk of the smoking unrelated 
group of site-specific cancers. However, these conclusions are difficult to generalize to the overall 
cancer analyses since the vast majority of observational studies reporting PD and all-cancer 
associations did not account for the smoking status by means of study design or adjustment. If 
smoking habits in PD patients can account for all the differences in cancer incidence and mortality 
observed could be only determined by further epidemiological research. 
 Third, some authors have suggested that the associations arise as a consequence of the 
intrinsic limitations of the epidemiologic studies or systematic biases. 
 Cancer screening and diagnosis could be compromised in the case of patients with 
dementia. A handful of epidemiologic studies have also acknowledged the possible existence of 
ascertainment bias in cognitively impaired persons [184-187], and at least one study has found that 
AD patients present stronger inverse associations in older age groups (higher neurocognitive 
impairment) [147]. Patients with dementia have been found to present difficult issues of 
communication and consent to testing [188] and lower rates of cancer screening[189]. It has also 
been suggested that AD patients tend to be diagnosed with cancers at more advanced stages [190]. 
 Cancer is also thought to be underdiagnosed in HD patients because its signs and symptoms 
may not be noticed or covered by HD symptoms. One interesting example in this regard is cachexia, 
which is a symptom common in both cancers and the latter stages of HD progression. In contrast, 
some authors have found an increased cancer diagnosis rate in the first year after admission for 
HD, suggesting that overdiagnosis rather than underdiagnoses are more likely in this population 
[191]. Finally, claims about the role of specific medications as modulating agents in the inverse 
comorbid association found between CNS and cancer have also been made. In this regard, some 
interesting hypotheses include the observations that the use of levodopa, dopamine agonists, 
monoamine oxygenase-B inhibitors, and anticholinergics possibly affect tumor growth and 
progression [192]. In addition, two kinds of cancer chemotherapy (bexarotene and carmustine) 
could induce the clearance of physiological Aβ and reduce the cognitive deficits produced by its 
accumulation in mice models. A more exhaustive description of the role of medications as 
comorbidity modulators will be provided in Chapter 5. 
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 BD, SCZ, and ASD patients did not present altered all-cancer incidence rates, whereas MD 
patients were found to be at higher risk of subsequent overall cancer incidence (17%). In contrast, 
BD, SCZ, ASD, and MD presented a significant increase in cancer mortality (16%, 34%, 92%, and 
24%). 
 In principle, neuropsychiatric patients are exposed to several factors that would make them 
prone to cancer. Stress, a common trait found in different mental disorders, is associated with 
physiological changes that promote cancer [193]. Mental disorders are also linked to poor health 
behaviors, which are associated with increases in cancer risk, including smoking, alcohol 
consumption, and obesity, among others [194, 195].  
 Those factors could partially account for the increased risk of cancer in MD patients 
observed in our analysis. Our results also provide additional evidence in this direction since the risk 
of smoking-related cancers was found to be significantly increased in MD patients (36% increase), 
whereas the risk of smoking unrelated cancers did not. Furthermore, depression has been linked to 
other cancer-promoting factors such as disturbances in the autonomic nervous system, increased 
inflammation, and the reduction in circulating endothelial progenitor cells [196-198]. 
 In the case of schizophrenia, gender-based differences were observed for overall cancer 
incidence, with men presenting a significant reduction in cancer risk (13% relative risk reduction) 
and women showing a non-significant trend towards an increase in cancer risk (8%). This 
disagreement could be due to the significant increase in breast cancer incidence and mortality risks 
observed in schizophrenic women (37% and 71% increase, respectively) and the reduction of 
prostate cancer risk observed in schizophrenic men (44% reduction in prostate cancer). According 
to the World Health Organization, breast cancer and prostate cancer are the second and fourth 
most incident cancers and probably significantly impact the sex-specific overall cancer incidence 
associations. In the case of MD, gender-specific analyses for incidence did not yield significant 
results, but a trend towards an increase in the relative risks was observed. This is probably due to 
the inclusion of a reduced number of studies compared with the joint analysis of both genders.  
. Some authors have proposed that SCZ would present a protective effect against cancer. 
Catts and co-workers examined the results of three studies of cancer incidence in first degree 
relatives of SCZ patients and found a reduced cancer incidence [86]. However, according to our 
results, SCZ patients do not present a lower-than-expected risk of overall cancer. In this context, it 
has been argued that the lifestyle differences observed in SCZ patients compared to controls (high 
smoke and alcohol consumption) would compensate for the underlying genetic protective effect 
[199]. 
 Patients with severe mental illnesses such as SCZ and BP present higher overall mortality 




diagnosed in patients older than 60 years, which makes it important to control for age in the studies. 
All the studies included in the meta-analysis of cancer incidence in SCZ patients accounted for age 
as a confounding factor, reducing the likelihood for this factor to distort the study outcomes. 
 A number of different but not mutually-exclusive explanations could account for the 
increased cancer mortality rates observed in patients with neuropsychiatric disorders. First, the 
mental disorder itself could complicate the disease's treatment, including the radiotherapy 
administration or the adherence to the pharmacological treatment. Second, severe mental 
disorders have been associated with alterations in cancer screening, which could explain the higher 
cancer death rates observed in the case of BD, MD, and SCZ. Howard and colleagues [199] gathered 
data from 12 observational studies investigating cancer screening services' uptake by patients with 
mental illness. Six of the available studies suggested that patients with severe mental illness 
presented lower cancer screening rates than controls, whereas the rest of them reported no 
associations. The authors also noted that the studies reporting no associations included fewer 
patients with psychotic disorders. Third, the inequity of access to care and treatment has also been 
observed in people with psychiatric disorders [199]. A variety of factors can explain unequal access. 
Delays in help-seeking have been found to be longer in psychiatric patients [202]. General 
physicians tend to underestimate the importance of neuropsychiatric patients' physical symptoms 
and attribute them to psychological or psychiatric causes, a term known as diagnostic 
overshadowing [203]. Some studies report that the cancer treatment of patients with severe 
mental illnesses presents specific challenges due to the frequent co-occurrence of cardiovascular 
and respiratory disease, obesity, and malnourishment [199]. Finally, specific oncological treatments 
can interact with psychotropic medications producing adverse-effects. For instance, clozapine used 
in conjunction with cytotoxic drugs can result in agranulocytosis, increasing infection risk. Several 
psychotropic drugs are known to inhibit the metabolism of chemotherapy, including clomipramine, 
duloxetine, haloperidol, paroxetine, sertraline, and fluoxetine, which can increase the side-effects 
of chemotherapy, whereas other psychotropic drugs such as carbamazepine have been shown to 
increase the metabolism of chemotherapy reducing their efficacy [199]. All these factors could 
account for the higher-than-expected probability of cancer mortality yielded by our analyses.  
 Different patterns of association were observed between CNS disorders and site-specific 
cancers. We will limit the discussion to those site-specific cancers for which significant associations 
were found in meta-analyses including three or more studies. 
 The incidence risks of lung cancer and malignant skin melanoma were reduced in AD, 
colorectal and prostate cancer risks were found to be lower in patients with HD, whereas PD 
patients presented a reduced risk in bladder, colorectal, larynx, lip and oral cavity, and lung cancers. 
Colorectal and lung cancer mortality were also found to be reduced in PD patients, as well as 
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pancreatic and stomach cancer. CNS and site-specific cancer associations which presented an 
opposed comorbidity pattern than the one observed in all-cancer analyses are particularly 
interesting. For instance, PD patients were found to be at an increased risk of brain and malignant 
skin melanoma. PD is characterized by the loss of dopaminergic neurons in the substantia nigra pars 
compacta (SNpc) and a depletion of dopamine in the striatum [204, 205]. Pigmentation has been 
found to play a crucial role in both PD and melanoma. Melanin is responsible for the hair and skin 
color pigmentation in humans. In the brain, pigmented neurons produce a pigment known as 
neuromelanin. Abnormalities in both melanin and neuromelanin have been associated with both 
cancer and PD, providing a potential link between both disorders. Besides, light skin populations 
present higher incidences of melanoma than darker skin populations [206, 207]. This protective 
effect is thought to be due to melanin's capacity to scatter or absorb UVR light, preventing DNA 
damage, which leads to skin cancers. The lack of neuromelanin in human neurons makes them more 
susceptible to oxidative stress [208, 209]. Other mechanisms have been proposed to explain the 
co-occurrence of PD and melanoma. First, the treatment with levodopa was found to increase the 
risk of melanoma in some studies [210, 211]. However, this hypothesis remains controversial, and 
at least one epidemiological study found no associations between levodopa treatment and the 
incidence of melanoma [212]. Shared genetic alterations, including genes with roles in cell 
detoxification such as CYPD6 and GSTM1, and genes linked to some forms of PD such as Parkin are 
other potential modulating agents. 
 Major depression was associated with an increased risk of brain, lung, and pancreatic 
cancer. MD women were found to be at a higher risk of both breast cancer incidence and mortality. 
Some hypotheses state that depression influences the neuroendocrine axis and the neuro-
immunological function. This CNS dysregulation would put the organism at greater risk of morbidity 
and mortality [213]. Moreover, depression renders breast cancer survivors less capable of 
functioning successfully in modern society. People with depression are less likely to receive 
appropriate and correct health screening [214]. Some studies suggest that cancer survivors may be 
faced with adherence difficulties to chemotherapy and other complementary treatment, leading to 
faster cancer progression [213] . Finally, the use of tricyclic anti-depressants has been associated 
with a higher risk of breast cancer [215, 216]. 
 Women with SCZ presented an increased risk of breast and uterine cancer incidence. Breast 
cancer mortality was also found to be increased in SCZ patients. The higher incidence of breast 
cancer found in SCZ women could be due to the lower parity observed in women with SCZ [217, 
218]. The use of antipsychotic drugs, such as risperidone to treat these patients, has also been 
suggested to increase breast risk through hyperprolactinemia [219]. In contrast, the use of some 




schizophrenia have a higher prevalence of other breast cancer risk factors, including unhealthy 
lifestyle, obesity, and diabetes [220-222]. SCZ men were found to be at a reduced risk of prostate 
cancer. The risks of mortality due to colorectal, liver, lung, and pancreatic cancer were also found 
to be increased in SCZ patients compared to controls. 
 In summary, the landscape of the associations between CNS disorders and cancer emerges 
as a complex picture with different associations pointing towards different directions. A large set 
of possible confounding factors and systematic biases difficult the interpretation of the results. 
Moreover, our study presents some limitations that will be summarized next. First, although the 
body of evidence devoted to the study of CNS and cancer associations has grown in the last 
decades, the number of available studies was insufficient to draw robust conclusions in many of 
the performed analyses. In the case of primary outcomes, there was an uneven distribution of 
studies available for the different disorders, which was especially low in the case of HD and ASD. 
This issue was worse in the case of secondary outcomes in which only a handful of site-specific 
versus CNS cancer associations could be investigated a sufficient number of studies. The lack of 
data was critical in the case of the site-specific cancer mortality analyses. Second, the effect of 
potential confounding factors cannot be properly appraised. Besides age and gender, which are 
usually accounted for in observational studies, other factors are rarely adjusted for or marched by 
design. An important example in this regard is the smoking status of the patients. Smoking is a 
major risk factor for cancer, and despite this fact, we observed that the inclusion of information 
regarding it in observational studies is the exception rather than the norm. We carried out a 
stratified analysis of smoking-related versus smoking-unrelated cancers. However, those analyses 
were based on data regarding site-specific cancers. Further epidemiological research will be needed 
to clarify the effect of smoking as a modulating agent in the comorbidity patterns observed 
between CNS disorders and overall-cancer. 
 This limitation also applies to other confounding factors such as the family history of cancer, 
the body mass index, the indicators of physical activity or alcohol consumption, as well as data 
regarding the parity status of women hormonal related cancers such as breast cancer. 
 Furthermore, some intrinsic limitations of meta-analyses should also be taken into account 
(e.g., the inclusion of studies with different designs, settings, populations, treatment strategies, and 
diagnostic tools).  
 In the following chapters, we will try to identify some of the potential modulating agents 
involved in CNS and cancer comorbidities, such as the presence of joint alterations in genes and 











































Chapter 3: Transcriptomic associations between CNS disorders and 
cancer 
3.1 Introduction 
 In the previous chapter, we synthesized the epidemiological evidence regarding the 
associations between a selection of CNS disorders and cancer incidence and mortality, which led to 
the identification of diverse comorbidity patterns between them. Several factors have been 
proposed to account for the observed associations, including the presence of shared biological 
alterations such as the altered expression of genes and pathways. 
 Since its emergence in the early two-thousands, high throughput technologies have been 
applied to query the transcriptomes of human disorders. In particular array-based methods have 
been widely employed to compare the gene expression levels of healthy versus diseased tissues by 
means of differential gene expression analysis. The evolution of the field in the subsequent decades 
involving the improvement of methodologies and the reduction of their cost has led to the 
placement of many of this data in public repositories freely accessible to the scientific community. 
 Differential gene expression profiles provide information about genes and biological 
pathways that are deregulated in a particular disorder, and they can be regarded as a phenotypic 
manifestation of the disease. Therefore, for a given pair of disorders, the analysis of their similarities 
and differences can be used as an instrument to shed light upon the genetic factors and biological 
processes underlying the comorbid associations observed at a population level. 
 The availability of multiple studies comparing the changes in gene expression in specific 
disorders carried out using different cohorts of patients and controls by diverse research groups 
opens the door to the application of differential gene expression meta-analysis methods to 
combine the results. Meta-analysis methods in the context of gene expression have been shown to 
increase the statistical power, reduce the noise of gene expression measurements and the presence 
of false positives, and improve the estimates of effect sizes [223, 224].  
 Two major meta-analysis methods are available to synthesize the evidence from individual 
differential gene expression studies, those based on the combination of p-values, such as Fisher’s 
method, and those based on the combination of effect sizes. We selected the method proposed by 
Choi et al. [36], which is based on the combination of the effect sizes of individual studies under a 
random effects model. It provides information about the strength and direction of gene expression 
changes and allows the downstream pathway-level analysis using methods like Gene Set 
Enrichment Analysis (GSEA).  
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 It has been previously hypothesized that population-level direct and inverse comorbidity 
patterns between a given pair of disorders could translate into the presence of significant patterns 
of deregulation of genes and pathways in the same or opposite directions, respectively [30, 31]. 
Accordingly, for a given pair of directly comorbid disorders, a significant overlap is expected in the 
number of jointly upregulated and downregulated genes. In contrast, in the case of a pair of 
diseases exhibiting epidemiological patterns of inverse comorbidity (lower-than-expected 
probability of co-occurrence), genes and pathways upregulated in one disorder are expected to be 
downregulated in the other and vice versa. 
 Following this principle, Ibañez and co-workers [34] observed significant opposite patterns 
of transcriptomic deregulation between a set of three CNS disorders (Alzheimer’s disease, 
Parkinson’s disease, and schizophrenia) and three tumor types (colorectal, lung, and prostate 
cancer), which had been previously reported to be inversely associated by observational studies. 
The authors also provided functional insight, identifying specific genes and pathways deregulated 
in opposite directions, including PIN1 and ATP13A2, and p53 signaling. Along the same lines, 
Sanchez and co-workers [35] identified potential molecular substrates that could underlie both the 
direct epidemiological association between Alzheimer’s disease and glioblastoma and the inverse 
associations observed between Alzheimer’s disease and lung cancer. Results pointed towards 
immune system-related processes and alterations in the mitochondrial metabolism as potential 
modulating agents. 
 This chapter aims to explore the transcriptomic associations between the set of seven CNS 
disorders included in the previous chapter (AD, ASD, BD, PD, MD, HD, and SCZ) and a large collection 
of twenty-two cancer types (i.e., acute lymphoblastic leukemia (ALL), acute myeloid leukemia 
(AML), bladder cancer (BLCA), breast cancer (BRCA), brain cancers (BRNCA), cervical cancer (CERV), 
cholangiocarcinoma (CHLCA), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), 
colorectal cancer (CRCA), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FLYMPH), 
head and neck carcinomas (HANC), kidney cancer (KDNCA), lung cancer (LGCA), liver cancer (LIVCA), 
ovarian cancer (OVCA), pancreatic cancer (PACA), prostate cancer (PRCA), melanoma (SKCM), 
gastric cancer (STCA), and thyroid cancer (THCA)) through the joint analysis of their differential gene 
expression profiles. For each disease, differential expression meta-analyses were carried using 
studies available in public repositories. First, we tested if CNS disorders were significantly associated 
with cancers by analyzing the intersections formed by the upregulated and downregulated genes 
in each given pair of disorders. Second, we characterized the functions of potential molecular 
substrates (genes and pathways) that could be involved in the disease-disease association 
modulation using gene set enrichment analysis methods. Finally, we introduced a systems biology 




expression modules were tested for their association with disease status. Then, co-expression 
modules significantly associated with each disorder were compared between all possible disease 
pairs by means of Fisher’s exact tests. 
 Additional analyses were carried out to test the potential impact of unknown confounding 
variables, and the observed associations were further validated using an alternative cancer cohort 




























3.2 Material and methods 
 3.2.1 Chapter workflow 
The workflow of this chapter is summarized in Figure 6. For a given disorder, we first 
searched for available transcriptomic data in public omics repositories. Each study was 
independently preprocessed and subjected to outlier detection analysis and removal. A study-level 
quality control step was carried out, and studies surpassing a defined quality threshold were 
excluded from downstream analyses. Differentially expressed genes (DEGs) were identified for each 
disorder by means of random effects model differential gene expression meta-analysis. The outputs 
of the analysis were used to carry out gene-set enrichment analysis. For a given disease pair, the 
four possible intersections formed by the jointly upregulated and downregulated genes were tested 
for significance using Fisher’s exact tests and, the joint deregulation of biological processes and 
pathways was explored by comparing gene-set enrichment analyses results. Finally, gene co-
expression networks were constructed for each disease, and the resulting modules were tested for 
association with disease status. Finally, modules significantly associated with each disorder were 














































 3.2.2 Search strategy 
 Searches for available datasets were performed in the following genomic data repositories: 
Gene Expression Omnibus (GEO), Array Express (AE), the Stanley medical research institute. (SMRI), 
and the cancer genome atlas (TCGA). In the case of CNS disorders, given the scarcity of studies 
including brain samples, additional non-systematic searches for previously published gene 
expression datasets were undertaken. Raw array data for such studies was directly requested to 
the authors when possible.  
 3.2.3 Inclusion and exclusion criteria 
 Transcriptomic datasets should include at least 3 cases and three control samples derived 
from matching tissues. To ensure that compatible preprocessing strategies could be applied to each 
study, we only selected one channel microarray data derived from the most popular Affymetrix, 
 




Illumina, and Agilent platforms. See Appendix 5 for a complete list of the included studies and their 
platforms.  
 In the case of CNS disorders, we focused on studies carried out using samples obtained 
from post-mortem brains and excluded datasets derived from blood samples. To reduce the 
heterogeneity that would be introduced by the inclusion of datasets from different brain regions, 
we selected one specific brain region for each disorder. The choice was based on two criteria, data 
availability and strong evidence linking the specific brain region with the physiopathology of the 
disease under consideration. Information regarding the brain regions selected for each CNS 
disorder can be found in Table 14. 
Cancer studies derived from primary tumor samples and matched tissue control samples 
were selected for inclusion, whereas datasets based on blood, metastatic, or cell line samples, were 
excluded. Since the presence of studies derived from the same cohort could artificially inflate the 
differential gene expression meta-analysis results, efforts were made to exclude datasets derived 
from potentially redundant cohorts of individuals. 
 Appendix 5 shows all the identified studies that met inclusion criteria, as well as 
information regarding the micro-array platform and the number of samples (cases and controls) 
included before and after outlier sample filtering. The summary values of the study-level quality 
control and each study's inclusion status based on these values are also provided in the same 
appendix. Appendix 6 shows the number of samples included in the TCGA cancer validation 
datasets. 
 3.2.4 Preprocessing steps for array and RNA-seq data 
 Datasets generated using Affymetrix platforms were preprocessed as follows: CEL files 
were retrieved from GEO, AE or directly from the study authors, and the R packages oligo [225] and 
affy [226] were used to read them and to perform RMA normalization and summarization, which 
was followed by quantile between-sample normalization and log2 transformation. 
 For Illumina platforms, non-normalized data was loaded to the R’s environment using the 
limma package [227] and a set of custom functions. The Lumi package [228] was used to perform 
background correction using a normal exponential model fitting with the normexp RMA option 
selected, followed by quantile normalization and log2 transformation. Agilent data was 
preprocessed using the limma package [227] following the same preprocessing steps. In the case of 
the RNA-Seq dataset used in the ASD meta-analysis, raw counts obtained from GEO were loaded in 
the R’s environment. The Rlog function from the DESeq2 package [229] was then used to transform 
the RNA-Seq count distribution to a continuous distribution suitable for integration with the array 




minimizing the differences between samples for rows with small counts and normalizing the data 
with respect to the library size. Further details about the ASD analysis, which include the addition 
of control samples from other studies and the elimination of samples derived from the same 
patients, can be consulted in reference [230]. 
 We transformed dataset-specific IDs into ENTREZ IDs using annotation packages to 
harmonize probe annotations between different dataset platforms. Probes targeting the same gene 
were collapsed using the collapseRows function from the WGCNA [231, 232] package using the 
MaxMean method. 
 RNAseq data derived from TCGA was preprocessed as follows: The TCGAbiolinks package 
[233] was used to download RNAseq counts derived from the HTSeq workflow. The 
TCGAanalyze_Preprocessing function was then applied with a correlation threshold of 0.6. Next, 
the TCGAAanalyze_Normalization function was employed to carry out normalization using the 
gcContent method. TCGAanalyze_Filtering was finally employed to remove mRNA transcripts with 
low expression values through the quantile method with a cutoff value of 0.30. 
 3.2.5 Quality control and outlier samples removal 
 We performed quality control and outlier sample detection using two different approaches 
for CNS and cancer-related datasets, respectively. Given the low amount of datasets and samples 
available for the analysis of CNS disorders, we selected a conservative and more computationally 
intensive approach to detect and remove outlier samples. We used three array quality measures 
described in detail below. Each one is aimed to evaluate a specific trait related to array quality in 
each sample. Measure 1 computes distances between arrays. The distance between two arrays 𝑎 
and 𝑏 (𝑑 ), is the mean absolute difference between the expression values of all probes. 𝑑 =
𝑚𝑒𝑎𝑛 |𝑀 −  𝑀 |, where 𝑀  is the value of the i-th probe of array a and 𝑀  is the is the value 
of the i-th probe of array b. Measure 1 tags a particular sample as an outlier when the sum of the 
distances to all other arrays 𝑆 =  ∑ 𝑑  is large. Measure 2 examines the array intensity 
distributions of the arrays. It is expected that the intensity distribution of the arrays has similar 
positions and widths. Intensity distributions of specific arrays that are very different from the rest 
of arrays distributions may indicate experimental problems. The Kolmogorov-Smirnov statistic 𝐾  
is used to measure the level of agreement between each array’s distribution and the distribution 
of the pooled data. Arrays presenting a large deviation from the pooled intensities distribution are 
tagged as potential outliers by this measure. Finally, Measure 3 appraises the individual array 
quality by examining MA plots. where 𝑀 is defined as 𝑀 = 𝑙𝑜𝑔 (𝐼 ) −  𝑙𝑜𝑔 (𝐼 ) and 𝐴 is defined 
as 𝐴 =   (𝑙𝑜𝑔 (𝐼 ) +  𝑙𝑜𝑔 (𝐼 ) ) where 𝐼  is the intensity of the studied array and 𝐼 is the intensity 
of a “pseudo”-array that consists of the median across arrays. It is expected that the mass of the 
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distribution concentrates around the M = 0 axis. Outlier detection was performed by computing 
Hoedffding’s statistic 𝐷  on the joint distribution of A and M for each array. Further information 
about the sample-level quality assessment can be found in the documentation of the 
ArrayQualityMetrics package [234]. Samples were removed from datasets only when the three 
measures tagged them as a potential outlier. To prevent that outlier samples were removed 
preferentially from cases or controls due to unbalanced study designs, the quality control and 
outlier detection procedures were carried out independently in each subgroup of samples. 
 For cancer data, given the high amount of available studies and samples, we applied a less 
conservative outlier detection method, which had the advantage of being less computationally 
intensive. For each dataset, we computed array-array correlations. Then, the mean inter-array 
correlation was calculated. If the mean inter-array correlation was higher than 0.9, samples were 
not removed, and the complete dataset was included for downstream analyses. On the contrary, 
when the mean inter-array correlation was lower than the selected threshold, samples presenting 
more than two standard deviations in mean correlation measures with all other arrays were tagged 
as outliers and removed from the dataset. This procedure was repeated iteratively until a global 
mean inter-array correlation higher than 0.9 was reached.  As in the instance of CNS-derived 
diseases, to prevent preferential removal of the case or controls samples due to unbalanced study 
designs, the method was applied independently to cases and controls. 
 3.2.6 Study-level quality assessment 
 Study-level quality control was carried out using the MetaQC package [235]. MetaQC 
computes six different quality control measures. IQC evaluates the homogeneity of the co-
expression structure across studies, and it is based on the comparison of the co-expression 
structure of study k to the co-expression structure of all other studies. EQC appraises the 
consistency of the co-expression information with a pathway database. AQCg assesses the accuracy 
of biomarker detection by comparing the list of differentially expressed genes derived from study 
k to the list of differentially expressed genes obtained by performing meta-analysis using all studies 
except study k. AQCp represents an extension of AQCq where enriched pathways substitute genes. 
CQCg evaluates the consistency of the gene differential expression ranking from single study to the 
rank of differentially expressed genes obtained by performing a meta-analysis with all studies 
except study k, and CQCp assesses the consistency of the enriched pathway ranking. In general low 
values of each quality measure suggest poor agreement of study k to the rest of the studies 
indicating that it is a potential outlier, whereas high values indicate good agreement of a specific 
study with all other studies. Finally, MetaQC employs principal component analysis (PCA) biplots 




studies. High SMR values indicate potential outlier studies. In the present study, we choose an SMR 
threshold of 7 as an exclusion criterion for potentially problematic studies. 
 3.2.7 Differential gene expression meta-analyses 
 Differential gene expression meta-analyses are known to increase the statistical power and 
reduce the noise of gene expression measurements [223]. For each disease, meta-analyses were 
carried out using Choi’s et al. method [36] implemented in the MetaDE package [235]. All meta-
analyses were performed using random effect models since high heterogeneity was expected, given 
our data's biological and technical variability. Meta-analysis methods based on effect size 
combinations have been described in detail in this manuscript's introductory section. Genes 
showing a false discovery rate (FDR) adjusted p-value lower than 0.05 were considered to be 
differentially expressed.  
 The potential impact of confounding factors was assessed as follows. For each study, 
surrogate variables (SV) were identified and computed using the SVA package's sva algorithm [236]. 
The algorithm is divided into two parts. The first part is oriented to the detection of the number of 
surrogate variables. We restricted the number of surrogate variables to 3 since the inclusion of a 
large number could remove true biological signal. The second part of the algorithm is dedicated to 
the computation of the values of the SVs. For each study, differential gene expression analysis was 
carried out using limma [227] in two different settings. In setting one, only the predictive variable 
of disease status was introduced in the model. In setting two, the model was constructed using the 
disease status, and the detected SVs were introduced as adjustment factors. Then for each disorder, 
differential gene expression meta-analyses were carried out under the two different settings (i.e., 
including the individual study differential gene expression result with and without adjustment for 
surrogate variables). Since MetaDE does not allow covariate adjustment, an alternative differential 
gene expression meta-analysis method based on the combination of the log-fold changes of 
individual differential gene expression analyses was used. This method is implemented in the 
MetaVolcanoR package [237], which internally makes use of the metafor package [122] to 
computed pooled estimates of the log-fold changes of each gene under a random effects model 
using the inverse of the variance method. Then the results (i.e., the differentially expressed genes) 
obtained under both settings were compared using Jaccard indexes. 
 3.2.8 Leave-one-out and cumulative analyses 
 We applied a leave-one-out strategy to detect individual studies' impact in our differential 
gene expression meta-analysis results. Therefore, we repeated each differential gene expression 
meta-analysis using Choi’s method for each disease by removing one of the studies at a time. Thus, 
for a particular disease with n available studies, n meta-analysis using n-1 studies were carried out. 
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Results were inspected to detect datasets displaying an abnormally large impact in the differential 
gene expression meta-analysis results. The significance threshold was set to a conventional level of 
0.05, and genes with a false discovery rate (FDR)-corrected p-value lower than 0.05 were 
considered to be differentially expressed.  
 In addition, we analyzed the impact of the stepwise inclusion of studies in the meta-
analysis. In order to do it, we sorted the studies based on their SMR quality score (Computed by 
MetaQC) from lowest to the highest quality. We first performed the meta-analysis using the two 
studies showing the lowest quality scores, and then we repeated it iteratively by adding one study 
at a time based on the cited order. 
 3.2.9 Measures of disease-disease transcriptomic associations 
 The expression profiles of each CNS disorder and all the studied cancer types were 
compared to evaluate the significance of the overlaps between the differentially expressed genes, 
as previously described in [34] and [35]. For each CNS disorder and-cancer pair, the significance of 
the four possible intersections formed by the upregulated and downregulated genes was evaluated 
by means of one-tailed Fisher’s exact tests. The intersections were: 
 1) Genes upregulated in both a specific CNS and the selected cancer type 
(Intersection A), 
 2) Genes downregulated in both a specific CNS and the selected cancer type 
(Intersection B), 
 3) Genes upregulated in a specific CNS and downregulated in the selected cancer 
type (Intersection C), and 
 4) Genes downregulated in a specific CNS and upregulated in the selected cancer 
type (Intersection D).  
 Fisher's test p-values were corrected by multiple testing using the false discovery rate 
method (FDR). Overlaps showing adjusted p-values lower than 0.05 were considered significant. 
The background number of genes was set as the number of genes jointly included in the two meta-
analyses under consideration, which depended on the platforms included in each meta-analysis. A 
cancer type was considered to be deregulated in the same direction as a CNS disorder when 
Intersections A and B were significant, and Intersections C and D were not. These cancer types were 
referred to as same direction deregulated cancers (SDDCs) and could be candidates for direct 
comorbidity with the specific CNS disorder. Conversely, a cancer type was considered to be 
deregulated in the opposite direction from a particular CNS disorder when intersections C and D 




opposite direction deregulated cancers (ODDCs) and could be candidates for inverse comorbidity 
with a specific CNS disorder. 
 Additionally, to determine the strength of the overall associations between differential 
expression profiles, Pearson’s correlations were computed using the Z-values obtained from each 
differential gene expression meta-analysis. Positive correlations suggest similar patterns of 
differential expression, while negative correlations would indicate opposite patterns.  
 3.2.10 Validation of the CNS and cancer associations using an independent cohort 
of cancers.  
 The cancer genome atlas was queried for RNAseq-based experiments interrogating tumor 
samples for the tumor types included in our array-based analysis. Data was downloaded and 
preprocessed using the R package TCGAbiolinks [233]. DEseq2 [229] was used in order to compute 
differential gene expression between cases and controls. Results were used to perform intersection 
analysis following the same methodology explained for arrays in the previous section. 
 3.2.11 Weighted co-expression network analyses 
We carried out consensus module detection for each disorder using all the datasets 
employed in the differential gene expression meta-analysis step and the WGCNA package [231]. 
Consensus modules are clusters of densely interconnected genes present across datasets. First, Bi-
correlation networks were constructed for each study resulting in a set of gene-gene correlation 
matrices. The parameter choices for consensus module detection analyses were based on the 
parameters selected by the authors of the package in their analysis of a set of eight lung cancer 
datasets reported in [238]. Bi-correlation matrices were transformed into signed-hybrid adjacency 
matrices as described in the following equations. 
𝑎 =  𝑐𝑜𝑟 𝑥 , 𝑥  𝑓𝑜𝑟 𝑐𝑜𝑟 𝑥 , 𝑥  > 0  
𝑎 = 0  𝑓𝑜𝑟 𝑐𝑜𝑟 𝑥 , 𝑥  ≤ 0  
Adjacency matrices are called “hybrid-signed” because they use a combination of hard and 
soft thresholding. A hard threshold is used for correlation values ≤ 0 and a soft threshold for values 
above 0. The parameter 𝛽 is selected such that the resulting adjacency matrix fits a power-law 
distribution by using the pickSoftThreshold function implemented in the package. Adjacency 
matrices. 𝐴 =  𝑎   have the following properties: 
𝑎 =  𝑎  
0 ≤  𝑎  ≤ 1 
𝑎 =  1 
The next step involves the transformation of adjacency matrices into topological overlap 
matrices using the following equation: 
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𝑇𝑂𝑀 (𝐴) =  
∑ 𝑎 𝑎 + 𝑎 ,
𝑚𝑖𝑛 ∑ 𝑎  , ∑ 𝑎 + 1 − 𝑎
 
The 𝑇𝑂𝑀 (𝐴) matrix is also an adjacency matrix. The topological overlap of two genes reflects 
their similarity in terms of the commonality of the genes to which they are connected. The TOM 
leads to a more robust network and larger modules which satisfies the same properties than 𝐴. 
Using the resulting topological overlap matrices derived from each individual dataset, a consensus 
TOM matrix was generated following the quantile method. For a set of K matrices 
𝑇𝑂𝑀( ), 𝑇𝑂𝑀( ), … 𝑇𝑂𝑀( ). A consensus adjacency matrix is constructed using the quantile 
method. 
𝑄𝑢𝑎𝑛𝑡𝑖𝑙𝑒 , 𝑇𝑂𝑀




  … 𝑡𝑜𝑚
( )  
 The consensus TOM was defined as the consensus of the individual TOM matrices with 
percentile q = 0.25. In the consensus TOM, two variables are connected with the strength that is 
common to all input networks. Finally, a dissimilarity matrix based on the consensus TOM matrix is 
fed as an input for the dynamic tree-cutting algorithm, which identifies co-expressed gene clusters 
(consensus modules). The steps described above were carried out using the 
blockwiseConsensusModules with the following parameters set to maxBlockSize = 30000, corType 
= "bicor", networkType = "signed hybrid", deepSplit = 3, mergeCutHeight = 0.25, and 
consensusQuantile = 0.25).  
 Once the consensus modules were identified, each module's eigengenes were computed, 
and correlations between them and disease status were calculated. A module eigengene is defined 
as the first principal component of the expression matrix of the genes included in a specific module. 
It typically explains more than 50% of the module expressions' variance [239]. Significant positive 
correlations between disease status and a particular module eigengene suggest that genes placed 
at that particular module tend to be upregulated in cases compared to controls. In contrast, 
significant negative correlations have the opposite implication (the genes places in the module tend 
to be downregulated in disease samples compared to controls).  
 3.2.12 Module-module overlap analyses 
 Genes contained in all modules significantly correlated to disease status were identified for 
all the included disorders. Then, associations between modules of co-expressed genes significantly 
correlated with disease status were computed for all possible pairwise comparisons through 
Fisher’s exact tests. The p-values of all pairwise module-gene overlap analyses were adjusted for 




 3.2.13 Functional and cell type-specific enrichment analyses 
 Diverse functional analysis methods and sources for sets of genes were used in the different 
sections. Classic overrepresentation analysis was carried out to compute enrichment in gene 
ontology (GO) terms for the genes placed at the intersections observed in the intersection analyses 
and for genes placed in the detected co-expression modules using the clusterProfiler [240] and 
anRichment [241] R packages. Gene Set Enrichment Analysis (GSEA) was used to identified 
upregulated and downregulated pathways in each disorder using as an input the list of genes 
ordered by its Z-score obtained by Choi’s differential gene expression meta-analysis. GSEA analyses 
were carried out using the fGSEA package implementation [242]. The sets of genes were retrieved 
from the molecular signatures database (MSigDB) [243]and included the hallmarks (H) set of genes, 
the canonical pathways subset (C2:CP) of the C2 curated set of genes, and the Gene Ontology (C5) 
set of genes.  
 Finally, enrichment in cell type-specific genetic markers was carried out for each detected 
consensus module using a collection of cell-specific gene markers derived from PanglaoDB database 
and hypergeometric tests. This database contains a list of gene expression markers used to define 
154 cell types. The obtained p-values were corrected for multiple comparisons using the false 
discovery rate (FRD) method. 
3.3 Results 
 3.3.1 Tissues selected for each CNS disorder 
 Tissues included to carry out the differential gene expression meta-analyses of CNS 
disorders were selected based on data availability and strong support linking the selected tissue 
with the disorder's physiopathology. In the case of AD, we only selected studies and samples 
derived from hippocampal tissues. For HD, studies based on caudate nucleus samples were 
selected, whereas, in the case of PD, we only picked datasets and samples derived from the 
substantia nigra. Reduced hippocampal volume, neural loss, and the presence of neurofibrillary 
tangles and beta-amyloid deposition are a core feature of AD [244]. Substantia nigra, placed in the 
ventral midbrain, contains groups of nerve cells that play a pivotal role in movement control. Those 
neurons communicate with the neurons in the basal ganglia by liberating the neurotransmitter 
dopamine. PD is characterized by the progressive degeneration and loss of neurons of the 
substantia nigra [245]. The striatum, which comprises the caudate nucleus and the putamen, is the 
HD's primarily affected region, where up to 90% of neurons have been found to be lost [246]. In the 
cases of ASD, BD, MD, and SCZ, we included datasets derived from the prefrontal cortex of disease 
patients and controls. One of SCZ patients' characteristic features is their difficulty in prioritizing, 
processing, and responding to information. Some studies have reported modified levels of activity 
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and structural and metabolic abnormalities in frontal regions in SCZ patients compared to controls. 
Alterations in the prefrontal cortex have also been observed in MD, BD, and ASD [247, 248]. Neuron 
overabundance has been found in the dorsolateral prefrontal cortex of ASD patients [249]. Table 
14 shows the selected tissues included in each differential gene expression meta-analysis for each 
CNS disorder. 
CNS disorder Studied tissue 
Alzheimer’s disease Hippocampus 
Autism spectrum disorders Frontal cortex 
Bipolar disorder Frontal cortex 
Huntington’s disease Caudate Nucleus 
Major depression Frontal cortex 
Parkinson’s disease Substantia nigra 
Schizophrenia Frontal cortex 
Table 14: Brain tissues studied in each CNS disorder. 
 
 3.3.2 Number of included studies and samples 
 In total, 192 unique datasets were identified and selected for potential inclusion in our 
analyses. After study-level quality control, 160 individual studies gathering 16132 samples 
remained. Note that several datasets included information for more than one disorder. Appendix 
5 shows information regarding the identified studies, including the initial number of samples in 
each dataset, the final number of samples after removal due to exclusion criteria application and 
outlier removal, and the study level quality control summary value (SMR), as well as the status of 
final inclusion in our analysis based on the reported SMR.  
Five studies from CNS disorders, all belonging to Parkinson’s disease, were excluded from 
subsequent analysis because they presented SMR values >= 7. A total of 29 CNS-related datasets 
gathering 1371 samples, divided into 618 cases and 753 controls, were selected after study-level 
quality control. The number of samples available for each CNS disorder ranged from 89 (47 cases 
and 42 controls) in the case of HD to 347 (166 cases and 181 controls) in the case of SCZ. Twenty-
seven cancer datasets were excluded after study-level quality control (AML = 1, BRNCA = 3, CRCA = 
8, KDNCA = 2, LGCA = 9, LIVCA = 4) because they presented SMR values higher than the selected 
threshold. One hundred and thirty-one datasets gathering 14761 samples (11152 cases and 3609 
controls) were included in cancer analyses. The total number of samples available for each site-
specific cancer ranged from 139 (82 cases and 57 controls) in the case of cervical cancer to 1500 
(1406 cases and 94 controls) in the case of ALL.  
The cancer validation dataset consisted of 7361 samples, including 6717 cases and 644 
controls from 17 tumor types corresponding to 15 of the cancer types included in our array-based 




available. Data for leukemias, lymphomas, melanoma, and ovarian cancer did not include matched 
normal tissue. Therefore, differential gene expression analysis could not be carried out. In addition, 
some tumor types were represented by more than one dataset. For instance, lung cancer was 
divided into two datasets corresponding to lung adenocarcinomas and lung squamous cell 
carcinomas. Appendix 6 shows the TCGA datasets used in the validation step, along with the 
correspondence between the array-based analysis and the number of samples and differentially 
expressed genes for each cancer type.  
 3.3.3 AD differential gene expression meta-analyses results 
In this section, we present the complete differential gene expression analysis results for 
AD. A summarized version of the results shown in this section for all the studied disorders will be 
presented in Section 3.3.4. 
Seven studies including samples derived from the hippocampus of AD patients and 
controls, were identified in public repositories. Individual datasets were preprocessed as described 
in methods and subjected to outlier sample detection and removal. Study-level quality control was 
then undertaken. All seven datasets presented SMR values under the selected threshold of 7 and 
were therefore selected for downstream analysis (See Table 15) 
 
Study IQC EQC CQCg CQCp AQCg AQCp SMR 
GSE48350 8.56 4.3 302.79 6.51 186.95 2.9 1.5 
E_MEXP_2280 3.48 4.3 103.81 1.35* 44.47 2* 3 
GSE36980 2.01* 4.3 127.17 0.63* 74.98 0.46* 3.88 
GSE5281 3.02 4.3 66.65 0.24* 42.57 1.3* 4.25 
GSE84422 3.85 2.34 0.76* 3.02 0.03* 0.52* 4.75 
GSE1297 5.59 1.95* 74.19 0.46* 36.33 0.39* 5.12 
GSE29378 0.44* 4.3 4.47 1.13* 3.3 0.01* 5.5 
Table 15: Study-level quality control of the datasets included hippocampal samples for AD and control 
subjects. 
In total, 226 samples derived in 124 cases and 102 controls distributed among the seven 
studies were available for downstream analysis. 
 Differential gene expression analysis of individual studies yielded heterogeneous results 
with three studies (GSE84422, GSE1297, E_MEXP_2280) presenting no significantly deregulated 
genes, one (GSE29378) showing only 2 DEGs, and three studies (GSE48350, GSE5281, GSE36980) 
showing 3275, 3667, and 1115 DEGs respectively (Figure 7 A). 
 Random effects models differential gene expression yielded 3341 DEGs, of which 1364 
were found to be significantly upregulated, whereas 1977 were found to be significantly 
downregulated after correction for multiple comparisons (FDR < 0.05) (Figure 7 B). The top 10 
upregulated genes in AD hippocampal samples compared to controls were PLEC, ITPKB, MTSS2, 
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TRIP10, PPP1R13L, KCNN3, PSD4, MXRA8, LPAR4, and PSTPIP1, whereas the top 10 downregulated 
genes were GAD1, MAK16, POLB, RPP40, NREP, TXNDC9, TNFRSF21, LRRC8B, MRPS22, PEX11B. 
Supplementary Appendix 1 Figure 77 shows the expression values of the top upregulated gene 
(PLEC) across studies, whereas Supplementary Appendix 1 Figure 78 does it for the top 
downregulated gene (GAD1) to exemplify how differential gene expression meta-analyses are able 
to capture DEGs that are consistently deregulated between studies even in the cases in which they 
are not found to be significantly deregulated in a subset of individual studies. 
 The mean Q value of the genes included in the analysis was Q = 10.59 and  the mean 𝜏  
was 033. Cumulative meta-analysis showed how the number of DEGs increases as higher-quality 
studies are introduced in the meta-analysis sequentially (Figure 7 C).  
 The leave-one-out analysis showed that the study with the highest impact on the final 
outcomes was GSE4835 since its exclusion from the meta-analysis produces the output with the 
lowest number of DEGs (Figure 7 D). 
Surrogate variable detection identified three significant surrogate variables for GSE84422 
and E_MEXP_2280, one for datasets GSE5281 and GSE29378, and none for the rest of the included 
studies. The alternative meta-analysis method using the raw data yielded 1856 up- and 2232 down-
regulated genes. In contrast, when the meta-analysis was carried out after adjustment for surrogate 
variables, only 963 up- and 1256 down-regulated genes were found. This indicates the presence in 
the data of unknown sources of variation, which could be linked to covariates not included in the 
analysis (i.e., age, sex, post mortem interval) (Figure 7 G). Most of the genes found to be 
differentially expressed in the surrogate variable adjusted analysis were also found to be 
differentially expressed in the raw dataset. Besides, the correlation of the log-fold changes of both 
analyses is was found to be large (r = 0.93).  
GSEA analysis showed that upregulated pathways in AD samples compared to controls 
included instances of immune-related pathways such as cytokine-cytokine receptor interaction (p-
adj: 4.85e-09), interleukin 4 and interleukin 13 signaling (p-adj: 1.77e-08), and complement cascade 
(p-adj: 3.54e-06), among others. Pathways downregulated in AD patients compared to controls 
were found to be linked to mitochondrial energy production and included instances, such as 
oxidative phosphorylation (p-adj: 4.85e-09) and respiratory electron transport and ATP synthesis 
by chemiosmotic coupling and heat production by uncoupling proteins (p-adj: 4.85e-09) alongside 
with other processes such as degradation of AXIN (p-adj: 7.34e-09), and  regulation of PTEN stability 
and activity (p-adj: 4.85e-09) as well as processes linked to the neuronal system (p-adj: 6.03e-09), 







































Figure 7: AD differential gene expression meta-analysis results. A) Differential expression results of the 
individual studies included in the meta-analysis. For each study, the bar's blue portion shows the 
number of genes for which no gene expression change was identified. Green and red segments depict 
the number of unregulated and downregulated genes, respectively. B) Volcano plot depicting the 𝝁 
values obtained in MetaDE meta-analysis (x-axis) against the negative logarithm of the false discovery 
rate adjusted p-values (y-axis). Horizontal dashed lines represent FDR thresholds of 0.05, 0.01, and 
0.001 from bottom to top. C) Cumulative meta-analysis results. The plot shows the number of total 
deregulated (blue), upregulated (green), and downregulated (red) genes obtained by performing the 
meta-analysis with an increasing number of studies. The addition of studies proceeded from those 
showing higher SMR values (lowest quality) to those presenting the lowest SMR values (highest 
quality). D) Leave-one-out meta-analysis. Each bar represents the meta-analysis results after removing 
only one study (the removed study is indicated in the x-axis labels). F) Histogram showing the 
distributions of heterogeneity 𝝉𝟐 values for all genes included in the meta-analysis. G) Results for the 
alternative meta-analysis method. The green Venn diagram represents the number of upregulated 
genes found in the meta-analysis performed with the raw expression values (lighter), whereas the right 
one (darker) shows the number of upregulated genes after performing the meta-analysis using 
adjustment for surrogate variables. The red Venn diagram follows the same scheme for downregulated 
genes. On top of each Venn diagram, the Jaccard indexes (JI) for the overlaps are shown.  
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 3.3.4 Summary of the differential gene expression meta-analysis results for all the 
included disorders 
 Differential gene expression meta-analyses were carried out for the seven CNS disorders 
and the 22 tumor types under consideration. The number of DEGs identified through meta-analysis 
varied greatly among the different disorders ranging from the three DEGs found in schizophrenia 
(representing 0.02% of the tested genes) to the 9575 DEGs (69.24% of the tested genes) observed 
in kidney cancer samples. BD, MD, and SCZ patients' brain transcriptomes did not differ 
substantially from their tissue-matched controls, with only 5, 15, and 3 DEGs identified, 
respectively. This fact prevented us from including those disorders in subsequent intersection 
analysis. Neurodegenerative disorders, including AD, PD, and HD, presented a large number of 
differentially expressed genes with 3341, 3473, and 4504 DEGs detected, respectively, under an 
FDR threshold of 0.05. One-thousand and three genes were found to be deregulated in ASD (FDR < 
0.05). Except for AML, cancers tended to present a large number of DEGs, which were found to be 
exceptionally high in the cases of BRNCA, CRCA, KDNCA, LGCA, and LIVCA (See table 16). In general, 
higher mean Q values and mean tau values were observed in cancer meta-analyses compared to 
CNS, suggesting the presence of higher heterogeneity among studies. The alternative meta-analysis 
method using both surrogate variable adjusted and un-adjusted datasets showed a lower level of 
agreement in CNS disorders than in cancer, indicating the unknown co-variates could have a higher 
impact in the differential gene expression meta-analyses results of CNS disorders than cancers (See 
Table 17). Note that nominal p-values instead of FDR adjusted p-values are used to call a gene 
differentially expressed when using the alternative meta-analysis method, partially explaining the 
disagreement between these results and those derived from Choi’s method. Supplementary 















Disease  Included 
studies 
 Nº samples   
(cases/control) 
DEGs 0.05 / 
Tested 
genes  / % 
  Up 0.05 /  
Down 0.05 
DEGs 0.01 / 
Tested 
genes  / % 
 Up 0.01 /  
Down 0.05 
Mean Q Mean tau 




563/1078 10.59 0.33 




170/121 2.5 0.2 




0/0 9.34 0.4 




0/2 10.57 0.28 




1842/1605 1.69 0.33 




949/1318 7.24 0.31 




0/1 8.83 0.16 






920/467 16.67 0.63 






163/54 39.52 0.47 




1983/1086 10.41 0.85 






3781/2881 33.97 0.46 






4437/3791 19.89 0.35 




1517/827 11.73 0.64 




346/189 15.6 1.55 






996/492 62.94 1.24 




461/279 6.88 0.33 






4235/3637 27.98 0.3 




2339/845 32.7 1.67 




542/312 26.71 1.22 




2874/2406 24.94 0.5 




4426/3767 31.65 0.38 




4695/3259 26.39 0.23 




2996/2405 26.91 0.23 




2496/919 21.1 0.9 




3061/3209 39.27 0.79 






1378/1875 24.06 0.17 




1453/1299 13.43 0.38 




2920/2323 44.96 0..42 




2975/3381 10.02 0.39 
Table 16: Number of differentially expressed genes found in each meta-analysis.  The results for two 
different FDR thresholds (FDR < 0.05 and FDR < 0.01) are provided. The number of DEGs and the percentage 
with respect to the total number of tested genes can be found in columns three and five, whereas the 
number of up and downregulated genes can be found in columns four and six for FDR thresholds of 0.05 
and 0.01. Columns seven and eight show the mean Q and tau values, respectively.  
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Disease UP raw Down Raw Up Surrogate Down Surrogate Jaccard Up Jaccard Down 
AD 1856 2232 963 1256 0.4 0.46 
ASD 1166 1468 845 1126 0.59 0.55 
BD 813 313 712 236 0.62 0.54 
MD 631 619 615 598 0.63 0.61 
HD 2463 1923 2483 2108 0.72 0.75 
PD 2016 2019 1786 1739 0.78 0.79 
SCZ 603 522 519 533 0.44 0.44 
ALL 1682 1392 1360 1336 0.7 0.7 
AML 1400 631 1440 676 0.78 0.77 
BLCA 3621 2226 3621 2226 1 1 
BRCA 4951 3819 4996 3848 0.97 0.98 
BRNCA 5045 4593 4897 4397 0.91 0.89 
CERV 2378 1737 2322 1915 0.84 0.77 
CHLCA 1572 737 1473 814 0.69 0.66 
CLL 2151 1463 2060 1454 0.75 0.73 
CML 1777 602 2008 535 0.73 0.71 
CRCA 4662 4181 4654 4101 0.97 0.96 
DLBCL 3916 1796 3940 1765 0.98 0.96 
FLYMPH 1896 1298 1948 1279 0.88 0.85 
HANC 3703 3296 3673 3253 0.96 0.92 
KDNCA 4974 4663 4950 4598 0.98 0.97 
LGCA 5574 3853 5590 3860 0.99 0.99 
LIVCA 3628 3133 3496 3061 0.95 0.95 
OVCA 4218 1930 4204 1963 0.92 0.89 
PACA 3817 4293 3717 4172 0.95 0.94 
PRCA 2204 3018 2233 2842 0.86 0.84 
SKCM 2387 2025 2500 1980 0.82 0.83 
STCA 3666 3204 3614 3120 0.96 0.93 
THCA 4573 4683 4340 4535 0.89 0.9 
Table 17: Jaccard indexes for the alternative meta-analysis method based on MetaVulcanoR. Comparison 
of the differentially expressed genes between the meta-analysis carried out without surrogate variables 
















 3.3.5 Intersection analysis results for each CNS disorder and the panel of 22 site-
specific cancer 
 This section compares the differential gene expression meta-analysis results of each CNS 
disorder with those derived from the panes of 22 site-specific cancers. The lack of DEGs observed 
in BD, MD, and SCZ prevented us from carrying out these analyses in those disorders. Tables 
showing the FDR adjusted p-values of the intersections formed by genes jointly upregulated, jointly 
downregulated, and upregulated in one disorder and downregulated in the other are shown. 
Besides, to determine if specific biological processes were overrepresented in the genes placed at 
the intersections, classic overrepresentation analysis (ORA) was carried out using the biological 
process BP branch of gene ontology. Those tumors presenting direct transcriptomic associations 
with cancer will be referred to as Same Direction Deregulated Cancers (SDDC), whereas those 
presenting inverse patterns of transcriptomic associations will be called Opposite Direction 
Derregulated Cancers (ODDC).  
AD and cancer 
AD was found to be directly associated with brain cancer and thyroid cancer since the 
intersections formed by the genes jointly upregulated and down-regulated were found to be 
significant after adjustment by multiple comparisons. Several cancer types were inversely 
associated with AD, including bladder, breast, cervical, colorectal, head and neck, lung, liver, 
pancreatic, and prostate cancers. In those cases, the intersections formed by genes upregulated in 
one disorder and down-regulated in the other were found to be significant. Melanoma also 
presented a significant inverse pattern of association with AD. Figure 8 shows the intersection 
analysis results. Genes jointly upregulated between AD and BRNCA were enriched in functions 
linked to blood vessel morphogenesis (GO:0048514, p-adj = 6.96e-10), extracellular matrix 
organization (GO:0030198, p-adj = 6.96e-10), and several immune-related processes such as, 
lymphocyte activation (GO:0046649, p-adj = 2.64e-06), T cell activation (GO:0042110, p-adj = 4.33e-
05), and adaptive immune response (GO:0002250, p-adj = 1.58e-04), among others, whereas jointly 
downregulated genes, were found to be enriched in neural-related processes including vesicle-
mediated transport in synapse (GO:0099003, p-adj = 1.83e-13), neurotransmitter transport 
(GO:0006836, p-adj = 2.69e-08), and processes linked to the mitochondrial energy production such 
as respiratory electron transport chain (GO:0022904, p-adj = 4.08e-06), and the oxidative 
phosphorylation (GO:0006119, p-adj = 2.19e-05). In the case of thyroid cancer, jointly upregulated 
genes were enriched in the extracellular matrix organization (GO:0030198, p-adj = 6.73e-10), 
myeloid cell activation involved in immune response (GO:0002275, p-adj = 2.12e-03), and positive 
regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043123, p-adj = 4.54e-03). Jointly 
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downregulated genes were found to be also enriched in neuronal-related processes such as vesicle-
mediated transport in synapse (GO: 0099003, p-adj = 1.83e-13), and bioenergetics processes like 
the electron transport chain (GO:0022904, p-adj = 4.08e-06), and oxidative phosphorylation 
(GO:0006119, p-adj = 2.19e-05) 
Some biological processes were found to be enriched in genes jointly up-regulated in AD 
and downregulated in different negatively associated cancers. They were found to be linked to 
immune-related processes, i.e. , regulation of cell activation (GO:0050865; BLCA: p-adj = 1.49e-04, 
CRCA: p-adj = 5.64e-08, LGCA: p-adj = 4.68e-06, LIVCA: p-adj = 6.65e-08), adaptive immune 
response (GO:0002250; BLCA: p-adj = 1.37e-03, CRCA: p-adj = 6.22e-07, LGCA: p-adj = 5.45e-06, 
LIVCA: p-adj = 4.18e-07), and to other processes such as, blood vessel morphogenesis (GO:0048514; 
BLCA: p-adj = 1.11e-04,  CERV: p-adj = 2.07e-02, LGCA: p-adj = 2.15e-08, PRCA: p-adj = 4.68e-07, 
SKCM: p-adj = 6.36e-03), and extracellular matrix organization (GO:0030198; BLCA: p-adj = 1.07e-
03, BRCA: p-adj = 3.76e-03, LGCA: p-adj = 1.15e-05, LIVCA: p-adj = 7.92e-03, PRCA: p-adj = 5.18e-
06).  
Genes downregulated in AD and upregulated in inversely associated cancers tended to be 
enriched in biological processes linked the G2/M transition of mitotic cell cycle (GO:0000086; BLCA: 
p-adj = 2.10e-04, BRCA: p-adj = 2.72e-05, CERV: p-adj = 1.22e-02, CRCA: p-adj = 5.21e-06, HANC: p-
adj = 2.43e-06, LGCA: p-adj = 2.38e-03, LIVCA: p-adj = 3.62e-12, PACA: p-adj = 8.01e-07), 
mitochondrial functions such as mitochondrial gene expression (GO:0140053; BLCA: p-adj = 8.84e-
07, BRCA: p-adj = 2.38e-06, CERV: p-adj = 1.32e-04, CRCA: p-adj = 2.30e-14, HANC: p-adj = 6.67e-
11, LGCA: p-adj = 2.69e-13, LIVCA: p-adj = 2.94e-09, PACA: p-adj = 2.46e-04, PRCA: p-adj = 5.95e-
06) and bioenergetics processes such as oxidative phosphorylation (GO:0006119; BLCA: p-adj = 
3.43e-02 , LGCA: p-adj = 2.96e-05, LIVCA: p-adj = 4.41e-07, PACA: p-adj = 4.27e-03), ATP synthesis 
coupled electron transport (GO:0042773; BLCA: p-adj = 1.25e-02, BRCA: p-adj = 3.35e-02, LGCA: p-
adj = 6.03e-05, LIVCA: p-adj = 1.09e-06, PACA: p-adj = 1.29e-03) as well as processes linked to 
proteasomal function such as, SCF-dependent proteasomal ubiquitin-dependent protein catabolic 
process (GO:0031146; BLCA: p-adj = 9.25e-04, BRCA: p-adj = 1.10e-04, CERV: p-adj = 1.24e-02, 
CRCA: p-adj = 2.07e-09, HANC: p-adj = 1.16e-10, LGCA: p-adj = 4.95e-04, LIVCA: p-adj = 4.07e-12, 
PACA: p-adj = 1.43e-11). The differential gene expression profiles of brain cancer and 
thyroid cancer were positively correlated with the AD profile (BRNCA r = 0.32, THCA r = 0.11). 
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Figure 8: AD and cancer intersection analysis results.  Each column shows the number of genes placed 
at the four possible intersections formed by the genes up and downregulated in each AD and cancer 
pair, as well as the FDR adjusted p-values of the exact Fisher’s tests. Column 1 shows the genes jointly 
upregulated, column 2 shows the genes jointly downregulated, column 3 shows the genes upregulated 
in AD and downregulated in each cancer, and column 4 shows the genes downregulated in AD and 
















Figure 9: Pearson’s correlations of the 𝝁 values derived from the differential expression profiles of AD 





PD and cancer 
 PD was found to present direct transcriptomic associations with thyroid, kidney, brain, and 
stomach cancers and inverse transcriptomic associations with breast, lung, and prostate cancers, 
and also CLL to a minor extent.  
 Jointly upregulated genes found in the intersections formed by PD and the three directly 
associated cancer types were mainly enriched in immune related processes including, leukocyte 
degranulation (GO:0043299; BRNCA: p-adj = 4.53e-06, KDNCA: p-adj = 2.40e-06, THCA: p-adj = 
8.29e-06), myeloid leukocyte activation (GO:0002274; BRNCA: p-adj = 1.50e-06, KDNCA: p-adj = 
4.11e-09), macrophage activation (GO:0042116; BRNCA: p-adj = 7.01e-03, KDNCA: p-adj = 4.94e-
05, THCA: p-adj = 7.33e-05), and toll-like receptor signaling pathway (GO:0002224; BRNCA: p-adj = 
2.28e-03, KDNCA: p-adj = 2.41e-04, THCA: p-adj = 2.47e-05), among others. 
 Genes placed at the intersections formed by jointly down-regulated genes in PD and each 
of the four directly associated cancer types were enriched in processes linked to oxidative 
phosphorylation (GO:0006119; BRNCA: p-adj = 2.17e-03, KDNCA: p-adj = 8.31e-21, THCA: p-adj = 
1.18e-25), ATP synthesis coupled electron transport (GO:0042773; BRNCA: p-adj = 5.53e-04, 
KDNCA: p-adj = 4.29e-19, THCA: p-adj = 1.24e-19). Jointly downregulated PD and BRNA genes were 
also heavily enriched in related neuronal processes, such as synaptic vesicle cycle (GO:0099504; 
BRNCA: p-adj = 1.59e-15) and neuron projection morphogenesis (GO:0048812; BRNCA: p-adj = 
1.05e-08).  
 In the case of inversely associated cancers, genes jointly upregulated in PD and 
downregulated in lung cancer were found to be enriched in positive regulation of cell migration 
(LGCA: p-adj = 1.50e-08) and regulation of vasculature development (LGCA: p-adj = 7.18e-08), 
whereas poor overrepresentation results were found for the rest of inversely associated cancers. 
 Genes jointly downregulated in PD and upregulated in inversely associated cancer types 
were enriched in mitochondrial processes such as, mitochondrial translation (GO:0032543; BRCA: 
p-adj = 3.79e-04, LGCA: p-adj = 2.60e-05, PRCA: p-adj = 5.49e-04), mitochondrial gene expression 
(GO:0140053; BRCA: p-adj = 7.01e-04, LGCA: p-adj = 9.16e-06, PRCA: p-adj = 5.49e-04). In the case 
of lung cancer enrichment in oxidative phosphorylation (GO:0006119; LGCA: p-adj = 1.02e-04) was 
also observed. Finally, genes linked to the regulation of cell cycle G2/M phase transition 
(GO:1902749; BRCA: p-adj = 6.31e-04, LGCA: p-adj = 3.58e-02) were also found to be 
downregulated in PD and upregulated in lung and breast cancers. 
The differential gene expression profiles of brain cancer and kidney cancer were found to be 
positively correlated with the PD profile (BRNCA r = 0.33, KDNCA r = 0.17), whereas the correlation 
between the Parkinson’s and thyroid cancer gene expression signatures was found to be negligible 
(THCA r = 0.03). Among the negatively associated cancers, only lung cancer presented a negative 
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correlation with an absolute value higher than 0.1 (BRCA r = -0.06, LGCA r = -0.13, PRCA r = -0.04, 






Figure 10: PD and cancer intersection analysis results.  Each column shows the number of genes placed 
at the four possible intersections formed by the genes up and downregulated in each PD and cancer 
pair, as well as the FDR adjusted p-values of the exact Fisher’s tests. Column 1 shows the genes jointly 
upregulated, column 2 shows the genes jointly downregulated, column 3 shows the genes upregulated 
in PD and downregulated in each cancer, and column 4 shows the genes downregulated in PD and 

















Figure 11: Pearson’s correlations of the  𝝁 values derived from the differential expression profiles of 




HD and cancer 
 Huntington’s disease was found to be directly associated with brain, kidney, pancreatic 
cancer, and to a minor extent with CLL, whereas negative associations between HD and breast, 
lung, and prostate cancers were also observed (See Figure 12). Genes jointly upregulated in HD and 
in the directly associated cancers were enriched in I-kappaB kinase/NF-kappaB signaling 
(GO:0007249; BRNCA: p-adj = 2.53e-03, KDNCA: p-adj = 8.48e-04, PACA: p-adj = 2.74e-03), defense 
response to virus (GO:0051607; BRNCA: p-adj = 6.12e-04, KDNCA: p-adj = 3.38e-05, PACA: p-adj = 
6.11e-04), and regulation of cytokine production (GO:0001817; BRNCA: p-adj = 1.53e-03, KDNCA: 
p-adj = 8.48e-04, PACA: p-adj = 4.36e-03), among others. On the other hand, jointly downregulated 
genes were found to be enriched in processes linked to synapse and neurons, such as modulation 
of chemical synaptic transmission (GO:0050804; BRNCA: p-adj = 1.75e-26, KDNCA: p-adj = 1.02e-
11, PACA: p-adj = 2.61e-12) and vesicle-mediated transport in synapse (GO:0099003; BRNCA: p-adj 
= 2.80e-18, KDNCA: p-adj = 2.60e-07, PACA: p-adj = 1.29e-08) among others. Genes linked to the 
ATP synthesis were also found to be jointly downregulated in HD and KDNCA ATP synthesis coupled 
electron transport (GO:0042773; KDNCA: p-adj = 1.12e-09), oxidative phosphorylation (KDNCA: p-
adj = 1.61e-10). For those cancers inversely associated with HD, jointly HD upregulated genes and 
cancer downregulated genes were enriched in angiogenesis (GO:0001525; BRCA: p-adj = 1.15e-04, 
LGCA: p-adj = 2.22e-06, PRCA: p-adj = 7.27e-03) and blood vessel morphogenesis (LGCA: p-adj = 
7.34e-08, PRCA: p-adj = 6.97e-03) whereas genes downregulated in HD and upregulated in inversely 
associated cancers were found to be poorly enriched in functional categories. Pearsons correlations 
between HD and SDDC were, r = 0.48, 0.16, 0.13, and 0.02 for bran, kidney, and pancreatic cancer, 
and CLL, respectively, whereas for ODDC were r = -0.09, -0.13, and -0.07 for breast, lung, and 





















Figure 12 HD and cancer intersection analysis results.  Each column shows the number of genes placed 
at the four possible intersections formed by the genes up and downregulated in each HD and cancer 
pair, as well as the FDR adjusted p-values of the exact Fisher’s tests. Column 1 shows the genes jointly 
upregulated, column 2 shows the genes jointly downregulated, column 3 shows the genes upregulated 
in HD and downregulated in each cancer, and column 4 shows the genes downregulated in HD and 
















Figure 13: Pearson’s correlations of the 𝝁 values derived from the differential expression profiles of 




ASD and cancer 
ASD presented significant direct associations with brain, kidney, thyroid cancer, and 
cholangiocarcinoma, whereas no inverse associations were found. Genes jointly upregulated in ASD 
and in the directly associated cancers were found to be enriched in innate immune response 
(GO:0045087; BRNCA: p-adj = 3.28e-14,  KDNCA: p-adj = 7.81e-18), cytokine production 
(GO:0001816; BRNCA: p-adj = 1.17e-10 , KDNCA: p-adj = 1.10e-14), wound healing (GO:0042060; 
BRNCA: p-adj = 1.83e-08, KDNCA: p-adj = 3.49e-06, THCA: p-adj = 1.11e-07), myeloid leukocyte 
mediated immunity (GO:0002444; BRNCA: p-adj = 8.52e-08, CHLCA: p-adj = 3.19e-03, KDNCA: p-adj 
= 5.39e-08, THCA: p-adj = 7.26e-11), T cell activation (GO:0042110; BRNCA: p-adj = 8.56e-08, 
CHLCA: p-adj = 4.08e-02, KDNCA: p-adj = 5.39e-08, THCA: p-adj = 3.43e-09), inflammatory response 
(GO:0006954; BRNCA: p-adj = 1.17e-10, CHLCA: p-adj = 1.41e-05, KDNCA: p-adj = 1.87e-13, THCA: 
p-adj = 6.32e-11), whereas genes jointly downregulated were enriched in biological processes 
linked to oxidative phosphorylation (GO:0006119; KDNCA: p-adj = 7.56e-06, THCA: p-adj = 1.10e-
07), ATP synthesis coupled electron transport (GO:0042773; KDNCA: p-adj = 7.56e-06, THCA: p-adj 
= 4.69e-07). Brain, kidney, tyroid cancers, and cholangiocarcinoma presented Pearson’s 




























Figure 14: ASD and cancer intersection analysis results.  Each column shows the number of genes placed 
at the four possible intersections formed by the genes up and downregulated in each ASD and cancer 
pair, as well as the FDR adjusted p-values of the exact Fisher’s tests. Column 1 shows the genes jointly 
upregulated, column 2 shows the genes jointly downregulated, column 3 shows the genes upregulated 
in ASD and downregulated in each cancer, and column 4 shows the genes downregulated in ASD and 


















Figure 15: Pearson’s correlations of the 𝝁 values derived from the differential expression profiles of ASD 
and all the included cancers.  
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 3.3.6 Gene set enrichment analyses comparison 
 In this section, we present the gene set enrichment analysis results. We carried out GSEA 
analysis using three molecular signature sets derived from the Molecular Signatures Database 
(MSigDB). The hallmarks gene sets (H, n = 50), the curated gene sets (C2, n =2868), which gathers 
information from canonical pathways derived from KEGG, REACTOME, and BIOCARTA, and the 
ontology gene sets (C5, n = 10271), which includes gene sets from the three Gene Ontology 
branches (BP, MF, and CC). These analyses serve to complement the overrepresentation analysis 
results of the genes placed at the intersections. In contrast to overrepresentation analysis, which 
works only with a list of genes of interest, Gene Set Enrichment Analysis (GSEA) uses the output of 
each differential expression meta-analysis to identify coordinated changes of expression in 
pathways even in the absence of significantly differentially expressed individual genes. Therefore, 
those disorders which were not included in the intersection analysis due to the lack of differentially 
expressed genes will be included in the GSEA enrichment analysis. For the sake of simplicity and 
interpretability, we will briefly summarize the number of pathways deregulated in the same and 
opposite directions on the of the three gene sets sources employed, and then we will focus on the 
results of the hallmarks gene sets, which include 50 specific well defined biological states which 
display coherent expression. The full GSEA enrichment analysis results for all the tested molecular 
signatures are provided in Supplementary Appendices 3, 4, and 5.  
  3.3.6.1 Pathways deregulated in the same and opposite directions in all pairwise 
CNS and cancer comparisons 
 Cancers that were found to present significant directly transcriptomic associations with CNS 
disorders had more pathways deregulated in the same direction than in the opposite direction. For 
instance, 11, 156, 648, H, C2, and GO gene sets presented significant joint deregulation in the same 
direction in AD and BRCNA (instance of direct transcriptomic association), whereas 6, 116, and 161 
did it in opposite directions. The same trend was observed for AD and KDNCA, showing 15, 111, and 
386 pathways deregulated in the same direction for H, C2, and GO, respectively and 6, 126, and 166 
pathways deregulated in opposite directions. In contrast, cancers found to present opposite 
transcriptomic association patterns with a particular CNS disorder had more pathways deregulated 
in opposite directions. AD and LGCA presented the following number of jointly deregulated 
pathways (Same direction: H = 1, C2 = 29, GO = 69, Opposite direction: H = 18, C2 = 174, GO = 547) 
whereas AD and LIVCA had (Same direction: H = 2, C2 = 21, GO = 86, Opposite direction: H = 19, C2 
= 233, GO = 514). Supplementary Figures 79, 80, and 81 show the number of jointly deregulated 
pathways in the same and opposite directions for every CNS disorder and cancer pair and each 




  3.3.6.2 Detailed hallmarks (H) gene set results 
Overall results  
The most frequent upregulated hallmark gene sets in CNS disorders were found to be epithelial-
mesenchymal transition, which was observed to be upregulated in all CNS disorders with the 
exception of MD, followed by IL6 JAK STAT3 signaling, which was found to be upregulated in AD, 
ASD, BD, PD, and SCZ but not in HD, and MD. Other immune-related sets of genes such as 
inflammatory response were found to be upregulated in AD, ASD, BD, and PD. In contrast, the most 
common downregulated hallmark gene sets in CNS disorders were oxidative phosphorylation, 
which was downregulated in all CNS disorders, MYC targets v1, and protein secretion. Those 
pathways were observed to be downregulated in all CNS disorders except in HD. Other important 
downregulated pathways in CNS disorders included MTORC1 signaling, and the unfolded protein 
response, which were downregulated in AD, BD, MD, PD, and SCZ and in AD, BD, MD, and PD, 
respectively. In contrast, MTORC1 signaling was found to be upregulated in ASD. For those CNS 
disorders that presented only a small amount of differentially expressed genes in the differential 
gene expression meta-analyses (BD, MD, and SCZ), gene set enrichment analysis also identified 
enriched pathways. This suggests the presence of small amounts of coordinated gene expression 
changes affecting specific pathways in those disorders. 
 For cancers, the most frequently upregulated hallmark gene sets were found to be MYC 
targets v1, E2F targets, and MYC targets v2. These pathways were found to be upregulated in 17, 
17, and 16 site-specific cancers, respectively. MTORC1 signaling and G2M checkpoints were 
upregulated in 16 cancers, whereas DNA repair, glycolysis, unfolded protein response, and E2F 
targets did it in 15 cancer types. The most common downregulated pathways in cancer were bile 
acid metabolism, which was found to be downregulated in 13 site-specific cancers, and KRAS 
signaling dn. Figure 21 summarizes the GSEA enrichment analysis results up- and downregulation 













Specific analysis results for each CNS disorder and their SDDC and ODDC 
 Here we focus on the jointly deregulated pathways observed in the CNS and cancer pairs 
that presented significant direct (SDDCs) or inverse (ODDCs) transcriptomic associations in the 
intersection analyses. All the pathways reported had adjusted p-values < 0.05 in the CNS disorder 
and cancer under consideration. 
AD and SDDC 
 For AD and its SDDCs, jointly upregulated pathways were mainly linked to immune function 
and included inflammatory response, allograft rejection, IL6 JAK STAT3 signaling, complement, 
TNFA signaling via NFKB, IL2 STAT5 signaling, and interferon-gamma response. Other pathways 
jointly upregulated in AD and its SDDCs were epithelial-mesenchymal transition, hypoxia, 
coagulation, and the P53 pathway, which were found to be jointly upregulated in AD and in BRNCA 
and THCA. Some instances of pathways jointly upregulated in AD and THCA were KRAS signaling 
and apical junction. Jointly downregulated pathways in AD and its SDDCs included oxidative 
phosphorylation, fatty acid metabolism, unfolded protein response, and adipogenesis. 
AD and ODDC 
 Pathways upregulated in AD and downregulated in its ODDCs were found to be linked to 
immune-related processes, such as inflammatory response, IL6 JAK STAT3 signaling, allograft 
rejection, TNFA signaling via NFKB, interferon-gamma response, complement, IL2 STAT5, and KRAS 
signaling. Following the same trend, other gene set hallmarks included epithelial-mesenchymal 
transition, myogenesis, coagulation, hypoxia, and estrogen response early. Note that not all the 
listed pathways were found to be downregulated in all AD’s ODDCs. The exact tumor types enriched 
in the reported processes can be consulted in Figure16.  
 Gene sets jointly downregulated in AD and upregulated in its ODDCs included MYC targets, 
the P53 pathway, MTORC1 signaling, DNA repair, unfolded protein response, UV response, MYC 
targets v2, and protein. Finally, oxidative phosphorylation was found to be downregulated in AD 
and upregulated in LGCA. 
PD and SDDC  
 Hallmark gene sets jointly upregulated in PD, and its SDDCs also included many instances 
of immune system-related processes, including inflammatory response, allograft rejection, IL6 JAK 
STAT3 signaling, TNFA signaling via NFKB, among many others. In addition, other processes such as 
epithelial-mesenchymal transition, coagulation, hypoxia, and the P53 pathway were found to be 
upregulated in PD and its SDDCs. Apoptosis was jointly upregulated in PD and its SDDCs, including 
BRNCA, KDNCA, STCA, and THCA. The G2M checkpoint pathway was slightly upregulated in PD and 




SDDCs were oxidative phosphorylation, which was found to be strongly downregulated in PD and 
KDNCA, STCA, and THCA and adipogenesis. 
PD and ODDC  
 Many processes upregulated in PD and downregulated in ODDCs were related to the 
immune system. Instances include inflammatory response, TNFA signaling via NFKB, IL2 STAT5 
signaling, allograft rejection, and IL6 JAK STAT3 signaling, among many others, as well as other 
pathways, such as epithelial-mesenchymal transition and P53. Apoptosis was found to be jointly 
upregulated in HD and BRNCA, KDNCA, and PACA, as well as epithelial-mesenchymal transition. 
Other jointly upregulated pathways included coagulation and the P53 pathway. In contrast, 
hallmarks jointly downregulated included spermatogenesis and oxidative phosphorylation in 
BRNCA and KDNCA.  
HD and SDDC  
 Like in the AD and PD cases, HD and its SDDCs presented a joint upregulation of immune 
system-related pathways, which involved TNFA signaling via NFKB, IL2 STAT5 signaling, and 
interferon-gamma and alpha response, among others. Apoptosis was found to be jointly 
upregulated in HD and BRNCA, KDNCA, and PACA, as well as epithelial-mesenchymal transition. 
Other jointly upregulated pathways included coagulation and the P53 pathway. In contrast, 
hallmarks jointly downregulated included spermatogenesis and oxidative phosphorylation in the 
cases of BRNCA, and KDNCA. 
HD and ODDC 
 Several processes were upregulated in HD downregulated in ODDCs including, TNFA 
signaling via NFKB, IL2 STAT5 signaling, interferon-alpha and gamma response, the P53 pathway, 
epithelial-mesenchymal transition, and apoptosis, whereas pathways downregulated in PD and 
upregulated in ODDCs included spermatogenesis and oxidative phosphorylation in the case of 
LGCA. 
ASD and SDDC  
 Hallmark gene sets jointly upregulated in ASD and its SDDCs were also linked to immune 
system-related functions, such as inflammatory response, allograft, IL6 JAK STAT3, TNFA signaling 
via NFKB, and IL2 STAT5 signaling, among many others, as well as other processes such as MTORC1 
signaling, KRAS signaling, epithelial-mesenchymal transition, coagulation, hypoxia, and the P53 
pathway. The apoptosis was also found to be jointly upregulated in ASD and BRNCA, KDNCA, and 
THCA. Jointly downregulated pathways included oxidative phosphorylation in the case of KDNCA 
and THCA and spermatogenesis. 
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 Supplementary Appendix 1 Tables 8 to 37 show all jointly deregulated pathways found in 
CNS disorders and their SDDCs and ODDCs displaying adjusted FDR values lower than 0.001 in all 




Figure 16: Heatmap representation of the Gene Set Enrichment Analysis (GSEA) results. The Hallmarks 
molecular signatures database was used as the source of gene set information. Green colors indicate 
that a pathway was found to be significantly upregulated in a particular disorder, whereas red colors 
indicate that the pathway was downregulated. White tiles are reserved for no significant associations. 
The intensity of the color is proportional to the value of NES. CNS disorders are annotated in purple, 





 3.3.7 Validation of the intersection analysis results using an independent cohort of 
cancers 
We carried out a validation step of the reported transcriptomic associations by performing 
differential gene expression analysis of independent cohorts of cancer samples derived from TCGA. 
The validation step using independent cancer data derived from TCGA confirmed the direct 
associations found between AD and brain cancer but not between AD and thyroid cancer, which 
was found to be slightly negatively associated with AD in the TCGA datasets. Regarding the 
negatively associated cancers, the intersection analysis carried out using TCGA data confirmed the 
inverse associations found between AD and BLCA, BRCA, LGCA, LIVCA, and PRCA. The significant 
negative associations observed between AD and CERV, CRCA, HANC, and PACA could not be 
validated using TCGA data. In the case of PD, the direct transcriptomic associations observed with 
BRNCA and KDNCA in the array analyses were validated using TCGA data, as well as the negative 
associations identified between PD and BRCA, LGCA, and PRCA. However, the direct transcriptomic 
associations observed between PD and THCA or STCA could not be validated. In the case of HD, the 
significant direct transcriptomic associations with BRNCA and KDNCA were validated, as well as the 
negative associations with BRCA and LGCA, whereas the rest of the significant associations 
observed in the array-based analyses could not be validated. Finally, the transcriptome associations 
observed between ASD and BRNCA, and KDNCA were validated using the TCGA data. Additional 
significant associations were observed in the TCGA analysis, including inverse associations between 
ASD and BRCA, LGCA, and PRCA. Appendix 6 includes the TCGA datasets employed in the validation 
analyses and a summary of the differential gene expression analysis results carried out for each, as 
well as the number of included samples and the correspondence with the respective array-based 
analysis. Supplementary Appendix 1 Figures 82 to 85 show the intersection analysis results 
between CNS disorders and the TCGA cancer cohorts. 
 3.3.8 Consensus module detection and module overlap analysis results 
 In the next paragraphs, we report the consensus module detection and the module 
overlaps analysis results. In 3.3.8.1, we provide a full description of the analyses for AD as an 
example. A summary of the results for all included disorders is available in Section 3.3.8.2. Finally, 
the module overlap analysis results are introduced in Section 3.3.8.3 
 
 3.3.8.1 Consensus gene co-expression module detection in Alzheimer’s disease 
Hybrid-signed weighted co-expression networks were constructed for AD. Guided by the 
picSoftThreshold function, the correlation matrices of each included dataset (GSE84422, 
GSE48350, GSE5281, GSE36980, GSE1297, E_MEXP_2280, and GSE29378) were raised to the 12, 
11, 3, 13, 10, 15, and 10 exponents to fit each individual adjacency matrix to a power-law 
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distribution (See methods section 3.2.11). Figures 17 A and B show the power-selection plots for 
the power-law distribution fit and the mean connectivity under the different tested powers for 
dataset GSE884422. 
Thirty-two consensus modules of co-expressed genes (excluding the grey module) were 
identified across the seven AD datasets included in the analysis (Figure 22 C and D). Thirteen 
modules were found to be significantly associated with disease status. On the one hand, six of them 
(AD_orange, r = 0.36, p-adj = 9.00e-07; AD_tan, r = 0.34, p-adj = 3.42e-06; AD_brown, r = 0.31, p-
adj = 5.15e-05; AD_purple, r = 0.29, p-adj = 1.81e-04; AD_darkred, r = 0.28, p-adj = 5.11e-04; 
AD_grey60, r = 0.21, p-adj = 2.60e-02) presented positive correlations with AD status, indicating 
that co-expressed genes included in these modules tend to be up-regulated in AD cases compared 
to controls. On the other hand, seven modules (AD_turquoise, r = -0.39, p-adj = 2.31e-08; 
AD_darkorange, r = -0.31 p-adj = 5.39e-05; AD_red, r = -0.29, p-adj = 1.71e-04; AD_paleturquoise, 
r = -0.29, p-adj = 2.96e-04; AD_skyblue, r = -0.24, p-adj = 5.26e-03; AD_saddlebrown, r = -0.23, p-
adj = 1.38e-02; AD_darkgreen, r = -0.2, p-adj = 4.89e-02) were found to be negatively correlated 
with AD status. A bar plot depicting the number of genes included in each AD consensus module 
can be found in Figure 17 E. Among the positively associated modules AD_brown was found to be 
enriched in genes related to biological adhesion (GO:0022610; p-adj: 2.11e-12), immune response 
(GO:0006955; p-adj: 6.31e-09), and vasculature development (GO:0001944; p-adj: 7.50e-08), 
among others, as well as and in macrophages (p-adj: 1.80e-06) and microglia (p-adj: 7.68e-05) cell 
type-specific markers. AD_turquoise was the most significant negatively associated module and 
included genes that were found to be heavily enriched in processes linked to mitochondrial inner 
membrane (GO:0005743; p-adj: 8.89e-34), mitochondrial protein complex (GO:0098798; p-adj: 
1.22e-33), and ATP synthesis coupled electron transport (GO:0042773; p-adj: 1.57e-21), and 
oxidative phosphorylation (GO:0006119; p-adj: 5.85e-21). Enrichment in cell type-specific markers 
related to neurons (p-adj: 3.07e-09), interneurons (p-adj: 1.08e-07), and purkinje neurons (p-adj: 
2.68e-03) was also observed in this module. 
AD_skyblue was enriched in protein processes linked to protein folding such as, unfolded 
protein binding (GO:0051082; p-adj: 7.77e-09), response to topologically incorrect protein 
(GO:0035966; p-adj: 9.13e-08), chaperone complex (GO:0101031; p-adj: 1.13e-07), response to 














Figure 17: AD consensus co-expression module analysis results.  A) Example of power selection based 
on the fit to a power law-distribution for dataset GSE88422 (Power selection is carried out 
independently for each dataset). B) Mean node connectivity base on the selected power. C) Module-
trait correlation and their FDR adjusted p-values (Computed as explained in method section….). D) 
Dendrogram and color tags of the consensus modules identified across datasets. E) Gene content of 




  3.3.8.2 Consensus module analysis summary results for all the included disorders 
 
 In the previous section, we detailed the workflow and results of the co-expression analyses 
in the case of AD. For brevity, we present a summarized version of the results of the full set of 
included disorders. Supplementary Appendix 6 contains information regarding all the modules 
significantly associated with disease status and their enrichment in biological processes and cell 
type-specific markers. 
 In total, 489 modules were found to be significantly associated with disease status after 
adjustment for multiple comparisons, of which 275 and 214 were found to present positive and 
negative correlations with disease status, respectively. Sixty-two modules belonged to CNS 
disorders, whereas 427 cancers were cancer-associated modules. In the case of major depression, 
only two gene co-expression modules were found to be significantly correlated with disease status, 
whereas no significantly associated modules were observed in the SCZ analyses. 
  In neurodegenerative disorders and ASD, several instances of co-expression modules 
enriched in immune system-related processes and specific cell-type markers were found to be 
positively correlated with disease status, including AD_brown (r = 0.31, p-adj: 5.15e-05), which was 
found to be enriched in immune response (GO:0006955; p-adj = 6.31e-09), and macrophages (p-
adj: 1.80e-06) and microglia (p-adj: 7.68e-05) cell type makers, ASD_midnightblue (r = 0.26, p-adj: 
2.52e-02), which was also enriched in  immune system process (GO:0002376; p-adj = 6.50e-26), 
macrophages (p-adj: 1.25e-12), and microglia (p-adj: 2.67e-12), HD_magenta (r = 0.46, p-adj = 
1.85e-04), which presented enrichment in  immune response (GO:0006955; p-adj = 2.96e-10) and 
inflammatory response (GO:0006954; p-adj = 3.13e-10), and PD_black (r = 0.3, p-adj: 2.93e-03), 
which was enriched in cytokine-mediated signaling pathway (GO:0019221; p-adj = 1.58e-05) and 
response to cytokines (GO:0034097; p-adj = 1.65e-05).  
 In contrast, immune system-related co-expression modules were found to be negatively 
correlated with disease status in the MD_royalblue module (r = -0.25, p-adj: 3.36e-03), immune 
response (GO:0006955; p-adj = 3.53e-19), and in the BD_orange (r = -0.27, p-adj: 6.72e-03) module, 
immune response (GO:0006955; p-adj = 2.26e-14). In the cases of HD and PD, instances of modules 
positively correlated to disease status which where enriched in oligodendrocyte cell type markers 
HD_black (r = 0.62, p-adj: 1.16e-09), oligodendrocytes (p-adj: 1.39e-05) and PD_yellow (r = 0.35, p-
adj: 1.64e-04), myelination (GO:0042552; p-adj = 1.98e-06), oligodendrocytes (p-adj: 2.56e-27) 
were observed.  
 Neurodegenerative disorders and ASD presented multiple instances of gene co-expression 
modules, which were negatively correlated to disease status and heavily enriched in mitochondrial 




adj: 2.31e-08) was found to be enriched in the mitochondrial inner membrane (GO:0005743; p-adj 
= 8.89e-34), ATP synthesis coupled electron transport (GO:0042775; p-adj = 1.57e-21), and synapse 
(GO:0045202; p-adj = 1.40e-23) functions, and in interneuron (p-adj: 1.08e-07) and neuron (p-adj: 
3.07e-09) cell-type markers. ASD_pink (r = -0.25, p-adj: 3.25e-02) was found to be enriched in 
mitochondrial ATP synthesis coupled to electron transport (GO:0042775; p-adj = 5.18e-08) and 
ASD_red (r = -0.26, p-adj: 2.38e-02) was enriched in presynapse (GO:0098793; p-adj = 5.01e-05) 
and synapse (GO:0045202; p-adj = 7.47e-04) gene ontology processes, and in Interneuron (p-adj: 
1.83e-03) cell type markers, whereas HD_yellow (r = -0.56, p-adj: 1.61e-07) presented enrichment 
in oxidative phosphorylation (GO:0006119; p-adj = 2.50e-26), and HD_turquoise (r = -0.7, p-adj: 
3.40e-14) was found to be enriched in synapse-related genes (GO:0045202; p-adj = 3.71e-51) and 
interneuron markers (p-adj: 1.52e-15). PD_turquoise (r = -0.41, p-adj: 1.49e-06), was enriched in 
mitochondrial ATP synthesis coupled electron transport (GO: 0042775; p-adj = 3.28e-25), 
dopaminergic neurons (p-adj: 6.11e-03) and interneurons (p-adj: 1.57e-04). 
 Most cancers presented gene co-expression modules positively correlated with disease 
status, which were enriched in cell cycle-related functions. A non-comprehensive list of instances 
includes BLCA_turquoise (r = 0.53, p-adj: 1.10e-17), cell cycle (GO:0007049; p-adj = 9.88e-69), 
BRCA_green (r = 0.43, p-adj: 2.03e-64), cell cycle (GO:0007049; p-adj = 3.98e-115), BRNCA_brown 
(r = 0.35, p-adj: 8.62e-37), cell cycle (GO:0007049; p-adj = 3.41e-97) or CHLCA_brown (r =  0.52,,p-
adj: 1.13e-11), mitotic cell cycle process (GO:1903047; p-adj = 1.81e-64).  
 Many of the studied cancer modules presenting significant negative correlations with 
disease status were enriched in biological processes and cell type markers characteristic from 
healthy tissues, suggesting that a process of dedifferentiation or tissue substitution has been taking 
place.  
 To cite some instances, the genes placed at the CERV_yellow module (r = -0.58, p-adj: 
3.14e-13), the top negative correlated co-expression module found in the cervical cancer analysis, 
was found to be enriched in biological processes linked to cornification (GO:0070268; p-adj = 4.56e-
28), keratinocyte differentiation (GO:0030216; p-adj = 3.12e-26), and epidermis development 
(GO:0008544; p-adj = 1.17e-25), as well as in keratinocyte (p-adj: 2.39e-13), epithelial (p-adj: 1.03e-
03) , and basal (p-adj: 3.11e-03) cell type-specific markers. The BRNCA_blue module (r = -0.55, p-
adj: 1.79e-100) was found to be enriched in biological process linked to synapse (GO:0045202; p-
adj = 2.59e-36), axon (GO:0030424; p-adj = 6.09e-33), and neuron projection (GO:0043005; p-adj = 
1.71e-27) and to Interneural (p-adj: 4.59e-10) and neural (p-adj: 6.24e-07) markers. CRCA_blue (r = 
-0.56, p-adj: 8.54e-109) was found to be enriched in lipid metabolic process (GO:0006629; p-adj = 
5.78e-20), extracellular exosome (GO:0070062; p-adj = 5.72e-18), and in cell type-specific markers 
of enterocytes (p-adj: 7.55e-11), paneth cells (p-adj: 1.03e-12), and goblet cells (p-adj: 1.00e-04). 
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Finally, LGCA_turquoise (r = -0.74, p-adj: 1.98e-169) and LGCA_pink (r = -0.63, p-adj: 1.73e-100) 
were found to be enriched in pulmonary alveolar type I cells (p-adj: 2.54e-10) and pulmonary 
alveolar type II cells (p-adj: 8.14e-05), respectively.  
 Immune system-related gene co-expression modules were observed to be both positive 
and negatively correlated to disease status in different cancer types. For instance, BRCA_darkgreen 
(r = 0.27, p-adj: 1.52e-24) was found to be enriched in type I interferon signaling pathway 
(GO:0060337; p-adj = 4.44e-35), and innate immune response (GO:0045087; p-adj = 2.80e-31) 
biological processes, and in monocytes (p-adj: 1.33e-11) specific cell type markers, whereas 
BRCA_tan (r = -0.31, p-adj: 2.11e-31) was enriched in immune system process (GO:0002376; p-adj 
= 1.86e-16) and macrophage (p-adj: 5.31e-10) markers. Colorectal cancer status was also found to 
be both positively and negatively correlated with co-expression modules linked to immune system 
functions. CRCA_grey60 (r = 0.12, p-adj: 2.25e-04) was enriched in defense response (GO:0006952; 
p-adj = 4.02e-32), response to type I interferon (GO:0034340; p-adj = 2.67e-29), and monocytes (p-
adj: 2.22e-07), whereas CRCA_black ( r =  -0.34, p-adj: 1.02e-34) was enriched in immune system 
process (GO:0002376; p-adj = 3.71e-71), lymphocyte activation (GO:0046649; p-adj = 2.06e-58), 
and the following specific cell type markers, B cells (p-adj: 1.17e-23), NK cells (p-adj: 1.43e-14), and 
T cells (p-adj: 3.20e-26). Lung cancer status was positively correlated to LGCA_grey60 (r = 0.37, p-
adj: 1.53e-28), a module which was found to be enriched in  B cell activation (GO:0042113; p-adj = 
3.75e-13) and lymphocyte activation (GO:0046649; p-adj = 2.28e-11), as well as, in B cell (p-adj: 
7.04e-28) markers, whereas it was also found to be negatively correlated to LGCA_green (r = -0.39, 
p-adj: 2.33e-32) which was enriched in immune response (GO:0006955; p-adj = 1.23e-62), and 
macrophage (p-adj: 3.84e-24), and dendritic cell (p-adj: 4.72e-12) markers. These findings underlie 
the complexity of the alterations of the immune function present in cancer.  
 Modules enriched in processes linked to the mitochondrial function were found to be 
correlated to the disease status of several cancer types. Both positive and negative correlations 
were observed. Instances of co-expression modules negatively correlated to disease status and 
enriched in mitochondrial function and ATP synthesis related processes are THCA_salmon (r = -0.32, 
p-adj: 7.71e-06), mitochondrial ATP synthesis coupled electron transport (GO:0042775; p-adj = 
2.47e-50), KDNCA_turquoise (r = -0.78, p-adj: 4.95e-155), mitochondrial ATP synthesis coupled 
electron transport, (GO:0042775, p-adj = 3.53e-15), CRCA_magenta (r = -0.44, p-adj: 1.61e-60), ATP 
synthesis coupled electron transport (GO:0042773; p-adj = 6.49e-53). Whereas instances of 
positively correlated modules include PACA_white (r = 0.23, p-adj: 8.77e-06), ATP synthesis coupled 
electron transport (GO:0042773; p-adj = 5.70e-16), LIVCA_darkmagenta (r = 0.17, p-adj: 4.36e-06),  
oxidative phosphorylation (GO:0006119; p-adj = 4.36e-09), LGCA_brown (r = 0.44, p-adj: 1.00e-41), 




adj: 3.06e-25), oxidative phosphorylation, (GO:0006119, p-adj = 3.08e-09), BLCA_black (r =  0.45, p-
adj: 3.17e-12), oxidative phosphorylation (GO:0006119, p-adj = 1.56e-07). These results suggest 
that different site-specific tumors employ diverse strategies regarding energy metabolism 
regulation.  
 Finally, many instances of modules enriched in extracellular matrix organization-related 
processes were also found to be positively and negatively correlated with disease status. A non-
exhaustive list of instances is provided next.  BRCA_cyan (r = 0.3 ,p-adj: 9.04e-30), extracellular 
matrix organization (GO:0030198; p-adj = 1.73e-30), CRCA_pink (r = 0.45, p-adj: 2.14e-64), 
extracellular matrix organization (GO:0030198; p-adj = 2.66e-35), HANC_green (r = 0.44, p-adj: 
1.08e-25), extracellular matrix organization (GO:0030198; p-adj = 3.10e-42), CERV_lightgreen  (r = 
-0.5, p-adj: 5.71e-09), extracellular matrix organization (GO:0030198; p-adj = 3.50e-07), 
LIVCA_purple (r = -0.49, p-adj: 1.53e-51), cell adhesion (GO:0007155; p-adj = 2.04e-11), 
SKCM_purple (r = -0.43, p-adj: 2.26e-22), extracellular matrix organization (GO:0030198; p-adj = 
1.28e-08). 
  3.3.8.3 Overlap analysis of the modules significantly associated with disease  
 Overall, six-thousand eight-hundred and ninety significant overlaps between modules 
significantly associated with disease status were observed after adjustment for multiple 
comparisons. One hundred and seventeen were pairs of CNS modules, 5566 were produced 
between pairs of cancer-associated modules, and 1207 were observed between CNS related and 
cancer-associated modules. Among the overlapping pairs of modules found between CNS disorders 
and cancers, 275 belonged to AD, 173 to ASD, 100 to BD, 400 to HD, 72 to MD, and 181 to PD. No 
significant module overlaps were observed between SCZ and cancer modules since no gene co-
expression modules significantly correlated with SCZ status were observed in our analyses. 
 In the case of AD, the AD_brown module (r = 0.31, p-adj: 5.15e-05), which was found to be 
enriched in biological processes linked to  cell adhesion (GO:0007155; p-adj = 6.62e-12) and 
immune response (GO:0006955; p-adj = 6.31e-09), and in macrophage (p-adj: 1.80e-06) and 
microglia (p-adj: 7.68e-05) cell markers, presented significant overlaps with 35 co-expression 
modules from 15 site-specific cancers which were found to be positively correlated with cancer 
status and which were mainly enriched in immune system and extracellular matrix organization 
related processes. Instances include but are not limited to modules linked to cancers which were 
found to present direct transcriptomic associations with AD, BRNCA_yellow (r = 0.12, p-adj: 9.43e-
05), immune response (GO:0006955; p-adj = 3.21e-147), macrophages (p-adj: 6.19e-24), and 
microglia (p-adj: 1.56e-13) or THCA_blue (r = 0.42, p-adj: 1.26e-10), immune system process 
(GO:0002376; p-adj = 1.96e-104), macrophages (p-adj: 1.79e-36).  
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 Examples of overlapping modules which were found to be jointly negatively correlated to 
AD and several site-specific cancers were also observed. AD_turquoise (r = -0.39, p-adj: 2.31e-08) 
which was eniched in ATP synthesis coupled electron transport (GO:0042773; p-adj = 1.57e-21) and 
in Interneurons (p-adj: 1.08e-07) and neuron (p-adj: 3.07e-09) markers presented significant 
overlaps with 25 cancer related modules derived from 12 site-specific tumors. For instance 
significant overlaps were found between AD_turquoise and BRNCA_blue (r = -0.55, p-adj: 1.79e-
100), which was found to be enriched in neuronal related processes and makers, synapse 
(GO:0045202; p-adj = 2.59e-36), interneurons (p-adj: 4.59e-10) and neurons (p-adj: 6.24e-07), 
CRCA_magenta (r= -0.44, p-adj: 1.61e-60), which was enriced in oxidative phosphorylation 
(GO:0006119; p-adj = 4.91e-60), mitochondrial ATP synthesis coupled electron transport 
(GO:0042775; p-adj = 2.99e-53), KDNCA_turquoise (r = -0.78, p-adj: 4.95e-155), with contained 
genes linked to mitochondrial ATP synthesis coupled electron transport (GO:0042775; p-adj = 
3.530167e-15) or THCA_salmon ( r =  -0.32, p-adj: 7.71e-06), which was also found to be enriched 
in mitochondrial ATP synthesis coupled electron transport (GO:0042775; p-adj = 2.47e-50).  
 Gene co-expression modules correlated in different directions with the disease status were 
observed between AD and cancer. AD_turquoise (r = -0.39, p-adj: 2.31e-08) presented significant 
overlaps with gene co-expression modules positively correlated with many cancers including 
BLCA_black (r = 0.45, p-adj: 3.17e-12), oxidative phosphorylation, (GO:0006119, p-adj = 1.55e-07), 
BRCA_red (r = 0.28. p-adj: 3.06e-25), oxidative phosphorylation, (GO:0006119; p-adj = 3.08e-09), 
LGCA_brown (r = 0.44, p-adj: 1.00e-41), ATP synthesis coupled electron transport, (GO:0042773, p-
adj = 5.38e-10), LIVCA_darkmagenta (r = 0.17, p-adj: 4.36e-06), oxidative phosphorylation 
(GO:0006119; p-adj = 4.36e-09), or PACA_white (r = 0.23, p-adj: 8.77e-06), ATP synthesis coupled 
electron transport (GO:0042773; p-adj = 5.70e-16). These observations highlight the importance of 
mitochondrial genes and energy synthesis related pathways in both AD and cancer and suggest that 
this could be an important axis in the modulation of their comorbidities. In addition, AD_skyblue ( 
r =  -0.24, p-adj: 5.26e-03), which was found to be enriched in protein folding (GO:0006457; p-adj = 
1.58e-11),  unfolded protein binding (GO:0051082; p-adj = 7.77e-09), response to topologically 
incorrect protein (GO:0035966; p-adj = 9.13e-08), and chaperone complex (GO:0101031; p-adj = 
1.13e-07) biological processes, presented significant overlaps with 17 up-regulated cancer related 
co-expression modules.  
 AD_orange, AD_brown, and AD_purple are instances of modules that were found to be 
positively correlated to AD status and for which significant overlap with many instances of 
downregulated cancer-related co-expression modules was observed. As discussed previously, 




presence of overlaps of this AD module with both upregulated and downregulated cancer modules 
indicates the complexity of cancer's immune system scenario.  
 ASD, PD, and HD followed a similar pattern of module overlap with cancer than AD. For 
instance, two ASD upregualted co-expression modules, ASD_salmon and ASD_midnightblue, which 
were found to be enriched in response to stress (GO:0006950; p-adj = 1.84e-14) and immune 
system-related processes (GO:0002376; p-adj = 6.50e-26) presented significant overlaps with 
several cancer modules, both up and downregulated, whereas ASD_pink, HD_yelow, and 
PD_turquoise, three modules found to be negatively correlated with disease status and heavily 
enriched in genes linked to the oxidative phosphorylation presented significant overlaps with many 
cancer consensus modules, which were, both positively and negatively correlated with disease 
status. In general, these results highlight the potential importance of immuneand mitochondrial-
related processes in the comorbid associations between CNS disorders and cancers.  
 A small number of co-expression modules were found to be associated with 
neuropsychiatric disorders. No disease module association was observed in SCZ, whereas only two 
co-expression modules were significantly correlated to MD. Both, MD_black (r = -0.23, p-adj: 1.29e-
02) and MD_royalblue (r= -0.25, p-adj: 3.36e-03) were found to be negatively correlated to disease 
status and were enriched in anatomical structure morphogenesis (GO:0009653; p-adj = 1.35e-09) 
and immune response (GO:0006955; p-adj = 3.53e-19), respectively. Both modules presented 
overlaps with modules significantly associated with cancer in both directions. BD status was found 
to be significantly correlated to 6 co-expression consensus modules, which also presented 


















 We observed significant differences in the number of differentially expressed genes among 
the tested CNS disorders. A substantial amount of transcriptomic alteration was present in the 
meta-analyses of the neurodegenerative disorders (AD, HD, PD) and ASD suggesting that they are 
characterized by important changes in gene expression patterns and tissue composition. On the 
contrary, in the cases of BD, MD, and SCZ, the analyses yielded a low number of DEGs, indicating 
that the brain transcriptomes of patients and controls do not differ considerably, at least in the 
brain regions selected for the study. Enrichment analysis results and consensus module analyses 
pointed towards the presence of aberrant expression of several pathways and biological processes. 
Immune system-related pathways were found to be upregulated in most CNS disorders, whereas 
ATP synthesis and oxidative phosphorylation-related genes were found to be downregulated in all 
of them. Interestingly, gene set enrichment analysis showed that pathways alterations were also 
present in BD, MD, and SCZ. This suggests that even if differential gene expression lacks the power 
to identify individually deregulated genes, slight coordinated changes of gene expression of specific 
pathways occur in these disorders. In addition, these changes resemble those observed in the set 
of neurodegenerative diseases and in ASD in terms of the affected pathways. mTORC1 signaling 
was another instance of a pathway that was found to be downregulated in all CNS disorders, with 
the exception of ASD, where it was found to be upregulated.  
 For cancers, differential gene expression analyses yielded large amounts of DEGs, ranging 
from 3.57% of the tested genes observed in AML to 69.24% of tested genes observed in KDNCA. 
These observations are in agreement with previous differential gene expression studies. In general, 
pathways and modules upregulated in cancers were linked to well-known cancer-related processes, 
such as cell cycle, DNA repair, and EF2 targets. mTORC1 signaling was also found to be upregulated 
in most site-specific cancers. More heterogeneous results were observed in pathways linked to the 
immune function. For instance, the inflammatory response was found to be downregulated in 5 
cancer types, whereas it was found to be upregulated in ten cancer types showing the complex 
interplay that takes place between the immune system and cancer. 
 The intersection analysis yielded several significant associations between CNS disorders 
and cancers. BRNCA was found to present significant direct patterns of transcriptomic deregulation 
with AD, PD, HD, and ASD. Thyroid cancer was found to be positively associated with AD, PD, and 
ASD, whereas kidney cancer was found to be directly linked to PD, HD, and ASD. In addition, PD was 
found to be directly linked to stomach cancer, ASD to cholangiocarcinoma, and HD to both 




 Opposite patterns of transcriptomic deregulation were also observed between CNS 
disorders and cancers. Breast, lung, and prostate cancers were negatively associated with the three 
neurodegenerative disorders (AD, PD, and HD). AD was also found to be negatively associated with 
four additional cancer types, including (BLCA, CERV, CRCA, HANC, LIVCA, and PACA). Finally, PD was 
also observed to be inversely linked to CLL. Neuropsychiatric disorders were not included in the 
intersection analyses due to the lack of differential gene expression observed in meta-analyses.  
 An important number of the associations observed in the array-based analyses were 
validated using an independent cohort of cancers derived from TCGA, including the direct 
associations observed between AD and BRNCA, the negative associations between AD and BLCA, 
BRCA, LGCA, LIVCA, and PRCA. The positive transcriptomic associations observed between PD and 
BRNCA and KDNCA were also validated, as well as the opposite patterns of transcriptomic 
deregulation observed between PD and BRCA, LGCA, and PRCA. In the case of HD, both the direct 
associations observed with BRCNA and KDNCA and the inverse associations observed with BRCA 
and LGCA were replicated using the independent cancer cohort. Finally, the transcriptome 
associations observed between ASD and BRNCA and KDNCA were also observed when using 
TCGA data. 
Differences with previously published studies  
 Previous studies have reported inverse transcriptomic associations between AD, PD, and 
SCZ and three tumor types (LGCA, PRCA, CRCA) and direct transcriptomic associations between AD 
and Glioblastomas [34, 250]. The inverse associations between LGCA, PRCA, and AD and PD were 
also observed in our analyses, as well as the inverse transcriptomic associations between AD and 
CRCA and the direct transcriptomic associations between AD and brain cancer. However, we could 
not reproduce the inverse transcriptomic associations between PD and CRCA, neither the 
associations between SCZ and LGCA, PRCA, or CRCA. 
 Several factors have the potential to account for these discrepancies. First, some 
methodological aspects are different in our study. The micro-array normalization method employed 
by the authors of the previous studies was fRMA [251], which utilizes information from publicly 
available Affymetrics microarray databases to precompute probe-specific effects and variances, 
whereas we used classic RMA. In addition, the authors limited the included array platforms to the 
two most popular Affymetrix microarray platforms. hgu133 plus2 and hgu133a, whereas we did 
integrate data from multiple single-channel microarray platforms from Affymetrix, Illumina, and 
Agilent. Second, the criteria for the cohort selection in CNS studies were different. We integrated 
data from only one specific brain region for each CNS disorder and included only datasets with 
samples not derived from the same subset of patients. In contrast, previous studies have included 
data from multiple brain regions, which in some instances were derived from the same subset of 
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patients. We tried to limit this since we consider that the inclusion of several samples derived from 
the same subset of patients could artificially inflate the differential gene expression meta-analyses 
results. In fact, the number of DEGs obtained in our analysis was comparatively lower than those 
observed both in [34, 35]. That is especially evident in the case of SCZ, for which we only observed 
3 DEGs compared to the 1619 DEGs observed by Ibañez and co-workers [34]. In addition, and 
probably as a consequence of the previous comments, the p-values of the intersections reported 
in our work are comparatively higher than those observed previously. There is a trade-off between 
the number of disorders for which data is available and the amount of heterogeneity introduced by 
the use of multiple platforms. 
 The overrepresentation analyses of the genes placed at the intersections, the gene set 
enrichment analyses, and the module overlap comparisons pointed towards several pathways that 
could be important in modulating CNS and cancer comorbidities. 
Cell cycle 
 Cell cycle alterations constitute one of the hallmarks of cancer [83]. Cell-cycle genes were 
found to be upregulated in the majority of our gene set enrichment analysis results of most cancers. 
In addition, the vast majority of cancer types were found to be positively correlated to gene co-
expression modules that were heavily enriched in cell-cycle related genes. In principle, cancer and 
neurodegeneration are placed at two opposite ends in terms of cell behavior since cancer is due to 
uncontrolled cell growth, and neurodegeneration involves post-synaptic cells' death. However, an 
increasing body of evidence suggests that a dysfunctional neuronal cell cycle re-entry could precede 
neurodegeneration. For instance, significantly elevated levels of cyclin D, Cdk4, and Ki67 have been 
observed in AD neurons, suggesting their exit from the G0 phase and their progression through G1.  
M-phase markers such as MPM2, Cdc25 A and B, and phosphatases have also been reported to be 
elevated in AD neurons [252]. In addition, the presence of cyclin E-cdk2 has also been reported, 
indicating that neurons have passed G1 and are committed to cell division or death. However, no 
mitotic structures have been observed in AD neurons re-entering into the cell cycle. This fact 
suggests that the aberrant cell cycle re-entry in susceptible neurons could contribute to their cell 
death [253]. The cell cycle alterations do not limit to AD. Immortalized lymphocytes derived from 
PD patients have been found to present increased cell cycle activity [254], and cell cycle re-entry 
has also been observed in post-mitotic neurons of HD [255]. Furthermore, cell cycle alteration has 
been reported to play a critical role in ASD [256]. Our data suggest the presence of cell cycle 
alterations in some CNS disorders. Several cell cycle-related pathways were found to be 
downregulated in our gene set enrichment analysis of AD and PD. The overrepresentation analysis 
of the genes jointly downregulated in AD and PD and upregulated in their respective opposite 




evidence point towards cell cycle alterations as a potential modulator of the comorbidities 
observed between CNS disorders and cancer. However, the mechanism by which the cell cycle is 
altered in CNS disorders and how it could modulate comorbid associations with cancer remains to 
be elucidated.  
Myc signaling 
 Connecting with the previous section, we observed that MYC targets were downregulated 
in all the studied CNS disorders except for HD and upregulated in most cancers. MYC constitutes a 
family of transcription factors classified as proto-oncogenes, which regulate the expression of genes 
that participate in cell proliferation (cyclins and p21). They also promote cell growth and modulate 
apoptotic processes by downregulation of Bcl-2. A member of this family (c-MYC) has been found 
to be constitutively expressed in many cancer types, including cervix, colon, breast, lung, and 
stomach cancers. However, MYC dysregulation alone has been found not to be sufficient to induce 
cellular proliferation or neoplastic transformation, and other genetic events (loss of p53) are 
necessary to allow MYC to exert its influence in cellular proliferation and neoplastic transformation 
[257]. MYC has also been described to play a role in CNS disorders. As we have seen, in the context 
of AD, the cell cycle hypothesis tries to explain the presence of classic pathological hallmarks of AD 
and the expression of markers of cell proliferation. According to it, some markers linked to cell cycle 
progression in specific neuronal populations are dysregulated in AD despite the fact that neurons 
are post-mitotic cells incapable of division. Reactivation of the cell cycle in adult neurons in vivo and 
in vitro has been shown to produce AD-like changes, including neurodegeneration [258]. It has been 
observed that the neural expression of MYC causes neurodegenerative phenotypes in transgenic 
mice [258]. Many different proteins associated with the cell cycle, including cyclins, cyclin-
dependent kinases, and proto-oncogenes such as c-MYC, are increased in degenerating neurons. 
This contrasts with our observations. A close examination of the differentially expressed pathways 
found in CNS disorders indicates that cell cycle-related genes are significantly downregulated rather 
than upregulated. However, the neurodegenerative process's dynamic nature makes it plausible 
that different pathway activation states are present as the disease progresses. The evidence of the 
involvement of the MYC family in neurodegeneration does not limit to AD. A member of the family 
of MYC (N-myc) has been found to regulate Parkin gene expression. Parkin expression was found 
to be inversely correlated with N-MYC levels in the developing mouse and human brains. In 
addition, tissue-specific induced expression of human c-MYC has been found to suppressed poly(Q)-
mediated neurotoxicity in Drosophila. 
The PI3K/AKT/MTOR axis 
 Genes belonging to the mTORC1 signaling pathway were found to be downregulated in five 
out of the seven CNS disorders included in our analysis. The exceptions were HD, for which no 
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association was found, and ASD, which was associated with a slight upregulation of this pathway. 
In contrast, sixteen of the 22 site-specific cancers, excluding ALL, AML, CHLCA, CLL, CML, and 
FLYMPH, were linked to an increase in the mRNA levels of mTORC1 signaling related genes. The 
PI3K/AKT/mTOR axis has a well-documented role in the nervous system where it participates in 
several processes, including neurogenesis, axonal sprouting, dendritic spine growth, myelination, 
axonal regeneration, and receptor channel expression [259]. In addition, a substantial amount of 
works have reported the involvement of the PI3K/AKT/mTOR axis in the pathology of central 
nervous system disorders using patients samples and animal models. AKT has been found to 
mediate the phosphorylation of the tau protein in AD through PI3K and GSK3β. GSK3β is inhibited 
by phosphorylation, which is produced as a consequence of PI3K/AKT activation. Therefore, the 
attenuation of PI3K/AKT/mTOR signaling would increase the unphosphorylated concentrations of 
GSK3β and, in turn, increase the levels of phosphorylated tau, inducing the formation of 
neurofibrillary tangles [260]. Moreover, it has been observed that increased concentrations of Aβ 
peptides enhance mTOR signaling, whereas further augments of the Aβ levels reaching cytotoxic 
concentrations produce decreases of the mTOR signaling. AD has also been linked to impaired 
insulin signaling [261]. And inhibition of PTEN has been found to recover synaptic function and 
cognition in AD animal models [262]. PI3K/AKT/mTOR signaling alterations have also been observed 
in PD and HD. In PD, the dysregulation of this axis has been linked to the loss of dopaminergic 
neurons [263] by a mechanism related to the regulation of apoptosis molecules [260] and has been 
observed in postmortem samples derived from PD patients [264]. Animal models of HD treated 
with insulin or insulin-like growth factor (IGF) presented improvements in microtubule transport, 
metabolic function, and autophagy, which resulted in the clearance of huntingtin aggregates and 
in the restoration of mitochondrial functions, and the amelioration of motor abnormalities [261]. 
Alteration of PI3K/AKT/mTOR signaling also seems to play an important role in bipolar disorder, 
major depression, and schizophrenia [259, 265-267]. In ASD, PTEN mutations (a negative regulator 
of the axis) have been found in patients with macrocephaly, and mutations in other genes encoding 
components of the PI3K/AKT/mTOR axis are responsible for disorders associated with syndromic 
cases of ASD, including fragile X syndrome, tuberous sclerosis, and type 1 fibromatosis [268-271], 
which are typically linked to an increase in the signaling of the pathway. Surprisingly, contrary to 
syndromic cases, idiopathic autism has been linked to a reduction of signaling through 
PI3K/AKT/mTOR in both patients and animal models [272]. Finally, PI3K/AKT/mTOR signaling plays 
a pivotal role in human tumors, in which it is involved in different processes, such as the regulation 
of cell proliferation, survival, metabolic reprogramming, invasion and metastasis, and the 
suppression of autophagy and apoptosis. A variety of the positive regulators of the axis, including 




and eIF4E present oncogenic potential and present activating mutations. The activation of tyrosine 
kinases and RAS (upstream modulators of the pathway activity) and the loss of function of negative 
regulators such as PTEN and TCS1 and 2, among others, are also usually found in cancer [273]. 
Mitochondrial dysfunction 
 Our results point towards mitochondrial dysfunction and alterations in the ATP synthesis 
process through oxidative phosphorylation as a shared feature of all the studied CNS disorders. 
These processes were found to be heavily enriched in genes that presented coordinated patterns 
of downregulation in our data. This was true even for the set of neuropsychiatric disorders for which 
no significant differentially expressed individual genes were identified. Impaired bioenergetic 
processes have been observed to be a common feature of neurodegenerative disorders [274]. 
Some authors have suggested that neuronal susceptibility to mitochondrial dysfunction might be 
explained by the fact neurons are highly dependent on oxidative phosphorylation [275]. Mounting 
evidence has been gathered for mitochondrial dysfunction in AD and includes the altered glucose 
metabolism observed in living AD subjects, the increased oxidative stress, and ROS damage 
observed in AD brains due to faulty electron transport chain, which results in DNA, lipids, and 
protein damage [274]. In addition, it has been recently demonstrated that mitochondrial 
dysfunction is already present in the parahippocampal region of early-stage AD patients [276]. 
Mitochondrial dysfunction has also been previously observed in the rest of the CNS disorders 
included in our analysis. Several genes linked to familial PD, such as SNCZ, LRRK2, Parkin, PINK1, 
and ATP13A2, have been associated with mitochondrial function. For instance, mutated α-Syn 
induces mitochondrial fragmentation, and Parkin has diverse functions in maintaining healthy 
mitochondria by regulating their biogenesis. Mutations in PINK1 , which encodes for a 
mitochondrial serine/threonine kinase involved in the maintenance of mitochondria homeostasis, 
constitute the second most common cause of autosomal recessive early-onset PD [263]. Altered 
mitochondrial morphology is a common feature of HD, and this diverse morphology can be 
observed in tissues beyond the central nervous system in HD patients [277]. In addition, the altered 
mitochondrial structure has been shown to correlate with decreased electron transport chain 
activity, oxygen consumption, and calcium buffering [277]. Several lines of evidence have also 
pointed towards the role of mitochondrial dysfunction in bipolar disorder, schizophrenia, and major 
depression, which include functional assays, magnetic resonance spectroscopy studies, gene and 
protein expression studies, the observation of structural abnormalities, and the fact that bona fide 
mitochondrial disease patients often present psychotic symptoms that are often misdiagnosed as 
cases of BD and SCZ [278, 279]. Mitochondrial dysfunction is also an important feature in ASD, as 
suggested by several lines of evidence, including the presence of elevated levels of lactate in the 
plasma of ASD patients, the decreased brain glucose utilization and ATP levels, as well as evidence 
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of abnormal electron transport chain function in peripheral tissues and brain tissues [280]. Higher 
rates of glycolysis and suppression of mitochondrial function, even in the presence of oxygen, are 
traits commonly observed in cancer cells. This phenomenon, known as the Warburg effect, has 
been found to be extended among cancers. Since the ATP yield obtained by glycolysis is very low 
compared to respiration, multiple hypotheses have been generated in order to explain its 
preponderance, including the presence of dysfunctional mitochondria in cancer cells, the rapid pace 
of the glycolytic pathway, which would allow meeting the fast rates of cell proliferation found in 
cancer, the presence of reduced mitochondrial activities in cancer cells due to hypoxia and the 
generation of reactive oxygen species, or the increased demand of NAD+. Some of these 
hypotheses are under discussion or have been refuted. In addition, It has been observed that the 
Warburg effect is a common characteristic of all proliferating cells, both tumoral and normal. In 
summary, advances in the understanding of cancer metabolism depict alterations in the oxidative 
phosphorylation and the metabolism of glucose as a more complex phenomenon than previously 
thought. In fact, our data suggest that at least seven tumor types (BLCA, DLBCL, FLYMPH, LGCA, 
LIVCA, and OVCA) present upregulation of genes linked to the oxidative phosphorylation and the 
electron transport chain, whereas five of them (BRNCA, CRCA, KDNCA, STCA, and THCA) present 
downregulation in genes linked to these processes, highlighting the heterogeneity present in cancer 
energy metabolism. In summary, given the joint involvement of the alterations of oxidative 
phosphorylation in both CNS disorders and cancer, this pathway represents a good candidate for 
modulating the diverse comorbidity patterns observed between both sets of disorders. 
p53 signaling, DNA damage, and apoptosis 
 The TP53 gene encodes for the P53 transcription factor, an extensively characterized tumor 
suppressor called “the guardian of the genome” that presents missense mutations in many human 
malignancies. The loss of function of p53 is linked to many cancer-related processes, including the 
cell cycle activation, the survival and avoidance of cell death, as well as the promotion of 
angiogenesis, anchorage-independent growth, cell migration and invasion capacities, and genomic 
instability [281]. The levels and activity of p53 have been previously found to be increased in 
neurodegenerative disorders. Accordingly, we observed that the p53 pathway was upregulated in 
AD, PD, and HD as well as in ASD and SCZ. AD and PD patients and mouse models present increased 
levels of p53 and apoptosis [281]. Moreover, increased levels of p53 have also been detected in 
patients and animal models of HD [282]. The increased p53 activity observed in CNS disorders could 
potentially be linked to a reduction in cancer risk. p53 can induce apoptosis by several mechanisms, 
the most frequent is by transcriptional induction of the intrinsic apoptotic pathway's genes, 
including the proteins of the Bcl2 family and caspases. In addition, proteins commonly associated 




Proper physiological APP processing has been found to be linked to p53 activity. Wild type α-
synuclein has also been found to protect cells from pro-apoptotic stimuli by reducing the 
transcriptional activity of p53. Besides, mutations in Parkin produce an increase in p53 mRNA levels, 
and its transcriptional activity and DJ-1 weakens the DNA binding affinity of p53. Overexpression of 
mutant huntingtin also increases p53 levels. Also, Aβ42 is transported to the cell under oxidative 
stress conditions and activates BACE1 and APP, intensifying erroneous APP cleavage [282]. 
Apoptotic pathways were found slightly upregulated in our data in the case of AD, in which the 
Reactome apoptotic execution phase pathway was found to be upregulated and in PD. Apoptosis 
was also found to be upregulated in HD hallmarks analysis. Upregulation of the cell death pathway 
was observed in AD. Genes belonging to this pathway, including NFKB1, CASP6, and BCL2, RELA, 
LMNA, APAF1, and CASP8, were found to be upregulated in AD samples compared to controls. 
Pathways associated with cell death were not found to be upregulated in HD. However, several 
caspase genes, such as CASP3, CASP6, CASP7, CASP9, FAS, were found to be significantly 
upregulated in HD brain tissues compared to controls. The death pathway was also found to be 
upregulated in PD brains. Caspases 1, 4, 6, and 3 were found to be upregulated in PD brains, as well 
as members of the apoptosome such as APAF1. Apoptosis is a known mechanism taking place in 
neurodegenerative disorders. For instance, in AD, neural apoptosis has been found to be induced 
by the Aβ [283]. Apoptosis is also the main mechanism of neural loss in Parkinson's disease and HD 
[284]. In contrast, one of the hallmarks of cancers is the evasion of cell death mechanisms. 
Therefore, if trends towards pro-apoptotic mechanisms are a widespread phenomenon in 
neurodegenerative disorders not limited to the central nervous system, it could constitute a 
potential additional barrier to tumor development in those patients. 
Proteasome and autophagocytosis 
 One important hallmark of neurodegenerative disorders is the impairment of systems 
linked to the maintenance of proteín homeostasis, including the ubiquitin-proteasome system 
(UPS) and the antiphagocytic mechanisms. Our data showed heavy downregulation of proteasome 
and autophagy-related pathways in the transcriptomes of AD and PD but not in HD. Impairments in 
the proteasome's function were also observed in ASD patients, as well as in SCZ, MD, and BD. 
Neurodegenerative disorders are characterized by deficits in the function of these systems and the 
accumulation of their idiosyncratic proteopaties. This is very clear in the case of PD and AD, which 
have been previously linked to the downregulation of the UPS, the impairment of autophagy, and 
the aggregation of α–synuclein and amyloid–β, respectively. In contrast, tumor cells have often 
been found to upregulate the USP and heat-shock protein systems since increased protein synthesis 
is required for the high rates of cell division observed in cancer cells [285]. Our analyses showed 
upregulation of unfolded protein response pathways in most of the studied cancer types in 
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concordance with this view. Therefore, the impaired proteostasis mechanism found in 
neurodegenerative disorder patients could constitute an impediment to tumor development. 
The role of the immune system 
 Increasing evidence has linked inflammation to neurodegenerative disorders. Inflammation 
in neurodegenerative disorders may be due to alterations in the functions of endogenous or 
exogenous cells. Endogenous CNS cells driving inflammation include astrocytes and mononuclear 
phagocytes (microglia and perivascular macrophages). Astrocytes provide trophic support for 
neurons and facilitate synapse formation and synaptic pruning by phagocytosis. In addition, they 
also participate in the modulation of ion and neurotransmitter concentrations and in the blood-
brain barrier maintenance. Inflamed astrocytes can produce proinflammatory cytokines and 
chemokines. Microglia are the resident macrophages of the central nervous system. Activated 
microglia has been found to be present in almost all neurodegenerative disorders. In addition, 
astrocyte activation and peripheral monocytes and lymphocytes can be detected in CNS disorders 
in certain cases [286]. It has been suggested that all neurodegenerative disorders present an 
inflammatory phenotype. Pro-inflammatory cytokines have been found to be upregulated in the 
brains of AD patients. Amyloid-β aggregates activate microglia, which transitions from its ramified 
form to its activated form and produces reactive oxygen species, IL-1β, and TNF-α or to its pro-
phagocytic form. Activated pro-phagocytic microglia helps to clear amyloid, whereas neurotoxic 
microglia secrete autocrine factors that reinforce the inflammatory phenotype. Factors secreted by 
microglia stimulate the astrocyte response, which could stimulate microglia back and drive the 
recruitment of neuroinflammatory modulators or act on neurons producing neurotoxic or 
neurotrophic effects [286]. Besides IL-1β other cytokines and chemokines have been detected in 
samples derived from AD patients, including (TNF-α), IL-6, IL-8, IL-12, IL-23, CCL2, CCL3, CCL4, 
CXCL2, among others. The presence of activated microglia is also a characteristic feature of PD 
brains. Besides, susceptibility genes linked to the immune function have been associated with AD 
and PD in GWAS studies [286]. HD has also been linked to microglia activation, deposition of 
complement factors, the release of proinflammatory cytokines, and impaired macrophage 
migration [287]. Immune system alterations have been found to have a dual role in ASD. First, 
prenatal insults, such as maternal immunological activation due to infection, have been found to 
increase the risk of ASD. Second, in the postnatal environment, ASD pathology is characterized by 
immune dysregulation, inflammation, and the presence of endogenous antibodies [288]. 
Neuropsychiatric disorders, including BD, MD, and SCZ, have also presented significant immune 
function alterations [289]. Finally, cancer's capacity to evade the host's immune system is one of 
the hallmarks of cancer and the cornerstone of immunotherapy [290]. The presented evidence 




jointly altered in CNS disorders and cancer. However, the complexities of the immune function 
alterations in both sets of disorders prevent us from hypothesizing further the potential influence 
that this joint dysregulation could have in the comorbidities between CNS disorders and cancers. 
Concluding remarks  
 The biological processes described in the previous sections represent instances of functions 
jointly altered in CNS disorders and cancers. In addition to them, our analyses also highlighted the 
presence of joint alterations of genes linked to other mechanisms such as the extracellular matrix 
or the epidermal to mesenchymal transition, which won’t be covered in detail. Besides, it is worth 
noticing that the reported pathways' alterations do not operate in isolation and often have a 
complex interplay. For instance, PI3K signaling has been implicated in the regulation of 
inflammatory response [291] and in the regulation of autophagocityosis [292], and p53 has been 
































































Chapter 4: Genetic associations between CNS disorders and cancer 
4.1 Introduction 
 In the previous chapters, we studied CNS and cancer associations at two different levels. In 
chapter two, we assessed the population-based patterns of comorbidity through meta-analyses of 
observational studies. In chapter three, their phenotypic similarities were appraised by comparing 
the outputs of disease-specific differential gene expression profiles and by the identification of gene 
co-expression modules jointly linked to each disorder. These analyses allowed us to observe diverse 
patterns of comorbid associations between CNS disorders and cancers and identify transcriptomic 
changes of genes and pathways involved in the process. 
 Alterations in joint sets of genes or genes linked to disease-associated variants (henceforth 
variants-genes) could contribute to the direct and inverse comorbidity patterns observed at a 
population level in chapter two and also could be involved in the emergence of the shared (direct 
and inverse) transcriptomic alterations described in chapter three.  
 Therefore, this chapter is devoted to the identification of shared genetic factors between 
disease pairs. Two complementary approaches were used for this purpose. The first approach relies 
on the measurement of the interactome-based overlap of lists of disease-associated genes. It has 
been shown that disease proteins (the products of disease genes) are not randomly scattered in 
the interactome [32]. Instead, they tend to interact with each other more than expected by chance 
forming connected subgraphs that are known as disease modules. According to this view, a disease 
would represent a local perturbation of the underlying disease module, and comorbidity would 
arise as a consequence of perturbations in overlapping disease modules. In other words, if two 
disease modules overlap, local perturbations leading to one disease will likely disrupt pathways 
involved in the other disease module, as well, resulting in shared clinical characteristics. 
 This method has been previously applied to uncover disease-disease associations [32]. In 
their work, Meanche and co-workers compiled 141296 interactions between 13460 proteins, which 
included protein-protein and regulatory interactions, metabolic pathways, and kinase-substrate 
interactions. They primarily focused on identifying the conditions by which disease modules could 
be detected in the incomplete human interactome and established that at least 20 disease-
associated genes would be necessary for disease-module detection in their interactome. Their work 
focused on the detection of direct comorbid associations between disorders. However, if inverse 
comorbid associations could also arise due to the involvement of sets of genes, which overlap in 
the interactome still is an open question. As we have seen, CNS and cancer comorbidities provide 
interesting examples of both direct and inverse associations that we can study using interactome-
based approaches.  
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 To this aim, we constructed a human interactome using multiple sources of protein-protein 
and gene-gene associations. We gathered data from protein-protein interactions from a state-of-
the-art human interaction dataset (HuRI), co-expression partners from GTEx, Transcription factor 
targets from Transfact, human protein complexes from CORUM, Kinase-substrate interactions from 
phosphosite plus, and metabolic association from KEGG. 
 Disease-associated genes and variants-genes were obtained for each disorder from 
different databases (eDgar, DisGeNet, and PheGenI) and tested for overlap in the interactome. Our 
analyses were repeated in two previously compiled human interactomes derived from STRING and 
BioGRID to test the results' stability. 
 The second approach was based on the computation of genetic correlations. In particular, 
a recent methodological development called cross-trait LD score regression was used to this aim 
[294]. There is evidence that most complex traits, including complex disorders, are influenced by 
hundreds of genetic loci with small effects. In recent years, high-throughput technologies have been 
applied to investigate complex disorders’ underlying genetic structure through GWAS studies. The 
intuition behind LD score regression is that if a trait is genetically influenced, then variants with 
higher LD-scores (i.e., variants that tag more of the genome) should have a greater opportunity to 
tag causal variants and therefore to have higher tests statistics on average than variants that have 
low LD-scores. Cross-trait LD score regression uses GWAS summary statistics to compute genetic 
correlations between a given pair of traits. It is based on the fact that the product of the z-statistics 
involving each variant for a given pair of disorders is proportional to their linkage disequilibrium 
scores.  
  Access to patient-level data from GWAS studies is often restricted due to anonymity issues 
making impractical the computation of genetic associations between disorders. In contrast, GWAS 
summary statistics can be increasingly found in public repositories such as the GWAS catalog. In 
addition, cross-trait LD score regression is not biased when sample overlap is present in a given pair 
of studies, and results derived from previous meta-analyses of GWAS data can be used as an input. 
  This methodology has been previously applied to investigate the correlation between AD 
and a set of cancer types [38], which revealed a positive genetic correlation between AD and breast 
cancer. To generate a more complete picture of the genetic associations between CNS disorders 
and cancers, we queried public repositories for GWAS summary statistics involving the seven CNS 
disorders included in previous chapters and the 22 tumor types under consideration. With the 
exception of Huntington’s disease (which is a monogenic or mendelian disorder), we were able to 
obtain GWAS summary statistics for all the CNS disorders included in the previous chapter. GWAS 
summary statistics were also retrieved for a subset of the studied site-specific cancers, including 




Cross-trait LD score regression was carried out for all disease pairs. Only European ancestry studies 
































4.2 Material and methods  
 4.2.1 Sources of human protein-protein/gene-gene interaction data. 
  4.2.1.1 Interactome 1: 
 We constructed a human interactome by integrating different sources of protein-protein 
and gene-gene interactions, including protein-protein interactions (PPI), gene co-expression data, 
information regarding protein complexes, data from transcription factors and their targets, and 
associations between genes participating in successive steps of metabolic pathways. 
 Binary PPIs: PPIs data was derived from the Human Reference Interactome (HuRI) [295]. 
HuRI is an initiative of the Center for Cancer System Biology at Dana-Farber Cancer 
Institute, which interrogated all pairwise combinations of human protein-coding genes to 
identify which are involved in binary protein-protein interactions [296] using yeast two-
hybrid (Y2H) screenings.  
 Co-expressed genes identification: Co-expression partners were identified using data 
derived from the Genotype-Tissue Expression (GTEx) [297], which contains gene expression 
datasets derived from multiple healthy human tissues. Twenty-six of them (adipose tissue, 
adrenal gland, blood, blood vessel, brain, breast, colon, esophagus, heart, liver, lung, 
muscle, nerve, ovary, pancreas, pituitary, prostate, salivary gland, skin, small intestine, 
spleen, stomach, testis, thyroid, uterus, and vagina) were represented by more than one 
hundred samples. Expression data (Transcripts Per Million Reads, TPM) and annotation files 
were downloaded for those tissues. Then we randomly selected 100 samples from each 
tissue and computed Pearson's correlations between all pairwise gene combinations'. We 
considered that two genes were co-expression partners if they presented values of 
correlation higher than 0.7 in at least 16 tissue types. 
 Human protein complexes: Data from human protein complexes was downloaded from The 
comprehensive resource of mammalian protein complexes (CORUM) [298]. Human 
complexes were selected, and self-interacting genes were removed from the data.  
 Transcription factor targets data: The transcription factor targets dataset (TRANSFAC)  was 
selected [299, 300] and retrieved from the Harmonizome database [301]. 
 Kinase-substrate interactions: Kinase substrate interactions were retrieved from 
PhosphoSitePlus [302], which gathers curated data from low and high-throughput 
phosphoproteomic studies. 
 Metabolic links: Data regarding metabolic links was obtained from The Kyoto Encyclopedia 
of Genes and Genomes (KEGG)[303]. In particular, the KEGG PATHWAYS database that 




was employed. In this database, pathways are represented using graphs where nodes are 
molecules (protein and compounds), and edges represent nodes' relations. First, the list of 
KEGG’s human metabolic pathways was retrieved, and KGML files, including them, were 
obtained using the retrieveKGML function from KEGGgraph package [304]. Then the files 
were parsed using parseKGML2Graph function included in the same package. Graphs were 
transformed to adjacency matrices, from which and all pairwise gene-gene associations 
were extracted.  
  4.2.1.2 Interactome 2: 
 The second interactome was obtained from STRING [305]. STRING gathers information 
about known and predicted protein-protein interactions, including direct or physical interactions 
and indirect or functional associations. In short, we downloaded the subset of human interactions 
subset of STRING. The database provides a score ranging from 0 to 1 that informs about the strength 
of each association's evidence. Only the high-quality associations (those presenting a quality score 
higher than 0.7) were selected. 
  4.2.1.3 Interactome 3: 
 The third interactome was derived from BioGriD [306]. BioGRID includes interaction data 
compiled through comprehensive curation efforts. We selected all human interactions included in 
the BioGRID database. 
 4.2.2 Sources of disease-associated genes and variants 
 Sets of genes and variant-genes linked to each studied disorder were extracted from the 
following repositories. Disease-associated genes were retrieved from DisGeNet [307]. This 
database gathers information from different sources, including curated data from UniProt, the 
Comparative Toxicogenomics Database (CTD), Orphanet, the Clinical Genome Resource (CLINGEN), 
Genomics England, The Cancer Genome Interpreter (CGI), and the Psychiatric disorders Gene 
association Network (PsyGeNET), as well as, sources of non-curated data. For each disease-gene 
association, DisGeNet provides a quality score that informs about the evidence supporting it. We 
excluded not-curated, literature-derived, and animal model-obtained association. Variants 
associated with each disease were retrieved from The Phenotype Genotype Integrator (PheGenI) 
[308], which contains information derived from the GWAS catalog, dbGaP, and dbSNP, among 
others. Genes mapped to each variant (henceforth variant genes) were selected and used for 
subsequent analysis. Finally, the eDGAR database [309], which collects information from OMIM, 
Humsvar, and ClinVar was also queried. Each included database employs its own dictionaries to 
identify phenotypes. Appendix 7 shows the identifiers employed to select disease-associated genes 
and variant genes and the list of disease-associated variants and variant-genes for each disorder 
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under the stringent setting. Supplementary Appendix 1 Table 38 provides the list of disease-
associated genes and gene-variants obtained in the relaxed selection setting. 
 For each disorder, two lists of disease-associated genes (stringent and relaxed) were 
created based on the use of two different thresholds for both the DisGeNET association quality 
score and the p-value associated with the variants linked to disease. The stringent sets were 
selected using a threshold of 0.6 for DisGeNET quality score and p-values lower than 1e-10 for the 
disease variant associations reported in PheGenI. In the case of the relaxed sets, the thresholds 
were 0.3 and 1e-08. The threshold selection was found to be a large but uneven impact on the 
number of included disease-associated genes.  
 4.2.3 Measures of network localization and statistical significance 
 For each set of disease-related genes and gene-variants, we computed two network 
localization measures to determine the degree to which disease proteins aggregate in specific areas 
of the interactome.  
 The first measure, termed as the intra-disease average distance 〈𝑑 〉, was computed as 
follows. Let N be a set containing the disease-associated genes and variant genes for a particular 
disorder. For each element n in N the interactome distance to the next closest element of the set 
is determined. Then, the average of all shortest distances computed for all the elements of N is 
computed. Note that the shortest distance is defined as the shortest path between a given pair of 
nodes (i.e., the lowest number of edges that separate a pair of specific nodes in the network). 
 To assess the computed intra-disease average distances' significance, we randomly 
selected 10000 sets of genes of the same size as the original set. The degree distribution of the 
genes placed at a given disease-associated gene list impacts the computed distances' values. 
Therefore, we should account for the degrees observed in the original gene set's genes for the 
randomization process to be accurate. 
 Given the scale-free topology of human interactomes, low degree nodes are much more 
abundant than high degree nodes. We grouped nodes within a certain degree interval together to 
avoid choosing the same high degree nodes repeatedly in the degree-preserving random sampling 
analysis. Let 𝑉 be the set of nodes in the interactome and 𝑢 a particular element of 𝑉 such that 𝑢 ∈
𝑉 and let 𝑘  be the set of all nodes with degree 𝑢 and 𝐵 ,  the bin containing the nodes with degree 
equal or higher than 𝑖 and lower than 𝑗. Nodes, with an increasing degree value are included in each 
bin such that it has at least 100 elements. Therefore, each bin will contain nodes such that, 𝐵 , =
 {𝑢 ∈ 𝑉 | 𝑖 ≤ 𝑘 < 𝑗} such that 𝐵 , ≥ 100. Once the bins have been created, the random 
sampling strategy proceeds as follows. The degree in the reference interactome of each gene in the 




matched bin. This is repeated for all genes in the studied set. The result is a randomly selected set 
of genes presenting the same size than the original set and an approximately equivalent degree 
distribution.  
 The original intra-disease average distance is then compared to the resulting random 
distribution of intra-disease average distances. 𝑑  as follows: 
 
𝑧 (𝑑) ≡
𝑑 − 〈𝑑 〉
𝜎(𝑑 )
 
 Finally, one-tailed p-values are computed by comparing the obtained z-scores to the 
standard normal distribution. 
 The second measure, termed module size S represents the largest connected component 
produced by a particular set of disease-associated proteins in the human interactome (i.e., the 
highest number of disease proteins directly connected to one another). A random distribution of 
module sizes 𝑆  was then generated using the same random degree-preserving strategy 
described for the intra-disease average measures. Z-scores and p-values were also computed using 
the same methodology. 
 4.2.4 Network-based separation measures between disease pairs. 
 The following equation shows the network-based overlap measure proposed by Menche 
and co-workers [32]. 
𝑆 =  〈𝑑 〉 −  
〈𝑑 〉 +  〈𝑑 〉
2
 
𝑆  compares the shortest distances between proteins within each disease 〈𝑑 〉 and 〈𝑑 〉, to the 
shortest distances 〈𝑑 〉 between A-B protein pairs. Proteins associated to both A and B have 𝑑  
= 0. Positive values of  𝑆  indicated separation between disease modules, whereas negative values 
suggest disease-disease overlaps. A null distribution of 𝑆  values 𝑆 was used to compute the 
significance of the observed overlaps following the same degree preserving strategy described in 
the previous section. Z-scores and p-values were computed likewise. 
 4.2.5 Cross-trait LD-score regression 
 GWAS summary statistics for the studied disorders were searched in public repositories 
(GWAS catalog) or directly requested to the authors. We were able to retrieve GWAS summary 
statistics for all the CNS disorders except for HD. Since HD is a monogenic disease, no genome-wide 
association studies have been carried out for it. GWAS summary statistics for a subset of the studied 
cancers were also obtained, including prostate cancer, breast cancer, cervical cancer, colorectal 
cancer, ovarian cancer, endometrial cancer, thyroid cancer, skin cancer melanoma, and lung cancer. 
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 In order to generate the appropriate files to compute genetic correlations, GWAS summary 
statistic files were preprocessed using custom scripts in R and the munge_sumstats.py function 
from the ldsc python package. Note that ldsc interprets the A1 field as the effect allele. In other 
words, it assumes that the sign of the reported summary statistics (betta values, odds ratios, or log-
odds ratios) are oriented in reference to the A1 allele. 
 Heritability estimates were computed for all disorders. Then disease-disease correlations 
were computed for those disease pairs that showed individually significant heritabilities.  
 Cross-trait LD score is a method for estimating genetic correlations from GWAS summary 
statistics data. It is based on the idea that GWAS effect-sizes estimates for a given SNP partially 
incorporate the effects of all SNPs in linkage disequilibrium (LD) with that SNP. For a polygenic trait, 
SNPs with high LD will have higher 𝑋  statistics on average than SNPs with low LD. A similar 
relationship holds if we  replace the 𝑋  statistics of a single study with the product of z-scores from 
two studies of traits with non-zero genetic correlation.  
 Under a polygenic model, the expected value of 𝑧 𝑧  is defined by the following equation:  
Ε 𝑧 𝑧 =  
𝑁 𝑁 𝜌
𝑀




Were 𝑁  is the sample size of study one, 𝑁 is the sample size of study two, 𝜌  is the genetic 
covariance. 𝑙  is the LD score of a particular SNP, 𝑁  is the number of included in both studies, and 
𝜌 is the phenotypic correlation among the 𝑁  overlapping samples. This setting allows estimating 
genetic covariance between two traits by identifying the slope from the regression of 𝑧 𝑧  on LD 
score. Sample overlap only affects the intercept of the regression because sample overlap creates 
spurious correlations between 𝑧  and 𝑧  but does not depend on LD score. 
 Then normalizing the genetic covariance by the SNP-heritability yields genetic correlation.  




Where ℎ the SNP-heritability of is study one and ℎ  is the study heritability from study two. Genetic 









 4.2.6 Sources of GWAS summary statistics 
 GWAS summary statistics were obtained from different sources, including the GWAS 
summary statistics section of the GWAS catalog [310] and the and UK biobank [311]. GWAS 
summary statistics for PD and SKCM were directly requested to the 23andME and Genomel 
consortia. Only studies that tested more than 450000 variants and included at least 5000 individuals 
between cases and controls derived from European ancestry populations were selected. 
Precomputed LD scores of individuals with European ancestry derived from the 1000 Genomes 































 4.3.1 Characteristics of the interactomes and the disease-associated gene lists used 
in this chapter 
 We computed measures of network localization (〈𝑑 〉 and S) and disease separation (𝑆 ) 
using the human interactome constructed by us (hereafter I1) and two additional interactomes, 
derived from STRING (I2) and BIOGRID (I3). Two different sets of disease-associated genes were 
used for each disorder. They were termed as the relaxed (R) and stringent (S) set and differed in 
gene selection thresholds applied when retrieving disease-associated genes from DisGeNet and 
PheGenId. 
 Table 18 shows the sources of protein-protein gene-gene association included in I1. I1 
covered 324377 unique interactions between 16954 genes or proteins. I1, I2, and I3 had increasing 
numbers of interactions and edge densities. They ranged from the 324377 interactions and 0.22% 
edge density found in I1 to the 800238 interactions and the 0.59% edge density observed in I3. 
Table 19 shows information regarding the basic parameters of I1, I2, and I3. The number of disease-
associated genes included in I1 ranged from 2 in CML to 126 BRCA. Different disease identifiers 
were used to retrieve disease-associated genes in the different consulted databases (DisGeNet, 
PhenGenI, and Edgar). The identifiers used to extract the disease-associated genes and variant-
genes in the stringent setting can be consulted in Appendix 7.  
Interaction source Type of interaction Nº of interactions Nº of unique genes 
HURI Binary protein-protein interactions 52248 8230 
GTEx Co-expression in multiple tissues 125803 6702 
CORUM Human protein complexes 39110 3432 
TRANSFACT Transcription  factors targets 100560 13238 
PhosphoSitePlus Kinase-substrate interactions 6013 2527 
KEGG Metabolic interactions 15180 1400 
Total All interactions 324377 16954 
Table 18: Sources of protein-protein/gene-gene interaction data included in I1. 
Interactome Nº Genes Nº Edges Av. degree Diameter Av. path length Edge density 
I1 16954 324377 38.26 9 2.93 0.22% 
I2 18870 445420 47.21 8 2.91 0.25 
I3 16381 800238 97.70 13 3.77 0.59% 
Table 19 Parameters of the interactomes.  
 
 4.3.2 Network localization measures of the genes associated with each disorder. 
 Network localization measures of the disease-associated gene lists showed mixed results, 
which depended upon the employed interactome and the type of disease-associated gene-set used 




expected by chance in 13, 13, 26, 22, 19, and 28 of the included disorders in the I1S, I2S, I3S, I1R, 
I2R, and I3R settings, respectively. Similar results were observed in the case of the size of the largest 
connected components, which were found to be larger than expected by chance in 14, 13, 26, 22, 
22, and 28 of the included disorders in the I1S, I2S, I3S, I1R, I2R, and I3R settings respectively. These 
results indicate that, in general, genes associated with a particular disorder tend to be more 
interconnected and to be placed in the same neighborhood of the human interactome than 
expected by chance. The number of disorders yielding significant values of their network 
localization measures increased as the employed interactomes' size and interconnectedness 
increased. The use of larger sets of disease-associated genes (relaxed sets) allowed the 
identification of a higher number of significant network localization measures. This suggests that 
we would be working under the detection level thresholds in certain settings given the incomplete 
nature of or interactomes and disease-associated gene sets. Tables 20 and 21 show the average 
intra-disease distance and the largest connected component analysis results under the six tested 
settings. The genes that conform each disorder's largest connected component under all settings 
can be consulted in Supplementary Appendix 1 Tables 39 and 40 include the genes placed in the 

















 Interactome 1 stringent Interactome 2 stringent Interactome 3 stringent Interactome 1 relaxed Interactome 2 relaxed Interactome 3 relaxed 
Disease Nº of genes 𝒅𝑨𝑨 (p-val) Nº of genes 𝒅𝑨𝑨 (p-val) Nº of genes 𝒅𝑨𝑨 (p-val) Nº of genes 𝒅𝑨𝑨 (p-val) Nº of genes 𝒅𝑨𝑨 (p-val) Nº of genes 𝒅𝑨𝑨 (p-val) 
AD 55  1.8 (2.35e-07) 57  1.54 (1.02e-04) 55  1.35 (3.86e-09) 138  1.7 (4.50e-04) 142  1.43 (3.88e-06) 137  1.3 (1.31e-15) 
ASD 19  2.05 (2.42e-01) 19  1.68 (1.15e-02) 17  1.59 (7.86e-07) 93  1.81 (3.51e-01) 98  1.68 (6.48e-04) 96  1.54 (7.34e-11) 
BD 22  1.82 (9.09e-02) 24  2.12 (9.49e-01) 23  1.48 (1.11e-05) 454  1.45 (9.27e-03) 465  1.29 (6.90e-11) 465  1.18 (8.75e-12) 
HD NA NA NA NA NA NA 15  2.13 (2.57e-01) 17  2.06 (3.92e-01) 17  1.88 (3.52e-03) 
MD 23  1.83 (8.51e-02) 26  1.96 (5.91e-01) 24  1.5 (1.95e-05) 432  1.38 (4.65e-03) 436  1.24 (1.74e-11) 440  1.14 (2.82e-11) 
PD 69  1.7 (1.24e-05) 77  1.69 (1.05e-01) 67  1.34 (4.46e-14) 138  1.72 (4.70e-03) 148  1.57 (4.44e-02) 137  1.24 (5.90e-13) 
SCZ 38  2 (5.05e-01) 43  1.74 (3.67e-03) 41  1.44 (7.77e-10) 888  1.31 (5.28e-03) 923  1.23 (6.04e-05) 890  1.15 (5.05e-12) 
ALL 16  1.56 (4.94e-03) 17  1.71 (5.86e-02) 18  1.39 (8.90e-11) 71  1.39 (1.03e-03) 74  1.31 (5.42e-05) 73  1.3 (4.09e-10) 
AML 34  1.47 (2.17e-02) 34  1.24 (3.27e-03) 31  1.13 (1.17e-09) 167  1.3 (7.39e-03) 172  1.22 (2.20e-02) 163  1.23 (5.65e-11) 
BLCA 22  2.05 (9.08e-01) 24  1.42 (3.85e-02) 23  1.48 (1.53e-03) 134  1.54 (2.48e-01) 142  1.3 (5.94e-03) 136  1.31 (1.04e-05) 
BRCA 126  1.47 (1.47e-02) 135  1.28 (4.91e-03) 125  1.34 (8.60e-05) 1044  1.15 (1.57e-03) 1094  1.16 (6.70e-02) 1029  1.24 (2.01e-03) 
BRNCA 17  1.82 (1.27e-01) 19  1.26 (6.97e-03) 17  1.41 (4.02e-04) 52  1.69 (1.75e-02) 57  1.28 (4.57e-02) 53  1.3 (7.93e-06) 
CERV 3  1.67 (2.08e-02) 4  2.5 (7.48e-01) 4  1.75 (3.33e-02) 5  1.8 (2.42e-02) 7  2.71 (9.99e-01) 7  1.57 (2.86e-05) 
CHLCA 3  2 (2.71e-01) 3  2 (8.45e-01) 3  1 (1.39e-02) 26  1.65 (1.16e-01) 26  1.31 (2.11e-02) 26  1.15 (9.74e-06) 
CLL 32  1.56 (3.60e-05) 33  1.73 (2.93e-02) 29  1.79 (1.22e-03) 85  1.45 (4.56e-05) 90  1.4 (1.45e-03) 82  1.48 (5.16e-04) 
CML 2  3 (5.47e-01) 2  2 (8.94e-02) NA NA 2  3 (5.49e-01) 2  2 (8.72e-02) NA NA 
CRCA 67  1.54 (2.08e-02) 68  1.18 (1.21e-04) 68  1.26 (1.10e-03) 672  1.27 (3.48e-04) 700  1.25 (6.90e-03) 680  1.36 (2.22e-05) 
DLBCL 7  2.43 (5.42e-01) 8  1.75 (1.16e-01) 7  1.29 (1.86e-04) 57  1.44 (8.87e-04) 59  1.24 (1.68e-03) 55  1.22 (5.61e-06) 
FLYMPH 7  2.29 (2.11e-01) 7  2.29 (7.97e-01) 7  1.86 (8.09e-02) 26  2 (8.78e-02) 28  1.82 (3.27e-01) 23  1.3 (2.09e-07) 
HANC 7  1.86 (5.21e-02) 7  1.57 (1.05e-01) 7  1.71 (1.95e-02) 51  1.39 (3.82e-04) 52  1.25 (3.28e-03) 51  1.24 (3.11e-05) 
KDNCA 17  1.71 (1.17e-01) 19  1.47 (1.46e-03) 17  1.41 (1.57e-05) 135  1.59 (1.33e-02) 146  1.4 (2.87e-02) 141  1.47 (4.63e-04) 
LGCA 33  1.64 (8.21e-02) 37  1.38 (8.68e-02) 34  1.35 (1.27e-04) 245  1.36 (1.91e-03) 261  1.27 (3.16e-02) 241  1.24 (3.40e-07) 
LIVCA 35  1.46 (6.05e-04) 35  1.34 (1.56e-02) 35  1.29 (1.93e-03) 469  1.29 (5.52e-02) 486  1.23 (2.38e-01) 480  1.21 (9.31e-07) 
OVCA 34  1.56 (3.51e-03) 35  1.17 (2.51e-03) 31  1.23 (2.75e-04) 144  1.38 (5.05e-03) 147  1.19 (3.62e-04) 141  1.3 (7.51e-04) 
PACA 19  1.63 (8.37e-03) 20  1.55 (1.16e-01) 19  1.26 (6.79e-09) 103  1.54 (4.57e-03) 110  1.32 (6.77e-03) 104  1.18 (8.12e-11) 




SKCM 32  1.44 (1.07e-04) 34  1.38 (7.64e-02) 32  1.19 (6.06e-07) 234  1.47 (1.74e-01) 249  1.33 (1.95e-01) 240  1.4 (1.62e-02) 
STCA 19  1.79 (1.92e-01) 20  1.6 (1.79e-01) 20  1.45 (1.04e-03) 289  1.33 (3.39e-03) 299  1.16 (5.51e-03) 287  1.18 (5.23e-07) 
THCA 13  1.69 (7.99e-02) 14  1.86 (7.17e-01) 11  1.27 (4.23e-07) 53  1.7 (1.74e-01) 55  1.42 (1.13e-01) 52  1.13 (5.47e-09) 
Table 20: Interactome average intra-disease distance localization measure under the six settings tested in the analysis. The first column of each group of two columns 
shows the number of genes associated with a particular disorder represented in the interactome under analysis. The second column provides the intra-disease distance 




























 Interactome 1 stringent Interactome 2 stringent Interactome 3 stringent Interactome 1 relaxed Interactome 2 relaxed Interactome 3 relaxed 
Disease Nº of genes S (p-val) Nº of genes S (p-val) Nº of genes S (p-val) Nº of genes S (p-val) Nº of genes S (p-val) Nº of genes S (p-val) 
AD 55 6 (3.27e-11) 57 28 (7.50e-09) 55 37 (0.00e+00) 138 15 (1.71e-01) 142 75 (6.06e-05) 137 94 (6.36e-13) 
ASD 19 1 (7.12e-01) 19 4 (8.85e-02) 17 6 (1.98e-12) 93 10 (4.06e-01) 98 17 (2.06e-02) 96 29 (0.00e+00) 
BD 22 5 (1.41e-02) 24 1 (8.56e-01) 23 12 (0.00e+00) 454 228 (1.37e-02) 465 316 (3.06e-08) 465 358 (9.76e-09) 
HD NA NA NA NA NA NA 15 1 (6.10e-01) 17 2 (1.23e-01) 17 3 (4.37e-03) 
MD 23 2 (5.60e-01) 26 3 (3.47e-01) 24 15 (0.00e+00) 432 260 (5.33e-03) 436 317 (5.05e-09) 440 376 (2.01e-11) 
PD 69 5 (2.58e-01) 77 24 (1.31e-02) 67 40 (0.00e+00) 138 12 (1.10e-01) 148 59 (2.77e-02) 137 101 (1.24e-09) 
SCZ 38 2 (7.35e-01) 43 5 (1.31e-01) 41 28 (0.00e+00) 888 594 (1.20e-02) 923 684 (3.08e-03) 890 759 (3.11e-14) 
ALL 16 7 (3.47e-06) 17 3 (8.11e-02) 18 14 (0.00e+00) 71 40 (1.18e-03) 74 51 (5.86e-05) 73 53 (9.54e-13) 
AML 34 16 (2.18e-02) 34 21 (5.04e-02) 31 22 (8.31e-13) 167 113 (9.89e-03) 172 133 (1.97e-02) 163 121 (2.56e-05) 
BLCA 22 2 (7.63e-01) 24 14 (2.69e-02) 23 14 (3.15e-09) 134 61 (1.07e-01) 142 99 (4.82e-03) 136 96 (5.68e-04) 
BRCA 126 61 (2.21e-02) 135 95 (1.04e-02) 125 86 (1.27e-03) 1044 882 (1.53e-03) 1094 922 (2.98e-02) 1029 777 (8.34e-04) 
BRNCA 17 4 (4.14e-02) 19 14 (8.51e-03) 17 12 (5.59e-10) 52 17 (1.36e-05) 57 42 (1.89e-02) 53 39 (7.80e-08) 
CERV 3 2 (0.00e+00) 4 1 (5.45e-01) 4 2 (4.69e-04) 5 2 (0.00e+00) 7 1 (5.79e-01) 7 2 (1.36e-03) 
CHLCA 3 1 (6.03e-01) 3 1 (8.29e-01) 3 3 (6.99e-04) 26 11 (3.46e-03) 26 18 (1.47e-02) 26 22 (6.46e-10) 
CLL 32 5 (1.89e-01) 33 11 (2.26e-05) 29 9 (2.92e-07) 85 42 (1.31e-03) 90 53 (1.33e-03) 82 41 (2.77e-04) 
CML 2 1 (5.06e-01) 2 1 (5.17e-01) NA NA 2 1 (5.04e-01) 2 1 (5.20e-01) NA NA 
CRCA 67 26 (4.04e-03) 68 56 (1.11e-04) 68 51 (1.47e-03) 672 489 (2.27e-04) 700 518 (7.43e-03) 680 415 (3.31e-04) 
DLBCL 7 1 (5.30e-01) 8 2 (2.02e-01) 7 3 (2.35e-04) 57 30 (1.44e-03) 59 41 (1.04e-02) 55 45 (1.18e-07) 
FLYMPH 7 1 (5.46e-01) 7 1 (6.87e-01) 7 2 (2.26e-01) 26 3 (2.71e-03) 28 3 (5.97e-01) 23 6 (5.00e-03) 
HANC 7 2 (8.07e-04) 7 3 (1.01e-01) 7 2 (8.68e-02) 51 34 (2.80e-06) 52 38 (4.60e-03) 51 40 (4.35e-09) 
KDNCA 17 5 (2.90e-02) 19 9 (5.55e-05) 17 5 (1.96e-05) 135 42 (2.49e-02) 146 85 (2.04e-02) 141 77 (1.68e-05) 
LGCA 33 12 (2.95e-02) 37 24 (5.48e-02) 34 24 (8.91e-11) 245 146 (6.02e-03) 261 191 (1.44e-02) 241 184 (1.35e-05) 
LIVCA 35 15 (6.34e-03) 35 21 (4.41e-02) 35 28 (1.69e-05) 469 329 (4.62e-02) 486 371 (2.28e-01) 480 378 (6.14e-07) 
OVCA 34 15 (1.29e-04) 35 29 (3.01e-03) 31 24 (8.87e-07) 144 86 (5.07e-03) 147 117 (8.41e-04) 141 97 (4.94e-03) 
PACA 19 4 (2.17e-01) 20 10 (3.98e-02) 19 13 (0.00e+00) 103 42 (2.09e-02) 110 70 (4.10e-02) 104 86 (1.88e-05) 




SKCM 32 14 (1.84e-04) 34 22 (2.65e-02) 32 24 (3.11e-11) 234 121 (1.02e-01) 249 163 (2.15e-01) 240 142 (9.98e-03) 
STCA 19 3 (4.40e-01) 20 8 (9.28e-02) 20 11 (3.06e-11) 289 185 (4.79e-03) 299 248 (6.99e-03) 287 233 (7.93e-07) 
THCA 13 4 (8.82e-02) 14 2 (7.93e-01) 11 8 (0.00e+00) 53 7 (6.22e-01) 55 32 (6.99e-02) 52 43 (2.30e-06) 
Table 21:  Sizes of the largest connected components under the six tested settings. The first column of each group of two columns shows the number of genes associated 



















 4.3.3 Interactome-based overlaps between disease pairs 
 In interactome one stringent analysis, one hundred and fourteen overlaps were found to 
present values lower than 0. Of those, only eight presented FDR adjusted p-values under 0.05, and 
thus, separation values lower than expected by chance. The significant overlaps included one 
formed by a pair of CNS disorders, BD and MD (𝑆  = -0.40, p-adj = 1.46e-03) and seven between 
cancer pairs, which included BRCA and LGCA (𝑆 = -0.17, p-adj = 4.31e-02), BRCA and PRCA (𝑆  = 
-0.18, p-adj = 8.70e-03), BRNCA and LGCA (𝑆  = -0.35, p-adj = 2.27e-02), CRCA and LGCA ( 𝑆  = -
0.28, p-adj = 6.30e-03), CRCA and OVCA (𝑆  = -0.28, p-adj = 7.00e-03), LGCA and OVCA (𝑆  = -
0.54, p-adj = 8.98e-09), and  LGCA and STCA (𝑆  = -0.41, p-adj = 3.02e-03). Interactome 2 stringent 
analysis yielded one hundred and twenty-one interactome overlaps with values lower than cero. 
Only four presented adjusted p-values lower than 0.05.  Including BD and MD (𝑆  = -0.68, p-adj = 
3.30e-14) as well as three instances of cancer pairs. BRCA and LGCA (𝑆 = -0.13, p-adj = 1.06e-02), 
CRCA and OVCA (𝑆  = -0.23, p-adj = 1.40e-02), and LGCA and OVCA (𝑆  = -0.39, p-adj = 1.13e-05). 
Finally, Interactome three analysis returned forty-four overlaps lower than cero for which only one 
was found to be significant, LGCA and OVCA (𝑆  = -0.4, p-adj = 1.68e-02). 
 In the case of the interactome one relaxed analysis, 114 overlaps presented values lower 
than 0, from which nineteen had adjusted p-values inferior to 0.05.  Significant overlaps were 
observed between pairs of CNS disorders, such as BD and MD (𝑆  = -0.59, p-adj = 5.24e-107), BD 
and  SCZ (𝑆  = -0.44, p-adj = 8.20e-79), and MD and SCZ (𝑆  = -0.35, p-adj = 3.14e-43), whereas 
the rest of significant overlaps belonged to cancer pairs, and included ALL and AML (𝑆  = -0.15, p-
adj = 4.06e-02) and  BLCA and LGCA (𝑆  = -0.16, p-adj = 1.93e-03), among others. The relaxed 
analysis of the interactome two also yielded 114 negative overlaps, of which nineteen were found 
to be significant, which included the same significant overlaps between CNS disorders and different 
instances of significant overlaps between diverse cancer types. Finally, in the case of the 
interactome three relaxed analysis, sixty overlap measures presented values lower than cero, but 
only eleven were found to be significant and included disease pairs similar to those reported under 
the rest of the settings. 
 In general, we did not observe significant negative separation values between CNS 
disorders and cancers' disease modules under any of the tested settings. Despite it, some instances 
of non- significant negative values were present in our results, including, ALL and ASD (𝑆  = -0.18), 
ASD and HANC (𝑆  = -0.11), ASD and KDNCA ( 𝑆  = -0.24), and ASD and STCA (𝑆  = -0.13) in the 
interactome one stringent analyses, or those observed between ASD and CHLCA (𝑆 = -0.16), ASD 
and THCA (𝑆 = -0.13), BD and CHLCA (𝑆 = -0.14), CHLCA and MD (𝑆 = -0.12) in the interactome 




CNS disorders and cancers were observed under the rest of the settings. Figure 18 shows a heatmap 
representation of the disease-disease overlap analyses carried out under the six different settings. 
The analysis results obtained in the different tested settings presented a variety of correlation 
strengths when compared to each other ranging from r = 0.29 in the comparison between I2S and 
I3R and r = 0.92 in the comparison between I1R and I3R (See Figure 19). The complete list of 
significant disease-disease interactome-based overlaps is provided in Supplementary Appendix 1 





































Figure 18:  𝑺𝑨𝑩 values under the six different tested settings. A) Interactome 1 stringent, B) Interactome 
2 stringent, C) Interactome 3 stringent, D) Interactome 1 relaxed, E) Interactome 2 relaxed, F) 
Interactome 3 relaxed. For subfigures A, B, and C the order of the disorders from left to right and from 
top to bottom is. AD, ASD, BD, MD, PD, SCZ, ALL, AML, BLCA, BRCA, BRNCA, CERV, CHLCA, CLL, CML, 
CRCA, DLBCL, FLYMPH, HANC, KDNCA, LGCA, LIVCA, OVCA, PACA, PRCA, SKCM, STCA, THCA. In the case 
of subfigures D, E, and F, HD is placed between BD and MD. Blue colors indicate negative  𝑺𝑨𝑩 values, 













Figure 19: Correlations between The Sab values obtained under each setting.  I1_St = Interactome 1 
stringent, I2_St = Interactome 2 stringent, I3_St = Interactome 3 stringent, I1_Rel = Interactome 1 
relaxed, I2_Rel = Interactome 2 relaxed, I3_Rel = Interactome 3 relaxed. Blue colors indicate positive 
correlations. The size and color intensity of the circles depicted in the upper-right corner is proportional 
to the correlation values, with higher values presenting bigger circles of more intense blue color. The 
lower-left corner contains the numeric values of the computed Pearson’s correlations. 
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 4.3.4 Genetic correlation analyses results 
 We were able to identify and retrieve GWAS summary statistics from 20 studies. Three of 
them examined the implication of genetic variability in AD's risk, whereas two did it for ASD and PD. 
BD, MD, and SCZ were represented with one GWAS study each. No GWAS summary statistics data 
was available for HD, given its monogenetic nature. We could only obtain information for six site-
specific cancers, which included BRCA (3 studies), PRCA (2 studies), CRCA (1 study), OVCA (1 study), 
SKCM (2 studies), and LGCA (1 study). The observed scale estimated heritabilities ranged from 
0.0058 in the case of CRCA to 0.45 in the case of the ASD 2 datasets. Table 22 shows information 
regarding the dataset's sample sizes, the number of cases and controls, and the parameters linked 
to the SNP heritability estimation using LD-score regression.  All pairwise genetic correlations were 
computed between the selected studies. Table 23 displays the significant genetic correlations 
detected, presenting nominal p-values under 0.05. The genetic correlations computed between 
pairs of studies targeting the same disorder were found to present the maximum correlation values 
as well as the lower p-values, and included the positive genetic correlations found between AD 2 
and AD 3 (𝑟 = 0.92, p-val = 1.60e-10), ASD 1 and ASD 2 (𝑟  = 0.84, p-val = 4.99e-87) or BRCA 1 and  
BRCA 3 (𝑟  =  0.92, p-val = 1.26e-32), among others (See Table 23 A). Significant positive genetic 
correlations were also observed between several pairs of CNS disorders. The most significant were 
those found between ASD 1 and MD (𝑟  = 0.37 , p-val = 9.34e-37), ASD 1 and SCZ (𝑟 = 0 .21, p-val = 
1.15e-08), BD and MD (𝑟 = 0.33, p-val = 3.42e-34), BD and SCZ (𝑟  = 0.68, p-val = 8.82e-229), as well 
as SCZ and MD (𝑟 = 0.31 p-val = 6.33E-38). More modest significant genetic correlations were also 
observed between other pairs of CNS disorders, including AD 3 and PD 1 (𝑟  = 0.20, p-val = 0.012), 
among others (See Table 23 B). Genetic correlations between cancer pairs tended to be lower than 
those observed between CNS pairs. Instances of those include the positive association observed 
between BRCA 2 and OVCA (𝑟  = 0.23, p-val = 2.00e-04), or PRCA 2 and BRCA 2 (𝑟  = 0.11, p-val = 
0.01) (Table 23 C). Finally, a number of significant genetic correlations were also observed between 
CNS disorders and cancers (Table 23 D). Those included the negative correlations between ASD 1 
and PRCA 2 (𝑟  = -0.16, p-val = 7.30e-03), ASD 2 and BRCA 2 (𝑟  = -0.1, p-adj = 1.60e-02), as well as 
the positive correlations identified between BD and BRCA 1 (𝑟  = 0.11, p-val = 6.00e-03), BD and 
BRCA 2 (𝑟  = 0.07, p-val = 1.32e-02), MD  and BRCA 1 (𝑟  = 0.08, p-val = 9.00e-03),  MD and BRCA 2 
(𝑟 = 0.085, p-val = 4.02e-05), and MD and LGCA (𝑟  = 0.28, p-val = 5.00e-04). Slight but significant 
positive correlations were also observed between PD and both PRCA and SKCM. PD 1 and PRCA 1 
(𝑟 = 0.09, p-val = 3.16e-02) and PD 1 and SKCM 2 (𝑟  = 0.14, p-val = 4.00e-02). Finally, Schizophrenia 
was found to be positively correlated with breast cancer, BRCA 1 (𝑟  = 0.11, p-val = 5.00e-04), BRCA 


















AD 1 IGAP 
[312] 
54162 (17008/37154) 1150200 1.11 1.09 565.21 165 0.07 
AD 2 GR@ACE 
project 
[313] 
21235 (11999/9236) 1204123 1.09 1.068 1123.06 59 0.13 





1203908 1.12 1.08 1009.11 320 0.01 
ASD 1 iPSYCH 
project 
[315] 
46350 (18381/27969) 1161575 1.186 1.16 35.93 28 0.20 
ASD 2 PGC 10610 (5305/5305) 1189408 1.05 1.04 24.09 0 0.45  
BD PGC 
[316] 
46582 (20352/31358) 1103145 1.39 1.33 56.53 74 0.35  
SCZ PGC [58] 150064 (36989/113075) 1140241 1.79 1.58 120.76 1725 0.24 
MD PGC 
[317] 
500199 (170756/329443 1217311 1.60 1.45 77.81 943 0.06 
PD 1 Nalls et al 
[318] 
 
482730 (33674/449056) 1137530 1.14 1.09 180.42 276 0.02 
PD 2 23 And 
Me [319] 
308557 (6477/302080 ) 1211658 1.10 1.08 164.95 142 0.02 
PRCA 1 GWAS 
catalog 
[320] 
140254 (79148/61106) 1206082 1.51 1.23 846.34 2733 0.16 
PRCA 2 UK 
Biobank 
206770 (6879/199891) 1211361 1.13 1.09 181.15 397 0.03 
BRCA 1 BCAC 
[321] 
247173 (133384/113789) 519352 1.72 1.38 481.43 1389 0.12 
BRCA 2 GWAS 
catalog 
[322] 
139274 (76192/63082) 1128758 1.68 1.36 1424.99 2832 0.22 
BRCA 3 UK 
Biobank 
245494 (10478/235016) 1211361 1.11 1.08 314.15 276 0.02 
CRCA UK 
Biobank 




85426 (16924/68502) 1149515 1.09 1.06 169.17 209 0.04 
SKCM 1 UK 
Biobank 
452264 (2465/449799) 1211361 1.04 1.03 121.09 144 0.00 
SKCM 2 Genomel 
[324] 
32383 (11523/20860) 1100284 1.12 1.08 372.76 561 0.17 
LGCA UK 
Biobank 
452264 (1655/450609) 1211361 1.02 1.01 26.03 0 0.00 
Table 22: Included studies and characteristics in the genetic correlation analyses. *This dataset includes as 
cases AD patients, as well as individuals with a family history of AD. PGC = Psychiatric Genomic Consortium. 










A) Significant genetic correlations between pairs of studies targeting the same disorder 
Disease 1 Disease 2 𝒓𝒈 𝒓𝒈 SE z p 
AD 1 AD 2 1.8 0.33 5.54 3.09e-08 
AD 2 AD 3 0.92 0.14 6.4 1.60e-10 
ASD 1 ASD 2 0.84 0.04 19.77 4.99e-87 
PD 1 PD 2 0.86 0.06 13.44 3.51e-41 
BRCA 1 BRCA 2 1.02 0 233.42 0.00e+00 
BRCA 1 BRCA 3 0.93 0.08 11.89 1.26e-32 
BRCA 2 BRCA 3 1 0.06 17.17 4.47e-66 
PRCA 1 PRCA 2 1.04 0.05 20.58 4.59e-94 
SKCM 1 SKCM 2 1.24 0.28 4.48 7.49e-06 
B) Significant genetic correlations between pairs of CNS disorders 
Disease 1 Disease 2 𝒓𝒈 𝒓𝒈 SE z p 
AD 3 BD 0.15 0.06 2.42 1.54e-02 
AD 3 MD 0.17 0.07 2.65 8.00e-03 
AD 3 PD 1 0.21 0.08 2.51 1.21e-02 
AD 3 SCZ 0.1 0.05 1.98 4.76e-02 
ASD 1 BD 0.15 0.04 3.52 4.00e-04 
ASD 1 MD 0.37 0.03 12.66 9.34e-37 
ASD 1 PD 2 -0.18 0.07 -2.64 8.20e-03 
ASD 1 SCZ 0.21 0.04 5.71 1.15e-08 
ASD 2 MD 0.1 0.04 2.43 1.49e-02 
ASD 2 PD 2 -0.2 0.07 -2.87 4.10e-03 
ASD 2 SCZ 0.18 0.05 3.82 1.00e-04 
BD MD 0.33 0.03 12.19 3.42e-34 
BD SCZ 0.68 0.02 32.29 8.82e-229 
SCZ MD 0.31 0.02 12.87 6.33e-38 
C) Significant genetic correlations between pairs of cancers 
Disease 1 Disease 2 𝒓𝒈 𝒓𝒈 SE z p 
BRCA 2 OVCA 0.23 0.06 3.68 2.00e-04 
BRCA 2 SKCM 2 0.12 0.04 2.68 7.40e-03 
BRCA 3 CRCA -0.22 0.13 -1.74 8.11e-02 
PRCA 1 BRCA 1 0.11 0.05 2.32 2.01e-02 
PRCA 1 BRCA 2 0.07 0.03 2.41 1.59e-02 
PRCA 2 BRCA 2 0.11 0.04 2.56 1.05e-02 
D) Significant genetic correlations between CNS disorders and cancers 
Disease 1 Disease 2 𝒓𝒈 𝒓𝒈 SE z p 
ASD 1 PRCA 2 -0.16 0.06 -2.68 7.30e-03 
ASD 2 BRCA 2 -0.1 0.04 -2.41 1.59e-02 
BD BRCA 1 0.11 0.04 2.71 6.70e-03 
BD BRCA 2 0.07 0.03 2.48 1.32e-02 
MD BRCA 1 0.08 0.03 2.63 8.60e-03 
MD BRCA 2 0.09 0.02 4.11 4.02e-05 
MD LGCA 0.28 0.08 3.46 5.00e-04 




PD 1 PRCA 1 0.09 0.04 2.15 3.16e-02 
PD 1 SKCM 2 0.14 0.07 2.01 4.41e-02 
PD 2 PRCA 2 0.16 0.08 2.01 4.44e-02 
SCZ BRCA 1 0.11 0.03 3.47 5.00e-04 
SCZ BRCA 2 0.14 0.02 5.63 1.75e-08 
SCZ OVCA 0.12 0.06 2.02 4.31e-02 
Table 23: Significant genetic correlations between dataset pairs. The first and the second column shows the 
involved datasets. Column three presents the measured genetic correlation between each pair. Column 
four shows the standard error of the computed genetic correlations. Finally, columns five and six indicate 






























This chapter investigated the potential implication of interactome-based overlaps and 
genetic correlations in the CNS and cancer comorbidities. 
First, our results suggest that disease-associated genes and variant-genes tend to be placed 
in nearby regions of the human interactome. This trend was observed in CNS disorders and cancers 
for both measures of network localization (the average intra-disease distance and the size of the 
largest connected components). The use of larger disease-associated sets of genes and more 
interconnected interactomes was linked to an increase in the number of disorders displaying 
significant closer distances and larger connected components.  
Second, we observed significant interactome-based overlaps between pairs of 
neuropsychiatric conditions, suggesting that MD, BD, and SCZ constitute a cluster of genetically 
linked disorders. Genetic correlation analyses based on GWAS summary statistics strengthened this 
idea since significant genetic correlations were observed between BD and MD, BD and SCZ, and SCZ 
and MD. These associations are interesting on their own and could arise as a consequence of many 
different factors. Some systematic artifacts could confuse studies trying to associated uncover 
genetic associations in neuropsychiatric disorders. For instance, some authors have stated that BD 
is often misdiagnosed as unipolar depression [325]. In psychiatry, nosology (the branch of medical 
sciences dealing with the classification of diseases), traditionally represented by the ICD and DSM 
classification systems, is based on a categorical classification of disorders. However, an open debate 
is still ongoing about such classification systems' adequacy in psychiatric nosology [326]. 
Transdiagnostic approaches represent an alternative to traditional classification systems that are 
more focused on identifying processes that underlie a given class of disorders. Although it is out of 
this thesis's scope, the interactome-based associations and genetic correlations observed between 
neuropsychiatric conditions add arguments to this debate. 
Third, significant overlaps were observed between the disease modules of many cancer 
pairs. This observation was expected since recurrent somatic mutations of many genes play a 
pivotal role in different cancer types.  The pan-cancer analysis of 2658 whole-cancer genomes 
derived from 38 tumor types and their matching normal tissues identified sets of genes that 
suffered somatic driver mutations across cancers, including TP53, CDKN2A, ARID1A, KRAS, and 
PTEN, among others [327]. Therefore, many shared genes, including those mentioned above, were 
repeatedly found across the different lists of cancer-associated genes included in our analysis. 
Besides, significant genetic correlations were also observed between some cancer pairs, which 
included BRCA and OVCA or BRCA and PRCA, among others. However, the genetic correlations 




disorders, indicating that even if somatic alterations are frequently shared among cancers, genetic 
susceptibility mechanisms could differ to a greater extent between them.  
Finally, we analyzed the interactome-based overlaps and genetic correlations between CNS 
disorders and cancers. One common trait of all the interactome-based disease-disease overlap 
analyses carried out under different settings was that no significant CNS-cancer overlaps were 
observed. Despite this fact, a number of negative interactome distance measures between CNS and 
cancers were observed. Some authors have recognized that the current state of knowledge limits 
network-based approaches' predictive power and that the high-throughput methods used to 
determine protein-protein interactions cover about 20% of all potential pairs in humans [32]. In 
addition, the information regarding disease-gene associations still is incomplete. Future studies 
employing more complete interactomes and better defined disease-associated gene lists could 
shed more light on this matter.  
 A number of significant genetic correlations between CNS disorders and cancers were 
identified in our analyses, which included the negative correlations observed between ASD and 
BRCA and PRCA, as well as several instances of positive genetic correlations. BD, MD, and SCZ were 
found to be positively correlated with BRCA. However, the correlation values were low and ranged 
between Rg = 0.09 in the case of MD and Rg = 0.14 in the case of SCZ. MD was found to be positively 
correlated with LGCA, and PD presented positive correlations with PRCA and SCKM. SCZ was also 
found to be present significant genetic correlations with OVCA. The assessment of the potential 
impact of such correlations should be the object of further research. 
 Previous studies have reported significant genetic correlations between AD and BRCA [38]. 
However, we could not reproduce these results. These differences could be explaining by the use 
of different datasets. The same authors reported significant genetic correlations between AD and 
LGCA, which we could not reproduce either. Probably due to the low statistical power of the LGCA 
dataset included in our analyses, which included a reduced number of cases. 
 Although efforts were made to obtain the LGCA and BRCA datasets employed in the 
previous reference, data access was not feasible due to time constraints. 
 In summary, we provided some specific instances of genetic correlations between CNS 
disorders and cancers, which implies that shared genetic variability could be involved in 













































Chapter 5. Role of pharmacological treatment in the CNS and cancer 
associations 
5.1 Introduction 
Pharmacological treatment could play a pivotal role in CNS and cancer comorbidities. 
Disulfiram (DSF), a drug that has been used for decades to treat alcohol dependence, provides a 
paradigmatic instance of the previous statement. Epidemiological research has shown that patients 
diagnosed with cancer who were under DSF treatment presented a reduced all-cancer and site-
specific cancer mortality compared to those who had been previous users of DSF but who had 
stopped its use at least one year before cancer diagnosis [13]. 
The mechanistic description of the anti-cancer effect of DSF, which relies on NPL4 protein 
targeting and aggregation, has also been reported [13, 328]. Other instances of CNS medications 
acting as potential cancer modulators are available in the literature. For example, antipsychotics 
have been linked to an increase in breast cancer risk in SCZ patients [85], and the use of levodopa 
has been implicated in the increased melanoma risk observed in PD patients [86].  
 In the previous chapter, we showed that genes associated with a particular disorder tend 
to cluster in the same network neighborhood, called the disease module, which represents a 
connected sub-network of the human interactome enriched in disease proteins.  
 It has been hypothesized that effective causative treatments have molecular targets placed 
significantly closer to the disease module of the disorder they are indicated to treat, whereas 
palliative medications do not. This point has been tested using Interactome-based drug-disease 
proximity measures [329]. In this context, research has shown that most traditionally used drugs 
lack sensitivity towards the genetic causes of disease, targeting their symptoms instead. 
 In this chapter, we used two alternative but complementary methods to identify 
medications that could influence CNS and cancer comorbidities. The first method relies on the 
computation of network-based proximity measures between drug targets and disease modules. 
With this aim, we first compiled a list of drug indications frequently used to treat CNS disorders and 
cancers and obtained information about their molecular targets. Network distances were 
computed between pairs of drug-associated proteins and disease modules. Using this approach, we 
identified medications which targets were significantly closer to specific disease modules than 
expected by chance. Then, we looked for CNS indications placed in the interactome vicinity of 
cancer-related modules and for cancer indications targeting proteins placed in the same 
interactome neighborhood as CNS disease modules.  
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 The second method was based on the computation of correlations between the differential 
expression profiles derived from our disease-specific meta-analyses (computed in Chapter 3) and 
the differential gene expression profiles of cell lines treated with the indicated drugs retrieved from 
the LINCS L1000 project [330]. LINCS L1000 contains an extensive collection of gene expression 
profiles generated using thousands of perturbagens (i.e., small molecules, ligands, micro-
environments, CRISPR gene over-expression, and knockdown perturbations) and different cell lines, 
doses, and exposure times. Positive correlations suggest that a specific medication has the potential 
to produce transcriptomic changes that tend to mimic those observed in a specific disease, whereas 
negative correlations indicate that a particular drug could revert the transcriptomic changes in a 
specific disorder. 
 Using this approach, we identified medications-indicated for the treatment of CNS 
disorders that induce transcriptomic changes that significantly mimic or reverse those observed in 
cancer and drugs used for cancer treatment with the potential to mimic or reverse the 






















5.2 Material and methods 
 5.2.1 Data sources 
 Drug indications 
 Drug indications for each of the included disorders were obtained from MEDI-an [331]. 
MEDI-an is a medication indication repository that gathers information from multiple resources 
including, RxNorm, MedlinePlus, and SIDER2) constructed using combining ontology-based and 
natural language processing (NLP) techniques. We selected the MEDI high precision subset (MEDI-
HPS), which contains 13400 unique indications regarding 2136 medications. The file 
(MEDI_HPS.csv) was downloaded from the site, and indications for all the studied CNS disorders 
and cancer types were selected by inspecting disease names and ICD codes. MEDI-HPS uses concept 
ids CUI IDs derived from the UMLS thesaurus to identify each available drug. Rxcui IDs were 
translated to Drugbank IDs using the restful web API from RxNav [332] through the use of the R 
packages httr [333]and rjson [334]. 
 Drug targets 
The molecular targets of the indicated drugs were retrieved from DrugBank [335]. In short, 
the XML file containing the full database was downloaded from DrugBank’s website and parsed 
using custom R scripts. Drugs and their targets were retrieved alongside information regarding their 
mechanism of action and the mapping to external identifiers such as PubChem substance and 
compound IDs. The drugs that did not have any target in the employed interactomes were 
excluded. The details of the used interactomes can be found in Chapter’s 4 material and methods 
section. 
 Differential expression profiles of cell lines treated with the indicated drugs 
 The differential gene expression profiles of those cell lines treated with the indicated drugs 
were retrieved from LINCS L1000. LINCS L1000 contains an extensive collection of gene expression 
profiles generated using thousands of perturbagens (i.e., small molecules, ligands, micro-
environments, CRISPR gene over-expression, and knockdown perturbations) and different cell lines, 
doses, and exposure times. Datasets from phases I (GSE92742) and II (GSE70138) of the project 
were downloaded from GEO. LINCS's perturbation IDs were mapped to Drugbank IDs through Inchi 
keys using the UnChem RESTful service [336]. All analyses were carried out using LINCS L1000 Level 
5 data, which includes differential gene expression signatures computed by comparing three 
technical replicates of the same perturbation to appropriate controls. In Level 5 datasets, each 
perturbation (drug treatment) is represented by several differential gene expression signatures 
generated by treating different cell lines at different times and concentrations. We constructed an 
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individual signature for each drug by combining all the available signatures generated using it, 
applying Stouffer’s method, as explained in (See section 5.2.3). 
 5.2.2 Network-based proximity measures between drugs and diseases 
  We measured drug-disease distances in the human interactome through a previously 
reported metric, which computes the average shortest path length between a specific drug's 
targets and the nearest disease protein. This metric has been found to better capture the 
associations in cases in which a drug does not directly target all disease-associated proteins and has 
shown superior performance in discriminating between the known and unknown drug-disease 
associations compared to similar metrics [329]. 
 Given sets S (the set of disease-associated proteins) and T (the set of protein targets for a 
specific drug) , let 𝑑(𝑠, 𝑡), be the shortest path length between nodes 𝑠 and 𝑡 in the interactome. 
The distance function, called the closest distance, is defined as follows: 
𝑑 (𝑆, 𝑇) =  
1
‖𝑇‖
𝑚𝑖𝑛  ∈ 
 ∈
𝑑(𝑠, 𝑡) 
were ‖𝑇‖ is the number of genes in set T. Basically, for each protein in the set of drug-associated 
proteins 𝑇 , the minimum distance to any element of the set of disease-associated proteins 𝑆 is 
selected. Then the average of the resulting values for all drug-associated proteins is computed.  
 The significance of the obtained 𝑑  values was assessed by constructing null distributions 
by randomly sampling 1000 sets of genes of the same dimension as those found in both the disease- 
and drug-associated sets. Z-values were computed as follows using the actual closest distance and 
the null distribution. 
𝑧(𝑆, 𝑇) =  
𝑑 (𝑆, 𝑇) − 〈𝑑  (𝑆, 𝑇)〉
𝜎𝑑  (𝑆, 𝑇)
 
Where 〈𝑑  (𝑆, 𝑇)〉 is the average of the random distribution and 𝜎𝑑  (𝑆, 𝑇) its standard 
deviation. P-values were computed by comparing the obtained Z-values to the standard normal 
distribution. The same degree-preserving sampling procedure described in Chapter 4 was applied 
to construct the null distributions accounting for the impact of the node degree distributions of the 




 5.2.3 Identification of drugs producing transcriptomic effects that mimic or reverse 
the differential gene expression signatures of the included disorders 
 To determine if a particular drug could induce transcriptomic changes that could resemble 
or revert the differential gene expression profiles of the disorders studied in this Thesis, we 
computed correlations between the drug signatures and the Z-values derived from the differential 
gene expression meta-analyses of each disorder obtained in Chapter 3. 
 Significantly positively correlated drugs exhibiting correlation values higher than 0.15 were 
selected as candidates to generate differential expression changes that would partially mimic those 
found in a particular disorder, whereas drugs showing significant correlation values lower than -
0.15 were selected as potential candidates to revert the differential gene expression profile 
generated by a particular disorder. 
 In LINCS L1000, each perturbation is represented by many differential gene expression 
signatures, which have been generated by treating different cell lines at different times and 
concentrations and by comparing them to appropriate controls. A consensus signature was 
computed for each perturbation using Stouffer's method.  
 For each signature, weights were computed as the average correlation to all other 






Where 𝑤  is the weight of the i-th signature and 𝑍  is the differential expression value of a particular 
gene in the i-th signature. 
 Finally, Pearson’s correlations between each disease signature and all drug consensus 














 5.3.1 Identified indications 
 Three-hundred and fifty drug indications encompassing two hundred and twenty-five drugs 
were found after merging MEDI-HPS and DrugBank data. Two-hundred and eight of them had 
known protein targets reported in DrugBank. Several medications were indicated for the treatment 
of more than one disorder. In the case of CNS diseases, selegiline, an antidepressive and 
antiparkinsonian which selectively inhibits monoamine oxidase B, was found to be indicated for AD, 
MD, PD, and SCZ, whereas risperidone, an atypical antipsychotic targeting several 5-HT serotonin 
receptor subtypes, was found to be indicated for the treatment of ASD, BD, MD, and SCZ. Several 
other drugs were indicated to treat more than one CNS disorder, including quetiapine, aripiprazole, 
valproic acid, and olanzapine, among others. Cyclophosphamide, a chemotherapeutic agent and 
immune system suppressor, was found to be indicated for the treatment of six cancer types, 
including AML, BRCA, BRNCA, CLL, CML, and LGCA, whereas cisplatin did it for BLCA, BRNA, CERV, 
HANC, LGCA, and OVCA treatment. The complete list of drug indications can be found in Appendix 
8. 
 5.3.2 Interactome-based distances between drug targets and disease modules 
 The interactome-based distances between drug targets and disease modules were 
computed using the interactome one described in Chapter 4. and both sets of disease-associated 
genes and variants (stringent and relaxed). We will refer to the analyses carried out using the 
stringent and relaxed lists of disease-associated genes as setting one and setting two, respectively. 
Two hundred and two drugs which targets were included in our interactome were selected for 
downstream analysis. Overall, 5656 distances between drugs and disease modules were computed 
under settings one and two.  
 5.3.2.1 Closest distances 𝑑  between disease modules and their drug indications. 
First, we investigated if drugs tended to present lower closest distances (𝑑 ) with the 
disorders for which they were indicated (target disorders) compared to those for which they were 
not (off-target disorders). 
Under setting one, the mean interactome distance between drugs and their target 
disorders (n = 312) was 1.72 (sd = 0.57) whereas in the case of drugs and off-target disorders pairs 
(n = 5344) was 1.96 (sd = 0.44). The differences in means between both groups were found to be 
significant (t = 7.35, p-val = 1.5e-12) (Figure 20 A). More pronounced differences between groups 
were observed under setting two, where the mean 𝑑  value between drugs and their target 
disorders was found to be 0.97 (sd = 0.71) compared to the mean 𝑑  value of 1.56 observed in off-




0.51 was found between the Z-scores computed under settings one and two (Figure 20 C), and the 
overlap coefficient of the significant associations (FDR < 0.05) identified under the two settings was 
0.72 (Figure 20 D). 
Next, we wondered if medications and the disease modules of their target disorders 
presented shorter interactome-based distances than expected by chance with their target 
disorders.  
Under setting one, we were able to compute 312 closest distances between disease 
modules and their indicated drugs' targets. One hundred and twenty of them (38.46%) were found 
to present 𝑑  values lower than expected by chance (p-val < 0.05), of those, 61 (19.6%) remained 
significant after adjustment by multiple comparisons (FDR < 0.05). The most significantly associated 
indications in the case of CNS disorders were two PD drugs, carbidopa (p-adj = 1.39e-05), and 
selegiline (p-adj = 4.16e-04), pimozide, which is indicated for the treatment of SCZ (6.00e-04), and 
clomipramine (p-adj = 6.15e-04) and olanzapine (p-adj = 2.28e-03), which were significantly 
associated with the disease modules of MD and BD, respectively. In the case of cancer drugs, the 
most significant associations were found between PRCA and cyproterone (p-adj = 3.75e-11), BRCA 
and methyltestosterone (p-adj = 6.61e-10), ALL and dasatinib (p-adj = 1.54e-05), and BRCA and 
toremifene (p-adj = 5.45e-05). Supplementary Appendix 1 Table 42 shows all drug indications 
displaying significant adjusted p-values under setting one.  
One hundred and seventy-four drug-disease indications (55.8%) presented 𝑑  values lower 
than expected by chance (nominal p-values < 0.05) in setting two analyses. After adjustment by 
multiple comparisons, 144 (46.15%) remained significant. For CNS disorders, the top associations 
were those found between the following drugs and disease modules, amoxapine and MD (p-adj = 
8.02e-23), loxapine and SCZ (p-adj = 5.85e-22), and trimipramine and MD (p-adj = 5.15e-21), 
whereas in the case of cancer the most significant associations were those found between 
capecitabine and CRCA (p-adj = 1.48e-07), mitoxantrone and PRCA (p-adj = 1.17e-06), and 
fluorouracil and CRCA (p-adj = 2.52e-06). Supplementary Appendix 1 Table 43 includes all drug 







5.3.2.2 Significant off-target drug-disease interactome-based closest distances 
In this section, we focus on off-target drug-disease associations. Those were defined as 
significant interactome-based associations between drugs and the disease modules of the disorders 
for which they were not indicated. 
Under setting one, eighty-six drugs indicated for the treatment of one or more CNS 
disorders presented significant off-target associations with the disease modules of other CNS 
disorders. Those included the associations found between phenelzine, a monoamine oxidase 
inhibitor indicated for the treatment of MD, which was found to be associated with the PD module 
(p-adj = 2.47e-07), mesoridazine, an SCZ medication, which was associated with PD (p-adj = 3.17e-
05), and tranylcypromine, another monoamine oxidase inhibitor indicated for the treatment of MD, 
which was found to be significantly associated with the PD module (p-adj = 1.72e-04). 
Under setting two, 243 drugs indicated for the treatment of one or more CNS disorders 
were found to present interactome-based associations with the disease modules of other CNS 
disorders for which they were not indicated. The most significant were those observed between 
loxapine, an antipsychotic drug indicated for the treatment of SCZ, which was significantly 
associated with the MD (p-adj = 1.12e-26) BD (p-adj = 2.10e-22) disease modules. The tetracyclic 
antidepressant amoxapine, which was indicated for the treatment of MD and was found to be 
heavily associated with the disease module of BD (p-adj = 7.08e-24) and SCZ (p-adj = 8.02e-23), and 
aripiprazole, an atypical antipsychotic medication indicated for the treatment of ASD, SCZ, and BD 
which presented significant associations with the disease module of MD (p-adj = 5.91e-21). 
Seventy-three off-target interactions were observed between drugs indicated for the 
treatment of one or more cancers and other cancer types under setting 1. Lapatinib, a tyrosine 
kinase inhibitor indicated for the treatment of BRCA, was significantly associated with the BRNCA 
module (p-adj = 1.56e-07). Imatinib, a chemotherapy medication used for CML treatment, was 
associated with the ALL module (p-adj = 1.30e-05). Dasatinib, another CML drug that acts as a 
tyrosine kinase inhibitor, was also found to be among the top off-target associations observed in 
cancer drugs and showed a significant closest distance with the ALL module (p-adj = 1.54e-05). 
Two hundred and eighty-seven off-target significant closest distances were observed 
between drugs indicated to treat one or more cancer types and other cancers. Those included the 
association found between idarubicin, an anthracycline indicated for the treatment of AML and 
CML, and the PRCA disease module (p-adj = 7.82e-10) and pemetrexed, a chemotherapy medication 
indicated for the treatment of LGCA, which was found to be significantly linked to the FLYMPH 
disease module (p-adj = 4.78e-09), among others. 
Under setting one, thirty-nine drugs indicated for treating one or more CNS disorders were 




found to target the disease module of ALL, such as imipramine (p-adj = 3.88e-05), aripiprazole (p-
adj = 3.43e-04), and clozapine (p-adj = 6.15e-04). Selegiline, a medication indicated for the 
treatment of SCZ, AD, MD, and PD, was associated with the disease module of HANC (p-adj = 6.15e-
04). 
Seventy-nine drugs indicated for the treatment of one or more CNS disorders presented 
significantly shorter closest distances than expected by chance with cancer disease modules under 
setting two.  Rivastigmine, a cholinesterase inhibitor indicated for AD and PD treatment, was found 
to be associated with the KDNCA disease module (p-adj = 1.97e-12). Tacrine, an 
acetylcholinesterase inhibitor used in AD with was also associated with the KDNCA disease module 
(p-adj = 6.66e-06). Fluoxetine, a selective serotonin reuptake inhibitor used in MD and BD, was 
found to be associated with the LGCA module (p-adj = 1.40e-04), and donepezil, a reversible 
acetylcholinesterase inhibitor indicated for the treatment of AD, was found to be linked to the BRCA 
disease module (p-adj = 1.76e-04). 
Under setting 1, eighteen drugs indicated for the treatment of one or more cancers were 
found to be associated with CNS modules, including crizotinib, which is indicated for LGCA and was 
found to be associated with the ASD module (p-adj = 2.28e-04), docetaxel, a chemotherapy 
medication indicated for the treatment of several cancers which was associated with the AD 
module (p-adj = 7.13e-04), and gemtuzumab, a CD33 antibody indicated for the treatment of AML, 
which was found to be associated with the disease module of AD (p-adj = 2.01e-03), 
Seventy drugs indicated for cancer treatment were found to present significant associations 
with CNS disease modules under setting two. Different drugs indicated for the treatment of breast 
cancer were found to present significant associations with the disease modules of CNS disorders 
that were placed among the most significant associations, including toremifene, a selective 
estrogen receptor modulator which was associated with AD’s disease module (p-adj = 6.30e-11), 
testosterone and testosterone enanthate, which were found to be significantly associated with MD 
(p-adj = 4.85e-09, 4.48e-07), and fulvestrant, a selective estrogen receptor degrader, which was 
found to be significantly associated with the AD module (p-adj = 2.11e-08). Other medications, such 
as arsenic trioxide, a compound used to treat AML, was found to be associated with the SCZ module 
(p-adj = 1.04e-07), whereas cisplatin, a chemotherapy medication which is indicated for BRNCA, 
CERV, BLCA, LGCA, HANC, OVCA, was found to be significantly associated with AD (p-adj = 4.41e-
05). Table 24 shows the most significant off-target associations between drugs indicated for the 
treatment of CNS disorders and cancer modules and the top significant drugs indicated for cancer 
treatment associated with CNS modules for settings 1 and 2. Supplementary Appendix 1 Tables 44 
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Figure 20:  Closest distance analysis results.  A) Differences between disease-drug target and off-target 
associations under setting one. B) Differences between disease-drug target and off-target associations 
under setting two. C) Scatter plot depicting the correlations between the Z-scores derived from the 
disease-drug associations computed under settings one and two. D) Venn diagram showing the overlap 








disorder DB ID Drug name 𝒅𝒄 Z p-val p-adj 
MD ALL DB00458 Imipramine 1.56 -5.25 7.54e-08 3.88e-05 
MD, ASD, SCZ, BD ALL DB01238 Aripiprazole 1.73 -4.7 1.33e-06 3.43e-04 
BD, SCZ ALL DB00363 Clozapine 1.7 -4.51 3.25e-06 6.15e-04 
BD, SCZ, MD ALL DB00334 Olanzapine 1.67 -4.36 6.62e-06 1.07e-03 
AD ALL DB01043 Memantine 1.43 -4.29 9.07e-06 1.35e-03 
SCZ ALL DB00408 Loxapine 1.79 -4.2 1.36e-05 1.79e-03 
SCZ, AD, MD, PD HANC DB01037 Selegiline 1 -4.13 1.79e-05 2.11e-03 
SCZ, MD ALL DB00477 Chlorpromazine 1.65 -4.12 1.92e-05 2.22e-03 
MD HANC DB01247 Isocarboxazid 1 -4.07 2.38e-05 2.49e-03 
MD ALL DB00726 Trimipramine 1.69 -4.03 2.76e-05 2.73e-03 
MD ALL DB01142 Doxepin 1.64 -4.02 2.91e-05 2.77e-03 
MD ALL DB00321 Amitriptyline 1.7 -3.97 3.65e-05 3.22e-03 
MD HANC DB00752 Tranylcypromine 1 -3.93 4.26e-05 3.55e-03 
SCZ, BD ALL DB00246 Ziprasidone 1.76 -3.86 5.62e-05 4.24e-03 
MD ALL DB00543 Amoxapine 1.74 -3.77 8.26e-05 5.52e-03 
HD, SCZ ALL DB01100 Pimozide 1.25 -3.71 1.03e-04 6.20e-03 
SCZ ALL DB00679 Thioridazine 1.4 -3.66 1.28e-04 6.82e-03 
PD FLYMPH DB01367 Rasagiline 1 -3.62 1.45e-04 7.60e-03 
SCZ ALL DB00434 Cyproheptadine 1.5 -3.59 1.66e-04 8.29e-03 




disorder DB ID Drug name 𝒅𝒄 Z p-val p-adj 
LGCA ASD DB08865 Crizotinib 1 -4.79 8.47e-07 2.28e-04 
LGCA, SKCM, 
PRCA AD DB01248 Docetaxel 1.33 -4.46 4.04e-06 7.13e-04 
AML AD DB00056 Gemtuzumab ozogamicin 1.58 -4.16 1.60e-05 2.01e-03 
LGCA, BRCA, 
HANC AD DB01229 Paclitaxel 1.33 -4.08 2.23e-05 2.38e-03 
CLL AD DB00087 Alemtuzumab 1.64 -3.67 1.21e-04 6.71e-03 
CML, ALL AD DB01254 Dasatinib 1.64 -3.65 1.29e-04 6.82e-03 
BRCA AD DB08871 Eribulin 1 -3.49 2.37e-04 1.07e-02 
LGCA, BRCA, 
CRCA, KDNCA AD DB00112 Bevacizumab 1.64 -3.49 2.45e-04 1.08e-02 
CRCA AD DB00002 Cetuximab 1.67 -3.43 3.04e-04 1.27e-02 
BRNCA, CERV, 
BLCA, LGCA, 
HANC, OVCA AD DB00515 Cisplatin 1.5 -3.31 4.64e-04 1.65e-02 
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PRCA, BRCA MD DB00351 Megestrol 0.5 -3.12 8.89e-04 2.65e-02 
AML MD DB00755 Tretinoin 1.59 -3.13 8.89e-04 2.65e-02 
KDNCA ASD DB06287 Temsirolimus 1 -2.97 1.49e-03 3.84e-02 
BRCA AD DB00072 Trastuzumab 1.69 -2.97 1.51e-03 3.84e-02 
AML SCZ DB01169 Arsenic trioxide 1.2 -2.92 1.73e-03 4.22e-02 
LGCA ASD DB00317 Gefitinib 1 -2.9 1.87e-03 4.40e-02 
SKCM SCZ DB06186 Ipilimumab 1 -2.88 1.99e-03 4.60e-02 
ALL, CML AD DB00619 Imatinib 1.67 -2.85 2.20e-03 4.88e-02 




disorder DB ID Drug name 𝒅𝒄 Z p-val p-adj 
AD, PD KDNCA DB00989 Rivastigmine 0 -7.54 2.33e-14 1.97e-12 
AD KDNCA DB00382 Tacrine 0.67 -5.07 2.03e-07 6.66e-06 
MD, BD LGCA DB00472 Fluoxetine 0.67 -4.4 5.53e-06 1.40e-04 
AD BRCA DB00843 Donepezil 0.5 -4.34 7.18e-06 1.76e-04 
PD STCA DB00248 Cabergoline 1.21 -4.21 1.26e-05 2.82e-04 
SCZ STCA DB00408 Loxapine 1.39 -4.06 2.49e-05 5.12e-04 
AD, PD BRCA DB00989 Rivastigmine 0 -4.03 2.84e-05 5.77e-04 
PD FLYMPH DB01367 Rasagiline 1 -3.94 4.12e-05 8.09e-04 
MD, ASD, SCZ, BD STCA DB01238 Aripiprazole 1.36 -3.85 5.86e-05 1.10e-03 
BD, SCZ STCA DB06216 Asenapine 1.24 -3.83 6.45e-05 1.20e-03 
AD KDNCA DB00843 Donepezil 1.17 -3.82 6.78e-05 1.24e-03 
SCZ, MD STCA DB00477 Chlorpromazine 1.25 -3.76 8.60e-05 1.51e-03 
AD, BD, MD SKCM DB00313 Valproic Acid 0.89 -3.75 8.73e-05 1.52e-03 
AD BRCA DB00382 Tacrine 0.33 -3.71 1.02e-04 1.74e-03 
BD, SCZ STCA DB00363 Clozapine 1.35 -3.69 1.14e-04 1.92e-03 
MD ALL DB00458 Imipramine 1.5 -3.66 1.27e-04 2.11e-03 
MD STCA DB01151 Desipramine 1.27 -3.48 2.51e-04 3.66e-03 
PD LGCA DB00810 Biperiden 0.5 -3.45 2.77e-04 4.00e-03 
PD HANC DB01367 Rasagiline 0.5 -3.43 3.03e-04 4.33e-03 
SCZ STCA DB04946 Iloperidone 1.11 -3.41 3.23e-04 4.54e-03 




disorder DB ID Drug name 𝒅𝒄 Z p-val p-adj 
BRCA AD DB00539 Toremifene 0 -7.04 9.47e-13 6.30e-11 
BRCA MD DB00624 Testosterone 0 -6.37 9.18e-11 4.85e-09 




AML SCZ DB01169 Arsenic trioxide 0.4 -5.85 2.45e-09 1.04e-07 
BRCA MD DB13944 Testosterone enanthate 0 -5.59 1.14e-08 4.48e-07 
BRCA MD DB06710 Methyltestosterone 0 -4.89 5.01e-07 1.53e-05 
BRNCA, CERV, 
BLCA, LGCA, 
HANC, OVCA AD DB00515 Cisplatin 1 -4.66 1.56e-06 4.41e-05 
BRCA SCZ DB00675 Tamoxifen 0.56 -4.49 3.58e-06 9.55e-05 
BRCA BD DB00539 Toremifene 0 -4.45 4.27e-06 1.11e-04 
KDNCA SCZ DB00603 Medroxyprogesterone 0.25 -4.35 6.75e-06 1.67e-04 
BRCA MD DB00675 Tamoxifen 0.67 -4.25 1.06e-05 2.42e-04 
BRCA BD DB00947 Fulvestrant 0 -4.18 1.44e-05 3.14e-04 
BRCA AD DB06710 Methyltestosterone 0.5 -4.17 1.49e-05 3.25e-04 
PRCA MD DB01196 Estramustine 0.25 -4.15 1.70e-05 3.65e-04 
BRCA SCZ DB00947 Fulvestrant 0 -4.1 2.03e-05 4.26e-04 
KDNCA MD DB06287 Temsirolimus 0 -4.01 3.09e-05 6.22e-04 
KDNCA, PRCA SCZ DB01041 Thalidomide 0.4 -3.99 3.35e-05 6.67e-04 
KDNCA MD DB01590 Everolimus 0 -3.89 4.97e-05 9.59e-04 
KDNCA, PRCA MD DB01041 Thalidomide 0.4 -3.82 6.54e-05 1.21e-03 
PRCA SCZ DB00513 6-Aminocaproic Acid 0 -3.81 7.08e-05 1.29e-03 
Table 24: Off-target associations between CNS indicated drugs and cancer modules and cancer indicated 
drugs and CNS modules.. Section A presents the top CNS indications displaying significant associations with 
cancer modules under setting 1. Section B shows the top cancer indications presenting significant 
associations with CNS modules under setting 1 whereas sections C and D present the same results for 
setting 2. 
 5.3.3 LINCS L1000 analyses results 
Transcriptomic signatures were available for one hundred and forty-nine out of the two 
hundred and twenty-five drugs indicated for the treatment of the studied disorders, which were 
represented by a total of twelve-thousand and sixty-one signatures. On average, each drug was 
used to produce 81 signatures employing different cell lines, treatment times, and concentrations. 
We applied Stouffer's method to combine the signature profiles generated using the same 
perturbations and obtained 149 consensus signatures. Drugs producing transcriptomic signatures 
presenting FDR-adjusted correlation p-values lower than 0.05 and absolute values of correlation 
higher than 0.15 were selected as medications with the potential of mimicking or reversing the 




5.3.3.1 Correlations between the transcriptomic signatures of drugs and the differential gene 
expression profiles of their target disorders 
 Forty-seven disease-drug correlations presented absolute values larger than 0.15 and 
adjusted p-values lower than 0.05. Twenty-one of them were negative, whereas twenty-six were 
positive. Among the top negatively correlated indications for CNS disorder, we found two anti-
epileptics, valproic acid (r = -0.33) and oxcarbazepine (r = -0.33) indicated for the treatment of BD, 
as well as isocarboxazid, a non-selective irreversible monoamine oxygenase inhibitor (MOI) used 
for the treatment of MD (r = -0.32). In the case of drugs indicated for cancer treatment, the highest 
negative correlations were found for topotecan, a topoisomerase inhibitor indicated for the 
treatment of cervical cancer (r = -0.32), doxorubicin, which is indicated for pancreatic cancer (r = -
0.29), and epirubicin used for the treatment of STCA (r = -0.25). In addition, the transcriptomic 
signatures of several drugs were found to be positively correlated with the gene expression profiles 
of the disorders for which they are indicated. For instance, BD's profile was found to be positively 
correlated with carbamazepine (r = 0.37), phenelzine, a non-selective monoamine oxidase inhibitor 
used as an antidepressant, presented positive correlations with MD (r = 0.33), and capecitabine, a 
chemotherapy medication presented positive correlations with one of the cancer types for which 
it is indicated, CRCA (r = 0.23). Supplementary Appendix 1 Table 46 shows the LINCS L1000 analysis 
results for the available drug indications and their target disorders. 
5.3.3.2 Correlations between CNS disorders indicated drugs and cancer profiles and cancer 
indicated drugs and CNS disorders profiles 
 Several drugs indicated to treat CNS disorders were found to present significant negative 
correlations lower than -0.15 with diverse cancer types. 
 First, two sodium channel blockers used as anticonvulsants, lamotrigine, and 
carbamazepine presented negative correlations with different cancers' gene expression signatures. 
Lamotrigine is used to treat epilepsy, and it is also indicated to prevent depressive episodes in BD 
and MD. The gene expression signature of lamotrigine was found to be negatively correlated with 
the differential expression profiles of 4 cancer types. Carbamazepine, primarily used in the 
treatment of epilepsy but also in schizophrenia and as a second-line agent in bipolar disorder, was 
negatively correlated with the differential gene expression profiles of nine cancer types with 
correlations ranging from r = -0.15 in the case of DLBCL and r = -0.30 in the case of PACA. 
 Second, many instances of antipsychotic drugs, including five dopamine receptors 
antagonists, such as pimozide, prochlorperazine, haloperidol, trifluoperazine, chlorpromazine, and 
one typical antipsychotic (risperidone), were found to be negatively correlated to 8, 7, 10, 7, 3, and 




drugs were CERV (n = 6), STCA (n = 6), LIVCA (n = 5), HANC (n = 5), PACA (n = 4), CRCA (n = 4), CHLCA 
(n = 5), and BRNCA (n = 4). Correlations ranged from r = -0.3 in the case of pimozide and CERV and 
r = -0.15 in the case of trifluoperazine and BLCA. 
 Third, antidepressant drugs (tricyclic and tetracyclic), selective serotonin reuptake 
inhibitors, and monoamine oxidase inhibitors were also found to present negative correlations with 
the gene expression signatures of different cancer types. The transcriptomic signatures produced 
by three tricyclic antidepressants, amitriptyline, doxepin, and desipramine, were negatively 
correlated with the differential gene expression profiles of 11 cancer types, including BRNCA, CERV, 
CHLCA, CRCA, DLBCL, FLYMPH, HANK, KDNCA, LIVCA, PACA, and STCA. Correlations ranged from r 
= -0.33 in the case of PACA and desipramine and r = -0.16 in the case of desipramine and FLYMPH. 
The tetracyclic antidepressant maprotiline was negatively correlated with the signatures of eight 
cancer types. Three selective serotonin reuptake inhibitors, sertraline, fluoxetine, and paroxetine, 
were anticorrelated with the transcriptomic signatures of 11, 5, and 11 cancer types, respectively. 
Furthermore, one monoamine oxidase inhibitor used in the treatment of PD, AD, and SCZ, 
selegiline, was negatively correlated with 11 cancer types and displayed correlations that ranged 
from r = -0.32 in the case of PACA and r = -0.15 in the case of KDNCA. 
One drug of the benzodiazepine family, alprazolam, and carbidopa, a medication that inhibits the 
peripheral metabolism of levodopa used for PD treatment, were negatively correlated with the 
transcriptomic signatures of 10 and 3 cancer types, respectively. 
 Finally, in addition to selegiline, two acetyl-cholinesterase inhibitors, donepezil, and 
galantamine, presented negative correlations with the differential gene expression profiles of 13 
and 7 cancer types. Correlations ranged from r = -0.3 in the case of galantamine and LIVCA and r = 
-0.15 in galantamine and BRCA. 
 Positive correlations were also found between the transcriptomic signatures of drugs used 
to treat CNS disorders and several cancer types. Oxcarbazepine, an anticonvulsant drug also used 
for the treatment of BD, was positively correlated with the expression profiles of 10 cancers. 
Mirtazapine, a tetracyclic antidepressant, was positively correlated with the expression profiles of 
three cancer types. Buspirone, an antianxiety serotonin receptor inhibitor indicated for the 
treatment of some patients with MD, presented positive correlations with the differential 
expression profiles of eight cancer types, isocarboxazid which acts as a monoamine oxidase 
inhibitor the treatment of MD, was found to be positively associated with the differential gene 
expression profiles of 11 cancers. Valproic acid, which is indicated for the treatment of MD, BD, and 
AD, was positively correlated with the differential gene expression profiles of 11 cancer types. 
Finally, Three Parkinson's treatments, trihexyphenidyl hydrochloride, entacapone, and pergolide, 
were linked to 4, 10, and 13 cancer types, respectively. In addition, three antipsychotic drugs used 
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for the treatment of schizophrenia treatments, loxapine, iloperidone, fluphenazine, were linked to 
8, 9, and 7 cancer types. Supplementary Appendix 1 Table 47 includes the complete information 
of the CNS drugs correlated with cancer gene expression signatures. 
 Thirty-three unique drugs indicated for the treatment of one or more cancers were 
significantly correlated with CNS disorders' transcriptomic signatures. The central nervous system 
disorders involved in the associations were AD, BD, and MD. 
 Cancer-related drugs showing negative correlations with AD, BD, and MD included 
hormones and drugs targeting hormone receptors, such as raloxifene, an agonist/antagonist of the 
estrogen receptor, exemestane, an aromatase inhibitor, which acts as an anti-estrogen. Lapatinib, 
an inhibitor of the Her2/Neu receptor, nilutamide, a non-steroidal antiandrogen, and estradiol. 
Some chemotherapy agents were also found to be negatively correlated with AD, BD, and MD and 
included the alkylating agent tiptepa, capecitabine, and 5-fluorouracil, which act as thymidylate 
synthase inhibitors, and vincristine. Two additional drugs, pazopanib, a tyrosine kinase inhibitor, 
and thalidomide, presented negative correlations with AD, BD, and MD. 
 Finally, a number of anti-cancer medications also presented positive correlations with AD, 
BD, and MD transcriptomic signatures. Those included instances of hormones and hormone 
receptors (i.e., methyltestosterone, medroxyprogesterone, a hormonal medication of the progestin 
type, and flutamide, a non-steroidal anti-estrogen), chemotherapy agents, such as alkylating agents 
(i.e., temozolomide, Chlorambucil, and cyclophosphamide), topoisomerase inhibitors (i.e., 
idarubicin, doxorubicin, epirubicin, and topotecan), a purine analog (fludarabine), and an RNA 
polymerase inhibitor (dactinomycin). In addition, everolimus, an MTORC1 inhibitor, was also found 
to be positively correlated with the differential gene expression profiles of AD, BD, and MD. 
Supplementary Appendix 1 Table 48 includes all the information related to cancer drugs correlated 




















Figure 21: Heatmap depicting the strongest correlations observed between drugs and disorders gene 





This chapter served to identify several drugs and drug-families that could play a role in 
modulating CNS disorders and cancer associations. The interactome-based analysis results were 
found to clearly depend upon the use of relaxed or stringent lists of disease-associated genes and 
produce a low yield in terms of off-target drug disease-module associations between drugs 
indicated for the treatment of CNS disorder and cancer modules and vice versa. However, some 
interesting candidates were extracted from this analysis. Three acetylcholinesterase inhibitor drugs 
used to treat AD (rivastigmine, tacrine, and donepezil) were associated with the disease module of 
kidney and breast cancers. In the nervous system, acetylcholinesterase (AChE) rapidly hydrolyzes 
the neurotransmitter acetylcholine and participates in the impulse transmission termination. In 
non-neural contexts, AChE is thought to participate in the control of cell proliferation, 
differentiation, and apoptosis and has been suggested to play a tumor suppressor role [337, 338]. 
Some cancer types such as leukemia, non-small cell lung cancers, and breast cancers have been 
reported to present increased activities of AChE, whereas hepatocellular carcinomas, gastric and 
prostate cancers seem to present reduced activities [338]. It has been shown that there is a clear 
link between AChE expression and cell cycle progression in hepatoma cell lines, in which inhibition 
of AChE activity increased cell proliferation, which was associated with a downregulation of p27 
and cyclins [337]. Some authors have defined AChE as an apoptotic marker and a promising tumor 
suppressor [339]. Therefore, the use of acetylcholinesterase inhibitors, such as rivastigmine, could 
have a cancer-promoting effect in some tumors. However, this seems to be a more complex issue 
than previously anticipated. Three different isoforms of AChE exist. They differ in their carboxy-
terminal sequences and include synaptic AChE (AChE-S), erythrocytic AChE (AChE-E), and read-
through AChE (AChE-R). Whereas AChE-S promotes cell death and plays a vital role in the 
apoptosome's formations, AChE-R positively regulates cell proliferation [340]. Given the dual role 
of AChE in cell survival and proliferation regulation, some authors have suggested the use of AChE 
inhibitors as anti-cancer agents for cancers displaying elevated AChE activities [340]. In addition, 
our analyses showed that cell lines treated using three acetylcholinesterase inhibitors (selegiline, 
donepezil, and galantamine) presented negative correlations with the differential expression 
profiles of several cancer types, suggesting that they could have anti-cancer effects. Therefore, 
acetylcholinesterase inhibitors' role in the reduction of cancer risk observed in AD patients cannot 
be excluded. 
The interactome-based analysis results also pointed towards the effect of breast cancer 
drugs and their association with the disease-modules of AD, MD, BD, and SCZ. Those drugs included 




receptor degraders (SERD) like fulvestrant, and testosterone and derivatives, such as testosterone 
enanthate, methyltestosterone. In our analyses, toremifene was associated with AD and BD's 
disease modules and tamoxifen with the disease module of SCZ. Toremifene and the closely related 
molecule, tamoxifen, can impair mice's learning and memory [341]. Estrogens are known to have a 
neuroprotective and antioxidant effect and inhibit neurotoxic glutamate and amyloid-beta 
accumulation, and therefore, to protect against cognitive dysfunction [342]. In fact, it has been 
observed that postmenopausal women present a higher incidence of AD than controls [343]. SERMs 
can act both as agonists or antagonists of estrogen receptors in a context-dependent fashion. Some 
authors have proposed that SERMs could present the same benefits as estrogen treatment but 
reduce the risks associated with it, like the development of estrogen-dependent tumors [344, 345]. 
In this respect, SERMs have been shown to display neuroprotective effects by reducing local brain 
inflammation [346].  
In our analyses, tamoxifen was found to be linked to the SCZ disease module. A series of 
studies have demonstrated that the use of estrogen is useful in schizophrenia patients and to treat 
the manic phase of bipolar disorder [345, 347, 348]. Estrogen treatment has also been found to 
reduce psychiatric symptoms in postmenopausal women with schizophrenia and bipolar mania. In 
addition, tamoxifen has been proven useful in preclinical models of schizophrenia-like symptoms 
and women with bipolar disorder experiencing episodes of mania [349]. Toremifene was also 
significantly associated with the disease module of bipolar disorder. In the past, testosterone was 
the most common form of hormonal therapy in breast cancer. We found that testosterone was 
associated with the disease module of major depression. Testosterone was a common form of 
hormonal therapy used for the treatment of breast cancer. Despite being progressively abandoned 
during the last four decades, some reports have tested its efficacy in refractory metastatic breast 
cancer, finding significant therapeutic activity [350]. A meta-analysis suggests that testosterone 
treatment could be effective in reducing depressive symptoms in men [351]. However, a recent 
randomized control trial examining the effects of low-dose testosterone in women with treatment-
resistant depression did not show efficacy compared with placebo [352]. Altogether, this data 
indicates that medications linked to the hormonal axis could play a role in the modulation of CNS 
and cancer associations.  
 Cisplatin is a chemotherapy medication used to treat an extensive collection of cancer 
types, including BRNCA, BLCA, LGCA, HANC, LGCA, and OVCA. In our analyses, cisplatin was found 
to present interactome associations with Alzheimer’s disease. There is evidence relating cisplatin 
treatment with the emergence of dementia-like symptoms. For instance, cisplatin is known to 
induce cell death in mice's hippocampus through changes in the expression of apoptotic-related 
genes [353] and accelerated the development of tauopathy signs and the loss of synaptic integrity 
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[354]. Besides, cognitive deficits are present in up to 75 percent of cancer patients treated with 
chemotherapy [355].  
LINCS L1000 analysis allowed us to identify a set of drugs indicated for the treatment of CNS 
disorders, which were found to produce opposite patterns of gene expression than those observed 
in the differential gene expression analysis profiles of several cancer types. The identified sets 
included sodium channel blockers, antipsychotics, antidepressants, benzodiazepines, and 
carbidopa, as well as acetylcholinesterase inhibitors. 
Different degrees of evidence have been gathered regarding the anti-cancer properties of 
these compounds. In the case of sodium channel blockers, some studies have reported that patients 
treated with them present a reduced risk of several tumor types, including colorectal, lung, gastric, 
and hematological malignancies [356]. In addition, it has been observed that lamotrigine inhibits 
breast cancer growth in cell lines and rodent models [357]. Furthermore, carbamazepine has been 
suggested to act as a histone deacetylase inhibitor, reduce the number of cells in S and G2-M 
phases, and decrease the viability of colon cancer cell lines. However, one study linked the use of 
carbamazepine and lamotrigine to an increase in the risk of skin cancer melanoma [358].  
Antipsychotic drugs have also been linked to anti-cancer properties. Pimozide presents a 
potent antitumor effect in breast cancer cell lines and xenograft models and reduces the number 
of lung metastases by blocking the vascular endothelial growth factor [359]. Pimozide also reduces 
the cell migration and invasion capacity of various cancer cells and inhibits the proliferation of liver 
and prostate cancer cell lines [360-362]. Prochlorperazine has been found to inhibit cell viability in 
a concentration-dependent fashion in melanoma cells [363]. Haloperidol presents growth-
inhibiting properties in prostate cancer cell line cultures [364].  
Moreover, trifluoperazine suppresses tumor growth and brain metastases in triple-negative 
breast cancer cell lines and mouse xenografts by inducing G0/G1 arrest and apoptosis [365] and 
also reduces the angiogenic and invasive potential of aggressive cancer cells by modulating the 
beta-catenin pathway [366]. Finally, chlorpromazine has been shown to present antiproliferative 
activity in brain tumors and colorectal cancer cell-lines [367]. In addition to the previous 
antipsychotics, which belong to the dopamine receptor antagonists' family, risperidone, an atypical 
antipsychotic was also found to be negatively correlated to cancer profiles. Second-generation 
antipsychotics in general and risperidone, in particular, have been associated with a lower risk of 
colorectal cancer through the induction of ROS-mediated apoptosis [368]. 
Different families of antidepressants, including tricyclic (TCA), tetracyclic, selective 
serotonin reuptake inhibitors (SSRI), and monoamine oxidases (MAO), were the next family of drugs 
that were found to be negatively correlated with cancer profiles. Among the tricyclic 




therapy. It induces cell toxicity due to an increase of oxidative stress by augmenting ROS levels and 
causing mitochondrial dysfunction [369] through the inhibition of mitochondrial complex III [370]. 
Desipramine, another tricyclic antidepressant, induces apoptosis in hepatocellular carcinoma [371]. 
However, a phase II study for the repositioning of desipramine in small cell lung cancer was 
discontinued, and no clinal benefits were observed in desipramine treated patients [372]. 
Maprotiline, a tetracyclic antidepressant, has demonstrated anti-tumor activity in previous drug 
repositioning studies [373] and has been observed to induce autophagic cell death in Burkitt's 
lymphoma [374]. Three members of the family of selective serotonin reuptake inhibitors (SSRI) 
were present among the antidepressant drugs negatively correlated with cancer profiles. SSRIs 
have been linked to anti-proliferative effects in experimental models. In particular, sertraline has 
been found to have anti-cancer activity in colon cancer cell lines and cancer xenograft models [375] 
and has been proposed to target prostate cancer stem cells [376]. Sertraline has also been found 
to have beneficial effects on tumor growth and cell dissemination in a mouse model of lymphoma. 
Furthermore, fluoxetine (Prozac) also presents anti-tumor progression effects on hepatocellular 
carcinoma and non-small cell lung cancer animal models [377]. Selegiline, a member of the 
monoamine oxidase family, also indicated for the treatment of SCZ, MD, PD, and AD was negatively 
correlated to several cancer transcriptomic signatures. Selegiline has been shown to induce 
apoptosis in a melanoma cell line and in acute myelogenous leukemia cells by inhibiting 
mitochondrial respiration [378, 379]. Downregulation of mitochondrial respiration genes was a 
shared feature of the transcriptomic alterations found in all the studied CNS disorders. This fact 
raises questions about the potential pharmacological origin of the mitochondrial dysfunction 
observed in CNS disorder transcriptomes. The overexpression MAO has been reported in different 
cancer types [380, 381]. In addition, phenelzine, a non-selective MAO inhibitor, is in a phase II 
clinical trial for the treatment of recurrent prostate cancer. Despite the fact that experimental 
evidence seems to point towards an anti-cancer effect of antidepressants, a number of 
epidemiological studies have not found changes in the risk of cancer according to antidepressant 
administration. One study found that overall cancer risk was altered in antidepressant users neither 
for TCA nor for SRRI [382]. Another study found no association between the use of antidepressants 
(TCA and SRRI) and epithelial ovarian cancer risk [383]. Furthermore, a nation-wide case-control 
study found no association between any class of antidepressant prescription and the risk of lung 
cancer [384], and meta-analysis did not find evidence of an association between exposure to SSRIs 
and colorectal cancer [385]. Exposure to SRRI was not associated with an increase in prostate cancer 
risk [386] neither in testicular cancer [387]. Finally, a meta-analysis found no association between 
the use of antidepressants en colorectal cancer morbidity or mortality. In particular, a lack of 
association was found for SSRIs or SNRIs, but a risk reduction was observed for TCA [388], and a 
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single study linked SSRI inhibitors to an increased risk of breast cancer. In particular sertraline, and 
paroxetine presented (RR = 1.58, 95% CI: 1.03-2.41) and (RR = 1.55, 95% CI: 1.00-2.40) (PMID: 
14681256). This contrasting evidence suggests that maybe antidepressant treatment has no effect 
on cancer initiation but could help to reduce the rates of tumor growth in already formed cancers. 
Two Acetylcholinesterase inhibitors donepezil, galantamine, were found to generate 
opposite patterns of transcriptomic changes compared to those observed in several cancer types. 
Donepezil induces apoptosis in human promyelocytic leukemia cell-lines though the mitochondria-
mediated caspase-dependent pathways [389]. 
Alprazolam, a benzodiazepine used to treat anxiety and indicated for depression, also 
presented negative correlations with ten cancer types.  We found negative correlations between 
the differential gene expression profile generated by alprazolam and the transcriptomic signatures 
of 10 cancer types. Surprisingly a 2016 meta-analysis showed that benzodiazepine treatment was 
associated with an increase in cancer risk in a dose-response manner. Alprazolam has been found 
to increase the levels of inflammation mediators [390]. A more recent meta-analysis also showed 
an increase of cancer risk in benzodiazepine treated patients for all-cancer and several site-specific 
cancers, including breast, ovarian, renal, brain, esophagus, prostate, liver, stomach, pancreatic, and 
lung cancers, as well as, for skin cancer melanoma [391]. 
Finally, carbidopa also showed a negative correlation with three cancers. Carbidopa has 
been found to inhibit pancreatic cancer cell proliferation in vitro and in vivo [392] and prostate 
cancer xenografted into immunocompromised mice [393]. 
To a lesser extent, some instances of drugs used for the treatment of CNS disorders 
belonging to the previously reported families also presented positive correlations with the 
differential gene expression profiles of several cancer types, which included instances of tetracyclic 
antidepressants (mirtazapine), anticonvulsant drugs (oxcarbazepine), the serotonin receptor 
buspirone or the MAO Isocarboxazid, as well as the antipsychotic drugs, loxapine, iloperidone, and 
fluphenazine. Surprisingly valproic acid, an antiseizure medication known to act as HDAC inhibitor 
that induces HDAC2 proteasomal degradation leading to cellular differentiation, cell growth arrest, 
inhibition of angiogenesis, and cell death [394], was found to be positively correlated with the 
differential gene expression profiles of 11 cancer types.  
Several drugs indicated for cancer treatment were found to be correlated with the 
differential gene expression profiles of AD, BD, or MD. Interestingly, hormonal drugs or drugs acting 
on hormonal receptors were positively and negatively correlated with those CNS disorders. Among 
the negatively correlated drugs, we found antiestrogens, agonists/antagonists of the estrogen 
receptor, estradiol, and antiandrogens, whereas testosterone derivatives and progesterone were 




of this axis in AD, BD, and MD and complements the results found in the interactome-based analysis 
section. Furthermore, it provides a potential link to explain the comorbidities between those 





































































6. General discussion, limitations, future directions and conclussions  
6.1 Final discussion, study limitations, and future directions 
 This manuscript provides a picture of the current knowledge about the epidemiological and 
molecular associations between CNS disorders and cancer. However, due to data availability 
limitations, both quantitative and qualitative, this landscape is still far from being completed. Here 
we discuss the limitations of our work and propose future directions to overcome them. 
  Despite several of the epidemiological associations reported in this Thesis were found to 
be well supported by epidemiological evidence, there was an evident lack of adjustment for some 
cancer-related covariates (e.g., smoking status and BMI) in most of the included observational 
studies. Therefore, the possibility that the reported associations are driven by uneven distributions 
of those covariates in the exposed and unexposed cohorts cannot be excluded. Further 
epidemiological research conducted through careful design will help to elucidate if those factors 
are responsible for the observed associations. In addition, the number of available studies 
dedicated to the analysis of each CNS-cancer pair was highly heterogeneous. It is fair to say that 
most of the potential CNS and site-specific cancer pairs are still poorly studied. This is especially 
evident in the case of mortality studies. Besides, for some CNS and overall cancer associations (HD 
and ASD), the number of available studies were found to be also low. We intend to keep conducting 
epidemiological research following two strategies, first, through the design and implementation of 
observational studies using the Spanish population's medical records. Second, by conducting 
updated systematic reviews and meta-analyses as new data is released.  
 In the context of the transcriptomic associations, we acknowledge some important 
limitations. The gene expression data included in our analyses provide a picture of a specific time-
point of the disease physiopathology. In the case of CNS disorders, working with post-mortem brain 
tissues gives us a view that is likely biased towards the disease's latest stages. This fact prevents us 
from characterizing the complex changes that take place in the disorder along the temporal axis. 
An interesting example of this is the role of the cell cycle in neurodegeneration. Despite there is 
previous evidence of cell cycle activation in post-mitotic cells preceding neurodegeneration, we 
observed the downregulation of cell cycle-related processes in both AD and PD. Besides, the 
transcriptomic datasets employed were derived from tissues that are composed of a 
heterogeneous set of cell types. Although this approach allowed us to identify the joint involvement 
of some biological processes in CNS disorders and cancer, such as the immune system, the cell cycle, 
and the oxidative phosphorylation, it precludes the possibility of clearly understand the changes 
that operate in specific cell types, as well as to determine if the alterations observed are due to 
changes in the patterns of gene expression of specific cell types or to differences in tissue 
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composition. This is a fundamental question in neurodegenerative disorders and cancer where the 
respective death and proliferation of specific cell types occur and is followed by a reconfiguration 
of the tissue's cellular architecture. 
 Furthermore, our analyses compared the differential gene expression profiles of disorders, 
which, in most instances, take place in different tissues. Supposing that the joint alterations in genes 
and pathways are the drivers of the reported comorbid associations, we should be able to find them 
in tissues other than those directly linked to the disease physiopathology. For instance, if the 
opposite patterns of transcriptomic deregulation observed in oxidative phosphorylation genes in 
AD and LGCA were to be, to some extent, the drivers of the inverse comorbidity observed at a 
population level between both disorders, we should expect to find alterations in oxidative 
phosphorylation processes in lung tissues derived from AD patients. However, little is known 
regarding the presence of those changes in tissues other than those directly linked to the disease 
physiopathology, with the exception of transcriptomic studies derived from peripheral blood. Some 
steps have already been taken in this direction. For instance, it has been argued that PD's 
pathological manifestations seem to extend beyond brain tissues. In particular, Lewy bodies have 
been found in both the peripheral and the enteric nervous system of PD patients, as well as changes 
in dopamine expression and mitochondrial and ubiquitin-proteasome dysfunctions [254]. Increased 
cell cycle activity has also been observed in immortalized lymphocytes derived from PD patients 
[254]. 
 The lack of control for potential confounding covariates in differential gene expression and 
gene co-expression analyses due to data availability and methodological matters constitutes 
another limitation of our study.  
 Further research is necessary to shed length on these topics. The analysis of transcriptomic 
deregulation patterns along the temporal axis would allow us to characterize the characteristic 
alterations of specific disorders better. The emergence of single-cell RNA-seq studies will allow the 
characterizations of the specific transcriptomic changes occurring in cell-types, and the analysis of 
transcriptomic changes in tissues other than those directly linked to disease could strengthen the 
evidence of the implication of specific molecular alterations as modulators in the comorbid 
associations. We aim to conduct new transcriptomic-based studies as new data suitable to explore 
these unanswered questions are available. 
 A number of inverse comorbid associations detected at a population level between 
neurodegenerative disorders and site-specific cancers were found to translate into significant 
opposite patterns of transcriptomic deregulation. Instances of those were the inverse associations 
reported between AD and LGCA, AD and LIVCA, AD and SKCM, PD and BRCA, PD and LGCA, HD and 




PD patients were found to be at an increased risk of brain cancer, and same-direction significant 
patterns of transcriptomic deregulation were observed between PD and BRNCA. Instances of 
significant epidemiological associations that did not translate into altered joint patterns of gene 
expression were also observed. PD and SKCM constitute an interesting example of the latter. We 
observed a well-supported risk increase in SKCM incidence in PD patients, which did not translate 
into significant direct transcriptomic patterns of association. 
 In general, the lack of complete reliable epidemiological and transcriptomic data covering 
all CNS and site-specific cancer associations did not allow us to test the predictive power that the 
presence of significant patterns of transcriptomic deregulation have on epidemiological 
associations. This should be the object of future research. 
 The study of genetic correlations between disorders is a promising tool to establish 
comorbidity's potential biological bases. Two big steps forward are enabling researchers to conduct 
large scale studies based on the computation of genetic correlations. The first is the availability of 
specific data repositories that facilitate the searches and direct access to GWAS data, such as the 
GWAS catalog. The second is linked to the development of methods to compute genetic 
correlations between disorders using GWAS summary statistics data alone, such as cross-trait LD 
score regression, which provides a computationally affordable approach compared to competing 
methods. Using this method, we were able to identify positive genetic correlations between CNS 
disorders that presented increased risks of different cancer types, including SCZ and BRCA, MD and 
LGCA, MD and BRCA, and PD and SKCM. 
 Despite this, we could not obtain GWAS summary statistics for most of the studied site-
specific cancers, which are in some cases under restricted access. In those instances, the data access 
application procedures have proven more challenging and time-consuming than anticipated 
precluding their use in our analyses. We think that the ongoing transitions towards open access 
data models will improve the future's access conditions. Therefore, we intend to complete the 
landscape of the genetic correlations between CNS disorders and cancers as more datasets are 
released. Furthermore, our genetic correlation analyses are limited to populations of European 
ancestry. Therefore, these studies should be extended to datasets derived from different 
populations. The study of the potential role of medications in disease-disease associations can 
be used to deepen our understanding of comorbidity but also opens the door to the identification 
of drug repurposing candidates. Drug development is a slow process. The complete journey from 
drug design until the completion of phase 3 clinical trials can take more than 12 years [395, 396]. In 
this context, we identified drugs indicated for the treatment of CNS disorders that targeted the 
disease module of several cancer types and produced transcriptomic alterations that could reverse 
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those found in some site-specific cancers. A number of these drugs have shown anticancer activity 
in previous in vitro and animal model studies. 
 Finally, although our study could be used as a tool to generate hypotheses, it needs to be 
completed through experimental research. The use of animal models of CNS disorders could 
constitute a valuable approach to establish the molecular bases of comorbidity. This raises 
questions about which models are best fitted to this end since most of the studied disorders are 































1) CNS disorders present diverse epidemiological patterns of comorbidity with cancer. 
Neurodegenerative disorders (AD, PD, and HD) display a reduced risk of subsequent all-
cancer incidence and mortality. BD, SCZ, and ASD do not present altered all-cancer 
incidence patterns compared to controls, whereas MD patients are at increased risk of 
subsequent all-cancer incidence. In contrast, BD, MD, SCZ, and ASD are associated with an 
increased risk of all-cancer mortality. 
2) The best-supported associations between CNS disorders and site-specific cancers were the 
following: AD presented a reduced incidence risk of liver and lung cancers. HD patients 
were found to be at a reduced risk of colorectal and prostate cancer incidence. PD 
presented reduced incidence risks of bladder, colorectal, larynx, lip and oral cavity, and lung 
cancers, whereas the incidence risks of brain and melanoma were found to be increased in 
PD patients. Colorectal, lung, pancreatic, and stomach cancer mortality risks were reduced 
in PD patients compared to controls. MD patients are at a higher risk of brain, lung, and 
pancreatic cancer than controls, and depressed women at a higher risk of breast cancer 
incidence and mortality. BD patients were found at an increased risk of stomach cancer. 
Women with SZC presented an increased risk of uterine and breast cancer incidence and 
were also found to be at an increased risk of breast cancer death, whereas SCZ men present 
a reduced risk of prostate cancer. The risks of mortality due to colorectal, liver, lung, and 
pancreatic cancer are also increased in SCZ patients compared to controls. Melanoma, 
nasopharynx, and thyroid cancer incidences were found to be reduced in SCZ patients. 
3)  The risk of smoking-related cancers was found to be reduced in PD patients, but not the 
risk of cancers not linked to smoking, whereas MD presented an increased risk in smoking-
related cancers but not in the smoking-unrelated cancers. This observation suggests the 
role of smoking as a potential modulator in some of the reported CNS and cancer 
associations. However, this is an indirect way of measuring smoking's impact, therefore 
these results should be confirmed by further epidemiological research which should take 
into account smoking status information by design or as an adjustment factor. In addition, 
gender-based differences in all-cancer incidence were observed in the case of SCZ. Men 
presented a significant reduction, whereas women presented a non-significant trend 
towards an increase in cancer risk. This could be due to the significant increase in the risk 
of breast cancer incidence and mortality observed in SCZ women and the significant 
reduction in prostate cancer observed in PD patients. 
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4) The reported meta-analysis results should be taken with caution since some of them are 
based on meta-analyses carried out using a small number of observational studies. In 
addition, important confounding variables, such as smoking status, are not accounted for 
in the vast majority of cases. Other potential sources of bias, such as ascertainment bias or 
diagnostic overshadowing, cannot be excluded either. There is considerable heterogeneity 
in the number of published studies reporting cancer associations for the different CNS 
disorders. ASD and HD are the poorest studied disorders in the context of their associations 
with cancer. In the case of mortality studies, site-specific cancer information was very 
scarce. 
5) Neurodegenerative disorders (AD, PD, and HD) and ASD presented a substantial amount of 
differentially expressed genes, whereas BD, MD, and SCZ did not. Cancers presented large 
amounts of differentially expressed genes when compared to healthy control tissues in 
both the array and RNA-seq-based analyses.  
6) Several significant patterns of joint transcriptomic deregulation were found between CNS 
disorders and cancers using array-based studies. Some of the associations were further 
validated using alternative RNA-seq cancer datasets. AD presented direct transcriptomic 
associations with BRNCA and inverse with BLCA, BRCA, LGCA, LIVCA, and PRCA. PD was 
found to present direct transcriptomic associations with BRNCA and KDNCA and inverse 
with BRCA, LGCA, and PRCA. HD was directly associated with BRNCA, KDNCA, and inversely 
with BRCA, LGCA. Finally, ASD was found to present significant direct patterns of 
transcriptomic deregulation with BRNCA and KDNCA.  
7)  Overrepresentation, GSEA, and consensus co-expression module overlap analyses suggest 
the joint involvement of alterations in biological processes in CNS and cancer, which 
included diverse instances of immune system-related pathways, as well as others, such as 
P53 signaling, unfolded protein response, mTORC1 signaling, DNA repair, cell cycle, 
apoptosis, and the oxidative phosphorylation, among others.  
8) CNS disorders and cancers did not present significant interactome-based overlaps. In 
contrast, significant genetic correlations were observed. ASD was found to present 
significant negative genetic correlations with PRCA and BRCA. BD was positively correlated 
with BRCA, whereas MD did it with BRCA and LGCA. PD presented positive genetic 
correlations with PRCA and SKCM. Finally, SCZ was also found to present significant positive 
genetic correlations with BRCA and OVCA. These observations suggest that shared variants 
could jointly influence the susceptibility to CNS and cancers. 
9) Several drugs indicated for the treatment of CNS disorders were placed close to the disease 




those found in different cancer types, suggesting their potential role in modulating CNS 
disorders and cancer associations. Instances span drugs from several families, including 
anticonvulsants, antipsychotics, antidepressants, and benzodiazepines, among others. 
Drugs indicated for cancer also have the capacity to produce transcriptomic changes that 
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Appendix 1: ICD-9 and ICD-10 codes for chapter’s two primary and secondary outcomes 
 CNS disorders ICD codes 9 ICD codes 10 Smoking- related 
Alzheimer's disease 331.0 G30.9 NA 
Autism spectrum disorders  299.0 F84.0 NA 
Bipolar disorder  296.80 F31 NA 
Huntington’s disease  333.4 G10 NA 
Major depression  296.3 F33 NA 
Parkinson’s disease  332 G20 NA 
Schizophrenia  295 F20.9 NA 
Cancers ICD codes 9 ICD codes 10 Smoking-related 
Overall cancer  140-239 C00-D48 NA 
Acute lymphoblastic 
leukemia  
204-208.92 (leukemia) C91-C95.92  (leukemia) Yes 
Acute myeloid leukemia  204-208.92  (leukemia) C91-C95.92  (leukemia) Yes 
Bladder cancer  188-188.9 C67-C67.9 Yes 
Brain and nervous system 
cancer  
191-192.9 C70-C72.9 No 
Breast cancer  174-175.9 C50-C50.929 No 
Cervical cancer  180-180.9 C53-C53.9 Yes 
Cholangiocarcinoma  156-156.9, 209.25-209.27 (Gallbladder 
and biliary tract cancer) 
C20.8, C23-C24.9 







204-208.92 (leukemia) C91-C95.92 (leukemia) Yes 
Chronic myeloid leukemia  204-208.92 (leukemia) C91-C95.92 (leukemia) Yes 
Colorectal cancer  153-154.9, 155.5, 155.9, 209.1-209.17 C18-C20.0, C20.9-C21.8 Yes 
Diffuse large B-cell 
lymphoma  





Esophageal cancer 150-150.9 C15-C15.9 Yes 





Gallbladder and biliary tract 
cancer 
156-156.9, 209.25-209.27 C20.8,C23-C24.9 No 
Stomach cancer  151-151.9, 209.23 C16-C16.9 Yes 
Head and neck carcinoma  195.0   
C76.0 
Yes 
Hodgkin lymphoma  201-201.98 C81-C81.99 No 
Kidney cancer  189.0, 189.1, 209.24 C64-C65.9 Yes 
Lip and oral cavity cancer  140-145.9 C00-C08.9 Yes 
Larynx cancer  161-161.9, 162.1 C32-C32.9 Yes 
Leukemia  204-208.92 C91-C95.2 Yes 
Liver cancer  155-155.3 C22-C22.9 Yes 
Tracheal, bronchus, and 
lung cancer  
162, 162.0, 162.2-162.9, 209.21 C33-C34.9 Yes 
Melanoma  172-172.9 C43-C43.9, C4A No 
Mesothelioma  58-158.9, 163-163.3, 163.8, 163.9 C45-C45.9 No 




Non-Hodgkin lymphoma  200-200.9, 202-202.98 C82-C86.6, C96-C97-9 No 
Multiple myeloma  203-203.9 C88-C90-32 No 
Ovarian cancer  183, 183.0 C56-C56.9 Yes 
Oral and lip  140-145.9 C00-C08.9 Yes 
Pancreatic cancer  157-157.9 C25-C25.9 Yes 
Prostate cancer  185-185.9 C61-C61.9 No 
Testicular cancer  186-186.9 C62-C62.92 No 
Thyroid cancer  193-192.9 C73-C73.9 No 
Uterine cancer  182-182.8 C54-C54.9 No 
Appendix 1: Table showing the ICD codes associates with each disorder and the classification of 




















Appendix 2: Templates for NOS observational studies quality appraisal 
  that the evaluation of some specific items of the scale involves the choice of some 
parameters by the researcher. For instance, item two of the outcome section of the Newcastle-
Ottawa scale of cohort studies asks the researcher if the follow-up time was long enough, but it 
does not specify a particular threshold. We set this threshold to three years. In item four of the 
selection section of cohort studies quality appraisal, we only assign a star for cancer mortality 
studies if the particular study reported that the CNS patients did not present incident cancer before 
























Appendix 3: Previous systematic reviews identified 
Disorders Author, year Cancer Incidence or Mortality 
AD, ALS, DS, HD,MS, PD, SCZ Catalá, 2014 [21] Incidence 
AD Ma, 2014 [397]  Incidence 
AD Shi, 2015 [398]  Both 
AD Zhang, 2015 [111]  Incidence 
AD Papageorgakopoulos, 2017 [399]  Incidence 
BD Hayes, 2015 [400]  Mortality 
MD McGee, 1994 [20]  Incidence 
MD Wulsin, 1999 [401]  Mortality 
MD Oerlemans, 2007 [402] Incidence 
MD Pinquart, 2010 [403]  Mortality 
MD Cuijpers, 2014 [404] Mortality 
MD Sun, 2015 [405] Incidence (Breast Cancer) 
MD Ahn, 2016 [85]  Incidence 
MD Jia, 2017 [406]  Incidence 
PD Bajaj, 2010 [114] Incidence 
PD Liu, 2011 [106] Incidence (Melanoma) 
PD Huang, 2015 [407] Incidence (Melanoma) 
PD Wang, 2015 [408]  Incidence  (Breast and prostate cancer) 
PD Ye, 2016 [409] Incidence (Brain cancer) 
PD Xie, 2016 [410] Incidence (Lung cancer) 
PD Xie, 2017 [411] Incidence (Colorectal cancer) 
SCZ Catts, 2008 [86] Incidence 
SCZ Bushe, 2009 [105]  Incidence (Breast cancer) 
SCZ Zhuo, 2017 [412] Mortality 
SCZ Xu, 2018 [413]  Incidence 
SCZ Li, 2018 [414] Incidence  
Appendix 3: Previous systematic reviews and meta-analysis identified including studies analyzing 





















Appendix 4: Characteristics of the observational studies included in meta-analyses  
 
Source Study Design 
(Country) 
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NA Overall cancer 
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mortality 
No MMSE; DSM-III-R; 
ICD-10 codes; 
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RR None, But the 
cognitive intact 
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(3.2  y in AD 
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4.3 years in 
the control 
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395 Female %: 63.8% in 
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Age: 




































71 Female %: 




77.9 y in incident 
dementia group. 
(mean) 
376 in the 
whole 
study group 






ICD-9 HR Sex, race, age, 
education, 


























159 Overall cancer No MMSE; NINCDS-
ADRDA 
ICD-O HR Age, sex, smoking, 













2832 Female %: 
66.6% 
Age: 
78.1 y in AD group 
(mean) 
Ethnicity: 
68 Overall cancer Yes Payment 
exemptions, 
hospitalizations, 
drug prescriptions  
ICD-10 RR Age, sex, calendar 
year 
8 (Low-risk) 











6960 Female %: 
60.3 % 
Age:  
76 y in AD group 
(median) 
Ethnicity: 








SIR Age, sex, calendar 
year 
9 (Low risk) 




















B infection and 
hepatitis C 
infection 
2 (High risk) 






















































































7321 Female %: 
45.5% 
Age: 
74 y (median) 
Ethnicity: 
5961 Overall cancer Yes One hospital or two 
physician/outpatient 
AD claims at least 30 
days apart 
ICD-9 
ICD-O-3 OR Sex, age category, 



























1341 Overall cancer Yes ICD-9-CM ICD-9-CM SIR Age, sex 9 (Low risk) 





















50% White, 13% 
Black, 6% Asian 
 
21 Overall cancer 
mortality 





























































8438 Female %: 
17.9% 
Age: 
5.3 y (mean) 
Ethnicity: 
100% Asian 
20 Overall cancer Yes ICD-9 codes ICD-9 codes SIR Age, sex, and 
calendar year 

































27122 Female %: 
31.1% 
Age: 
19.8 y (mean) 
Ethnicity: 
NA 
88 Overall cancer 
mortality 
No ICD-9 or ICD-10 
codes; DSM-V  
ICD-9 or ICD-10 
codes 












118 Female %: 
30% 
Age: 
4.9 y (mean) 
Ethnicity: 
NA 
8 Overall cancer Yes IDC-9, ICD-10 ICD-8, ICD-10 OR Age, Sex, place of 
birth, and social 
group 
9 (Low risk) 




















38.5 y (mean) 
Ethnicity: 
NA 
4 Overall cancer 
mortality 




















53 Overall cancer 
mortality 
No ICD-8 codes ICD-8 codes SMR Age, sex, and time 
at risk 
























6 Overall cancer 
mortality 
No DSM-III-R codes ICD-9 
codes 























2602 Overall cancer 
death 





















43 y (mean) 
Ethnicity: 
NA 
475 Overall cancer 
death 
No ICD-8 and ICD-9 
codes 
Death certificates SMR Age, sex, and 
calendar period 
7 (Low risk) 






Inpatient, Single-center 1959-1997 
 
(22 y) 






22 Overall cancer 
death 
No ICD-8 codes ICD-8 codes SMR Age, sex, and 
calendar period 


















44.6 y   
Ethnicity: 
NA 
1217 Overall cancer Yes ICD-7 and ICD-8 ICD-7 and ICD-8 SIR Age, sex, and 
calendar period 
7 (Low risk) 
 













235 BD Female %: 
56.6% 
Age: 
32.7 y (mean) 
Ethnicity: 
NA 
11 Overall cancer 
mortality 





















123 Specific cacner Yes Clinical diagnosis 








and use of 
medication 



















NA Overall cancer 
death 
No ICD-10 codes Death certificates SMR Age, sex, and 
calendar year 






























Mixed, Population-based 1973-1993 
 
(21 y ) 
NA BD Female %: 
NA 
Age: 
2740 Overall cancer 
death 
No ICD-8 codes ICD-8 codes SMR Age, sex, and 
calendar year 


















(Up to 8 
years) 






NA Overall cancer 
death 
No Clinical diagnosis Medical records SMR Age, sex, and 
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72 Overall caner Yes DSM criteria ICD-9 codes SIR Sex 3 (High risk) 


















9 Overall cancer 
mortality 
No ICD-8, ICD-9, and 
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attainment,  body 
mass index, 
comorbidities, 
and age at cancer 
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54% White, 45% Black 
























15 Overall cancer 
mortality 
No ICD-9 and ICD-10 
codes 
ICD-9 and ICD-10 
codes 

















3200 BD Female %: 
NA 
Age:  
41.8 y (mean) 
Ethnicity: 
NA 
21 Overall cancer 
death 


















178 Overall cancer 
mortality 








9 (Low risk) 











2077 BD Female %: 
55.2% 
Age: 
44.8 y (mean) 
Ethnicity: 
81.1% White 
31 Overall cancer 
mortality 
No DSM-IV codes ICD-10 codes HR Age, sex, ethnicity, 
and income 
9 (Low risk) 










20567 BD Female %: 
54.3% 
Age:  






























NA Overall cancer Yes Clinical diagnosis in 
medical records. 
Clinical diagnosis 
in medical records 
IRR Age, Sex, General 
























11 Overall cancer 
death 
No ICD-9 or ICD-10 
codes  
ICD-9 or ICD-10 
codes  
HR Age, time at risk 
(competing risks) 
8 (Low risk) 













10207 BD Female %: 
50.8% 
Age: 
Most < 40 y 
Ethnicity: 
100% Asian 










Mixed, Multi-center 2000-2009 
 
10 y 
131 BD Female %: 
100% Women 
Age: 
>30 (mean age) 
Ethnicity: 
87.8% White, 3.0% 
Black, 2.3% Asian 
NA Specific cancer 
death 
Yes ICD-10 codes ICD-10 codes HR Age, sex, ethnicity, 
comorbidity stage 














4.5 y  
5442 BD Female %: 
58.8% 
Age: 63.1 y (mean) 
Ethnicity: 
NA 
327 Overall cancer Yes ICD-9 and ICD-10  
codes  
ICD-9 and ICD-10  
codes 



















110 Overall cancer No ICD-9 codes ICD-9 codes SIR Age and sex 7 (Low risk) 








Mixed, population-based 1943-1981 
 
NA 








5 Overall cancer 
death 







Mixed, population-based 1943-1993 
 
16 y 








55 Overall cancer Yes ICD-7 codes ICD-7 codes SIR Age, sex, and 
calendar year 
8 (Low risk) 






Mixed, population-based 1969-2008 
 
>5 y 
1510 HD Female: 
52% 
Age: 
91 Overall cancer Yes ICD-7-ICD-10 codes ICD-7-ICD-10 
codes 
SIR Age, calendar 
year, socio-
economic status, 
9 (Low risk) 
220 
 

















Inpatient, multicenter 1999-2010 
 
>5 y 








160 Overall cancer Yes ICD-7, ICD-8, ICD-9, 
and ICD-10 codes 
ICD-7, ICD-8, ICD-
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codes 
RR Age, sex, calendar 
























NA Overall cancer Yes Huntington’s disease 
network REGISTRY 











Mixed, population-based 1986-2015 
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NA Overall cancer 
death 
No ICD-10 ICD-10 OR No 6 
(Moderate 
risk) 





















6 Overall cancer 
death 






























12 Overall cancer No HNTQ NA 
 
OR NA 2 (High risk) 
WEHS, 1987 
(Shekelle 1981 


















15 Overall cancer; 
Overall cancer 
death 
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RR Age and sex 6 
(Moderate 
risk) 






Inpatient, Single-center 1968-1982 
 
14 y 
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(biopsy) and 
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Overall cancer 
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RR Age, sex, marital 
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39% never, 11% past 
25 Overall cancer No CES-D Death records, 
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confirmation 


















83% White, 10% 
Black, 7% Other 
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Overall cancer 
death 







SIR; SMR Age and sex 8 (Low risk) 
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socioeconomic 





8 (Low risk) 
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NA Overall cancer 
death 
Yes Geriatric Depression 
Scale 
 







8 (Low risk) 
222 
 

















































331 Overall cancer, 
Overeall 
cancer death 
Yes ICD-9 ICD-9 RR Age and sex 8 (Low risk) 
Brådvik, 2001 
(+Berglund, 






Inpatient, single-center 1949-2000 
 
>10 y  








121 Overall cancer 
death 














25 y  








95 Overall cancer Yes GP diagnosis ICHPPC-2 codes RR Age, sex, and 
socioeconomic 
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7 (Low risk) 







Inpatient, single center 1959-1997 
 
22 y 








23 Overall cancer 
death 
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calendar period 














































3 Specific cancer Yes EDS and clinical 
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Inpatient, multi-center 1993-1996 
 
3y 





90.8% White, 4% 
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NA Overall cancer 
death 
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33 Specific cancer Yes Clinical diagnosis 
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to confirm cancer 
diagnosis 































1319 Overall cancer Yes ICD-7, ICD-8, ICD-9, 
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ICD-7, ICD-8, ICD-
9, ICD-10 codes 























non-White < 3% 
Smoking history: 
NA 
NA Overall cancer 
death 
No HADS scale, DSM-
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NA Overall cancer 
death 
No Geriatric depression 
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and clinical interview 




















NA Overall cancer 
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61% White, 35% 
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Smoking history: 
34% never, 38% past, 
27% current 






HR Age, sex, smoking, 
and parity (only 
for breast cancer) 
9 (Low risk) 















































19% current smoking 
NA Overall cancer 
death 
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HR Age and sex 5 
(Moderate 
risk) 






















321 Overall cancer Yes ICD-9-CM codes ICD-9-CM codes RR Age, sex, 
urbanization and 
comorbidity 
7 (Low risk) 






Inpatient, multi-center 1950-1976 
 
10 y 
230MD Female %: 
0% 
Age: 





76 Overall cancer 
death 
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codes 
ICD-8 and ICD-9 
codes 




body mass index, 
and comrbidities 























50 Overall cancer 
mortality 
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HR Age, sex, calendar 
year, deprivation 






















15 Overall cancer 
death 
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year, deprivation 
































and End Results 
(SEER) 
RR Age, sex, smoke, 
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7 (Low risk) 




















274 Overall cancer 
death 
No DSM-IV codes ICD-10 codes HR Age, sex, ethnicity, 
and income 
9 (Low risk) 








Mixed, population-based 1988-2007 
 
>5 y 
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ICD-O codes RR Age and sex 8 (Low risk) 
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NA 
499 MD Female %: 
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Age: 
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D-ICD-10 codes 
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7 (Low risk) 




















29% Never, 57%Past, 
14% current 
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men), time at risk 
(competing risks) 
8 (Low risk) 



























































NA Overall  cancer No GHQ-30 depression 
subscale 




















47317 MD Female %: 
 21.4% 
Age: 




5-10% never smoking, 













































to confirm cancer 
diagnosis. 
HR Age, parity, 
hormone, history 

































to confirm cancer 
diagnosis. 
HR Age, parity, 
hormone, history 

























NA Overall cancer No DSM-IV Self-reports of 
diagnosis 



















Mixed, multi-center 2000-2009 
 
10 y  





86.7% White, 3.1% 
Black, 2.8% Asian 
Smoking history: 
NA 
NA Specific cancer  Yes ICD-10 codes ICD-10 codes HR Age, sex, ethnicity, 
deprivation, 
comorbidity, stage 
at diagnosis and 
treatment 
8 (Low risk) 







Mixed, population-based 1993-2003 
 
3 y 










































41% Never smoker 
29 Specific cancer 
death 
Yes CES-D National death 
registry 
























Mixed, poputaltion-based 1987-2012 
 
NA 








NA Overall cancer 
mortality 
No Purchase of 
antidepressants 
(ATC codes) 
ICD-8, ICD-9, and 
ICD-10 


















Inpatient, single-center 1917-1950 
 
>5 y 








7 Overall cancer 
death 





SMR Age, calendar year 4 
(Moderate 
risk) 



















SIR Age 5 
(Moderate 
risk) 








Inpatient, single-center 1949-1964 
 
9 y 


























Inpatient, single-center 1965-1967 
 
3 y 








17 Overall cancer 
death 
Yes Clinical diagnosis 
(medical charts and 
interviews) 











Mixed, population-based 1975-1981 
 
5 y 





5 Overall cancer 
death 
No Clinical diagnosis 





















Inpatient, single-center 1978.1984 
 
8.6 y 





































548 Overall cancer 
death 
No ICD-8 and ICD-9 
(medical records, 
death registry) 
ICD-8 and ICD-9 
(medical records, 
death registry) 


























9 Overall cancer 
death 















Mixed, population-based 1973-1991 
 
NA 








26 Overall cancer 
death 
No Clinical diagnosis 
(medical reords) 
Death certificates SMR Age and sex 6 
(Moderate 
risk) 










2.3 y  








2 Overall cancer 
death 
No Clinical diagnosis 
(medical records) 
Death certificates RR None 3 (High risk) 






Mixed, multi-center 1984-1997 
 
10 y 








12 Overall cancer 
death 



























ICD-9 SMR Age, sex, and 
calendar period 

























15 Overall cancer  Yes Clinical diagnosis 
(Survey) 
Cancer registry SIR Age and sex 7 (Low risk) 


















14 Overall cancer 
death 
No Clinical diagnosis ICD-9 or ICPC RR Age and sex 8 (Low risk) 


















10 Overall cancer 
death 








Mixed, population-based 1993-1999 
 
6 y 
15306 PD Female %: 
NA 
Age: 











RR Age and sex 6 
(Moderate 
risk) 










>5 y  










Overall cancer  Yes Clinical diagnosis 
(medical records) 
ICD Adapted Code 
for Hospitals (H-
ICDA) 
RR Age, sex, and 
smoking 























3 Overall cancer 
death 




















NA Overall cancer No REP diagnostic index 















Inpatient, multicenter 1987-1994 
 
NA 








2 Specific cancer Yes Clinical diagnosis 
(records from 
observation period 




period of a 
randomizer trial) 























51.3% never, 42.3% 
past, 6.4% current 
53 Overall cancer Yes Self-report by US 
male physician 
(validation study by 
medical records) 





RR Smoking, alcohor 
use, BMI category, 
and exercise 




















51.3% never, 42.3% 
past, 6.5% current 
22 Overall cancer 
death 
Yes Self-report by US 
male physician 
(validation study by 
medical records) 





















2993 PD Female %: 















IRR None (Crude IRR 












 Mixed, population-based 1994-2008 
 
>5 y 





80.3% White, 8.2% 
Hispanic, 7.7% Asian, 
3.2% Black 
Smoking history: 
50.4% never, 49.4% 
ever, 0.1% missing 
90 Overall cancer  Yes Clinical diagnosis 






RR Age, sex, smoking, 
alcohol, body 
mass index 
9 (Low risk) 



























RR Age, sex, calendar 
year, and district 
of residence 























Rating Scale (UPDRS) 






34.8% ever smoker 








Mixed, population-based 2000-2008 
 
>5 y 























Mixed, population-based 1904-2008 
 
NA 








NA Specific cancer 
death 
Yes Clinical diagnosis 
(death records) 




Rugbjerg, 2012 (+ 
Olsen, 2005, + 
Moller, 1995) 






Mixed, population-based 1977-2008 
5.7 y 








2218 Overall cancer Yes ICD-8 and ICD-10 
codes 
ICD-8 and ICD-10 
codes 
SIR Age and sex 8 (Low risk) 








Mixed, population-based 2000-2009 
 
NA 
397 PD Female %: 
32.3% women with 
lung cancer 
Age: 






NA Specific cancer Yes ICD-9 ICD-9 OR sex, age and 
index date 
 





























19 Specific cancer Yes Clinical diagnosis 
(records from 
observation period 




period of a 
randomizer trial) 
SIR Age and sex 3 (High risk) 








Mixed, population-based 1999-2011 
 
>5 y 
219194 PD Female %: 
43.0% 
Age: 





17524 Overall cancer Yes Clinical diagnosis 
(hospital 
admissions) 
ICD-10 RR Age, sex, calendar 
year and district of 
residence 










Outpatient, single-center 1974-2012 
 
32.5 y 








25 Overall cancer 
death 








Mixed, population-based 1958-2009 
>5 y  








562 Overall cancer  Yes ICD-7, ICD-8, ICD-9, 
and ICD-10 codes 
ICD-7, ICD-8, ICD-
9, and ICD-10 
codes 









Mixed, population-based 2005-2011 
 
NA 
170 PD Female %: 
65.7% in pancreatic 
cancer group 
Age: 







NA Specific cancer Yes ICD-9 ICD-9 OR sex, age, 
comorbidities, 
and index year of 
diagnosing 
pancreatic cancer 
8 (Low risk) 








Mixed, population-based 2004-2012 
3.4 y 
62023 PD Female %: 
50.8% 
Age: 

















































Mixed, population-based 1992-2005 
 
NA 





86.1% White, 13.9% 
Non-white, 7.8% 
African American, 
2.5% Asian, 1.4% 





5829 Overall cancer Yes Clinical diagnosis 
(ICD-9, with full 
claim information in 
the registry system) 





























245 Specific cancer Yes Clinical diagnosis 




OR Age, sex, and 
comorbidity 






















1302 Overall cancer Yes  Clinical diagnosis Clinical diagnosis SIR Age, sex 7 (Low risk) 








Mixed, population-based 1999-2010 
 
NA 








19 Specific cancer Yes ICD-9-CM codes ICD-9-CM codes HR Age and sex 6 
(Moderate 
risk) 







Mixed, population-based 1997-2010 
 
4.4 y 








110 Overall cancer Yes ICD-9-CM codes ICD-9-CM codes SIR Age and sex 7 (Low risk) 







Mixed, population-based 2005-2011 
 
NA 
641 PD Female %: 











255 Specific cancer Yes ICD-9 ICD-9 OR Sex, age, 
comorbidities, 
and index year of 
diagnosis of 
colorectal cancer  
8 (Low risk) 








Inpatient, single-center 1934-1974 
 
35 y 








8 Overall cancer 
death 
No Clinical diagnosis 




SMR Age, sex, and 
admission pay 
status (public or 
private) 











Mixed, population-based 1970-NA 
 
10 y 











































20 Overall cancer 
death 
No Clinical diagnosis Clinical diagnosis SMR Age and sex 3 (High risk) 


















20 Overall cancer 
death 
No ICD-8 codes ICD-8 
codes 






















44 Overall cancer Yes Clinical diagnosis Clinical diagnosis RR Age and sex 8 (Low risk) 







Inpatient, single-center 1934-1974 
 
40 y 








14 Overall cancer 
death 
















1190 SCZ Female %: 
51.9 
Age: 





34 Overall cancer 
death 




(+ Dupont 1986; 
Mortensen, 



























IRR Age and sex 7 (Low risk) 



















74 Overall cancer 
death 















Mixed, population-based 1957-1980 
 
>5 y 








895  Overall cancer Yes Clinical diagnosis 
and DMS-III-R codes 
ICD-8 codes RR Age and sex 8 (Low risk) 






















133 Overall cancer; 
Overall cancer 
death 
Yes ICD-8/DSM-III-R medical records 
(cancer registry) 
SIR; SMR Age, sex, and 
calendar period 
7 (Low risk) 






Inpatient, single-center 1948-1982 
 
NA 








41 Overall cancer 
death 






































Mixed, population-based 1986-1993 
 
NA 








NA Overall cancer 
deaths 








Mixed, population-based 1966-1995 
 
13 y 








496 Overall cancer; 
Overall cancer 
death 
Yes ICD-9 codes ICD-9 codes RR Age and sex 8 (Low risk) 



















225 Overall cancer 
death 














93 SCZ Female %: 
57.0% 
Age: 
7 Overall cancer 
death 
No Clinical diagnosis 
(coputer catego-ID) 















Mixed, population-based 1971-1996 
 
>5 y 








724 Overall cancer Yes DSM-III-R, ICD-8 , 
and ICD-9 codes 
ICD-8 , and ICD-9 
codes 
SIR Age, sex, and 
follow-up 
8 (Low risk) 
Barak, 2005 (+ 








Inpatient, single-center 1990-2011 
 
>5 y 








320 Overall cancer Yes DSM-IV ICD-C and ICD-9 
codes 
SIR Age, sex 7 (Low risk) 
Dalton, 2005 (+ 
Dalton 2003 for 




















1299 Overall cancer Yes ICD-7 and ICD-8 
codes 
ICD-7 and ICD-8 
codes 
































































1504 Overall cancer Yes ICD-10 codes ICD-03 codes SIR Age, sex, place of 
birth 
7 (Low risk) 



















2320 Overall cancer 
death 
No ICD-8, ICD-9, and 
ICD-10 codes 
ICD-8, ICD-9, and 
ICD-10 codes 











Mixed, population-based 1995-2000 
 
5 y 






NA Overall cancer 
death 
No DSM-IV ICD-9 codes RR 
 




































use of medication 





















NA Overall cancer 
death 
No ICD-10 codes Death certificates SMR Age, sex, and 
calendar year 








Mixed, population-based 1973-1993 
 
21 y 








467 Overall cancer 
death 
No ICD-8 codes ICD-8 codes SMR Age, sex, and 
calendar year 
8 (Low risk) 






Mixed, population-based 1993-2003 
 
11 y 








74 Overall cancer 
death 
Yes ICD-10 codes ICD-10 codes SMR Age, sex, BMI, 
smoking, alcohol 





8 (Low risk) 















370 SCZ Female %: 
42.4% 
Age: 





30 Overall cancer 
death 
Yes ICD-9 and ICD-10 
codes 
ICD-9 and ICD-10 
codes 













NA Female %: 
51% 
Age: 





NA Overall cancer 
death 




SMR Age, sex, and 
ethnicity 
7 (Low risk) 








Mixed, population-based 1999-2008 
 
9 y 
59257 SCZ Female %: 
44.2% 
Age: 


























894 SCZ Female %: 
53% 
Age: 

































40 Overall cancer 
death 
No ICD-8 and ICD-9 
codes 
ICD-8 and ICD-9 
codes 




mass index, and 
comorbidities 


















43% White, 56% Black 
Smoking history: 
NA 






SIR Age, sex, ethnicity 
(race) 








Mixed, population-based 1999-2008 
 
9 y 








827 Overall cancer 
death 
No ICD-8, ICD-9, and 
ICD-10 
ICD-8, ICD-9, and 
ICD-10 


















































12 Overall cancer 
death 
No ICD-9 and ICD-10 
codes 
ICD-9 and ICD-10 
codes 
SMR Age, sex, calendar 
year, deprivation 









Mixed, population-based 1995-2008 
 
6.6 y 








29 Overall cancer 
death 







Mixed, population-based 2003-2009 
 
7 y 
8377 SCZ Female %: 
42.2% 
Age: 
487 Overall cancer; 
Overall cancer 
death 
Yes ICD-10 codes ICD-10 codes HR Age, sex, income, 
socio-
demographic 

















Mixed, population-based 1999-2008 
 
6.3 y 









87 Overall cancer 
death 
No DSM-IV codes ICD-10 codes HR Age, sex, ethnicity, 
and income 
9 (Low risk) 






Mixed, population-based 1965-2008 
 
>5 y 








5101 Overall cancer Yes ICD-7, ICD-8, ICD-9, 
and ICD-10 codes 
ICD-7, ICD-8, ICD-
9, and ICD-10 
codes 





9 (Low risk) 




























No ICD-9 or ICD-10 
codes 
ICD-O codes RR Age and sex 8 (Low risk) 








Mixed, population-based 1997-2009 
 
6.6 y  






























NA Overall cancer Yes Clinical diagnosis 
(medical records) 
























16% never, 67% past, 
16% current 
61 Overall cancer 
death 
No ICD-9 or ICD-10 
codes 
ICD-9 or ICD-10 
codes 
HR Age, sex (only 
men), time at risk 
(competing risks) 
















30 Overall cancer 
death 



























NA Overall cancer 
death 
Yes ICD-9 and ICD-10 
codes 
ICD-9 and ICD-10 
codes 
RR Age and Sex 7 (Low risk) 












25 y  








17 Overall cancer 
death 
Yes ICD-9 or ICD-10 
codes 
ICD-9 or ICD-10 
codes 








Mixed, population-based 2000-2009 
 
>5 y 








966 Overall cancer No ICD-9 or ICD-10 
codes 
ICD-9 or ICD-10 
codes 








Mixed, population-based 2001-2007 
 
>5 y 
1138853 SCZ Female %: 
46.4% 
Age: 
most > 35 
Ethnicity: 
52% White, 29% 




9638 Overall cancer 
death 
Yes ICD-10 codes ICD-10 codes SMR Age, sex, ethnicity 
and geographic 
region 
7 (Low risk) 






Mixed, population-based 1995-2009 
 
NA 








NA Overall cancer 
deaths 
No ICD-10 ICD-10 SMR NA 7 (Low risk) 








Mixed, population-based 2002-2007 
 
5 y 
NA Female %: 
44% 
Age: 












No ICD-9 ICD-O RR Age and sex 7 (Low risk) 









Mixed, population-based 1998-2011 
>5 y 
10727 SCZ Female %: 
100% 
Age: 
44.1 y  
Ethnicity: 










































Mixed, population-based 1995-2011 
 
5.5 y 








86 Specific cancer 
deaths 
No ICD-8 and ICD-10 
codes 
ICD-8 and ICD-10 
codes 




















100%  White 
Smoking history: 
NA 
NA Overall cancer 
deaths 
No ICD-8, ICD-9. and 
ICD-10 codes 
ICD-8, ICD-9. and 
ICD-10 codes 
SMR Age and sex 7 (Low risk) 













Appendix 5: Transcriptomic datasets included in the differential gene expression meta-analyses and 
the consensus co-expression module analyses.  












AD GSE1297 [557] 2004 1 31 31 22 9 5.12 Yes 
AD GSE5281 [558] 2006 2 161 23 10 13 4.75 Yes 
AD E_MEXP_2280 
[559] 
2010 2 31 12 7 5 2.88 Yes 
AD GSE36980 [560] 2013 3 79 17 7 10 3.75 Yes 
AD GSE29378 [561] 2013 4 63 27 15 12 5.38 Yes 
AD GSE48350 [562] 2014 2 253 61 19 42 1.38 Yes 
AD GSE84422 [563] 2016 2 2004 55 44 11 4.75 Yes 
ASD 
 
GSE28521 [564] 2011 5 79 72 16 56 1.25 Yes 
ASD GSE28475 [565]  2012 5 143 65 8 57 2.5 Yes 
ASD Gupta [566] 2014 NA 120 27 10 17 2.25 Yes 
ASD 
contols 
GSE36192 [567] 2012 3 911 NA NA NA NA NA 
BD GSE53987 [568] 2014 2 36 36 17 19 2.75 Yes 
BD GSE92538 [569] 2016 2 386 65 12 53 2.12 Yes 
BD AltarC [570] NA 1 22 22 11 11 3 Yes 
BD Dobrin [571] NA 2 86 50 26 24 2.12 Yes 
HD GSE3790 [572] 2005 1 404 70 38 32 NA Yes 
HD GSE26927 [573] 2011 5 118 19 9 10 NA Yes 
MD GSE54570 [574] 2014 1 26 26 13 13 4.25 Yes 
MD GSE54567 [574] 2014 2 28 28 14 14 3.38 Yes 
MD GSE54568 [574] 2014 2 30 29 14 15 2.88 Yes 
MD GSE53987 [568] 2014 2 205 36 17 19 2.88 Yes 
MD GSE92538 [569] 2016 2 363 82 29 53 3.25 Yes 
MD AltarC [570] NA 1 72 22 11 11 4.38 Yes 
PD GSE7621 [575] 2007 2 25 25 16 9 3 Yes 
PD GSE8397 [576] 2008 1 94 38 24 14 1.88 Yes 
PD E_MEXP_1416 
[577] 
2008 6 16 16 8 8 7.5 No 
PD GSE20141 [578] 2010 2 18 17 9 8 6.75 Yes 
PD GSE20163 [578] 2010 1 17 17 8 9 5.88 Yes 
PD GSE20164 [578] 2010 1 11 11 6 5 8 No 
PD GSE20295 [578] 2010 1 93 29 11 18 4.5 Yes 
PD GSE20159 [578] 2011  4 33 33 16 17 7.62 No 
PD GSE49036 [579] 2013 2 28 23 15 8 5.25 Yes 
PD GSE54282 [580] 2014 3 33 6 3 3 8.38 No 
PD GSE24378 [578] NA  6 17 17 8 9 7.25 No 
SCZ Mirnics [581] 2000 1 18 18 12 6 5.12 Yes 




SCZ GSE17612 [583] 2009 2 51 51 28 23 2.62 Yes 
SCZ GSE21138 [584] 2010 2 59 57 29 28 3.38 Yes 
SCZ GSE53987 [568] 2014 2 205 34 15 19 3.5 Yes 
SCZ GSE92538 [569] 2016 2 363 79 27 52 4.12 Yes 
SCZ Dobrin [571] NA 2 86 48 24 24 5.12 Yes 
SCZ AltarC [570] NA 1 72 22 11 11 5.62 Yes 
ALL GSE13204 [585] 2009 2 3248 824 750 74 1.88 Yes 
ALL GSE26713 [586] 2011 2 124 124 117 7 2.38 Yes 
ALL GSE28497 [587] 2011 1 288 288 284 4 3.38 Yes 
ALL GSE46170 [588] 2013 2 38 38 32 6 3.75 Yes 
ALL GSE79533 [589] 2017 2 226 226 223 3 3.62 Yes 
AML GSE12662 [590] 2008 2 106 81 76 5 5.75 Yes 
AML GSE13204 [585] 2009 2 3248 574 501 73 2.88 Yes 
AML GSE30029 [591] 2011 4 121 121 90 31 3.38 Yes 
AML GSE34577 [592] 2011 4 89 75 57 18 3.88 Yes 
AML GSE48558 [593] 2013 3 170 21 18 3 5.88 Yes 
AML GSE67936 2015 7 168 168 150 18 4.88 Yes 
AML GSE68172 2015 2 77 15 10 5 8.25 No 
AML GSE63270 [594] 2016 2 104 104 42 62 3.62 Yes 
AML GSE76340 [595] 2016 4 166 18 15 3 6.5 Yes 
BLCA GSE7476 [596] 2007 2 12 12 9 3 1.88 Yes 
BLCA GSE13507 [597] 2008 8 256 84 75 9 3.5 Yes 
BLCA GSE52519 [598] 2013 9 12 8 5 3 3.38 Yes 
BLCA GSE38264 [599] 2014 3 51 38 28 10 2.25 Yes 
BLCA E_MTAB_1940 
[600] 
2015 2 86 86 82 4 4 Yes 
BRCA GSE7904 [601] 2007 2 62 47 40 7 6.12 Yes 
BRCA GSE10780 [602] 2009 2 185 185 42 143 3.62 Yes 
BRCA GSE10810 [603] 2009 2 58 58 31 27 2.38 Yes 
BRCA GSE29431 2011 2 66 54 44 10 4.38 Yes 
BRCA GSE31448 [604] 2011 2 357 356 352 4 3.88 Yes 
BRCA GSE42568 [605] 2013 2 121 114 98 16 3.12 Yes 
BRCA GSE54002 [606] 2014 2 433 433 417 16 6.12 Yes 
BRCA GSE45827 [607] 2016 2 155 149 140 9 6.38 Yes 
BRNCA GSE4290 [608] 2006 2 180 176 153 23 3.25 Yes 
BRNCA GSE9385 [609] 2008 10 55 55 49 6 4.5 Yes 
BRNCA GSE16011 [610] 2010 2 284 278 270 8 2.25 Yes 
BRNCA GSE21354 [611] 2010 2 18 18 14 4 9 No 
BRNCA GSE15824 [612] 2011 2 45 32 27 5 7.12 No 
BRNCA GSE42656 [613] 2013 4 73 55 44 11 6.5 Yes 
BRNCA GSE44971 [614] 2013 2 58 58 49 9 7.5 No 
BRNCA GSE50161 [615] 2013 2 130 128 115 13 4.75 Yes 
BRNCA GSE68848 [616] 2015 2 580 482 454 28 3.5 Yes 
BRNCA GSE74195 [617] 2015 2 51 44 39 5 6.62 Yes 
CERV GSE6791 [618] 2007 2 84 28 20 8 3.75 Yes 
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CERV GSE39001 [619] 2013 3 79 24 19 5 3.08 Yes 
CERV GSE63514 [620] 2015 2 128 52 28 24 1.67 Yes 
CERV GSE67522 [621]  2015 7 42 35 15 20 2.5 Yes 
CHLCA GSE26566 [622] 2012 5 169 17 11 6 1.75 Yes 
CHLCA GSE32879 [623] 2012 3 37 23 16 7 1.75 Yes 
CHLCA GSE32225 [624] 2013 1 155 88 83 5 3.38 Yes 
CHLCA GSE22633 [625] 2014 8 63 24 20 4 3.12 Yes 
CLL GSE13204 [585] 2009 2 3248 522 448 74 2 Yes 
CLL GSE13987 [626] 2009 2 24 8 4 4 3.62 Yes 
CLL GSE26725 [627] 2011 2 17 17 12 5 5 Yes 
CLL GSE31048 [628] 2013 2 221 221 188 33 4.25 Yes 
CLL GSE51528 [629] 2015 3 2299 229 217 12 3.12 Yes 
CLL GSE67640 [630] 2017 7 24 24 15 9 3 Yes 
CML GSE13204 [585] 2009 2 3248 139 66 73 1.88 Yes 
CML GSE43754 [631] 2013 10 20 20 10 10 2 Yes 
CML GSE47927 [632] 2013 3 67 67 52 15 2.12 Yes 
CRCA GSE9348 [633] 2007 2 82 82 70 12 4.88 Yes 
CRCA GSE18105 [634] 2010 2 111 94 77 17 11.38 No 
CRCA GSE20916 [635] 2010 2 145 105 81 24 5.12 Yes 
CRCA GSE24550 [636] 2011 10 167 90 77 13 13.25 No 
CRCA GSE31279 [637] 2011 5 110 53 30 23 8.38 No 
CRCA GSE33113 [638] 2011 2 96 96 90 6 9.38 No 
CRCA GSE31737  2012 10 80 80 40 40 6.62 Yes 
CRCA GSE37182 [639] 2013 4 172 168 84 84 8.62 No 
CRCA GSE37364 [640] 2013 2 94 52 14 38 4.62 Yes 
CRCA GSE39582 [641] 2013 2 585 585 566 19 5.62 Yes 
CRCA GSE35834 [642] 2014 10 158 53 30 23 9 No 
CRCA GSE44076 [643] 2014 11 246 246 98 148 5.38 Yes 
CRCA GSE41657   2015 12 88 37 25 12 10.88 No 
CRCA GSE62932 [644] 2015 2 68 68 64 4 10.25 No 
CRCA GSE71187 [645] 2017  12 189 111 99 12 6.62 Yes 
DLBCL GSE12453 [646] 2008 2 67 36 11 25 1.88 Yes 
DLBCL GSE12195 [647] 2009 2 136 88 73 15 2 Yes 
DLBCL GSE56315 [648] 2015 2 122 122 89 33 2.12 Yes 
FLYMPH GSE12453 [646] 2008 2 67 30 5 25 4.62 Yes 
FLYMPH GSE12195 [647] 2009 2 136 53 38 15 2.25 Yes 
FLYMPH GSE14214 [649] 2011 13 13 12 9 3 4.62 Yes 
FLYMPH GSE48047 2014 14 55 26 18 8 4.12 Yes 
FLYMPH GSE55267 [650] 2014 2 69 69 63 6 2.62 Yes 
FLYMPH GSE65135 [651] 2015 2 28 24 14 10 2.75 Yes 
HANC GSE9844 [652] 2008 2 38 38 26 12 3.12 Yes 
HANC GSE23558 [653] 2011 12 32 28 23 5 4.62 Yes 
HANC GSE25099 [654] 2011 10 79 79 57 22 5 Yes 
HANC GSE30784 [655] 2011 2 229 212 167 45 2.12 Yes 




HANC GSE29330 [657] 2014 2 18 18 13 5 4.25 Yes 
HANC GSE55550 [658] 2014 16 155 86 73 13 6.12 Yes 
HANC GSE59102 2014 12 42 32 23 9 4 Yes 
HANC GSE75538 [659] 2016 15 28 10 5 5 6.75 Yes 
KDNCA GSE11024 [660] 2008 2 79 22 10 12 6.38 Yes 
KDNCA GSE17895 [661] 2010 2 160 157 135 22 6.88 Yes 
KDNCA GSE36895 [662] 2012 2 76 52 29 23 2.62 Yes 
KDNCA GSE40435 [663] 2013 7 202 202 101 101 4.88 Yes 
KDNCA GSE47032 [664] 2013 10 40 20 10 10 5.12 Yes 
KDNCA GSE46699 [665] 2014 2 130 94 49 45 4.62 Yes 
KDNCA GSE76351 2015 17 24 24 12 12 7.62 No 
KDNCA GSE66272 [666] 2016 2 54 54 27 27 3.38 Yes 
KDNCA GSE68417 [667] 2016 3 49 49 35 14 6.38 Yes 
KDNCA GSE71963 [668] 2016 12 48 48 32 16 7.12 No 
LGCA GSE12236  2008 10 40 40 20 20 8.25 No 
LGCA GSE18842 [669] 2010 2 91 91 46 45 7 No 
LGCA GSE19188 [670] 2010 2 156 156 91 65 3.38 Yes 
LGCA GSE19804 [671] 2011 2 120 120 60 60 5.12 Yes 
LGCA GSE31210 [672] 2011 2 246 246 226 20 6.88 Yes 
LGCA GSE31552 [673] 2011 3 131 75 43 32 9.88 No 
LGCA GSE32863 [674] 2012 17 116 87 33 54 7.12 No 
LGCA GSE40275 2012 10 10 72 29 43 11.38 No 
LGCA GSE30219 [675] 2013 2 307 307 293 14 8.12 No 
LGCA GSE40791 [676] 2013 2 194 194 94 100 3.38 Yes 
LGCA GSE32665 [677] 2013 8 179 170 81 89 10.88 No 
LGCA GSE43458 [678] 2013 3 110 110 80 30 9.62 No 
LGCA GSE33532 2014 2 100 34 14 20 8.38 No 
LGCA GSE75037 [679] 2016 9 134 134 51 83 5.62 Yes 
LIVCA GSE6764 [680] 2007 2 75 75 65 10 7.12 No 
LIVCA GSE17967 [681] 2009 1 63 63 16 47 10.25 No 
LIVCA GSE12941 [682] 2010 10 20 20 10 10 8 No 
LIVCA GSE36376 [683] 2012 7 433 273 80 193 5.88 Yes 
LIVCA GSE50579 [684] 2013 14 80 34 26 8 9.12 No 
LIVCA GSE41804 [685] 2013 2 40 40 20 20 5.12 Yes 
LIVCA GSE17548 [686] 2013 2 37 37 17 20 6.88 Yes 
LIVCA GSE54236 [687] 2014 12 161 133 55 78 6.38 Yes 
LIVCA GSE55092 [688] 2014 2 140 44 20 24 4.38 Yes 
LIVCA GSE62232 [689] 2014 2 91 86 81 5 6.12 Yes 
LIVCA GSE76427 [690] 2015 7 167 101 50 51 5.12 Yes 
LIVCA GSE64041 [691] 2016 3 44 125 60 65 3.62 Yes 
OVCA GSE10971 [692] 2008 2 37 37 13 24 3.62 Yes 
OVCA GSE14407 [693] 2009 2 24 19 7 12 4.12 Yes 
OVCA GSE36668 [694] 2012 2 12 12 8 4 3.38 Yes 
OVCA GSE40595 [695] 2014 2 77 75 61 14 2.38 Yes 
OVCA GSE69428 [696] 2015 2 29 17 8 9 3.5 Yes 
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OVCA GSE66957 2015 18 69 62 57 5 4 Yes 
PACA GSE15471 [697] 2009 2 78 72 36 36 4.38 Yes 
PACA GSE19650 [698] 2010 2 22 19 12 7 6.62 Yes 
PACA GSE32676 [699] 2011 2 32 32 25 7 5.62 Yes 
PACA GSE41368 [700] 2013 3 12 12 6 6 3.75 Yes 
PACA GSE43795  2013 7 31 11 6 5 6.12 Yes 
PACA GSE55643 [701]  2014 12 53 21 18 3 6.75 Yes 
PACA GSE62165 [702] 2016 11 131 131 118 13 2.38 Yes 
PACA GSE62452 [703] 2016 3 130 130 69 61 2.88 Yes 
PACA GSE63111 [704] 2017 10 35 35 28 7 6.5 Yes 
PRCA GSE21034 [705] 2010 10 370 160 131 29 3.5 Yes 
PRCA GSE29079 [706] 2011 10 95 95 47 48 5.12 Yes 
PRCA GSE62872 [707] 2014 3 424 424 264 160 2.38 Yes 
PRCA GSE46602 [708] 2015 2 50 50 36 14 4.12 Yes 
PRCA GSE70768 [709] 2015 7 199 199 125 74 3.12 Yes 
PRCA GSE71016 [710] 2016 16 95 91 45 46 2.75 Yes 
SKCM GSE3189 [711] 2005 1 70 69 44 25 3.75 Yes 
SKCM GSE7553 [712] 2008 2 87 18 14 4 3.12 Yes 
SKCM GSE15605 [713] 2012 2 74 62 46 16 2.38 Yes 
SKCM GSE46517 [714] 2013 1 121 45 30 15 2 Yes 
SKCM GSE57715 [715] 2014 19 297 292 275 17 3.75 Yes 
STCA GSE13911 [716] 2008 2 69 69 38 31 3.88 Yes 
STCA GSE13195 2009 10 100 50 25 25 4.5 Yes 
STCA GSE27342 [717] 2011 10 160 146 73 73 5 Yes 
STCA GSE29998 [718] 2012  4 99 99 50 49 4.12 Yes 
STCA GSE30727 2014 10 60 60 30 30 4.5 Yes 
STCA GSE51575 2014 14 52 36 15 21 6.25 Yes 
STCA GSE26899 [719] 2016 4 108 52 41 11 5.88 Yes 
STCA GSE79973 [720] 2016 2 20 20 10 10 4.88 Yes 
STCA GSE54129 2017 2 132 132 111 21 6 Yes 
THCA GSE3467 [721] 2005 2 18 18 9 9 2.75 Yes 
THCA GSE53157 [722] 2013 2 27 27 24 3 4.5 Yes 
THCA GSE35570 [723] 2015 2 116 116 65 51 1.75 Yes 
THCA GSE60542 [724] 2015 2 92 59 29 30 2.62 Yes 
THCA GSE65144 [725] 2015 2 25 25 12 13 3.38 Yes 
Appendix 5: Study characteristics for CNS disorders. Platform codes: 1- hgu133a, 2- hgu133plus2, 
3- Human Gene 1.0 ST, 4- Illumina HumanHT-12 V3.0, 5- Illumina humanRef-8 v2.0, 6- Affymetrix 
Human X3P Array, 7- Illumina HumanHT-12 V4.0, 8-Illumina human-6 v2.0 expression beadchip, 
9- Illumina HumanWG-6 v3.0, 10- Affymetrix Human Exon 1.0 ST Array, 11- Affymetrix Human 
Genome U219 Array, 12- Agilent-014850 Whole Human Genome Microarray 4x44K G4112F, 13- 
Sentrix HumanRef-8 Expression BeadChip, 14- Agilent-028004 SurePrint G3 Human GE 8x60K 




SurePrint G3 Human GE v2 8x60K Microarray 039381, 17- Affymetrix Human Gene 1.1 ST Array, 


























































Nº Up Nº Down 
BLCA Bladder Urothelial 
Carcinoma 
BLCA 433 414 19 16251 9043 6045 2998 
BRCA Breast Invasive 
Carcinoma 











CERV 307 304 3 16251 4418 2407 2011 
CHOL Cholangiocarcino
ma 
CHOL 45 36 9 16251 8989 6055 2934 
COAD Colon 
Adenocarcinoma 





CRCA 176 166 10 16251 9481 5934 3547 
HNSC Head and Neck 
Squamous Cell 
Carcinoma 





KDNCA 89 65 24 16251 1166
5 
7257 4408 
KIRC Kidney Renal 
Clear Cell 
Carcinoma 





LGCA 592 533 59 16251 1283
4 
8590 4244 
LUSC Lung Squamous 
Cell Carcinoma 











PACA 181 177 4 16251 842 94 748 
PRAD Prostate 
Adenocarcinoma 










THCA 560 502 58 16251 1163
8 
6040 5598 
Appendix 6: Table summarizing the types of cancers derived from TCGA and the results of the 




Appendix 7: Disease identifiers used to query each databse. Disease associated genes and variant-
genes for each disorder included in interactome 1 stringent analysis and genes included in the 
largest connected component. 
Disorde
r 
IDs used in the different DBs. Disease associated genes and variant-
genes (stringent) 
Genes included in the largest 
connected component in the 
interactome 1 stringent analysis 
AD -DisGeNet MESH: D000544 
-EDGAR: 104300 
-PhenGeID trait: Alzheimer Disease 
 
SORL1, NOS3, ACE, PLAU, MPO, APP, 
PSEN1, APBB2, PAXIP1, BLMH, PSEN2, 
HFE, A2M, ADAM10, GSK3B, APOE, MAPT, 
TREM2, BACE1, IDE, IL1B, INSR, LEP, NPY, 
BCL2, BDNF, CASP3, IL6R, CR1, MRPL50P4, 
SPON1, MS4A2, MS4A6A, MIR6503, 
PICALM, MMP3, BCAS3, CYB561, ABCA7, 
PVRL2, TOMM40, APOC1, BIN1, ACKR2, 
CCRL2, LOC102724297, SUCLG2, SNAR-I, 
RANP6, LOC100289673, HLA-DRB1, 
CD2AP, GAPDHP15, BZW2, EPHA1-AS1, 
PTK2B, CLU, MIR6843, HNF4G, SLC16A9, 
MS4A4A, FNTAP1, MMP12, CYP27C1, 
OSTN, FBXO8, HLA-DQA1, RBBP4P4, 
LINC01111 
 
PSEN1, APP, TOMM40, GSK3B, 
PSEN2, MAPT 
ASD -DisGeNet MESH: D000067877 
-EDGAR: PS209850, 605309 
-PhenGeID trait: Autism Spectrum 
Disorder|Autistic Disorder|Child 
Development Disorders, Pervasive| 
Asperger Syndrome 
 
NLGN3, CHD8, MECP2, NLGN4X, SLC9A9, 
MET, EN2, CNTNAP2, RPL10, PTCHD1, 
EIF4E, SHANK2, TMLHE, PTEN, NRXN2, 
SHANK3, NRXN1, ITIH3, TRIM26 
EIF4E 
BD -DisGeNet MESH: D001714 
-EDGAR: NA 
-PhenGeID trait: Bipolar Disorder 
S100B, COMT, ANK3, CACNA1C, NCAN, 
SP4, ADCY2, POLG, LMAN2L, FADS2, DRD1, 
GAD1, NR3C1, GSK3B, ITIH1, MTHFR, 
BDNF, SLC6A4, CLOCK, ITIH3, TRIM26, 
MAD1L1 
ANK3, NR3C1, GSK3B, CLOCK, BDNF 
HD -DisGeNet MESH: D006816 
-EDGAR:  143100 
-PhenGeID trait: NA 
HTT HTT 
MD -DisGeNet MESH: D003866 
-EDGAR:  608516 
-PhenGeID trait: 
Depression|Depressive 
Disorder|Depressive Disorder, Major 
FKBP5, TPH2, APOE, DISC1, SLC6A4, 
FGFR1, SOD1, CRH, NR3C1, IL6, KCNK2, 
MTHFR, NPY, PTGS2, BDNF, S100A10, 
TOMM40, SEPT3, WBP2NL, CYP2D6, ITIH3, 
TRIM26, CYP2C9 
NR3C1, BDNF 
PD -DisGeNet MESH: D010300 
-EDGAR:  PS168600 
-PhenGeID trait: Parkinson Disease 
 
GIGYF2, GBA, PODXL, PINK1, HTRA2, 
CHCHD2, LRRK2, PARK7, ATP13A2, PARK2, 
PLA2G6, SYNJ1, DNAJC13, VPS13C, NR4A2, 
UCHL1, VPS35, SNCAIP, TBP, EIF4G1, 
GLUD2, ADH1C, MAPT, SNCA, ATXN2, 
ATXN3, FGF20, DDC, DRD2, MAOB, 
SLC18A2, TH, RAB25, NUCKS1, RAB29, 
TIAL1, INPP5F, SLC2A13, CNTN1, GCH1, 
TMEM229B, TPM1, BCKDK, CRHR1, 




SPPL2C, NSF, WNT3, RIT2, DCUN1D1, 
MCCC1, GAK, TMEM175, DGKQ, BST1, 
FAM47E-STBD1, LHFPL2, HLA-DRB1, HLA-
DQB1, FAM126A, GPNMB, KRTCAP2, 
SLC41A1, SYT10, ACMSD, CERS6, DDRGK1, 
MMRN1, HLA-DRA, HLA-DQA1 




-PhenGeID trait: Schizophrenia 
DRD3, DISC1, MTHFR, DAO, COMT, 
SETD1A, AKT1, RTN4R, CHI3L1, DTNBP1, 
APOL4, SYN2, APOL2, MC4R, SLC1A1, 
SHANK3, PRODH, NRG1, MAGI2, CHRNA7, 
GRIN2B, NOS1, RELN, SRR, TCF4, NRXN1, 
SP4, PPP3R1, SYNGAP1, MDK, GRM5, 
GSK3B, ZDHHC8, APOE, NR4A2, SLC6A3, 
PPP1R1B, KMO 
AKT1, GSK3B 
ALL -DisGeNet MESH: D054198 
-EDGAR:  613065 




TAL1, TCF3, TAL2, BAX, PAX5, NBN, 
NUP214, FLT3, BCR, IKZF1, CDKN2A, ABL1, 
GATA3, LHPP, CEBPE, C14orf119 
TCF3, ABL1, GATA3, TAL1, FLT3, BCR, 
CEBPE 
AML -DisGeNet MESH: D015470 
-EDGAR:  601626 
-PhenGeID trait: Myeloproliferative 
Disorders 
TGM6, SETBP1, SH3GL1, FLT3, CHIC2, 
CEBPA, NPM1, WHSC1L1, CBFB, JAK2, 
NUP214, TERT, MLF1, MLLT10, LPP, 
GATA2, KRAS, ETV6, DDX41, KIT, RUNX1, 
NSD1, PICALM, DNMT3A, PTPN11, IDH1, 
IDH2, NRAS, TP53, WT1, SBDS, CREBBP, 
KMT2A, SPI1 
CBFB, PICALM, MLLT10, CHIC2, 
DNMT3A, RUNX1, NSD1, KMT2A, 
CREBBP, NRAS, SPI1, TP53, CEBPA, 
ETV6, LPP, WHSC1L1 
BLCA -DisGeNet MESH: D001749 
-EDGAR:   109800 
-PhenGeID trait: Urinary Bladder 
Neoplasms 
HRAS, FGFR3, RB1, KRAS, ATM, CDH1, 
NQO1, ERCC2, GSTP1, TP53, CDKN2A, 
TSC1, SLC14A1, CBX6, TACC3, CLPTM1L, 
CWC27, NAT2, PSCA, CCNE1, APOBEC3A, 
PSD3 
ATM, TP53 
BRCA -DisGeNet MESH: D001943 
-EDGAR:   
 114480 
-PhenGeID trait: Breast 
Neoplasms|Triple Negative Breast 
Neoplasms 
TSG101, HMMR, ATM, NQO2, AKT1, BRIP1, 
XRCC3, RB1CC1, PPM1D, RAD54L, 
FAM175A, NBN, CDH1, CHEK2, BRCA1, 
BRCA2, BARD1, KRAS, TP53, SLC22A18, 
ESR1, PHB, PALB2, CASP8, RAD51, PIK3CA, 
ERBB2, PTEN, CAV1, EP300, FGFR2, 
NOTCH2, CDKN1B, PARP1, NQO1, AKT2, 
ESR2, FGF3, FGFR1, FLT1, FN1, GATA3, 
FOXA1, HRAS, IGF1, AR, MDM2, MMP1, 
NOS2, NOTCH1, ROR1, FBXW7, PTHLH, 
RB1, STAT1, TBX3, NCOA3, BAP1, FGF4, 
TRIM33, MDM4, MLLT10, DNAJC1, 
ZNF365, ZMIZ1, LSP1, KRT8, USP44, PAX9, 
PELI2, RAD51B, NTRK3, TOX3, FTO, CDYL2, 
HNF1B, STXBP4, BABAM1, ELL, ERBB4, 
IGF1, SLC4A7, HMMR, MLLT10, 
AKT2, BABAM1, GATA3, CDKN1B, 
NQO2, BARD1, ESR2, AKT1, ATM, 
TNXB, PAX9, BAG6, CDSN, MDM4, 
EP300, PRRC2A, RAD54L, TRIM33, 
PIK3CA, RB1CC1, NBN, RAD51, 
NOTCH4, RB1, PHB, NCOA3, BAP1, 
CAV1, PPM1D, STXBP4, ELL, STAT1, 
TP53, MDM2, BRCA1, CCND1, ESR1, 
BRCA2, AR, CHEK2, ERBB2, FGFR2, 
NOTCH1, FAM175A, SEMA3A, 
FOXA1, ERBB4, ENPP2, HNF1B, 
BRIP1, HNF4G, PTEN, PTHLH, NTRK3, 




TNP1, NRIP1, CYYR1, MKL1, ITPR1, NEK10, 
SLC4A7, TERT, MAP3K1, MIER3, EBF1, 
CDSN, PSORS1C1, DDX39B, MCCD1, AIF1, 
BAG6, EHMT2, C2, TNXB, NOTCH4, HLA-
DRA, HLA-DRB1, HLA-DQA1, HLA-DQB1, 
TAP2, ADGRB3, UST, CCDC170, SEMA3A, 
ARHGEF5, NOV, SNX32, MYEOV, CCND1, 
CCDC91, GLI2, MRPS30, GPBP1, HLA-C, 
PRRC2A, HLA-DRB5, HLA-DOB, TAB2, 
HNF4G, ENPP2 
BRNCA -DisGeNet MESH: D001932 
-EDGAR:  PS137800 
-PhenGeID trait: Glioblastoma|Glioma 
ERBB2, BRCA2, TP53, PTEN, IDH2, IDH1, 
POT1, PPARG, ALK, RTEL1, TERT, SEC61G, 
ZBTB16, PHLDB1, POLR2A, EGFR, PHLDA1 
TP53, EGFR, ERBB2, PTEN 
CERV -DisGeNet MESH: D002583 
-EDGAR:  603956 
-PhenGeID trait: Uterine Cervical 
Neoplasms 
FGFR3, HLA-DRB1, HLA-DQA1 HLA-DRB1, HLA-DQA1 
CHLCA -DisGeNet MESH: D018281 
-EDGAR:  NA 
-PhenGeID trait: NA 
IDH1, TP53, KRAS TP53 
CLL -DisGeNet MESH: D015451 
-EDGAR:  NA 
-PhenGeID trait: Leukemia, 
Lymphocytic 
TP53, ATM, PLCG2, POT1, ID3, ACTA2, FAS, 
TSPAN32, C11orf21, BMF, MNS1, RPLP1, 
PHLPP1, BCL2, ACOXL, BCL2L11, CFLAR, 
SP110, SP140, FARP2, EOMES, ULK4, IRF4, 
HLA-DRB1, BAK1, TMPRSS5, BUB1B, 
ZNF280D, IRF8, CMC1, EXOC2, HLA-DQA1 
BMF, ATM, ZNF280D, TP53, BCL2 
CML -DisGeNet MESH: D054438 
-EDGAR:  NA 
-PhenGeID trait: Leukemia, Myeloid, 
Chronic-Phase 
SETBP1, BCR SETBP1 
CRCA -DisGeNet MESH: D015179 
-EDGAR:  114500 
-PhenGeID trait: Colorectal Neoplasms 
MT-CO1, BUB1B, MLH3, BAX, PDGFRL, 
CTNNB1, AKT1, ODC1, AXIN2, RAD54B, 
PIK3CA, NRAS, AURKA, DLC1, TRIM28, 
PLA2G2A, EP300, FGFR3, TP53, CCND1, 
PTPN12, MCC, KAT5, TLR2, BRAF, TLR4, 
APC, PTPRJ, MLH1, MSH2, CHEK2, SMAD3, 
SMAD4, MMP2, TCF7L2, BUB1, KLF5, 
MSH6, IGFBP3, KDR, KRAS, ABCB1, POLD1, 
POLE, RET, STK11, DPYD, TYMS, NKX2-3, 
CYP17A1, FGFR2, MYRF, POLD3, SPSB2, 
ETV6, KRT8, BRCA2, GREM1, HNF1B, 
SMAD7, UTP23, SLC25A28, MYEOV, 
RPS21, MAP3K1, EIF3H, RAD21 
MLH1, SMAD4, AKT1, TCF7L2, 
SMAD3, BUB1, TRIM28, EP300, 
BRAF, BUB1B, PIK3CA, RAD21, 
MSH6, TYMS, AURKA, APC, STK11, 
TP53, MSH2, CTNNB1, RET, CHEK2, 
FGFR2, KDR, FGFR3, NKX2-3 
DLBCL -DisGeNet MESH: D016403 
-EDGAR:  NA 
-PhenGeID trait: Lymphoma, Large B-
Cell, Diffuse 







-DisGeNet MESH: D008224 
-EDGAR:  NA 
-PhenGeID trait: Lymphoma, Follicular 
EZH2, BCL2, HLA-DQB1, CXCR5, FLI1, 
C6orf15, HLA-DRB5 
EZH2 
HANC -DisGeNet MESH: D006258 
-EDGAR:  275355 
-PhenGeID trait: Carcinoma, squamous 
cell of head and neck|Head and Neck 
Neoplasms 
PTEN, TNFRSF10B, EGFR, ING1, ING3, 
ADH1B, ADH7 
EGFR, PTEN 
KDNCA -DisGeNet MESH: D002292 
-EDGAR:  144700|605074 
-PhenGeID trait: Carcinoma, Renal Cell 
DIRC2, HNF1B, VHL, HNF1A, RNF139, 
OGG1, PRCC, MET, EPAS1, PTEN, SETD2, 
PBRM1, PTGS2, MTOR, TSC1, KDM5C, 
BAP1 
SETD2, PBRM1, HNF1A, PTGS2, 
HNF1B 
LGCA -DisGeNet MESH: D008175 
-EDGAR:  211980  
-PhenGeID trait: Adenocarcinoma of 
lung|Carcinoma, Non-Small-Cell 
Lung|Small Cell Lung Carcinoma 
ERBB2, IRF1, SLC22A18, ERCC6, RASSF1, 
PIK3CA, EGFR, MAP3K8, CASP8, PARK2, 
FASLG, BRAF, PPP2R1B, KRAS, CYP2A6, 
CDKN2A, TP53, BRCA2, PTEN, GSTP1, 
ERCC1, STK11, VTI1A, FGFR2, KRT8, 
HNF1B, BPTF, TP63, TERT, BAG6, APOM, 
MYEOV, MAP3K1 
GSTP1, BRAF, STK11, TP53, EGFR, 
ERBB2, FGFR2, PARK2, IRF1, CYP2A6, 
CDKN2A, PTEN 
LIVCA -DisGeNet MESH: D006528 
-EDGAR:   114550 
-PhenGeID trait: Carcinoma, 
Hepatocellular 
TP53, AXIN1, MTUS1, CDKN3, PIK3CA, 
CASP8, PDGFRL, CTNNB1, MET, APC, 
IGF2R, HNF1A, CDKN2A, IGF2, KRAS, 
HTATIP2, ARID2, FOXM1, GPC3, GNMT, 
MYC, ABCB1, PTEN, PTGS2, PTK2, HAMP, 
SKP2, TERT, TGFA, CCNE1, CDK1, KIF1B, 
HLA-DRB1, HLA-DQB1, HLA-DQA1 
CASP8, MTUS1, PTK2, FOXM1, CDK1, 
AXIN1, APC, TP53, CTNNB1, MYC, 
MET, IGF2R, HNF1A, PTGS2, GPC3 
OVCA -DisGeNet MESH: D010051 
-EDGAR:   
 167000 
-PhenGeID trait: Ovarian 
Neoplasms|Ovarian epithelial cancer 
BRCA1, PIK3CA, RRAS2, PARK2, CTNNB1, 
AKT1, SEPT9, CDH1, OPCML, BRCA2, 
ERBB2, KRAS, MLH1, MSH2, PTEN, TP53, 
RAD51C, BRIP1, PMS2, ESR1, CCNE1, 
RAD51D, BRAF, RSPO1, FGFR2, KRT8, 
HNF1B, NSF, SKAP1, BABAM1, HOXD3, 
MYEOV, MAP3K1, IFNL3 
MLH1, AKT1, BRAF, PMS2, TP53, 
BRCA1, MSH2, ESR1, CDH1, CTNNB1, 
BRCA2, ERBB2, FGFR2, BRIP1, PTEN 
PACA -DisGeNet MESH: D010190 
-EDGAR:    
 260350|613348|606856|6
14320|613347 
-PhenGeID trait: Pancreatic 
Carcinoma|Pancreatic Neoplasms 
RBBP8, TP53, ACVR1B, SMAD4, STK11, 
KRAS, PALLD, BRCA2, PALB2, BRCA1, 
CDKN2A, BACH1, TFF2, TERT, CLPTM1L, 
ABO, NR5A2, PRLHR, TFF1 
RBBP8, BRCA1, BACH1, BRCA2 




-PhenGeID trait: Prostatic Neoplasms 
EPHB2, BRCA2, PTEN, MAD1L1, HIP1, 
CD82, ZFHX3, KLF6, AR, MXI1, CDH1, 
FGFR4, MSR1, CHEK2, HOXB13, RNASEL, 
MSMB, ELAC2, EHBP1, APC, SPOP, 
CTNNB1, IGF1, NKX3-1, KRAS, CCND1, 
TGFBR2, KCND3, GOLPH3L, MDM4, FGFR2, 
MMP7, TUBA1C, KRT8, FERMT2, VPS53, 
HNF1B, DPF1, PCAT19, KLK15, KLK3, GGCX, 





TANC1, ITGA6, ADNP, ZGPAT, XAGE3, 
TEX11, SIDT1, PRKCI, SKIL, AFM, PDLIM5, 
TERT, RFX6, RGS17, SLC22A1, JAZF1, EBF2, 
FAM84B, RAD23B, ASCL2, MYEOV, PRPH, 
TBX5, PPP1R14A, KLK2, LILRA5, VAMP8, 
BIK, NUDT11, SLC7A3, CLDN11, MAP3K1, 
SLC22A2 
SKCM -DisGeNet MESH: D008545 
-EDGAR:  PS155600 
-PhenGeID trait: Melanoma 
CDKN2A, STK11, POT1, PTEN, CDK4, BRAF, 
MITF, XRCC3, TERT, TYR, HRAS, ERBB4, 
GNA11, GNAQ, NRAS, MAP2K1, TP53, 
BAP1, MAP2K2, NF1, RAC1, FTO, CDK10, 
AFG3L1P, RALY, PIGU, MYH7B, SLC45A2, 
IRF4, MTAP, CCND1, EXOC2 
MTAP, RALY, MAP2K2, FTO, 
MAP2K1, NF1, BRAF, GNAQ, STK11, 
TP53, GNA11, TYR, PTEN, MITF 
STCA -DisGeNet MESH: D013274 
-EDGAR:  137215|613659 
-PhenGeID trait: Stomach Neoplasms 
ERBB2, MUTYH, IRF1, PIK3CA, CASP10, 
KLF6, APC, FGFR2, KRAS, CDH1, IL1RN, 
IL1B, MET, ATM, MUC1, ASH1L, PRKAA1, 
DNAH11, PSCA 
ERBB2, IRF1, KLF6 
THCA -DisGeNet MESH: D013964 
-EDGAR:   PS188550 
-PhenGeID trait: Thyroid Neoplasms 
NKX2-1, FOXE1, BRAF, HABP2, RET, KRAS, 
TSHR, TP53, PCNXL2, OBFC1, NRG1, SLK, 
MBIP 
NRG1, BRAF, TP53, TSHR 
Appendix 7: Table including the disease identifiers employed to query the gene-disease 
association databases. Genes and variant-genes identified for each disorder using the stringent 




















Appendix 8: Drug indications identified for all the included disorders  
Disorder ICD9 Drug name Drugbank_ID RXCUI_IN 
AD 331.0 Galantamine DB00674 4637 
AD 331.0 Memantine DB01043 6719 
AD 331.0 Selegiline DB01037 9639 
AD 331.0 Tacrine DB00382 10318 
AD 331.0 Valproic Acid DB00313 11118 
AD 331.0 Vitamin E DB00163 11256 
AD 331.0 Tocopherol Acetate DB14003 39625 
AD 331.0 donepezil DB00843 135447 
AD 331.0 rivastigmine DB00989 183379 
AD 331.0 alpha-Tocopherol Acetate DB14002 1046243 
ASD 299.0;299.00 Fenfluramine DB00574 4328 
ASD 299.0;299.00 Risperidone DB00734 35636 
ASD 299.0;299.00 venlafaxine DB00285 39786 
ASD 299.0;299.00 quetiapine DB01224 51272 
ASD 299.0;299.00 aripiprazole DB01238 89013 
BD 296.7;296.80 Carbamazepine DB00564 2002 
BD 296.80 Clonazepam DB01068 2598 
BD 296.80 Clozapine DB00363 2626 
BD 296.80 Fluoxetine DB00472 4493 
BD 296.80 Valproic Acid DB00313 11118 
BD 296.80 gabapentin DB00996 25480 
BD 296.7;296.80 lamotrigine DB00555 28439 
BD 296.80 tiagabine DB00906 31914 
BD 296.80 oxcarbazepine DB00776 32624 
BD 296.80 Paroxetine DB00715 32937 
BD 296.80 Risperidone DB00734 35636 
BD 296.80 topiramate DB00273 38404 
BD 296.80 Lithium Carbonate DB14509 42351 
BD 296.7;296.80 quetiapine DB01224 51272 
BD 296.80 lithium citrate DB14507 52105 
BD 296.7;296.80 olanzapine DB00334 61381 
BD 296.80 aripiprazole DB01238 89013 
BD 296.80 ziprasidone DB00246 115698 
BD 296.7;296.80 Asenapine DB06216 784649 
BD 296.80 gabapentin enacarbil DB08872 1101333 
HD 333.4 Baclofen DB00181 1292 
HD 333.4 Perphenazine DB00850 8076 
HD 333.4 Pimozide DB01100 8331 
HD 333.4 coenzyme Q10 DB09270 21406 
MD 311 Alprazolam DB00404 596 
MD 311 Amitriptyline DB00321 704 




MD 311 Buspirone DB00490 1827 
MD 311 Chlorpromazine DB00477 2403 
MD 296.20;311 Citalopram DB00215 2556 
MD 311 Clomipramine DB01242 2597 
MD 311 Desipramine DB01151 3247 
MD 311 Dexamethasone DB01234 3264 
MD 311 Doxepin DB01142 3638 
MD 296.20;311 Fluoxetine DB00472 4493 
MD 296.20;311 Imipramine DB00458 5691 
MD 311 Isocarboxazid DB01247 6011 
MD 311 Isoflurane DB00753 6026 
MD 311 Lithium DB01356 6448 
MD 311 Lorazepam DB00186 6470 
MD 311 Maprotiline DB00934 6646 
MD 311 Methylphenidate DB00422 6901 
MD 296.20;311 Nortriptyline DB00540 7531 
MD 311 Phenelzine DB00780 8123 
MD 311 Protriptyline DB00344 8886 
MD 296.20;311 Selegiline DB01037 9639 
MD 311 Temazepam DB00231 10355 
MD 311 Tranylcypromine DB00752 10734 
MD 296.20;311 Trazodone DB00656 10737 
MD 296.20;311 Trimipramine DB00726 10834 
MD 311 Tryptophan DB00150 10898 
MD 296.20 Valproic Acid DB00313 11118 
MD 296.20;311 Mirtazapine DB00370 15996 
MD 311 lamotrigine DB00555 28439 
MD 311 nefazodone DB01149 31565 
MD 296.20;311 Paroxetine DB00715 32937 
MD 311 Risperidone DB00734 35636 
MD 296.20;311 Sertraline DB01104 36437 
MD 296.20;311 venlafaxine DB00285 39786 
MD 296.20;311 Bupropion DB01156 42347 
MD 311 Lithium Carbonate DB14509 42351 
MD 311 Fluvoxamine DB00176 42355 
MD 311 quetiapine DB01224 51272 
MD 311 lithium citrate DB14507 52105 
MD 311 olanzapine DB00334 61381 
MD 296.20 duloxetine DB00476 72625 
MD 296.20;311 aripiprazole DB01238 89013 
MD 311 Pramipexole dihydrochloride DB00413 236747 
MD 311 Kava preparation DB01322 285228 
MD 296.20;311 Escitalopram DB01175 321988 
MD 296.20 Desvenlafaxine DB06700 734064 
MD 296.20 vilazodone DB06684 1086769 
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PD 332 Amantadine DB00915 620 
PD 332 Apomorphine DB00714 1043 
PD 332 Trihexyphenidyl 
Hydrochloride 
DB00376 1115 
PD 332 Hyoscyamine Sulfate DB00424 1225 
PD 332 Benztropine DB00245 1424 
PD 332 Biperiden DB00810 1589 
PD 332 Bromocriptine DB01200 1760 
PD 332 Carbidopa DB00190 2019 
PD 332 Levodopa DB01235 6375 
PD 332 Pergolide DB01186 8047 
PD 332 Selegiline DB01037 9639 
PD 332 cabergoline DB00248 47579 
PD 332 entacapone DB00494 60307 
PD 332 ropinirole DB00268 72302 
PD 332 tolcapone DB00323 72937 
PD 332 rasagiline DB01367 134748 
PD 332 rivastigmine DB00989 183379 
PD 332 Pramipexole dihydrochloride DB00413 236747 
PD 332 Rotigotine DB05271 616739 
SCZ 295;295.9;295.90 Carbamazepine DB00564 2002 
SCZ 295;295.9;295.90 Chlorpromazine DB00477 2403 
SCZ 295.3 Chlorprothixene DB01239 2406 
SCZ 295;295.9;295.90 Clonazepam DB01068 2598 
SCZ 295;295.9;295.90 Clozapine DB00363 2626 
SCZ 295;295.9;295.90 Cyproheptadine DB00434 3013 
SCZ 295;295.9;295.90 Fluphenazine DB00623 4496 
SCZ 295;295.9;295.90 Haloperidol DB00502 5093 
SCZ 295;295.9;295.90 Loxapine DB00408 6475 
SCZ 295;295.9;295.90 Mesoridazine DB00933 6779 
SCZ 295;295.9;295.90 Molindone DB01618 7019 
SCZ 295;295.9;295.90 Perphenazine DB00850 8076 
SCZ 295;295.9;295.90 Pimozide DB01100 8331 
SCZ 295;295.9;295.90 Prochlorperazine DB00433 8704 
SCZ 295;295.9;295.90 Reserpine DB00206 9260 
SCZ 295;295.9;295.90 Selegiline DB01037 9639 
SCZ 295;295.9;295.90 Thioridazine DB00679 10502 
SCZ 295;295.9;295.90 Thiothixene DB01623 10510 
SCZ 295;295.9;295.90 Trazodone DB00656 10737 
SCZ 295;295.9;295.90 Trifluoperazine DB00831 10800 
SCZ 295;295.9;295.90 acetophenazine DB01063 16735 
SCZ 295;295.9;295.90 Risperidone DB00734 35636 
SCZ 295;295.9;295.90 quetiapine DB01224 51272 
SCZ 295;295.9;295.90 olanzapine DB00334 61381 




SCZ 295;295.9;295.90 iloperidone DB04946 73178 
SCZ 295;295.9;295.90 aripiprazole DB01238 89013 
SCZ 295;295.9;295.90 ziprasidone DB00246 115698 
SCZ 295;295.9;295.90 paliperidone DB01267 679314 
SCZ 295;295.9;295.90 Asenapine DB06216 784649 
SCZ 295;295.9;295.90 Lurasidone Hydrochloride DB08815 1040027 
ALL 204.0;204.00 mercaptopurine DB01033 103 
ALL 204.0;204.00 ASPARAGINASE DB00023 1156 
ALL 204.0;204.00 Cytarabine DB00987 3041 
ALL 204.0;204.00 Daunorubicin DB00694 3109 
ALL 204.0;204.00 Doxorubicin DB00997 3639 
ALL 204.0;204.00 Teniposide DB00444 10362 
ALL 204.0;204.00 pegaspargase DB00059 34132 
ALL 204.0;204.00 clofarabine DB00631 44151 
ALL 204.0;204.00 imatinib DB00619 282388 
ALL 204.0;204.00 dasatinib DB01254 475342 
AML 205.00 ASPARAGINASE DB00023 1156 
AML 205.0;205.00 Cyclophosphamide DB00531 3002 
AML 205.0;205.00 Cytarabine DB00987 3041 
AML 205.0;205.00 Daunorubicin DB00694 3109 
AML 205.0;205.00 Doxorubicin DB00997 3639 
AML 205.0;205.00 Etoposide DB00773 4179 
AML 205.0;205.00 Idarubicin DB01177 5650 
AML 205.0;205.00 Mitoxantrone DB01204 7005 
AML 205.0;205.00 Thioguanine DB00352 10485 
AML 205.00 Tretinoin DB00755 10753 
AML 205.0;205.00 arsenic trioxide DB01169 18330 
AML 205.0;205.00 sargramostim DB00020 69634 
AML 205.0;205.00 Gemtuzumab ozogamicin DB00056 1294580 
BLCA 188;188.9;239.4 Mitomycin DB00305 632 
BLCA 188;188.9;239.4 Cisplatin DB00515 2555 
BLCA 188.9;239.4 Doxorubicin DB00997 3639 
BLCA 239.4 Etoposide DB00773 4179 
BLCA 188;188.9 Fluorouracil DB00544 4492 
BLCA 188;188.9;239.4 Thiotepa DB04572 10473 
BLCA 188;188.9 gemcitabine DB00441 12574 
BLCA 188;188.9;239.4 valrubicin DB00385 31435 
BLCA 188;188.9;239.4 Carboplatin DB00958 40048 
BRCA 174.9 Cyclophosphamide DB00531 3002 
BRCA 174.9 Epirubicin DB00445 3995 
BRCA 174.9 Estradiol DB00783 4083 
BRCA 174.9 Estrogens  Conjugated (USP) DB00286 4099 
BRCA 174.9 Fluorouracil DB00544 4492 
BRCA 174.9 Fluoxymesterone DB01185 4494 
BRCA 174.9 Ifosfamide DB01181 5657 
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BRCA 174.9 Megestrol DB00351 6703 
BRCA 174.9 Methotrexate DB00563 6851 
BRCA 174.9 Methyltestosterone DB06710 6904 
BRCA 174.9;233.0 Tamoxifen DB00675 10324 
BRCA 174.9 Testolactone DB00894 10378 
BRCA 174.9 Testosterone DB00624 10379 
BRCA 174.9 Thiotepa DB04572 10473 
BRCA 174.9 pamidronate DB00282 11473 
BRCA 174.9 gemcitabine DB00441 12574 
BRCA 174.9 testosterone enanthate DB13944 37859 
BRCA 174.9 Toremifene DB00539 38409 
BRCA 174.9 vinorelbine DB00361 39541 
BRCA 174.9 Dexrazoxane DB00380 42736 
BRCA 174.9 Goserelin DB00014 50610 
BRCA 174.9 Paclitaxel DB01229 56946 
BRCA 174.9;233.0 Raloxifene DB00481 72143 
BRCA 174.9 letrozole DB01006 72965 
BRCA 174.9 zoledronic acid DB00399 77655 
BRCA 174.9 anastrozole DB01217 84857 
BRCA 174.9 capecitabine DB01101 194000 
BRCA 174.9 Estrogens  Esterified (USP) DB09381 214549 
BRCA 174.9 trastuzumab DB00072 224905 
BRCA 174.9 bevacizumab DB00112 253337 
BRCA 174.9 exemestane DB00990 258494 
BRCA 174.9 fulvestrant DB00947 282357 
BRCA 174.9 ixabepilone DB04845 337523 
BRCA 174.9 lapatinib DB01259 480167 
BRCA 174.9 eribulin DB08871 1045453 
BRNCA 191.9 Carmustine DB00262 2105 
BRNCA 191.9 Cisplatin DB00515 2555 
BRNCA 191;191.9 Cyclophosphamide DB00531 3002 
BRNCA 191.9 temozolomide DB00853 37776 
CERV 180.9 Cisplatin DB00515 2555 
CERV 180.9 Ifosfamide DB01181 5657 
CERV 180.9 Topotecan DB01030 57308 
CLL 204.1 mercaptopurine DB01033 103 
CLL 204.1 Chlorambucil DB00291 2346 
CLL 204.1 Cyclophosphamide DB00531 3002 
CLL 204.1 Etoposide DB00773 4179 
CLL 204.1 Ifosfamide DB01181 5657 
CLL 204.1 Mechlorethamine DB00888 6674 
CLL 204.1 Pentostatin DB00552 8011 
CLL 204.1 fludarabine DB01073 24698 




CLL 204.1 Immunoglobulins  
Intravenous 
DB00028 42386 
CLL 204.1 Cladribine DB00242 44157 
CLL 204.1 alemtuzumab DB00087 117055 
CLL 204.1 bendamustine DB06769 134547 
CLL 204.1 ofatumumab DB06650 712566 
CML 205.1 Busulfan DB01008 1828 
CML 205.1 Cyclophosphamide DB00531 3002 
CML 205.1 Cytarabine DB00987 3041 
CML 205.1 hydroxyurea DB01005 5552 
CML 205.1 Idarubicin DB01177 5650 
CML 205.1 Interferon Alfa-2b DB00105 5880 
CML 205.1 Plicamycin DB06810 6995 
CML 205.1 Thioguanine DB00352 10485 
CML 205.1 imatinib DB00619 282388 
CML 205.1 dasatinib DB01254 475342 
CRCA 153.9 Fluorouracil DB00544 4492 
CRCA 153.9 oxaliplatin DB00526 32592 
CRCA 153.9 irinotecan DB00762 51499 
CRCA 153.9 capecitabine DB01101 194000 
CRCA 153.9 bevacizumab DB00112 253337 
CRCA 153.9 cetuximab DB00002 318341 
HANC 195.0 Bleomycin DB00290 1622 
HANC 195.0 Cisplatin DB00515 2555 
HANC 195.0 Amifostine DB01143 4126 
HANC 195.0 Vinblastine DB00570 11198 
HANC 195.0 Carboplatin DB00958 40048 
HANC 195.0 Paclitaxel DB01229 56946 
KDNCA 189.0 Dactinomycin DB00970 3100 
KDNCA 189.0 hydroxyurea DB01005 5552 
KDNCA 189.0 Interferon Alfa-2a DB00034 5879 
KDNCA 189.0 Interferon Alfa-2b DB00105 5880 
KDNCA 189.0 Interferon gamma-1b DB00033 5882 
KDNCA 189.0 Medroxyprogesterone DB00603 6691 
KDNCA 189.0 Thalidomide DB01041 10432 
KDNCA 189.0 Vincristine DB00541 11202 
KDNCA 189.0 interferon alfacon-1 DB00069 59744 
KDNCA 189.0 Aldesleukin DB00041 70223 
KDNCA 189.0 peginterferon alfa-2a DB00008 120608 
KDNCA 189.0 everolimus DB01590 141704 
KDNCA 189.0 bevacizumab DB00112 253337 
KDNCA 189.0 peginterferon alfa-2b DB00022 253453 
KDNCA 189.0 sunitinib DB01268 357977 
KDNCA 189.0 sorafenib DB00398 495881 
KDNCA 189.0 temsirolimus DB06287 657797 
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KDNCA 189.0 pazopanib DB06589 714438 
LGCA 162.9 Cisplatin DB00515 2555 
LGCA 162.9 Cyclophosphamide DB00531 3002 
LGCA 162.9 Epirubicin DB00445 3995 
LGCA 162.9 Amifostine DB01143 4126 
LGCA 162.9 Etoposide DB00773 4179 
LGCA 162.9 hydroxyurea DB01005 5552 
LGCA 162.9 Ifosfamide DB01181 5657 
LGCA 162.9 Methotrexate DB00563 6851 
LGCA 162.9 Procarbazine DB01168 8702 
LGCA 162.9 Vinblastine DB00570 11198 
LGCA 162.9 gemcitabine DB00441 12574 
LGCA 162.9 vinorelbine DB00361 39541 
LGCA 162.9 Carboplatin DB00958 40048 
LGCA 162.9 irinotecan DB00762 51499 
LGCA 162.9 Paclitaxel DB01229 56946 
LGCA 162.9 Topotecan DB01030 57308 
LGCA 162.9 pemetrexed DB00642 68446 
LGCA 162.9 docetaxel DB01248 72962 
LGCA 162.9 bevacizumab DB00112 253337 
LGCA 162.9 gefitinib DB00317 328134 
LGCA 162.9 erlotinib DB00530 337525 
LGCA 162.9 crizotinib DB08865 1148495 
LIVCA 155.0 Interferon Alfa-2a DB00034 5879 
LIVCA 155.0 Interferon Alfa-2b DB00105 5880 
LIVCA 155.0 Interferon gamma-1b DB00033 5882 
LIVCA 155.0 interferon alfacon-1 DB00069 59744 
LIVCA 155.0 peginterferon alfa-2a DB00008 120608 
LIVCA 155.0 peginterferon alfa-2b DB00022 253453 
LIVCA 155.0;155.2 sorafenib DB00398 495881 
OVCA 183.0 Cisplatin DB00515 2555 
OVCA 183.0 hydroxyurea DB01005 5552 
PACA 157.9 Doxorubicin DB00997 3639 
PACA 157.9 Fluorouracil DB00544 4492 
PACA 157.9 gemcitabine DB00441 12574 
PACA 157.9 erlotinib DB00530 337525 
PRCA 185 6-Aminocaproic Acid DB00513 99 
PRCA 185 Cyproterone DB04839 3014 
PRCA 185 Doxorubicin DB00997 3639 
PRCA 185 Estradiol DB00783 4083 
PRCA 185 Estramustine DB01196 4089 
PRCA 185 Estrogens  Conjugated (USP) DB00286 4099 
PRCA 185 Flutamide DB00499 4508 
PRCA 185 Ketoconazole DB01026 6135 




PRCA 185 Mitoxantrone DB01204 7005 
PRCA 185 Thalidomide DB01041 10432 
PRCA 185 nilutamide DB00665 31805 
PRCA 185 Triptorelin DB06825 38782 
PRCA 185 Leuprolide DB00007 42375 
PRCA 185 Goserelin DB00014 50610 
PRCA 185 histrelin DB06788 50975 
PRCA 185 docetaxel DB01248 72962 
PRCA 185 zoledronic acid DB00399 77655 
PRCA 185 bicalutamide DB01128 83008 
PRCA 185 Estrogens  Esterified (USP) DB09381 214549 
PRCA 185 abarelix DB00106 301739 
PRCA 185 degarelix DB06699 475230 
PRCA 185 denosumab DB06643 993449 
PRCA 185 cabazitaxel DB06772 996051 
PRCA 185 sipuleucel-T DB06688 997261 
PRCA 185 abiraterone acetate DB05812 1100071 
SKCM 172.9 Bleomycin DB00290 1622 
SKCM 172.9 Carmustine DB00262 2105 
SKCM 172.9 Dacarbazine DB00851 3098 
SKCM 172.9 Dactinomycin DB00970 3100 
SKCM 172.9 hydroxyurea DB01005 5552 
SKCM 172.9 Interferon Alfa-2a DB00034 5879 
SKCM 172.9 Interferon Alfa-2b DB00105 5880 
SKCM 172.9 Interferon gamma-1b DB00033 5882 
SKCM 172.9 Lomustine DB01206 6466 
SKCM 172.9 Melphalan DB01042 6718 
SKCM 172.9 Procarbazine DB01168 8702 
SKCM 172.9 temozolomide DB00853 37776 
SKCM 172.9 interferon alfacon-1 DB00069 59744 
SKCM 172.9 Aldesleukin DB00041 70223 
SKCM 172.9 docetaxel DB01248 72962 
SKCM 172.9 peginterferon alfa-2a DB00008 120608 
SKCM 172.9 peginterferon alfa-2b DB00022 253453 
SKCM 172.9 ipilimumab DB06186 1094833 
SKCM 172.9 Vemurafenib DB08881 1147220 
STCA 151.9 Mitomycin DB00305 632 
STCA 151.9 Epirubicin DB00445 3995 
STCA 151.9 Fluorouracil DB00544 4492 
STCA 151.9 capecitabine DB01101 194000 
THCA 193 Vandetanib DB05294 1098413 
Appendix 8: Table showing the drug indications identified for all the included disorders. 
 
 
